

# **UNIVERSITY OF FOGGIA**

### PhD RESEARCH IN

"TRANSLATIONAL MEDICINE AND FOOD: INNOVATION, SAFETY AND MANAGEMENT"

(cycle XXXII)

"Life style, medicine and anabolic steroids: organ damages, new molecular biomarkers, epidemiology, pathology and toxicology"

**Tutor:** 

Prof. Cristoforo Pomara

PhD Candidate:

Dott. Francesco Sessa

Academic Triennium 2016-2019

### STATEMENT OF ORIGINALITY

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution, and contains no material previously published or written by another person, except where due reference has been made in the text.

Francesco Sessa

November 10, 2019

#### ABSTRACT

**Background:** To date, even if anabolic androgenic steroid (AAS) abuse is clearly associated with a broad spectrum of collateral effects, adolescents and athletes frequently use a large group of synthetic derivatives of testosterone, both for esthetical purposes and for improving their performance. AAS use is frequently associated with different substances such as energy drinks and dietary supplements. The combined use of different substances, such as AASs, energy drinks, and dietary supplements, could worsen each adverse effect, worsening the risk for several pathologies such as cardiovascular disease. Moreover, the presence of other silent substrates (for example, the genetic predisposition to cardiovascular diseases, the presence of the Metabolic Syndrome or physical inactivity) combined with the use of this kind of substance can represent an explosive mix for the users, causing severe consequences and, in particular cases, death.

**Open questions**: One common factor between detecting each of these performanceenhancing drugs is that the traditional methods of drug testing were taken at a single time point. An enhanced method of detection has been required to counter the increasingly sophisticated doping regimens and the ongoing development of new substances.

The contemporary use of these substances could represent an important warning for public health, worsening the cost of health care.

**Aims:** The goal of this PhD project was to analyze several important aspects linked to the use of AASs, defining the following: 1 - organ damage; 2 - new molecular biomarkers; 3 - epidemiology; 4 - pathology; 5 - toxicology.

**Research plan**: (i) During the project, two complete literature reviews were performed using the most used scientific databases. (ii) All samples were selected analyzing the documentation of all autopsies performed by the Institute of Legal Medicine of Foggia from 2001 to July 2018 (about 1700 autopsies): - 5 cases of young men positive for AAS use were selected for the "AAS group"; - 6 cases of men who died of heart failure were enrolled as the "HF (heart failure) group", with the aims to evaluate the heart damages; - 15 cases composed the three groups enrolled to analyze brain injury (5 for the "Stroke group (SG)", 5 for the "Drug group (DG)", and 5 for the "Aging group (AG)"); - 5 cases of men who died of cardiac arrest who had suffered from cirrhosis caused by non-alcoholic fatty liver disease (NAFLD group), were selected to evaluate the liver damages; - 5 cases of men who had died of cardiac arrest after a long period (more than 10 years) of Chronic kidney disease (CKD group), were enrolled to compose the control groups: 4 cases (age mean  $28 \pm 7.4$ 

with negative anamnesis for heart suffering and negative for the toxicological examination were selected as Control Group in the Quantitative Real-Time PCR (qRT-PCR) reactions for the miRNA tested in cardiac and musculoskeletal tissues, and 2 cases (mean age 41.5  $\pm$  2.12 years), who died in car accidents for causes other than brain trauma, NAFLD, CKD and negative for toxicological examination were selected as Control group in the qRT-PCR reactions performed on brain, liver, and kidney. (iii) Histological and toxicological examinations were performed in all groups; (iv) miRNA quantification through qRT-PCR was performed; (v) for each miRNA the prediction effect analysis was carried out through both with the literature review and "*in silico*", using several informatics tools; (vi) two surveys using online data collection tools were performed: "Multidimensional Body-Self Relations Questionnaire (MBSRQ)" and "in house" questionnaire to define the voluptuary habits of the interviewees; (vii) Statistical analysis was carried out through the software Statistica for Windows.

**Results:** The literature reviews were very important to define the main adverse effects linked to AAS use/abuse and to identify the "candidate miRNAs" to test on the tissue samples of the selected cases. The main adverse effects concerning AAS use were strictly linked to the reproductive systems, particularly in adolescents. Moreover, other organs that are severely damaged by AAS use were heart, kidney, liver, and brain. For these reasons, several miRNAs related to these organs were selected and tested in the selected groups. For heart and musculoskeletal tissues, the miRNA expression values of miRNA has-133a-3p, hsamiR-208a-3p, hsa-miR-499a-3p, and hsa-miR-1-3p were tested. The expression levels of miR-133 in heart tissue (HF and AAS groups) and muscle tissue (AAS group) resulted upregulated compared to controls. The expression levels of miR-208 in heart tissue (HF and AAS groups) resulted upregulated compared to controls. These results were not confirmed in muscle tissue (AAS group), where expression levels were similarly to controls. The expression levels of miR-499 resulted upregulated in the HF group, while in the AAS group, the expression levels of this miRNA were similar to controls. The expression levels of miR-1 3 both in HF and AAS groups resulted upregulated compared to controls. Moreover, this miRNA resulted overexpressed in the muscle (vastus lateralis) of the AAS group.

In kidney tissue, miR-21 and miR-205 were tested. The expression values of miR-21 in kidney tissues were upregulated compared to controls, even if the CDK values were significantly higher than the AAS group. The expression levels of miR-205 were higher in the CKD group compared to the AAS group, even if they were overexpressed in both groups compared to controls.

Analyzing the results on the liver tissue, comparing the expression values of miR-21 in the

two tested groups (AAS vs NAFDL), even if the values were higher compared to controls, this miRNA resulted overexpressed in the AAS group with a statistical significant difference. Concerning the expression levels of miR-122 in each group, even if the values were overexpressed compared to controls, the NAFDL values were significantly higher than the AAS group. Analyzing the expression levels of miRNA-132, there were no significant differences comparing the AAS group to the NAFDL group, even if both miRNAs were higher compared to controls. The same results were obtained analyzing the data about miR-155.

On brain tissue, several miRNAs were tested (miR-21, miR-34, miR-124, miR-132, and miR-200b) in four groups (SG, AG, DG, and AAS groups). For miR-21 the expression values of the AAS group were similar to the expression values of the SG and AG groups and was significantly higher compared to DG. For miR-34, the AAS group showed expression levels of this miRNA similar to the DG group, resulting higher compared to the AG and SG groups. The tissue levels of miR-124 were higher in the AAS and SG groups compared to the AG and SG groups. Finally, miR-132 was higher in the DG and AAS groups compare to the AG and SG groups. Finally, miR-200b was significantly overexpressed in the AAS group, even if this miRNA was higher in all groups than in controls.

The interpretation of miRNA expression was performed through several web tools ("*in silico*" analysis) ascertaining the possible effects of the aberrant expression at cellular levels. In this way, it was possible to achieve the main goal of this project, to ascertain the pivotal roles for several miRNAs expressed in specific tissue, linking them to specific organ damage.

Finally, from the analysis of the questionnaires it was possible to create the first Italian map on the phenomenon linked to the use of several substances, such as AASs, Energy Drinks and Supplements. The collected data demonstrated that there was a significant association (p < 0.05) between the use of anabolic steroids and consumption of other substances, such as energy drinks and supplements. The potential health risks related to heavy consumption of these products have largely gone unaddressed. For these reasons, the effort of the scientific community both for a better understand and to better communicate the risks linked to the use of these substances should be improved.

**Significance and Impact of research**: In the light of the results discussed in this project, it would appear that concerns in the scientific community and among the public regarding the potential adverse health effects of the increased consumption of energy drinks, supplements and AASs are broadly valid. As extensively discussed, AAS use is not limited

to athletes, but concerns young people who use these kinds of substances for esthetical purposes. For these reasons, this ongoing field of research is very challenging for the scientific community, in particular for the forensic field, involving a large number of people. As demonstrated in this PhD project, the main organs involved as targets of the adverse effects of AAS use are heart, kidney, liver, and brain; in several cases, the pathologies could be fatal for the abusers as described in the discussed cases. The identification of new molecular biomarkers can be considered of interest for the scientific community, not only for anti-doping purposes but for public health, too.

Indeed, considering the results of the questionnaires, the combined use of AASs with other substances such as supplements or energy drinks, is significantly higher compared to non-users, demonstrating the idea of polypharmacy for AAS users. These substances can be anonymously supplied by the internet, where they are sold with alleged effects on mental, physical and sexual performance without any real evidence-based research. Obviously, the adverse effects of each substance are combined with each other, increasing the health risks for users and the public health cost for assistance in severe cases such as cardiovascular diseases.

**Future trends:** The potential health risks related to a heavy consumption of these products have largely gone unaddressed. For these reasons, the effort of the scientific community both for a better understanding and to better communicate the risks linked to the use of these substances should be improved.

Key words: Anabolic Androgenic Steroids (AASs), Adverse effects, Abuse, Kidney, Liver,

Heart, Brain, miRNAs, new molecular biomarkers, Molecular mechanisms

### **TABLE OF CONTENTS**

Chapter 1. INTRODUCTION	1
1.1. The use of Anabolic Androgenic Steroids (AASs)	1
1.2. Anabolic Androgenic Steroids: Mechanisms of Action	5
1.3. Adverse Effects of Androgen Abuse	9
1.4. The role of miRNA in the research project	11
1.5. Circulating MicroRNAs: New Molecular Biomarkers in the fight agains	st doping 13
Chapter 2. AIMS AND PLANNING OF RESEARCH	15
Chapter 3. MATERIALS AND METHODS	18
3.1. Literature review	18
3.2. Case selection	18
3.2.1 AAS group	18
3.2.2 Heart failure (HF) group	20
3.2.3 Brain injury: Stroke group (SG), Drug group (DG), and Aging gro	oup (AG) 21
3.2.4 Non-alcoholic fatty liver disease (NAFLD) group	22
3.2.5 Chronic kidney disease (CKD) group	24
3.2.6 Control groups	24
3.3. Histological examination	25
3.4. Toxicological examination	26
3.5. miRNA quantification through quantitative real-time PCR (qRT-PCR)	27
3.6. miRNA database and target prediction tools	28
3.7. Questionnaires	28
3.7.1 Survey 1: Multidimensional Body-Self Relations Questionnaire (ME	BSRQ) 29
3.7.2 Survey 2: voluptuary habitudines	30
3.8. Statistical analysis	31
Chapter 4. RESULTS AND DISCUSSION	32
4.1. Literature review	32
4.2. Autopsy, histological and toxicological examination on AAS abuser	37

4.2.1. Autopsy and histological examination	37
4.2.2. Toxicological examination	42
4.3. miRNA quantification through qRT-PCR	44
4.3.1. Heart tissue and musculoskeletal system	44
4.3.2. Kidney tissue	51
4.3.3. Liver tissue	52
4.3.4. Brain tissue	54
4.4. miRNA database and target prediction tools	59
4.5. Questionnaire results	71
Chapter 5. CONCLUSIONS	76
5.1. AAS adverse effects and miRNAs applications: a literature review	76
5.2. Abuser characteristics	79
5.3. miRNA quantification	81
5.4. Questionnaire results	92
5.5. Significance and impact of PhD research	96

### REFERENCES

### PUBLICATIONS ARISING FROM THIS PhD PROJECT


- BERTOZZI, G., SALERNO, M., POMARA, C., <u>SESSA, F.</u> Neuropsychiatric and Behavioral Involvement in AAS Abusers. A Literature Review (2019) Medicina (Lithuania), 55 (7), art. no. 396. DOI: 10.3390/medicina55070396
- BERTOZZI, G., <u>SESSA, F.,</u> MAGLIETTA, F., CIPOLLONI, L., SALERNO, M., FIORE, C., FORTAREZZA, P., RICCI, P., TURILLAZZI, E., POMARA, C. Immunodeficiency as a side effect of anabolic androgenic steroid abuse: a case of necrotizing myofasciitis (2019) Forensic Science, Medicine and Pathology, DOI: 10.1007/s12024-019-00144-z in press
- SESSA, F., MAGLIETTA, F., BERTOZZI, G., SALERNO, M., DI MIZIO, G., MESSINA, G., MONTANA, A., RICCI, P., POMARA, C. Human brain injury and miRNAs: an experimental study (2019) International Journal of Molecular Sciences, 20 (7), art. no. 1546, . DOI: 10.1186/s41935-019-0116- 8. DOI: 10.3390/ijms20071546
- <u>SESSA, F.,</u> SALERNO, M., DI MIZIO, G., BERTOZZI, G., MESSINA, G., TOMAIUOLO, B., PISANELLI, D., MAGLIETTA, F., RICCI, P. AND POMARA C. Anabolic androgenic steroids: searching new molecular biomarkers. (2018) Front. Pharmacol. 9:1321. doi: 10.3389/fphar.2018.01321
- SALERNO, M., CASCIO, O., BERTOZZI, G., <u>SESSA, F.,</u> MESSINA, A., MONDA, V., CIPOLLONI, L., BIONDI, A., DANIELE, A., POMARA, C. Anabolic androgenic steroids and carcinogenicity focusing on Leydig cell: A literature review. (2018) Oncotarget, 9 (27), pp. 19415-19426. DOI: 10.18632/oncotarget.24767
- BERTOZZI, G., <u>SESSA, F.</u>, ALBANO, G.D., SANI, G., MAGLIETTA, F., ROSHAN, M.H.K., VOLTI, G.L., BERNARDINI, R., AVOLA, R., POMARA, C., SALERNO, M. The Role of Anabolic Androgenic Steroids in Disruption of the Physiological Function in Discrete Areas of the Central Nervous System (2018) Molecular Neurobiology, 55 (7), pp. 5548-5556. DOI: 10.1007/s12035-017-0774-1
- ALBANO, G.D., <u>SESSA, F.</u>, MESSINA, A., MONDA, V., BERTOZZI, G., MAGLIETTA, F., GIUGLIANO, P., VACCHIANO, G., GABRIELLA, M., SALERNO, M. AAS and organs damage: A focus on Nandrolone effects (2017) Acta Medica Mediterranea, 2017 (6), pp. 939-946.


## **Chapter 1. INTRODUCTION**

### 1.1. The use of Anabolic Androgenic Steroids (AASs)

To date, even if anabolic androgenic steroid (AAS) abuse is clearly associated with a broad spectrum of collateral effects, frequently adolescents and athletes use a large group of synthetic derivatives of testosterone, both for esthetical use and to improve their performance (Bailey et al., 2013; Dickinson et al., 2014). The market for performance-enhancing drugs is continuously increasing. Indeed, the phenomenon of doping no longer affects only professional athletes, but it is continually expanding to subjects practicing sports activities at the amateur level (Reardon and Creado, 2014).

The main AASs are summarized in Table 1. AASs are administered, both orally and by injection, cyclically, for periods ranging from 6-8 weeks followed by equivalent periods of abstinence.





**Table 1.** The main AASs: the endogenous AASs are produced by the human body, the exogenous ones can be obtained synthetically and are commonly used in therapy and doping

AAS use is frequently associated with different substances such as energy drinks and dietary supplements. The use of these products has become widespread: while it is known that acute overdose has been associated with toxicity, there is growing concern that chronic use of energy drinks and dietary supplements may cause neurologic and cardiovascular toxicity, particularly when they are combined with AAS use (Grasser et al., 2014; Hajsadeghi et al., 2016; Rottlaender et al., 2012).

Performance-enhancing drugs is an umbrella term used to describe those substances that give an athlete an unfair physical or mental advantage over a competitor. Prohibited substances or techniques are categorized by their target outcome: to improve strength, endurance or mental tolerance (Lippi and Plebani, 2011). Athletes involved in drug doping may employ a masking agent to avoid detection. Diuretics are by far the most common and are used to lower the concentration of the drug or its metabolite in the urine by increasing urinary volume. Although diuretics are detectable with multi-analytic screening, other masking agents including desmopressin and glycerol require more sophisticated methods (World Anti-Doping Agency,2014; Cadwallader et al., 2010).

One common factor in detecting each of these performance-enhancing drugs is that the traditional methods of drug testing were taken at a single time point. An enhanced method of detection has been required to counter the increasingly sophisticated doping regimens and the ongoing development of new substances. The athlete's biological passport is the evolution of drug testing techniques that WADA has developed for this purpose (Bucknall et al., 2014). For these reasons, the identification of new molecular biomarkers remains an ambitious target for the scientific community.

In recent years, energy drinks and dietary supplement use have increased, especially among young people, because these substances are sold as cognitive enhancing supplements. However, many of these new products produce altered psychological states, like

-3-

amphetamine effects (fatigue resistance, mood increase) and performance enhancement (Cole et al., 2018; Enriquez and Frankel, 2017; Grgic and Mikulic, 2017; Pomportes et al., 2017).

The combined use of different substances, such as AASs, energy drinks, and dietary supplements, could worsen each single adverse effect, increasing the risk for several pathologies such as cardiovascular disease. Moreover, the presence of other silent substrates (for example, genetic predisposition to cardiovascular diseases, the presence of the Metabolic Syndrome or physical inactivity) combined with the use of this kind of substance can represent an explosive mix for users, causing severe consequences and, in particular cases, death.

For these reasons, it is very challenging for the scientific community to improve our knowledge in this research field.

### 1.2. Anabolic Androgenic Steroids: Mechanisms of Action

AASs are synthetic derivatives of testosterone and their pharmacodynamics are similar to all other steroid hormones. Testosterone exerts different functions: in particular, it has a pivotal role in sexual differentiation, and it is produced more in men than in women. The biochemical pathway to obtain testosterone starts from cellular cholesterol, which after enzymatic cleavage of the lateral chain becomes pregnenolone. This molecule can then follow two different metabolic patterns. In the first 3-beta-hydroxysteroid dehydrogenase transforms pregnenolone into progesterone, then 17-a-hydroxylase adds an oxidrile group to pregnenolone and progesterone, synthesizing, respectively, 17-a-OH-pregnenolone and 17-a-OH-progesterone (DHEA) and androstenedione. Androstenediol and testosterone are produced by the action of 17-beta-hydroxysteroid dehydrogenase on the two molecules. Androstenediol, moreover, can be transformed into testosterone by 3-beta-hydroxysteroid dehydrogenase (Bremner et al., 1983; Saad et al., 2013).

Testosterone can exert its action itself but, more commonly, via the work of two enzymes called 5-a-reductase and CYP19-aromatase; in fact, it is possible to distinguish active (di-hydro-testosterone and estradiol respectively) and inactive (androsterone and etiocholanolone respectively) testosterone metabolites. In particular, di-hydro-testosterone and testosterone, acting through the binding androgen receptor, have a different affinity, the first being higher than the second. As has been stated above, testosterone is the primary androgen in men, primarily produced by Leydig cells and, in less quantity, by adrenal glands, in a relatively constant amount, with some diurnal variation that is age correlated. Indeed, daily variations of testosterone are well documented with specific levels that peak between 05:30 and 08:00 and trough levels occurring approximately 12 h later (de la Torre et al., 1981; Montanini et al., 1988; Walker, 2009; Wittert, 2014).

Androgens have several actions in the human body, in particular, in males, they deal with body growth and sexual differentiation acting on all tissues and organs. Testosterone production, after a role in fetal development, starts its effect during puberty, under the metabolic stimuli of gonadotropins, regulating, above all, spermatogenesis (Unger, 2014; Walia et al., 2011).

AASs are membrane-permeable and influence the nucleus of cells by direct action. Synthetically, when the exogenous hormone penetrates the membrane of the target cell, the first step is their link to an androgen receptor (AR) located in the cytoplasm of the cell. From there, the compound hormone-receptor diffuses into the nucleus, it either alters gene expression (Sanchez et al., 2012), or activates processes that send signals to other parts of the cell (Hampl et al., 2016).

Thanks to drug designers, to date, more than 100 AAS compounds have been synthesized. Analyzing their chemical structure, metabolic half-life, and physiological effects, three classes of AASs can be identified. The first class was obtained by the esterification of the 17 $\beta$ -hydroxyl group of testosterone and includes testosterone propionate and testosterone cypionate. The second class is composed of esterified AASs, connected with the long side chain moieties, with a substitution of hydrogen for the methyl group at C19. The third class of AASs comprises those compounds that are alkylated at C17, such as  $17\alpha$ methyltestosterone and stanozolol (Oberlander et al., 2012).

The most frequently abused androgens are nandrolone, testosterone, stanozolol, methandienone, and methenolone (Kicman, 2008; Sessa et al., 2018).

The anabolic androgenic effects are linked to the androgen receptor (AR)-signaling action. Androgen receptors are expressed in myosatellite cells (also named satellite cells); these are the precursors of skeletal muscle cells (Sinha-Hikim et al., 2004).


AASs exert their action by several different mechanisms: (i) they modulate androgen

-6-

receptor expression as a consequence of intracellular metabolism; (ii) they affect the androgen receptor directly and thus subsequent interactions with co-activators and transcriptional activity; (iii) they interfere with the glucocorticoid receptor expression eliciting an anticatabolic effect; and (iv) they act on the Central Nervous System (CNS) resulting in behavioral changes, following genomic and non-genomic pathways (Kicman, 2008; Parkinson and Evans, 2006).

In particular, free testosterone is transported into target tissue cell cytoplasm; binding to the androgen receptors (AR) takes place either directly or after conversion to  $5\alpha$ -dihydrotestosterone (DHT) by the cytoplasmic enzyme 5-alpha reductase. In the cell nucleus, both free and bound testosterone act on specific nucleotide sequences of the chromosomal DNA. The produced mRNA can activate DNA transcription of specific responsive genes (Handelsman et al., 2015).

AASs mimic testosterone physiological effects, and primarily act via the androgen receptor (figure 1).



**Figure 1: Mechanism of testosterone action.** Free testosterone is transported into the target tissue cell cytoplasm, where it can either bind the androgen receptor, or be reduced to  $5\alpha$ -di-hydro-testosterone (DHT) by the cytoplasmic enzyme 5-alpha reductase. The T-receptor complex undergoes a structural change that allows its translocation into the cell nucleus, where it directly binds to specific nucleotide sequences of the chromosomal DNA. The produced mRNA promotes the biosynthesis of testosterone: our own picture, previously published (Salerno et al., 2018).

#### **1.3.** Adverse Effects of Androgen Abuse

AAS use/abuse is frequently linked to widespread serious health damage: indeed, even in cases of a one-time cycle (use over a specific time-period) at very low doses can cause irreversible harmful effects after the cycle is completed. Moreover, recreational users and/or athletes use AASs in association with other drugs, such as stimulants and/or depressants. In this way, the correct attribution of adverse effects on AAS use/abuse becomes very difficult. Furthermore, when a side effect occurs in athletes or bodybuilders, it is complicated to elucidate if the adverse effects were linked to androgen use or to "athlete" status (Pope et al., 2014a, 2014b).

Nonetheless, as illustrated in figure 2, a large number of side effects related to AAS use/abuse has been described. The illicit use of AASs provokes or favors the development of serious pathological conditions, such as hypertension, atherosclerosis, hepatic damage and tumors, tendon ruptures, reduced libido, and psychiatric/behavioral disorders such as aggressiveness and irritability (Bertozzi et al., 2017; Junior et al., 2018; Mewis et al., 1996; Stannard and Bucknell, 1993; White and Noeun, 2017; Yesalis and Bahrke, 1995). The effects on mood and behavior are also well established: depressive, hypomanic or manic episodes, sometimes associated with psychotic symptoms, increased risk of suicidal or homicidal death have been observed in AAS users (Bertozzi, Salerno, Pomara, & Sessa, 2019; Kanayama, Hudson, & Pope, 2008; Piacentino et al., 2015; H.G. Pope & Katz, 1994). Some studies reported adverse renal, immunologic and musculoskeletal effects (Kanayama et al., 2010; Pope et al., 2014b). The main adverse effects linked to AAS use/abuse are summarized in figure 2.





Figure 2. Principal adverse effects of AAS use/abuse: own picture, previously published (Sessa et al., 2018)

Therefore, even if there are well-known consequences of AAS abuse because of their particular chemical structure that is similar to corticosteroids and their use at supraphysiological doses, their full pathway of action is still under study. In this context, a recently published case report discussed and provided evidence on unusual adverse effects linked to immunodeficiency in an AAS abuser. This kind of chronic complication, even if not usually considered, may lead to sudden death (Bertozzi et al., 2019b). For these reasons, further studies are needed to completely clarify the main adverse effects linked to AAS use/abuse.

### 1.4. The role of miRNA in the research project

Over the last few years, the development of MicroRNA (miRNA) technologies has become an essential part of research projects and their role as potential molecular biomarkers is being investigated by the scientific community.

MicroRNAs (miRNAs) are 20–22 nucleotide non-coding RNA molecules, which regulate gene expression at the post-transcriptional level, located in intergenic or intronic regions as individual or clustered genes (Bartel, 2004). Several steps must occur before miRNAs can act, including the action of many enzymes, such as RNA polymerase II, Drosha, Exportin 5, Dicer and Argonaute (Ago). Figure 3 shows a schematic description of miRNA biogenesis (MacFarlane and Murphy, 2010; Slezak-Prochazka et al., 2010).



**Figure 3.** Schematic description of miRNA biogenesis. In the nucleus, RNA polymerase II transcribed the long primary miRNA, which is later converted by the endonuclease Drosha intopre-miRNA. This pre-miRNA is exported into the cytoplasm and further cleaved by Dicer, developing mature miRNAs. This latter recognizes 3' untranslated regions, guided by RNA, inducing silencing complexes (RISC). The result is the silencing of target expression. This picture is our own, previously published (Sessa et al., 2018)

miRNA nomenclature was based simply on the sequence of discovery, with few notable exceptions (such as let-7 and lin-4). Subsequently, the identifiers indicating the species (hsa, human; mmu, murine; etc.) were added. Moreover, other symbols (such as "\*") or numbers (-5p or 3p) could be added, identifying better the miRNAs (for example indicating the homology, the guide miRNA strand, etc...) (Desvignes et al., 2015).

These small noncoding RNAs regulate gene expression by RNA-RNA interactions, but this is not the only mechanism to control protein production; other mechanisms are: ribosomal RNA modifications, repression of mRNA expression by RNA interference, and alternative

splicing (Catalanotto et al., 2016).

Main clinical applications of miRNA dosage and deregulation are: i) cancer characterization and prediction of the course of a disease (Segura et al., 2010; Yu et al., 2008); ii) viral infection diagnosis (Lecellier et al., 2005); iii) implications in nervous system development (Mehler and Mattick, 2007); iv) cardiovascular disorder diagnosis (Ai et al., 2010; Van Rooij et al., 2006; Wang et al., 2010a); v) identification of specific patterns in primary muscular disorders (Eisenberg et al., 2007); vi) differences among diagnosed type 1 diabetes and healthy control diabetes (Nielsen et al., 2012). These associations demonstrate that using these abnormally expressed miRNAs as biomarkers for diseases is a valuable diagnostic strategy.

The discovery of miRNAs has opened up new avenues of research in biomedicine. It is remarkable to note the fast rate of fundamental discoveries made in two decades (illustrated by the exponentially growing number of publications). These molecules indeed harbor specific features (stability, easy manipulation, reasonably simple detection, tissue specificity) that make them appealing candidates as diagnostic, prognostic, or theranostic biomarkers and even therapeutic targets (Leuenberger and Saugy, 2015).

However, some uncertainties remain that may prevent their immediate large-scale exploitation: for these reasons, collective efforts made by clinicians, academic and industrial researchers are needed to better clarify possible miRNA applications.

-12-

### 1.5 Circulating MicroRNAs: New Molecular Biomarkers in the fight against doping

Circulating miRNAs are highly stable in several body fluids, including plasma and serum. Moreover, emerging evidence demonstrates that serum miRNAs remain stable at different temperature conditions if compared to other sources of miRNAs. Hence, in view of their potential use as novel, non-invasive biomarkers, the profiles of circulating miRNAs have been explored in the field of anti-doping (Chana et al., 2013; Leuenberger and Saugy, 2015). To date, several papers have described the potential use of circulating miRNAs as specific biomarkers in the anti-doping field. For example, the use of a continuous erythropoietin receptor activator induces higher plasma levels of miR-144: the plasma dosage of this miRNA could be used for the detection of erythropoiesis-stimulating agents (Zhou et al., 2015). Another study described a relationship between the expression of 4 miRNAs and the use of recombinant human GH (Keane et al., 2015). Moreover, the study of Leuenberger et al. highlighted the importance of circulating miRNAs as biomarkers for autologous blood transfusions (Leuenberger et al., 2013b).

The use of circulating miRNAs to detect performance-enhancing agents, such as AASs, could become very important in the near future, considering that currently the gold standard method of detecting exogenous testosterone administration is gas chromatography-mass spectrometry analyses of urine samples (Leuenberger and Saugy, 2015).

Quantitative RT-PCR is the gold standard method of quantifying circulating miRNAs. This technique has high sensitivity and specificity and is suitable for quantification across a wide dynamic range (the ratio between the largest and smallest values of a changeable quantity). Two major strategies enable the specific amplification of mature miRNAs via RT-PCR. In the first strategy, a stem-loop-shaped primer binds specifically to the mature miRNA to generate a unique template for RT (Chen et al., 2005). Alternatively, in poly(A)-tailed PCR, a poly(A) tail is added to the 3' UTR of a mature miRNA by a polyadenylating enzyme, and

-13-


then universal primers containing 5' terminal oligo (dT) sequences are used to initiate the RT reaction (Kroh et al., 2010).

Although the technical variability of circulating miRNA extraction can be normalized by using a non-human spike-in control, no absolute internal controls exist due to the cell-free condition of the sample. Invariant (non-changing) miRNAs are sometimes selected as endogenous controls; however, the biological significance of specific miRNAs can be underestimated using this approach (Kroh et al., 2010).

In the near future, new molecular biomarkers it could be incorporated into the adaptive model of the Athlete Biological Passport (ABP), considering their high stability in blood and unmodified characteristics when exposed to environmental factors (Ponzetto et al., 2016). Furthermore, the possibility to detect miRNAs not only in serum and plasma but also in urine, saliva and other body fluids (Gilad et al., 2008), makes these new molecular biomarkers the new frontier in the fight against doping.

# **Chapter 2. AIMS AND PLANNING OF RESEARCH**

The goal of this work was to analyze several important aspects linked to the use of anabolic androgenic steroids, defining the following: - organ damage; - new molecular biomarkers; - epidemiology; - pathology; - toxicology. The research hypothesis at the base of the present project is summarized in figure 4.



**Figure 4:** The research hypothesis of the project is that AAS abuse has side effects on the health of the user; after a middle term use/abuse, organ damage could occur, with a dysregulation of miRNA expression. These miRNAs could become new molecular biomarkers of AAS use/abuse. This picture is my own, previously published (Sessa et al., 2018)

In particular, during the first year of this project, the evaluation of adverse effects generated by AAS use/abuse was performed. To achieve these goals, a literature review, histological and toxicological examinations on selected cases (5 young people who had died with toxicological positive tests) were performed. This step was very important in order to better define the adverse effects linked with AAS use/abuse.

In the light of these findings, the second year activities of the project were performed. Firstly, a systematic literature review and meta-analysis on miRNA expression dysregulated in organ

damage related to AAS use/abuse was performed. This activity allowed us to select the "candidate miRNAs" as new molecular biomarkers linked to each adverse effect of AAS use/abuse. Finally, a miRNA quantification in heart and musculoskeletal tissues was performed in two groups, "AAS group" (composed of 5 cases, positive for toxicological analysis for AAS abuse), and "Heart Failure (HF) group" (composed of 6 cases who had died of heart failure, with negative toxicological analysis).

Finally, the third year activities of this PhD project were performed both at the University of Foggia and the University of Malta:

• Detection of new molecular biomarkers ("miRNA signatures") in other tissues sampled from the "AAS group": kidney, liver, and brain. For each tissue, subjects who had died of pathologies concerning the main organs tested as listed below were enrolled. The data about miRNA expression in kidney tissue were compared between the "AAS

group" and CKD group.

The data obtained in the liver tissue of the "AAS group" were compared with the data collected in the "NAFLD" group.

Finally, the CNS was extensively studied. Indeed, on brain tissue, miRNA expression was evaluated in four selected groups of cadavers: "AAS group", Drug group (DG), ischemic stroke-related deaths (SG group), aging damage in older people who died from other causes (AG group).

• Realization of the first map of the phenomenon through anonymous questionnaires to evaluate the voluptuary practices linked to AAS use, in the South of Italy. To achieve this goal, two questionnaires were administered:

 Survey 1: composed of the Multidimensional Body-Self Relations Questionnaire (MBSRQ); - *Survey 2*: composed of 48 questions in order to determine the voluptuary habits of the interviewees about their use of "Smart Drugs", "Energy drinks" and "AASs", their mental status and the interactions with doctors regarding performance-enhancing drugs.

## **Chapter 3. MATERIALS AND METHODS**

### **3.1. Literature Review**

During the project, two complete literature reviews were performed at different times: firstly, at the beginning of the research project, and secondly, before the second year activities.

The first review was conducted using PubMed, Scopus, Web of Science, and Google Scholar databases. On these database websites, I searched for articles from 1 January 1980 to March 2019 using the following key terms: "Anabolic Androgenic Steroid", "death", "toxicity", and "side/adverse effects". The main keyword "Anabolic Androgenic Steroid" was individually searched for in association with each of the others. Articles were excluded by title, abstract, or full text for irrelevance to the investigated issues. Lastly, to identify further studies that met the inclusion criteria, the references of the selected articles were also reviewed.

For the second review, some databases, from 1990 to June 2017, were searched: Medline, Cochrane Central, Scopus, Web of Science, Science Direct, EMBASE and Google Scholar, using the following keywords: "miRNA", "Anabolic Androgenic Steroid", "side/adverse effects", organs and systems ("Cardiovascular system", "reproductive system", "central nervous system", "liver", "kidney", and "skin"). The main keywords, "Anabolic Androgenic Steroid", organs and systems (Cardiovascular system, reproductive system, central nervous system, liver, kidney, and skin), and "miRNA" were individually searched for in association with each of the others.

### **3.2.** Case selection

All samples were selected analyzing the documentation of all autopsies performed by the Institute of Legal Medicine of Foggia from 2001 to July 2018 (about 1700 autopsies). All procedures were performed in accordance with international guidelines and were approved by the Scientific Committee of the University of Foggia.

#### 3.2.1 AAS group

Five cases of young men (29 - 40 years), with toxicological positive test for anabolic agents, were selected (age mean  $32.4 \pm 4.39$  years; mean body mass index (BMI)  $26.9 \pm 1.26$ ). For cases 1, 2 and 3 (table 2) all the information was obtained analyzing the medico-legal documentation produced for juridical purposes and/or through the analysis of the case report listed in the references. On the Formalin-Fixed Paraffin-Embedded (FFPE) tissues, collected during the autopsies, miRNA quantifications were performed. On the other hand, all investigation concerning cases 4 and 5 were performed during activities, considering that each case occurred between 2016 and 2019.

**Case 1** - The case of a 29-year-old bodybuilder who suddenly collapsed after dinner in his apartment (weight 72 kg, height 166 cm; BMI= 26.1) was selected. He had a weightlifting workout at the gymnasium a few hours before. Cardiopulmonary resuscitation, initiated by an emergency physician, was unsuccessful. According to his friends, he had been taking anabolic steroids (testosterone, nandrolone, and stanozolol) parenterally for several years, mainly to improve his appearance. Several glass vials were found in his room and were labeled Winstrol (stanozolol), Deca (nandrolone), Testoviron Depot, and Andriol (testosterone) (Fineschi et al., 2007).

**Case 2** - The case of 30-year-old male, first an amateur, and later a competitive bodybuilder, who worked out regularly at the gymnasium, suddenly collapsed at home and was found dead (weight 90 kg, height 178 cm; BMI=28.4). He had a weightlifting workout at the gymnasium a few hours before. In an ashtray near the body, a 2-ml vial of nandrolone decanoate was found along with a used 2.5-ml syringe. The apartment contained other drugs too, most of which fell into the AAS and supplements categories. All witnesses confirmed that the subject had started using AASs approximately 6 months prior to his death. Baseline blood tests, performed a few days before death, were unremarkable except for a slight increase in hepatic enzymes (Fineschi et al., 2007).

**Case 3** – The case of 32-year-old bodybuilder was selected (weight 90 kg, height 189 cm; BMI= 25.19). He suddenly lost consciousness during a weight lifting workout at the gymnasium and died. Two weeks earlier, he had experienced an episode of chest pain for a few minutes, with pain radiating to his left arm. According to relatives and friends, the patient did not consult a doctor and continued training, believing that his physical activity had caused the pain. For several months, he had been taking testosterone propionate (700 mg/ wk) and nandrolone (200 mg/wk) parenterally, and he had been taking stanozolol per os (70 mg/wk). His medical history was unremarkable. (Fineschi et al., 2001).

**Case 4** – the case of a 40-year-old man was selected: the corpse was found by his wife in his covered garage (weight 83 kg, height 175 cm, and BMI=27.1). His t-shirt was completely sweaty. At the external examination, three acupuncture signs were found on the super-external quadrant of the left gluteal. No other significant signs were reported. Nearby, a

blood-stained 10-ml syringe was found, even if the cap was on. Finally, a small glass vial labeled as Trenbolone Acetate was found.

**Case 5** – The case of a 31-year-old male, competitive bodybuilder, was selected (weight 80 kg, height 170 cm; BMI=27.7). He went to hospital for a trauma on his leg. At blood tests, liver damage was described, but he went home against medical advice. After two days, his health conditions got worse and he returned to the hospital. In only a few hours he went into a coma due to crush syndrome, a medical condition characterized by major shock and renal failure after a crushing injury to skeletal muscle. Crush injury is compression of extremities or other parts of the body that causes muscle swelling and/or neurological disturbances in the affected areas of the body, while crush syndrome is localized crush injury with systemic manifestations. After 10 days he died. All witnesses confirmed that the subject had started using AASs approximately 18 months prior to his death (Bertozzi et al., 2019b).

GROUP	AGE	CAUSE OF DEATH	MACROSCOPIC FINDINGS	MICROSCOPIC HEART FINDINGS
AAS				
1	29	Heart failure secondary to AAS assumption	The heart had a normal shape and weighed 380 g	Segmentation of the myocardial cells, widening of intercalated discs, and foci of contracted myocardium alternated with bundles, distended myocardium with granular disruption of the myocytes.
2	30	Heart failure secondary to AAS assumption	The heart had a normal shape and weighed 400 g	Histopathologic examination of the heart revealed focal myocardial fibrosis.
3	32	Heart failure secondary to AAS assumption	The heart had a normal shape and weighed 450 g	Histologically, the grayish area corresponded to typical infarct necrosis with a histologic age of approximately 15 days. The lesion was characterized by hyperdistended myocardial cells with sarcomeres in registered order, circumscribed at its periphery by young collagen tissue containing numerous macrophages.
4	40	Heart failure secondary to AAS assumption	The heart had a normal shape and weighed 380 gr.	Histopathologic examination of the heart revealed widespread fibrotic areas in myocardial tissue.
5	31	Septic shock subsequent to necrotizing myofasciitis	The heart had a normal shape and weighed 350 g.	Histopathologic examination revealed at the myocardium level limited areas of fibrosis. Finally, in some fields there were aspects of dissolving myofibers (colliquative necrosis).

The main characteristics of the AAS group are summarized in table 2.

**Table 2.** The main characteristics of the AAS group (subjects died with toxicological positive tests for anabolic androgenic steroids). These samples were tested for all miRNA experimentation. Each case was tested for all selected miRNAs, changing the tissue (Heart, Liver, Kidney, Brain, Musculoskeletal).

### 3.2.2 Heart failure (HF) group

Six cases of men who died of heart failure with negative toxicological analysis were enrolled

as the "HF (heart failure)" group (mean age  $54.33 \pm 9.97$  years; BMI mean  $26.9 \pm 1.4$ ). The main information for each case is summarized in table 3.

GROUP	AGE	CAUSE OF DEATH	MACROSCOPIC FINDINGS	MICROSCOPIC FINDINGS
			CARDIAC TISSUE	
HF				
1	72	Sudden cardiac death (SCD) in a patient with coronary heart disease (CHD)	Abnormal heart form (such as "ball" kind) with increased dimension (542 gr). The epicardium appeared strongly at the left ventricular wall, carton consistency.	Extensive areas of colliquative myocytolysis (grade I); extended areas of necrosis; arteriolosclerosis.
2	58	Acute heart failure (AHF)	Increased heart dimensions (510 gr) of a red-brownish color, with abundant subepicardial fat. The cardiac cavities contained abundant dark-red fluid blood. Aortic arch affected by atheromatous alterations.	Significant areas of necrosis on the left ventricle; areas of connective tissue damage, important presence of leukocytes.
3	54	SCD caused by Myocardial Ischemia	Regular heart in form and dimensions (weight 557gr).	Contraction band necrosis, coronary sclerosis, colliquative myocytolysis. Presence of recent thrombus in posterior descending artery (PDA).
4	51	SCD due to cardiac degeneration	Normal heart in dimension and form (480 gr).	Contraction band necrosis, fibrosis, stasis, and colliquative myocytolysis.
5	47	Cardiac failure with histopathological aspects of severe heart failure	Regular size of the heart (measuring 12x11.5x7 cm, weight 440 gr). Normal vascular structures.	Classical signs of chronic pericarditis; contraction-band necrotic areas, perivascular and interstitial fibrosis, stasis, grade III colliquative myocytolysis, arteriolosclerosis.
6	44	Acute myocardial necrosis with electromechanical dissociation with several ischemic areas	Regular heart (640 gr), with moderate subepicardial adipose tissue.	Contraction band necrosis,, acute stasis, coronary sclerosis.

**Table 3.** The main characteristics of the HF group (subjects died of heart failure with negative toxicological analysis). These samples were tested for cardiac and musculoskeletal tissues.

### 3.2.3 Brain injury: Stroke group (SG), Drug group (DG), and Aging group (AG)

To perform the analysis on the brain tissue, 3 groups were tested: 5 cases of men who died of brain stroke were selected (mean age  $57.8 \pm 6.7$  years), making up the SG group; 5 cases of men who died with a toxicological test positive for drug abuse (cocaine) were selected (mean age  $29.2 \pm 5.6$  years), forming the DG group; 5 cases of older men who died of Sudden Cardiac arrest (mean age  $75.8 \pm 6.9$  years), generating the AG group (Table 4).

GROUP	AGE	CAUSE OF DEATH	MACROSCOPIC FINDINGS	MICROSCOPIC FINDINGS
			BRAIN TISSUE	
SG				
1	80	ischemic stroke	brain edema; reddish punctiform areas of the white matter.	perineuronal and perivasal edema, red neurons, malacic areas.
2	79	ischemic stroke from a vertebrobasilar embolism	brain edema; reddish punctiform areas of the white matter.	perineuronal edema, red neurons.
3	34	ischemic stroke in a subject with atheromatous formation at the Willis polygon	atherosclerotic alterations in the Willis polygon.	vasogenic edema, red neurons.
4	24	ischemic stroke from a systemic massive bleeding	post-hypoxic malacic areas of the white matter.	perivasal edema, red neurons, hemorrhages of Duret.
5	72	ischemic stroke	brain edema; reddish punctiform areas of the white matter.	vasogenic edema, ischemic areas, "red neurons".
DG				
1	29	sudden cardiac death secondary to cocaine intake	brain edema.	cortical edema.
2	32	fatal ventricular arrhythmia secondary to cocaine intake	brain edema.	vasogenic edema.
3	30	sudden cardiac death secondary to cocaine intake	brain edema.	perineuronal and perivasal edema.
4	20	fatal cardiac arrhythmia secondary to cocaine intake	brain edema.	cortical edema, arteriolosclerosis.
5	35	fatal ventricular arrhythmia secondary to cocaine intake	brain edema, stasis.	perineuronal edema, small perivascula hemorrhages
AG				
1	80	fatal cardiac arrhythmia	brain edema.	vasogenic edema, arteriolosclerosis.
2	83	ventricular arrhythmia	brain edema.	perineuronal and perivasal edema.
3	77	cardiac failure	brain edema.	vasogenic edema, small periventricular hemorrhages.
4	65	sudden cardiac death	brain edema.	cortical edema.
5	74	fatal cardiac arrhythmia	brain edema.	perineuronal and perivasal edema, small perivascular hemorrhages.

**Table 4.** The main characteristics of three groups tested for brain tissues: SG, stroke group; DG, drug group; AG, aged group.

### 3.2.4 Non-alcoholic fatty liver disease (NAFLD) group

Furthermore, to perform the liver tissue analysis, 5 cases of men who died of cardiac arrest (mean age  $47.4 \pm 4.03$  years). During their life, all subjects had suffered from cirrhosis caused by NAFLD. The main characteristics are summarized in table 5.

GROUP	AGE	CAUSE OF DEATH	MACROSCOPIC FINDINGS	MICROSCOPIC FINDINGS
			LIVER TISSUE	
NAFLD				
1	43	Heart failure in a subject suffering from cirrhosis caused by NAFLD	The presence of micronodular cirrhosis in the liver with fatty change was detected by small, yellow nodules.	Presence of regenerative nodules of hepatocytes surrounded by connective tissue that bridges between portal tracts. Within this collagenous tissue lymphocytes were detected as well as a proliferation of bile ducts.
2	53	Heart failure in a subject suffering from cirrhosis caused by NAFLD	The presence of micronodular cirrhosis in the liver with fatty change was detected by small, yellow nodules.	Presence of regenerative nodules of hepatocytes surrounded by connective tissue that bridges between portal tracts.
3	49	Heart failure in a subject suffering from cirrhosis caused by NAFLD	The presence of micronodular cirrhosis in the liver with fatty change was detected by small, yellow nodules.	Presence of regenerative nodules of hepatocytes surrounded by fibrous connective tissue that bridges between portal tracts was reported. Within this collagenous tissue lymphocytes were detected as well as a proliferation of bile ducts.
4	44	Heart failure in a subject suffering from cirrhosis caused by NAFLD	The presence of micronodular cirrhosis in the liver with fatty change was detected by small, yellow nodules.	Presence of regenerative nodules of hepatocytes surrounded by connective tissue that bridges between portal tracts.
5	48	Heart failure in a subject suffering from cirrhosis caused by NAFLD	The presence of micronodular cirrhosis in the liver with fatty change was detected by small, yellow nodules.	Presence of regenerative nodules of hepatocytes surrounded by fibrous connective tissue that bridges between portal tracts.

 Table 5. The main characteristics of the NAFLD group.

### 3.2.5 Chronic kidney disease (CKD) group

To analyze the kidney tissue, 5 cases of men who died of cardiac arrest after a long period of time (from 2 to 5 years) of Chronic kidney disease (CKD) were selected (mean age  $66.2 \pm 5.4$  years). The main characteristics are summarized in table 6.

GROUP	AGE	CAUSE OF DEATH	MACROSCOPIC FINDINGS	MICROSCOPIC FINDINGS
			KIDNEY TISSUE	
CKD				
1	67	Heart failure in a subject suffering from Chronic kidney disease (CKD)	Abnormal kidney dimensions (reduced).	Diffuse hypocellular interstitial fibrosis of the cortex as well as of the medullae with tubular atrophy and global glomerular obsolescence. Moderate amounts of interstitial lymphocytes in the less fibrotic areas mainly located in the medullary rays and at the cortico-medullary junction.
2	69	Heart failure in a subject suffering of Chronic kidney disease (CKD)	Abnormal kidney dimensions (reduced).	Diffuse hypocellular interstitial fibrosis of the cortex as well as of the medullae with tubular atrophy and global glomerular obsolescence. Moderate amounts of interstitial lymphocytes in the less fibrotic areas mainly located in the medullary rays and at the cortico-medullary junction.
3	59	Heart failure in a subject suffering of Chronic kidney disease (CKD)	Abnormal kidney dimensions (reduced).	Perihilar focal segmental sclerotic lesion affecting enlarged glomeruli. Area of scarring with interstitial fibrosis, tubular atrophy, glomerulosclerosis.
4	73	Heart failure in a subject suffering of Chronic kidney disease (CKD)	Abnormal kidney dimensions (reduced).	Area of scarring and interstitial fibrosis, tubular atrophy.
5	63	Heart failure in a subject suffering of Chronic kidney disease (CKD)	Abnormal kidney dimensions (reduced).	Mild to moderate interstitial fibrosis and enlarged glomerulus.

Table 6. The main characteristics of the CKD group.

### 3.2.6 Control groups

Four cases of healthy men (age mean  $28 \pm 7.4$ ), died from a car accident with negative anamnesis for heart suffering. The toxicological examination was negative for all subjects. This group was selected as reference samples in the Real-Time PCR reactions for the miRNA tested in cardiac and musculoskeletal tissues (Table 7).

GROUP	AGE	CAUSE OF DEATH	MACROSCOPIC FINDINGS	MICROSCOPIC FINDINGS
CONTROL				
1	29	Hypovolemic shock in polytrauma	Regular heart in form and dimensions	No pathological signs on the heart tissues
2	38	Hypovolemic shock in polytrauma	Regular heart in form and dimensions	No pathological signs on the heart tissues
3	24	Hypovolemic shock in polytrauma	Regular heart in form and dimensions	No pathological signs on the heart tissues
4	21	Hypovolemic shock in polytrauma	Regular heart in form and dimensions	No pathological signs on the heart tissues

**Table 7.** The main characteristics of the CONTROL group (subjects died from a car accident with negative anamnesis for heart suffering), utilized for miRNA quantification in the heart and musculoskeletal tissues.

Finally, 2 cases of healthy men (mean age  $41.5 \pm 2.12$  years), who died in car accidents, for causes other than brain trauma, NAFLD, CKD and negative for toxicological examination were selected as controls in the Real-Time PCR reactions. The main data are reported in table 8.

GROUP	AGE	CAUSE OF DEATH	MACROSCOPIC FINDINGS	MICROSCOPIC FINDINGS
			BRAIN, LIVER, AND KIDNEYS TISSUES	
CONTROL				
1	40	Hypovolemic shock in polytrauma	Regular brain, liver and kidneys both in form and dimensions	No microscopic alteration on brain, liver and kidneys
2	43	Hypovolemic shock in polytrauma	Regular brain, liver and kidneys both in form and dimensions	No microscopic alteration on brain, liver and kidneys

**Table 8.** The main characteristics of the CONTROL group (subjects died in car accidents with negative anamnesis for brain, liver, and kidney diseases), used for miRNA quantification in the brain, liver, and kidney tissues.

#### 3.3. Histological examination

The histological examination was performed for all cases. Histology is of value in confirming, evaluating and sometimes revising the course of natural disease processes that may have contributed to the cause of death. The sections were obtained from different tissues (Heart, Muscoloskeleton -Vastus lateralis-, Brain, Liver, Kidney) as indicated above. All slides were stained with hematoxylin and eosin, mounted with coverslips and finally observed with a Leica DM5000 upright microscope (Leica Microsystems).

### 3.4. Toxicological examination

All chemicals were analytical grade and were supplied by Analyticals Carlo Erba, Milan, Italy. AAS standards were supplied by Sigma and SALARS, Como, Italy. The solvents were purchased from Fluka Chemie. The extraction was performed according to Varian's procedure for C18 Bond-Elut used in AAS separation from the biological sample.

From each sample, 1  $\mu$ l was injected into a gas chromatography/mass spectrometry (GC/MS) Hewlett Packard 6890/5973 system. The method was previously described (Pomara et al., 2016).

### 3.5. miRNA quantification through quantitative real-time PCR (qRT-PCR)

Total RNA, including miRNAs, was isolated from formaldehyde-fixed paraffin-embedded (FFPE) samples (four 20 $\mu$ m sections) using the Recover All Total Nucleic Acid Isolation Kit (Life Technologies) with minor modifications. Briefly, before RNA extraction, all samples were deparaffinated and processed as indicated in the protocol. Finally, the purified RNA was eluted with 65  $\mu$ L RNAse-free-water. Quantification was performed in kidney, liver and central nervous system tissues.

The quantification of RNA was performed with the Qubit RNA HS Assay Kit (Life Technologies), using the Qubit Fluorometer; it provides an accurate and selective method for the quantitation of low-abundance RNA samples.

For miRNA profiling, the TaqMan Advanced miRNA Assay (Applied Biosystems Darmstadt, Germany) was used. This kit is composed of a pre-formulated primer and probe sets that are designed for the analysis of miRNA expression levels. The assays were selected at thermofisher.com/advancedmirna.

Tissue	Assay Name	Mature miRNA Sequence:	Chromosome Location
	hsa-miR-1-3p	UGGAAUGUAAAGAAGUAUGUAU	Chr.18: 21829015 - 21829036
Heart and	hsa-miR-133a-3p	UUUGGUCCCCUUCAACCAGCUG	Chr.18: 21825712 - 21825733
Muscle	hsa-miR-208a-3p	AUAAGACGAGCAAAAAGCUUGU	Chr.14: 23388602 – 23388623
	hsa-miR-499a-3p	AACAUCACAGCAAGUCUGUGCU	Chr.20: 34990445 - 34990466
K: Las	hsa-miR-21-5p	UAGCUUAUCAGACUGAUGUUGA	Chr.17: 59841266 - 59841337
Kidney	hsa-miR-205-5p	UCCUUCAUUCCACCGGAGUCUG	Chr.1: 209432133 - 20943224
	hsa-miR-21-5p	UAGCUUAUCAGACUGAUGUUGA	Chr.17: 59841266 - 59841337
Liver	hsa-miR-122-5p	UGGAGUGUGACAAUGGUGUUUG	Chr.18: 58451074 - 58451158
Liver	hsa-miR-132-3p	UAACAGUCUACAGCCAUGGUCG	Chr.17: 2049908 - 2050008
	hsa-miR-155-3p	CUCCUACAUAUUAGCAUUAACA	Chr.21: 25573980 - 25574044
	hsa-miR-132-3p	UAACAGUCUACAGCCAUGGUCG	Chr. 17 - 2049908 - 2050008
	hsa-miR-200b-3p	UAAUACUGCCUGGUAAUGAUGA	Chr.1: 1167104 - 1167198
Brain	hsa-miR-21-5p	UAGCUUAUCAGACUGAUGUUGA	Chr.17: 59841266 - 59841332
	hsa-miR-34a-5p	UGGCAGUGUCUUAGCUGGUUGU	Chr.1: 9151668 - 9151777
	hsa-miR-124-5p	CGUGUUCACAGCGGACCUUGAU	Chr.8: 9903388 - 9903472
		Endogenous control genes	
(for all tissues)	hsa-miR-186-5p	CAAAGAAUUCUCCUUUUGGGCU	Chr.1: 71067631 - 71067716
(only for heart and muscle)	hsa-miR-361-5p	UUAUCAGAAUCUCCAGGGGUAC	Chr.X: 85903681 - 85903702

The miRNAs tested on the selected samples are summarized in table 9:

Table 9. Tested miRNAs with relative tissues.

cDNA was obtained following TaqMan Advanced miRNA Assays User Guide (Applied Biosystems, Publication number 100027897 Rev. C). Quantitative real-time PCR (qRT-PCR) was performed using the StepOnePlus Real-Time PCR System (Applied Biosystems Darmstadt, Germany), and raw data were analyzed using the relative software (version 2.3). As described in the user's guide for Fast reaction plate, the qRT-PCR reactions (in triplicates) were performed with an incubation at 95 °C for 20 s, followed by 40 cycles of 95 °C for 1 s and 60 °C for 20 s. A negative control without cDNA was also included in parallel.

The data obtained were compared with the data from endogenous controls; as described in the user guide, they showed that gene expression was relatively constant across tissues. Normalization to endogenous control genes is currently the most accurate method to correct for potential biases that are caused by sample collection, variation in the amount of starting material, RT efficiency, and RNA preparation and quality. For this experiment "has-miR-186-5p" (TaqMan Advanced miRNA Assays, ThermoScientific) was used as an endogenous control for all tests, while "hsa-miR-361-5p" (TaqMan Advanced miRNA Assays, ThermoScientific) was used for heart and muscle tissues (table 9).

Expression fold changes were computed using the  $2^{-\Delta\Delta Ct}$  calculation (Livak and Schmittgen, 2001), where  $\Delta Ct = Ct$  (test miRNA) – Ct (mir-186-5p/mir-361-5p) and  $\Delta\Delta Ct = \Delta Ct$  (individual sample) -  $\Delta Ct$  (control median samples).

#### 3.6. MiRNAs database and target prediction tools

The analysis of each miRNA was performed through a literature review, and several informatics tools: miRBase (available to http://www.mirbase.org/), TargetScanVert (available to http://www.targetscan.org/) and miRDB (available to http://mirdb.org/).

#### 3.7. Questionnaires

Two surveys using online data collection tools were performed (google forms online survey, available at www.google.com):

- Survey 1, entitled "Multidimensional Body-Self Relations Questionnaire (MBSRQ)" (Cash, 2000a);
- Survey 2: was composed of 48 questions to know voluptuary habits.

Both questionnaires were filled in by a group of university students. Both surveys were performed between October 2018 and March 2019.

Guidelines from our local research and development department determined that the project

was an audit project and formal ethical approval was therefore not required. No personally identifiable data were collected or stored by the investigators.

### 3.7.1. Multidimensional Body-Self Relations Questionnaire (MBSRQ)

The MBSRQ was used to assess attitudes towards body image, physical activity, and health. These attitudes were evaluated in nine different scales, and then a tenth scale was added to the revised scoring system (Brown et al., 1990; Cash, 2000b, 2017).

To assess attitudes towards physical appearance, two main scales were used: "the appearance evaluation" scale that evaluates how attractive or unattractive and how happy or unhappy the person feels with his physical appearance and "the appearance orientation" scale to assess the time and effort spent by the person to "look good" (Brown et al., 1990; Cash, 2000b, 2017).

As for physical activity, the following scales were used: "the fitness evaluation" scale is how the person rates himself/herself as fit or not and how he/she feels involved in physical activities and the "fitness orientation" scale to assess the time and effort spent to improve his/her physical fitness (Brown et al., 1990; Cash, 2000b, 2017).

For attitudes towards health, the "health evaluation" scale was used to identify whether the person felt healthy or susceptible to disease, "the health orientation" scale was used to identify whether a person was health alert or neglected his/her health and "illness orientation scale" was used to assess how cautious she/he was to physical health and how he/she reacted to medical signs and symptoms (Brown et al., 1990; Cash, 2000b, 2017).

Finally to assess attitudes towards body weight, the "overweight preoccupation" scale tested fat anxiety, attention paid to body weight, dieting and controlled eating behaviors, the "self-classified weight" scale was used to assess how the person perceived his/her weight and the "body area satisfaction scale" was how satisfied or dissatisfied he/she was with specific parts of his/her body (Brown et al., 1990; Cash, 2000b, 2017).

This questionnaire was made up of 69 items. Each of the MBSRQ scales had its corresponding items. These items could be answered by a primary number ranging from 1 to 5; a low score of "1" indicated that the participant highly disagreed with the given statement, whereas a high score of 5 indicated that the participant highly agreed with it (Brown et al., 1990; Cash, 2000b, 2017). There were two scoring systems for the MBSRQ, a conceptual scoring system and a revised version (Brown et al., 1990; Cash, 2000b, 2017). The main differences between the two scoring systems fall into the following three scales: fitness evaluation, fitness orientation and health orientation (which was divided into two scales

health orientation and illness orientation in the revised scoring system). However, the conceptual scoring and the revised scoring were similar for the six remaining MBSRQ subscales (Brown et al., 1990; Cash, 2000b, 2017). In this study, the conceptual scoring system was used to score the MBSRQ.

#### 3.7.2 Survey 2: voluptuary habits

Survey 2 was composed of 48 questions in order to know the voluptuary habits of the interviewees about the use of "Smart Drugs and Energy drinks", "Supplements" and "anabolic-androgenic steroids (AAS)".

Each part of Survey 2 was further subdivided into three parts. The first part concerned the knowledge of specific substances and their use. For the "Smart Drugs and Energy drinks" use/abuse about these substances were questioned: Cannabinoids, Synthetic cations (similar to amphetamines), Sexual performance-enhancing drugs, Coffee, Tea, Classic cola, WhoopAss, VitaminWaterEnergy Citrus, Bomba Energy, HiBall Energy, Red Bull, Powershot, Full Throttle, Monster, RockStar, V, Ammo, Fuel Cell, Blow Energy Brink Mix, NOS, Jolt Cola, Cocaine Energy Drink, Spike Shooter, Viso Energy Vigor, RedLine Power rush, Bookoo Energy, Fixx, and Wired X505.

For the "Supplements" use/abuse these substances were questioned: Soy protein, Oxygen, Creatine monohydrate, Carnosine, Organic Iron, APL, Magnesium Liquid, Thermo Fit 2, Arginine, GTS (Glucose Transport System), Mega Ram Plus, Vitamin C, Maltodex, Organic Magnesium, Carbo Burner, B Complex, Lipo Burner, Amino Drink, BCAA. For each question, the answers could be chosen between 4 with a relative score-value: - Never / Unknown (0 points); - Sometimes (1 points); - In training (2 points); - Near to the competition (3 points); Always (4 points).

For "AAS" use, an open answer was used to respond to this question:

- Which kind of AASs have you used?

In the case of a positive answer, other questions were given in order to ascertain the frequency, the cycles, the training, and other useful information.

The second part of the questionnaire allowed us to understand mental status during use. The questions are listed below:

- Does your mental state improve using ("Smart Drugs"/"Energy Drink", "Supplements", "AASs")? For example, in cognitive functioning, are you happier, more attentive, more concentrated and generally better? (Score: - 0, No; -1, no worse, no better; - 2, better).

- How would you classify your mental status during the use of ("Smart Drugs"/"Energy

Drink", "Supplements", "AASs")? (scale score from 0 to 10: 0, not worrying; 10, worrying). The last part of the questionnaire concerned physical perception during the use of the substances. The questions are listed below:

- Does your physical condition improve using ("Smart Drugs"/"Energy Drink", "Supplements", "AASs")? For example, you feel stronger, leaner, faster, fitter, healthier. (Score:- 0, No; -1, no worse, no better; - 2, better).

- How would you classify your physical condition during the use of ("Smart Drugs"/"Energy Drink", "Supplements", "AASs")? (scale score from 0 to 10: 0 "not healthy", 10 "very healthy").

## **3.8.** Statistical analysis

Unless specified otherwise, data are expressed as means  $\pm$  SEM versus baseline. The results were analyzed through student's t-test (paired comparison) or one-way ANOVA using Tukey's test as the post-hoc test (multiple comparisons) (P<0.05). Statistics were performed through the software Statistica for Windows (Statsoft, Tulsa, and Okhla.). Descriptive statistical analysis was performed using Microsoft Office Excel 2007.

# 4.1. Literature review

During the three years of activity, two important literature reviews were performed. The first literature review ascertained the main adverse effects of AAS use/abuse. Even if this topic has been extensively investigated by the scientific community, to date, it is very important to better define the mechanisms of action that underline the adverse effects.

The main adverse effect with relative differences are reported in table 10.

Targets	Adverse Effects
Cardiovascular system	<ul> <li>myocardial infarction due to premature atherosclerosis (Montisci et al., 2012);</li> <li>left ventricular hypertrophy (Büttner and Thieme, 2010);</li> <li>impaired left ventricular function (D'Andrea et al., 2007; Thiblin et al., 2009);</li> <li>arterial thrombosis (Parkinson and Evans, 2006)</li> <li>pulmonary embolism (Payne et al., 2004)</li> <li>fibrosis (Sader et al., 2001);</li> <li>SCD (Fineschi et al., 2007; Montisci et al., 2012);</li> <li>myocardial infarction without significant atherosclerotic coronary artery (Ferenchick and Adelman, 1992; Kierzkowska et al., 2005)</li> </ul>
Genitourinary, reproductive complications, and sexual secondary factors	<ul> <li>Female:</li> <li>Hirsutism and Lowered voice tone (Damrose, 2009)</li> <li>disruption of the ovarian function (Christou and Tigas, 2018);</li> <li>delayed menarche, clitoromegaly, dysmenorrhoea, oligomenorrhoea, secondary amenorrhoea, anovulation and, as their consequence, infertility, (Nieschlag and Vorona, 2015);</li> <li>breast reduction ((Demers et al., 1991))</li> <li>the female athlete triad (low energy intake, menstrual disorders and low bone mass) (Nieschlag and Vorona, 2015)</li> <li>male-pattern baldness in women (Glaser and Dimitrakakis, 2013)</li> <li>Male:</li> <li>suppression of spermatogenesis (Christou et al., 2017);</li> <li>testicular atrophy (El Osta et al., 2016);</li> <li>infertility and erectile dysfunction (Rahnema et al., 2014);</li> <li>gynaecomastia (Sansone et al., 2017)</li> <li>acceleration of baldness in men (Pan and Kovac, 2016)</li> </ul>
Bone and muscles	- premature closure of the epiphysis in children(Hoffman and Ratamess, 2006)
Central nervous system	- aggressive behavior, anxiety, extreme mood swings from depression to mania or hypomania (Bertozzi et al., 2019a);

	<ul> <li>increased aggression and hostility (van Amsterdam et al., 2010);</li> <li>destructive impulses and/or self-destructive impulses (Harmer, 2010);</li> </ul>
Liver	<ul> <li>hepatic cholestasis (bile canal obstruction) causing jaundice (Elsharkawy et al., 2012; Ibrahim et al., 2018);</li> <li>peliosis hepatitis (blood-filled sacs in the liver)(Bond et al., 2016; Solimini et al., 2017);</li> <li>liver tumors (increased risk)(Niedfeldt, 2018)</li> </ul>
Skin	- cystic acne (Goldman and Basaria, 2018)
Immune system	<ul> <li>immunosuppressive effects (Bertozzi et al., 2019b; Demling and DeSanti, 2003);</li> <li>reducing immune cell number and function (Marshall- Gradisnik et al., 2009)</li> </ul>

Table 10. Adverse effects generated by the use/abuse of anabolic androgenic steroids.

Moreover, to achieve the goals of the present research project, another literature review was performed with the aim of analyzing the literature production about all side effects related to AAS abuse, searching for the candidate miRNAs investigated in previous studies for their possible use as molecular biomarkers. Notably, the research hypothesis underlying this research project is that the same miRNAs investigated for similar damage generated by AAS use could be useful for developing new anti-doping tools. All miRNAs linked to specific damage are summarized in table 11.

This review was published during the activities of this project in 2018:

SESSA, F., SALERNO, M., DI MIZIO, G., BERTOZZI, G., MESSINA, G., TOMAIUOLO, B., PISANELLI, D., MAGLIETTA, F., RICCI, P. AND POMARA C. Anabolic androgenic steroids: searching new molecular biomarkers. (2018) Front. Pharmacol. 9:1321. doi: 10.3389/fphar.2018.01321

Cardiovascular	Differentially Ex	xpressed miRNAs	Deferrer
System and Heart	Upregulated	Downregulated	Reference
ischemia		miR-1 miR-133	(Song et al., 2015)
hypertrophy	miR-208a; miR-150; miR-23a; miR-24; miR-21; miR-195; miR-199	miR-1; miR-26b; miR-27a; miR-143; miR-29; miR-133	(Hata, 2013; Joladarashi et al., 2014; Wong et al., 2016)
cardiac fibrosis	miR-21; miR-133	miR-29	(Joladarashi et al., 2014)
arrhythmia	miR-1; miR-133; miR-133a; miR-212;miR-17- miR- 92;miR-106bb-; miR-25	miR-150	(Joladarashi et al., 2014)
Musculoskeletan	Differentially Ex	xpressed miRNAs	Defenence
Musculoskeletan	Upregulated	Downregulated	Reference
after 7 days of mechanical overload		miR-1; miR-133	(Kirby et al., 2015)
slow twitch fibers	miR-208b; miR-499		(Kirby et al., 2015)
Reproductive	Differentially Ex	xpressed miRNAs	
system disease (Male)	Upregulated	Downregulated	Reference
	miR-200c, miR-20a, miR-20b, miR-182	miR-222, miR-221, miR-145, miR-214, miR-125b, miR- 143, miR-29a, miR-24, miR-199a	(Afshar et al., 2014)
	miR-375; miR-17; miR-93; miR-106a; miR-141; miR-720; miR-7a; miR-200b; miR-21; miR-106b; miR-375; miR- 663b; miR-615-3p; miR-425-5p; miR-663a; miR-182-5p; miR-183-5p	miR-205-5p; miR-221-3p; miR-222-3p; miR-376c-3p; miR- 136-5p; miR-455-3p; miR-455-5p; miR-154-5p	(Kristensen et al., 2016; Porkka et al., 2007; Volinia et al., 2006)
prostate cancer	miR-let-7a-2, miR-let-7i, miR-16-1, miR-17-5p, miR-20a, 21, miR-24-1, miR-25, miR-27a, miR-29a, miR-29b-2, miR-30c, miR-32, miR-34a, miR-92-2, miR-93-1, miR-95, miR-101-1, miR-106a, miR-124a-1, miR-126a-1, miR-135-2, miR-146, miR-149, miR-181b-1, miR-184, miR-187, miR-191, miR-196-1, miR-197, miR-199a-1, miR-214, miR-128a, miR-195, miR-198, miR-199a-1, miR-199a-2, miR-203, miR-206, miR-2014, miR-2018-2, miR-223, miR-202, miR-210, miR-296, miR-320, miR-370, miR-373, miR-498, miR-503	Let 7a, let- 7b, let-7c, let-7d, let-7g, 16, 23a, 23b, 26a, 92, 99a, 103, 125a, 125b, 143, 145, 195, 199a, 221, 222, 497	

	miR-Let-7a-5p, miR-let-7d-3p, miR- let-7d-5p, miR- 7b-5p, miR-20a- 5p, miR-21-3p, miR-25-3p, miR-29b-2-5p, miR- 30d-3p, miR-92a-3p, miR-92b-3p, miR-93-3p, miR-96-5p, miR-103b-3p, miR-182-5p, miR-183-5p, miR-375, miR- 421, miR-423-3p, miR-423-5p, miR-425-5p, miR-484, miR-615-3p, miR-663a, miR-663b, miR-664a-3p, miR- 1248, miR-1260a		(Kristensen et al., 2016)
Reproductive	Differentially Ex	xpressed miRNAs	
system diseases (female)	Upregulated	Downregulated	Reference
premature ovarian failure (Blood)	miR-202; miR-146a; miR-125b-2; miR-139-3p; miR-654- 5p; miR-27a; miR-765; miR-23a; miR-342-3p; miR-126	miR-Let-7c; miR-144	(McGinnis et al., 2015)
follicle atresia	miR-936; miR-26b; miR-149; miR-10b; miR-574-5p; miR- 149; miR-1275; miR-99a	miR-Let-7i; miR-92b; miR-92a; miR-1979; miR-1308; miR- 1826	(Li et al., 2015)
ovarian cancer	miR-21; miR-203; miR-205	miR-200 (ovarian cancer cell migration)	(Donadeu et al., 2017)
Central nervous	Differentially Ex	xpressed miRNAs	Reference
system	Upregulated	Downregulated	Kelerence
depression (LH)	miR-96, miR-141, miR182, miR-183, miR-183*, miR-198, miR-200a, miR-200a*, miR-200b, miR-200b*, miR-200c, and miR-429.		(Dwivedi, 2014)
non depression (NLH)		miR-96, miR-141, miR182, miR-183, miR-183*, miR-198, miR-200a, miR-200a*, miR-200b, miR-200b*, miR-200c, and miR-429.	(Dwivedi, 2014)
τ.	Diferentially Ex	pressed miRNAs	Df
Liver	Upregulated	Downregulated	Reference
hepatic hypercholesterol and hyperlipid metabolism	miR-122; miR-21; miR-23		(Szabo and Bala, 2013)
inflammatory response hyperinflammation	miR-155, miR-132, miR-125b, miR-146a, miR-150, miR- 181, let-7 and miR-21.20,21		(Szabo and Bala, 2013)
drug-induced liver injury (DILI)	miR-710 and miR-711 miR-16a, miR-328 and miR-299-5p	miR-122 and miR-192 miR-122a	(Szabo and Bala, 2013)
		pressed miRNAs	
Kidney	Upregulated	Downregulated	Reference
kidney fibrosis	miR-21		(Badal and Danesh, 2015)

renal fibrosis, tubular	miR-200a, miR-200b, miR-141, miR-429, miR-205, and		(Wei et al., 2013)
hypertrophy,	miR-192.		
glomerular alterations			
acute kidney injury	mir-21, mir-205, mir-127 and mir-494		(Wei et al., 2013)
(AKI)			
Skin	Diferentially Ex	pressed miRNAs	– Reference
Skin	Upregulated	Downregulated	Reference
	D 14(1 - 1 - D 155	miR-1, miR-133, miR-206, miR-11040; miR-30a-3p	(I us and Mastaglia
dermatomyositis	miR-146b and miR-155	IIIK-1, IIIK-155, IIIK-200, IIIK-11040, IIIK-50a-5p	(Luo and Mastaglia,

 Table 11. Organ damage and miRNA expression profiles investigated in the literature.

### 4.2. Autopsy, histological and toxicological examination on AAS abuser

For each selected case the autopsy examination combined with the histological and toxicological investigation were performed.

	Case 1	Case 2	Case 3	Case 4	Case 5
Age	29	30	32	40	31
Body weight	72 kg	90 kg	90 kg	83 kg	80 kg
Height	166 cm	178 cm	189 cm	175 cm	170
BMI	26,1	28,4	25.19	27.1	27,7
Bodybuilder	Yes	Yes	Yes	No	Yes
Hospitalization	No (he died at home)	No (he died at home)	No (he died at the gym)	No (he died in his own garage)	Yes (10 days)
Cause of death	Heart failure secondary to AAS assumption	Heart failure secondary to AAS assumption	Heart failure secondary to AAS assumption	Heart failure secondary to AAS assumption	Septic shock, starting as necrotizing myofasciitis

The main characteristics relative to each case are reported in table 12.


**Table 12.** In this table the main characteristics about each case were summarized.

#### 4.2.1 Autopsy and Histological examination

#### Case 1

At the autopsy, all organs were macroscopically normal, except the heart. It had a regular shape and weighed 380 g, with a predicted weight of 304 g (range 215–429 g). No pathological signs were detected analyzing the coronary arteries, the myocardium, and the valvular apparatus. Both ventricular wall thicknesses were normal.

Microscopic examinations were performed on the ventricles, revealing numerous foci of contraction band necrosis. There were two foci of fibrosis, one at the subendocardial anterior left ventricle and another at the interventricular septum. These findings were noted in all myocardial sections: segmentation of the myocardial cells and/or widening of intercalated discs and bundles of contracted myocardium alternating; bundles of distended myocardium with granular disruption of the myocytes (Figure 5). No pathological signs were noted on the coronary arteries, reporting only the physiologic intimal thickening typical of the subepicardial arterial vessels.



**Figure 5:** Segmentation of the myocardial cells, widening of intercalated discs, and bundles of contracted myocardium alternating with bundles of distended myocardium with granular disruption of myocytes (H & E  $\times$ 250). This picture is my own picture, previously published (Fineschi et al., 2007)

# Case 2

The autopsy revealed abnormal muscle development, testicular atrophy, and hepatomegaly. The heart was normal in shape (weight was 400 g).

Histopathologic examination of the heart revealed focal myocardial fibrosis (Figure 6); no alterations were detected on the conduction system. The liver showed cholestasis and vascular gaps compatible with the diagnosis of peliosis hepatis (Drug abuse handbook, 1998).





Figure 6. Scar fibrosis (H & E ×100)

#### Case 3

The external examination showed a male body with prominent muscular masses. At the autopsy, the heart weight was 450 g, normal for dimension and form. Heart structures (pericardium, cardiac valves, endocardium, and coronary arteries) were normal. No thrombi were detected both in vessels and in the cardiac cavities. Several samples were taken for histologic examination.

A grayish area similar to typical infarct necrosis with a histologic age of approximately 15 days was detected. The lesion was characterized by hyperdistended myocardial cells surrounded by sarcomeres, circumscribed at its periphery by young collagen tissue containing numerous macrophages (Figure 7). At other cardiac sites, the pathologic findings were represented by occasional foci of contraction band necrosis and few fibrotic microfoci in the internal portion of the posterior left ventricle and interventricular septum.




**Figure 7**. Many hypercontracted, deeply eosinophilic myocardial cells (early contraction band necrosis) external to a 15-day-old infarct already surrounded by collagen tissue plus macrophage reaction (phosphotungstic acid hematoxylin ×80).

A segmentation of the myocardial cells was found in all myocardial samples. Granular disruption of the myocardial cells was occasionally observed. No other signs of pathologic change were reported.

# Case 4

The external examination showed a regular heart shape both in consistency and color (the weight was 380 g). At the autopsy, no pathological signs were found: the identification of the macroscopic cause of death was not possible.

Histopathologic examination of the heart revealed fibrotic areas of myocardial tissue substitution with interruption in the muscular continuity (Figure 8). Liver slides were characterized by the presence of micro and macrocytic steatosis areas.




**Figure 8**. Heart slide showing grade II colliquative myocytosis, contraction bands, necrosis foci and perivasal fibrosis (H &  $E \times 100$ ).

### Case 5

The autopsy revealed abnormal muscle development, testicular atrophy, and hepatomegaly. The heart weight was 350 g.

The heart showed regular thickness of the subepicardial fat layer and arteriole walls. The myocardium presented, in some fields, limited areas of fibrosis as well as scattered interstitial hemorrhages. Finally, in some fields, there were aspects of dissolving myofibers (colliquative necrosis). Sampling from rectus femoris and vastus lateralis was remarkable for the abundant presence of polymorphonuclear cells and erythrocytes both at the perimysial level and between the fascicles (Figure 9a). In some fields, the muscular structure appeared completely subverted with large spaces occupied by erythrocytes and myocellular residue (Figure 9b, 9c). Immunohistochemical anti-myoglobin showed myofibrillar rexis (Figure 9d).



**Figure 9.** Muscle tissue: abundant polymorphonuclear cells and erythrocytes both at the perimysal level and between the fascicles themselves (a). In some fields, the muscular structure appears completely subverted with large spaces occupied by erythrocytes and myocellular residue (b, c). Immunohistochemical anti-myoglobin staining showing myofibrillar rexis (d).

### 4.2.2 Toxicological examination

For all cases, abuse substances tests were performed with negative results.

In case 1 the urine concentration for nandrolone was not measurable, stanozolol 43  $\mu$ g/l, and testosterone/epitestosterone ratio (T/E)=28.7. Complete toxicologic examination was negative for drugs of abuse, including ethanol.

In case 2 the blood concentration for nandrolone was 19 ng/ml; in the urine the concentration for Norandrosterone was 208.4 ng/ml, while testosterone/epitestosterone ratio (T/E) = 42.

In case 3 the urine concentration for nandrolone was 16 ng/ml, stanozolol 33  $\mu$ g/l, and testosterone/epitestosterone ratio (T/E)=23.4. The Gas chromatographic-mass spectrography of urine showed 19-nor-androsterone, 19-nor-etiocholanolone, and nor-epiandrosterone (metabolites of nandrolone), as well as 3-idrossi-stanozolol and 3-idrossi-17-epistanozolol (metabolites of the anabolic steroid stanozolol).

In case 4, the toxicological assessments performed on the blood sample showed a positive result for stanozolol 53 ng/mg and tamoxifen 19 ng/mg. Moreover, toxicological investigations were also performed on other items found at the crime scene: a blood-stained 10-ml syringe. The analysis performed on non-biological items showed only traces of trenbolone acetate in the syringe.

In case 5, the toxicological examination was carried out on hair: in toxicology it is an important bio-monitor that can extend the window of drug detection to weeks, months or even years. In this biological matrix the concentration of testosterone propionate was 24 pg/mg, clenbuterol was 26 pg/mg, stanozolol 66 pg/mg, trenbolone 28 pg/mg, oxandrolone 33 pg/mg and tamoxifen 84 pg/mg. Furthermore, the blood sample was analyzed: there was positivity for stanozolol 46 ng/mg and tamoxifen 15 ng/mg.

### 4.3. miRNA quantification through qRT-PCR

The quantitative analysis step aimed to evaluate the expression levels of several miRNAs in the AAS group, compared to other groups composed of subjects suffering from related pathologies.

For heart and musculoskeletal tissues, the miRNA expression values of miRNA has-133a-3p, hsa-miR-208a-3p, hsa-miR-499a-3p, and hsa-miR-1-3p were tested. The results were analyzed using the expression values of two different endogenous controls: hsa-miR-186 and miR-361.

For kidney tissue, miRNA expressions of hsa-miR-21-5p and hsa-miR-205-5p were evaluated in the AAS group compared to the CKD group.

hsa-miR-21-5p, hsa-miR-122-5p, hsa-miR-132-3p and hsa-miR-155-3p expression values were evaluated in liver tissue and compared with the AAS group and NAFLD group.


Finally, in the brain tissue samples, the quantitative analysis was performed to evaluate the expression levels of several miRNAs: hsa-miR-21-5p, hsa-miR-132-3p, hsa-miR-200b-3p, hsa-miR-34a-5p, and hsa-miR-124-5p, in the four groups (AASs, SG, DG, and AG).

For the kidney, liver and brain tissues, the expression values were compared with the expression levels of the endogenous control, hsa-miR-186.

Moreover, a statistical analysis was performed analyzing the expression values of each miRNA tested, comparing the tested groups.

# 4.3.1. Heart tissue and muscoleskeletal system

The first step of quantitative analysis evaluated the expression levels of the tested miRNAs (has-133a-3p, hsa-miR-208a-3p, hsa-miR-499a-3p, and hsa-miR-1-3p), in the HF group. A box plot analysis was performed for each endogenous control, hsa-miR-186 and has-miR-361 (Figures 10 and 11).




	-	levels (HF group) ntrol: miR-186)	
miR-133	miR-208	miR-499	miR-1-3
$0.94\pm0.57$	4.51 ± 2.21	$2.32\pm0.89$	$1.21 \pm 1.02$
	-	levels (HF group) ntrol: miR-361)	
$2.22 \pm 1.17$	$16.75 \pm 9.73$	$6.43 \pm 3.01$	$1.81 \pm 1.04$

As illustrated in the figures 10 and 11, all tested miRNAs were upregulated compared to endogenous controls. In table 13 the expression levels are reported.

**Table 13:** Expression levels of the tested miRNAs in the HF group.

Comparing the expression values for each tested miRNA, there were statistically significant differences: miR-208 expression was significantly higher compared to the other tested miRNAs [F(3,20) = 8.88, p = 0.0006(has-miR-186); F(3,20) = 10.93, p = 0.00018 (has-miR-361)].

The second step is the quantification of the expression levels of miRNA has-133a-3p, hsa-miR-208a-3p, hsa-miR-499a-3p, hsa-miR-1-3p, in the AAS group. A box plot analysis was performed for each endogenous control (Figures 12 and 13).



	-	levels (AAS group) ntrol: miR-186)	
miR-133	miR-208	miR-499	miR-1-3
$1.07\pm0.4$	2.19 ±0.39	$0.1\pm0.17$	$1.16 \pm 0.24$
	-	levels (AAS group) ntrol: miR-361)	
$1.14\pm0.36$	$2.6 \pm 0.91$	$0.05\pm0.08$	$1.19\pm0.45$

Table 14 summarizes the data indicating the expression levels of each tested miRNA.

Table 14: Expression levels of miRNAs analyzed in the AAS group, in heart tissue.

Comparing the expression values for each tested miRNA, there were statistically significant differences: the expression of miR-208 was significantly higher compared to the other tested miRNAs [F(3,20) = 42.23,  $p = 7.67 \times 10^{-9}$ (has-miR-186); F(3,20) = 22.21,  $p = 1.41 \times 10^{-6}$  (has-miR-361)].

Moreover, the statistical analysis was performed comparing the data of each miRNA between the two groups (AASs vs HF). Analyzing the expression values of miR-133, using mir-186 as endogenous control, it was expressed similarly in two tested groups (t-test, p=0.33); no significant differences were found analyzing the expression values of miR-1\_3 (t-test, p=0.33). The expression values were significantly higher in the HF group compared to the AAS group both for miR-208 and miR-499: indeed, even if these miRNAs were overexpressed in both groups compared to controls, the t-test highlighted a statistical difference in the results (HFvsAASs: miR-208, t-test, p=0.02; miR-499, t-test, p=0.001). Approximately the same results were reported using the other endogenous control, miR-361, even if, in this case, the statistical analysis showed that miR-133 (t-test, p=0.03) was overexpressed in the HF group more than in the AAS group. No statistical differences were reported analyzing the data from miR-1\_3 (t-test, p=0.011), while both miR-208 and miR-499 were expressed higher in the HF group (miR-208, t-test, p=0.008; miR-499, t-test, p=0.001).

Moreover, the quantification of the expression levels of miRNAs has-133a-3p, hsa-miR-208a-3p, hsa-miR-499a-3p, and hsa-miR-1-3p, in the AAS group, was performed testing muscle tissue (vastus lateralis) (figures 14 and 15).





Table 15 summarizes the data indicating the expression levels of each tested miRNAs.


	-	levels (AAS group) ntrol: miR-186)	
miR-133	miR-208	miR-499	miR-1-3
$1.37\pm0.35$	$1.39^{-10} \pm 2.58^{-11}$	$1.42^{-10} \pm 6.93^{-10}$	$6.44\pm3.67$
	(endogenous co	levels (AAS group) ntrol: miR-361)	
$1.94\pm0.91$	$4.59^{-10} \pm 3.3^{-10}$	$1.95^{-10} \pm 1.37^{-10}$	$13.63 \pm 2.76$

**Table 15:** Expression levels of miRNAs analyzed in the AAS group, in muscle tissue (vastus lateralis).

Finally, all data for each tested miRNA are summarized in box plots elaborated for each single tissue analyzed (figures 16-19). These schematic representations are more useful to compare the expression level variations of each tested miRNA.



The expression levels of miR-133 in heart tissue (HF and AAS groups) and muscle tissue (AAS group) were upregulated compared to controls. No statistical differences were reported analyzing data both with miR-186 [F(2,15) = 1.59, p = 0.23] and with miR-361 [F(2,15) = 2.48, p = 0.11].




**Figure 17a.** The box plot represents the expression levels of miR-208 (endogenous control miR-186) in heart tissue (HF and AAS groups) and muscle tissue (AAS group). **Figure 17b.** The box plot represents the expression levels of miR-208 (endogenous control miR-361) in heart tissue (HF and AAS groups) and muscle tissue (AAS group).


The expression levels of miR-208 in heart tissue (HF and AAS groups) were upregulated

compared to controls. These results were not confirmed in the muscle tissue (AAS group),

where it was expressed similarly to controls. The differences reported were statistically significant with both endogenous controls, miR-186 [F(2,15) = 17.35, p = 0.0001] and with miR-361 [F(2,15) = 15.19, p = 0.0002].



The expression levels of miR-499 were upregulated in heart tissue in the HF group. In the heart and muscle tissues of the AAS group, the expression levels were similar to controls. The differences reported were statistically significant with both endogenous controls, miR-186 [F(2,15) = 35.97, p =  $1.89 \times 10^{-6}$ ] and with miR-361 [F(2,15) = 26.87, p =  $1.1 \times 10^{-5}$ ].




The expression levels of miR-1\_3 in heart tissue (HF and AAS groups) and muscle tissue (AAS group) were upregulated compared to controls. This miRNA was overexpressed in the muscle tissue (vastus lateralis). The described differences were statistically significant with both endogenous controls, miR-186 [F(2,15) = 12.52, p = 0.0006] and with miR-361 [F(2,15) = 113.34, p =  $8.83 \times 10^{-10}$ ].

## 4.3.2 Kidney tissues

The expression values of miR-21 in kidney tissues of all tested groups are summarized with a box plot analysis (Figure 20).

Comparing the expression values in the two tested groups (AASs vs CKD), even if the values were improved compared to controls, the CDK values were statistically significantly higher than the AAS group [F(1,8) = 5.31, p = 0.013].


Performing a box plot analysis of the expression levels of miR-205 in each group (figure 21), even if it was higher in the CKD group compared to the AAS group, it was not statistically significant [F (1.8) = 5.31, p = 0.21].



### 4.3.3 Liver tissues


The expression values of miR-21 in the liver tissues of all tested groups are summarized with a box plot analysis in Figure 22. Comparing the expression values in the two tested groups (AASs vs CKD), even if the values were higher compared to controls, this miRNA was overexpressed in the AAS group with a statistically significant difference [F(1,8) = 5.31, p = 0.023].

Performing a box plot analysis of the expression levels of miR-122 in each group (figure 23), even if the values were improved compared to controls, the NAFDL values were significantly higher than the AAS group [F(1,8) = 5.31, p = 0.017].




Analyzing the expression levels of miRNA-132, there were no significant differences comparing the AAS Group to the NAFDL group [F(1,8) = 5.31, p = 0.54] and AG [F(1,8) = 5.31, p = 0.59] (figure 24).

Finally, analyzing the expression levels of miRNA-155, there were no significant differences comparing the AAS Group with the NAFDL group [F(1,8) = 5.31, p = 0.59] (Figure 25).



### 4.3.4 Brain tissues


The expression values of miR-21 in brain tissues of all tested groups are summarized with a box plot analysis in Figure 26.



**Figure 26.** Box plot analysis comparing expression levels of miR-21 (endogenous control miR-186) in each group.


There were statistically significant differences among group means as determined by oneway ANOVA [F(3,16) = 3.23, p = 0.00019]. Moreover, comparing the expression levels of miRNA-21 singularly (AAS group vs each other group), there were no significant differences comparing the AAS group to the SG [F(1,8) = 5.31, p = 0.54] and AG [F(1,8) = 5.31, p = 0.59] groups. The expression levels were significantly higher in the AAS group compared to the DG group [F(1,8) = 5.31, p < 0.05 (8.27 x10<sup>-9</sup>)].

Analyzing the expression values of miR-34 (figure 27), the data showed that this miRNA was significantly higher in the AAS and DG groups with respect to the SG and AG groups  $[F(3,16) = 3.23, p < 0.05 (1.23 \times 10^{-9})]$ . Analyzing the AAS group values compared to each other group, there were no statistical differences in the mir-34 expression values between AAS and DG groups [F(1,8) = 5.31, p = 0.09], while the expression levels were significantly higher with respect to both the AG group  $[F(1,8) = 5.31, p < 0.05 (1.08 \times 10^{-6})]$  and the SG group  $[F(1,8) = 5.31, p < 0.05 (4.09 \times 10^{-5})]$ .




**Figure 27.** Box plot analysis showing the expression levels of miR-34 (endogenous control miR-186) in each group.

The data of miR-124 showed a significant difference among the tested groups  $[F(3.16) = 3.23, p < 0.05 (9.05 \times 10^{-12})]$  (figure 28); comparing singularly (AAS groups vs other groups), its expression levels were significantly lower compared to the SG group [F(1.8) = 5.31, p = 0.000262], while they were significantly higher with respect to both the DG group [F(1.8) = 5.31, p = 5.31, p = 0.000152] and the AG group  $[F(1.8) = 5.31, p = <0.05(1.36^{-5})]$ .



**Figure 28.** Box plot analysis showing the expression levels of miR-124 (endogenous control miR-186) in each group.

Analyzing the expression levels of miR-132, there were statistical differences among group means as determined by one-way ANOVA [F (3.16) = 3.23, p =  $<0.05(3.95^{-7})$ ]. Moreover, comparing the expression levels of miRNA-132 singularly, there were no significant differences between the DG and AAS groups [F (1.8) = 5.31, p = 0.41], even if the DG values were higher. Contrariwise, analyzing the data of the AAS group with the other groups, there were significantly higher expression levels compared to both the SG group [F (1.8) = 5.31, p = 0.000149], and the AG group [F (1.8) = 5.31, p = 0.000264] (figure 29).



**Figure 29.** Box plot analysis showing the expression levels of miR-132 (endogenous control miR-186) in each group.

Performing a box plot analysis of the expression levels of miR-200b in each group (figure 30), its expression levels were higher in the AAS group compared to the other groups [F (3.16) = 3.23, p = 0.000234]. Furthermore, comparing singularly the expression values of miR-200b with the AAS group and the other groups, there are significant differences both with DG [F (1.8) = 5.31, p = 0.000397] and AG [F (1.8) = 5.31, p = 0.0169] groups, while no significant differences were found between the expression values of this miRNA comparing the AAS group vs the SG group [F (1.8) = 5.31, p = 0.06].




Figure 30. Box plot analysis showing the expression levels of miR-200b (endogenous control miR-186) in each group.

## 4.4 MicroRNAs database and target prediction tools

The analysis of each miRNA was performed through a literature review, and several informatics tools: miRBase (available to: http://www.mirbase.org/), TargetScanVert (available to: http://www.targetscan.org/) and miRDB (available to: http://mirdb.org/).

On cardiac and muscle tissues the following miRNAs were tested: hsa-miR-1-3p, hsa-miR-133a-3p, hsa-miR-208a-3p, and hsa-miR-499a-3p.

Figure 31 screens of each database interrogated for hsa-miR-1-3p.

miRBase	•																				MANCH
me Seard	h Browse	Help	Download	Blog Su	bmit h	ısa-mir-1-2															
em-loop	o seque	nce hs	a-mir-1	l <b>-2</b>																	
Acces	ision MI0	000437 (	<u>change log</u>	)																	
Previous		-mir-1d																			
Syn	nbol <u>HG</u>	NC:MIR1-	2																		
Descrip			s miR-1-2	stem-loop																	
Gene fa		PF0000038	3; <u>mir-1</u>																		
Litera	arch		<u>520 oper</u> (2604 se	<u>access pap</u> ntences)	<u>ers</u> men	ntion hsa-m	nir-1-2														
Stem-	5' 3'	ggaugg uu : u	aguacauacu            uuauguauga	ac ucuuuaugu c IIIIIIIII   agaaaugua g -a	ugaa :caua      iguau cgua	ica u a iac															
C sequen	Deep 11	t sequence 5 <u>18588</u> re	ads, <u>1.33e</u>	<u>+04</u> reads p	oer millio	on, 159 exp	periments	1													
	ACO	UNCUCAGAGUA	CAUACUUCUUU	UGUNCCCAUNUGA	INCAURCARU	IGCUNUGGANUGI		JOGIMOOC													
	(T		<b>C</b>																		
<b>N</b>	Tar	get	Sca	nHu	m	an		7.2 now av													
	Predictio	n of micr	oRNA targ	gets		Releas	se 7.1: June 201	16 Ag	arwal et a	1., 20	015										
3 transcrip	ots with con	served si		ning a total o lude some f			sites and <b>336</b> poo	orly conserve	ed sites.												
3 transcrip ease note t enes with o ble sorted	that these ponly poorly by cumula	iserved si predicted conserve tive weigh	targets inc d sites are ted contex	lude some f not shown. t++ score	alse pos [Sor	itives. [Re [View to rt table by a	ad more] op predicted targ aggregate P <sub>CT</sub> ]	gets, irrespec	tive of site				longe	et 3'   1	P in c	ase of	a tio)	Down	ood table]		
3 transcrip ease note t enes with o ble sorted	ots with con that these p only poorly by cumulat ows at mos	iserved si predicted conserve tive weigh t one tran	targets inc d sites are ted contex	lude some f not shown. t++ score	alse pos [Sor	itives. [Re [View to rt table by a	ad more] op predicted targ	gets, irrespectased on 3P-s	tive of site	the o	one wi			st 3' UT Poorly					oad table]	e Total	
33 transcrip ease note t enes with o ble sorted the table sho	that these ponly poorly by cumula	served si predicted conserver tive weigh t one tran	targets inc d sites are ted contex	lude some f not shown. t++ score	alse pos [Sor	sitives. [Re [View to rt table by a eing the mo	ad more] op predicted targ aggregate P <sub>CT</sub> ]	gets, irrespectased on 3P-s	ctive of site eq tags (or	the o	one wi	ith the rved site 7mer-			onserv	ed sites		[Downl Representative miRNA	e Cumulativ weighted context++	e Total context+ score	+ Aggrega PcT
33 transcrip ease note t enes with o bble sorted the table sho	ots with con that these p only poorly by cumulat ows at mos Represent transcri	eserved si predicted conserve tive weigh t one tran	targets inc d sites are ted contex script per g	lude some f not shown. :t++ score gene, select	alse pos [Sor ed for bo Gene na	sitives. [Re [View to rt table by a eing the mo	ad more] op predicted targ aggregate P <sub>CT</sub> ]	gets, irrespectated on 3P-s	eq tags (or Link to sites in	the c	one wi Conse	ith the rved sit	es 7mer-	Poorly	onserv er 7me m8	ed sites	6mer	Representative	e Cumulativ	context+	
33 transcrip ease note t enes with o able sorted te table sho arget gene DRO1C E	onts with contrast these poly poorly by cumulat by cumulat by cumulat by start most the second start the sec	aserved si predicted conserver tive weigh t one tran ative pt 31401.3 cor	targets inc d sites are ted contex script per g	lude some f not shown. (t++ score gene, select	alse pos [Sor ed for be Gene na 1C	sitives. [Re [View to rt table by a eing the mo	ad more] op predicted targ aggregate P <sub>CT</sub> ]	gets, irrespect ased on 3P-s Number of 3P-seq tags supporting UTR + 5	tive of site eq tags (or Link to sites in UTRs	the c total	one wi Consei 8mer	ith the rved site 7mer- m8	es 7mer- A1	Poorly total 8n	er 7me m8	r- 7mer A1	6mer - sites	Representative miRNA	e Cumulative weighted context++ score	context+ score	Рст
3 transcrip ease note t enes with o ble sorted e table sho arget gene DRO1C E MIM14 E	the with contract these points with contract these points poorly by cumulated by cu	aserved si predicted conserve tive weigh t one tran ative pt 61401.3 cor 05958.5 sm	targets inc d sites are ted contex script per g onin, actin bi all integral m	lude some f not shown. :t++ score gene, select	Sor Sor Gene na 1C in 14	sitives. [Re [View to rt table by a eing the me	ad more] op predicted targ aggregate P <sub>CT</sub> ]	gets, irrespect ased on 3P-s Number of 3P-seq tags supporting UTR + 5 1970	eq tags (or Link to sites in UTRs	the o	one wi Consei 8mer	ith the rved site 7mer- m8 0	es 7mer- A1 0	Poorly total 8n	er 7me m8 0	r- 7mer A1 0	6mer sites 2	Representative miRNA hsa-miR-206	Cumulativ weighted context++ score	-1.09	Рст 0.96
13 transcrip ease note to enes with ouble sorted e table shot       arget gene       DR01C       E       WIM14       E       RPC3	the with contract these points of the these points poorly by cumular by cumul	ative pt 100 ative pt 100 bit 00 bit	targets inc d sites are ted contex script per o onin, actin bi all integral m in related pro	lude some f not shown. tt++ score gene, select nding protein, embrane prote	Sor (Sor ed for be Gene na 1C in 14 ex, subuni	itives. [Re [View to rt table by a eing the me ame	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, ba	Sets, irrespect assed on 3P-s 3P-seq tags supporting UTR + 5 1970 601	eq tags (or Link to sites in UTRs Sites in UTF	the o	Consel Consel 2 2 2	ith the rved site 7mer- m8 0 0	es 7mer- A1 0	Poorly total 8n 0 3	er 7me m8 0 1 1	r 7mer A1 0 2	6 Gmer sites 2 3	Representative miRNA hsa-miR-206 hsa-miR-206	e Cumulativ weighted context++ score -1.08 -1.03	-1.38	Рст 0.96 0.98
I3 transcrip ease note te enes with o bible sorted te table sho arget gene NIII 14 BORO1C E WIIII14 E WIIII14 E RPC3 E TPLAD1 E	the with contract these points of the these points poorly by cumular by cumul	served si predicted conserver tive weigh t one tran stive pt 31401.3 cor 05958.5 sm 28825.7 act 31875.5 pro	targets incc d sites are ted contex script per g onin, actin bi all integral m in related pro tein tyrosine	lude some f not shown. tt++ score gene, select nding protein, embrane prote tein 2/3 compl	Sor (Sor ed for be Gene na 1C in 14 ex, subuni	itives. [Re [View to rt table by a eing the me ame	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, ba	Sets, irrespect ased on 3P-s 3P-seq tags supporting UTR + 5 1970 601 323	eq tags (or Link to sites in UTRs Sites in UTF Sites in UTF	the o	Consel Consel 2 2 2	ith the rved site 7mer- m8 0 0	es 7mer- A1 0 0 0	Poorty total 8 0 3 2	er 7me m8 0 1 1 1 1	F 31 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	- <mark>6mer</mark> sites 2 3 0	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99	-1.38 -1.30	Рст 0.96 0.98 < 0.1
3 transcrip pase note to pres with o ble sorted e table sho rroet gene MIM14 E RPC3 E FPLAD1 E RCN1 E	ts with contrast to see the set of the set o	served si predicted conserver tive weigh t one tran stive pt 31401.3 cor 25958.5 sm 28825.7 act 31875.5 pro 34182.2 arc	targets incc d sites are fed contex script per g onin, actin bi all integral m in related pro- tein tyrosine hain 1	lude some f not shown. tt++ score gene, select nding protein, embrane prote tein 2/3 compl	Sor (Sor ed for be Gene na 1C in 14 ex, subuni	itives. [Re [View to rt table by a eing the me ame	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, ba	A seed on 3P-s Number of 3P-seq tags supporting UTR + 5 1970 601 323 11697	eq tags (or Link to sites in UTR Sites in UTF Sites in UTF Sites in UTF	the o	Consel Consel 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1	es 7mer- A1 0 0 0 0	Poorty total 8n 0 2 1 1	er 7me m8 0 0 1 1 1 1 1	r 7mer A1 0 2 0 0 0	6mer sites 2 3 0 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-206	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97	-1.09 -1.38 -1.30 -1.11	Рст 0.96 0.98 < 0.1 0.95
3 transcrip passe note te annes with o ble sorted e table shot rget gene DROIC E RPC3 E PLAD1 E RCN1 E GGLN2 E	the with contrast the set of the	Inserved si predicted conservertive weight t one trans ative pt 31401.3 cor 05058.5 sm 28825.7 act 31875.5 pro 34182.2 arc 38096.1 trans	targets incc d sites are ted contex script per g onin, actin bi all integral m in related pro tein tyrosine hain 1 asgelin 2	lude some f not shown. tt++ score gene, select nding protein, embrane prote tein 2/3 compl	alse pos [Sor ed for bo Gene na 1C in 14 ex, subuni ike A domi	itives. [Re [View to rt table by a eing the me ame	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, ba	Number of 3P-sed supportine support is 1970 601 323 11697 1139	tive of site eq tags (or link to sites in UTRs Sites in UTF Sites in UTF Sites in UTF Sites in UTF	the contract of the contract o	Sine Wi Consel 2 2 1 1 1 1 0	ith the rved site 7mer- m8 0 0 0 0 1 0	es 7mer- A1 0 0 0 0 0	Poorty total 8 0 2 1 4 1	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	r 7mer A1 0 2 0 0 0	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative mIRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-206 hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97 -0.91	-1.09 -1.38 -1.30 -1.11 -0.91	Рст 0.96 0.98 < 0.1 0.95 0.95
3 transcrip passe note te annes with o ble sorted e table shot rget gene DROIC E RPC3 E PLAD1 E RCN1 E GGLN2 E	the with contrast the set of the	Inserved si predicted conservertive weight t one trans ative pt 31401.3 cor 05058.5 sm 28825.7 act 31875.5 pro 34182.2 arc 38096.1 trans	targets incc d sites are ted contex script per g onin, actin bi all integral m in related pro tein tyrosine hain 1 asgelin 2	lude some f not shown. It++ score gene, select nding protein, embrane prote tein 2/3 compl phosphatase-I	alse pos [Sor ed for bo Gene na 1C in 14 ex, subuni ike A domi	itives. [Re [View to rt table by a eing the me ame	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, ba	ased on 3P-s Number of 3P-se tags supporting UTR + 5 1970 601 3233 11697 1139 2192 1732	etive of site eq tags (or sites in UTRS Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
3 transcrip passe note te annes with o ble sorted e table shot rget gene DROIC E RPC3 E PLAD1 E RCN1 E GGLN2 E	the with contrast the set of the	Inserved si predicted conservertive weight t one trans ative pt 31401.3 cor 05058.5 sm 28825.7 act 31875.5 pro 34182.2 arc 38096.1 trans	targets incc d sites are ted contex script per g onin, actin bi all integral m in related pro tein tyrosine hain 1 asgelin 2	lude some f not shown. It++ score gene, select nding protein, embrane prote tein 2/3 compl phosphatase-I	alse pos [Sor ed for bo Gene na 1C in 14 ex, subuni ike A domi	itives. [Re [View to rt table by a eing the me ame	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, ba	ased on 3P-s Number of 3P-se tags supporting UTR + 5 1970 601 3233 11697 1139 2192 1732	tive of site eq tags (or Link to sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
3 transcrip sase note i sase note i ble sorted e table sho rrost gene kinnt = kinnt RPC3 = kinnt RCN1 = kinnt	ts with con that these p inly poorly by cumulatory was at mos Represent transcri INSTO000022 INSTO000022 INSTO000022 INSTO000022 INSTO000022 INSTO000022 INSTO000022	served si ar serve	targets inc f sites are fed contex script per g onin, actin bi n related prof tein tyrosine hain 1 nsgelin 2 o junction pro	lude some f not shown. It++ score gene, select nding protein, embrane prote tein 2/3 compl phosphatase-I	[Sories of the second s	ittives. [Re [View tr I table by eing the m ame it 3, 21kDa ain containin	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, ba	ased on 3P-s Number of 3P-se tags supporting UTR + 5 1970 601 3233 11697 1139 2192 1732	etive of site eq tags (or sites in UTRS Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
3 transcrip base note t ble sorted a table short rost gene RRO1C E HIM14 E PC3 E PLAD1 E CN1 E GLN2 E A1 E	ts with con that these junctions by cumulation of the transcritering of the instruction o	esserved is: predicted conservever tive weight statute	targets inc d sites are teld contexes script per g onin, actin bi all integral m in related pro tein tyrosine hain 1 isgelin 2 o junction pro	Iude some f not shown. It+ score gene, select nding protein, embrane prote tein 2/3 compi phosphatase-I tein, alpha 1, 4 r hsa-miR Gene Symb	Sorrest States (Sorrest States	ittives. [Re [View tr t table by eing the me and t 3, 21kDa ain containing in miRD Descriptio	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, bat g 1 g 1 B.	ased on 3P-s Number of 3P-se tags supporting UTR + 5 1970 601 3233 11697 1139 2192 1732	etive of site eq tags (or sites in UTRS Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
3 transcrip asse note t ble sorted e table short rrost cene RPC1C E RPC3 E PLAD1 E RPC3 E PLAD1 E CN1 E GUN2 E HA1 E	ts with con that these junction of the second by cumulation of the second secon	esserved size predicted to one trans- stive to one trans- stive seeses 7 sizes	targets ince d sites are co script per g onin, actin bi an related protection and a script per g onin, actin bi an related pro- tein tytosian an related pro	Iude some f not shown. It+ score gene, select nding protein, embrane prote tein 2/3 compi phosphatase-I tein, alpha 1, 4 r hsa-miR Gene Symb HCCG3	Sorrest States (Sorrest States	ittives. [Re [View tr t table by eing the me ame it 3, 21kDa ain containing <b>in miRD</b> Description recyarcyl- Car	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, bat g 1 g 1 B. DA dehydratase 3 A dehydratase 3 Jily 44 member 1	ased on 3P-s Number of 3P-se supporting 1970 601 323 11697 1139 2192 1732	eq tags (or link to sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
3 transcrip base note t ble sorted e table shore roet genes RRO1C E HIM14 E HPC3 E PLAD1 E CON1 E GLN2 E A1 E Freet Target table 1 Target table 1 table 1 CON1 E CON1 E CO	sta with constant the original poorly by cumulat these in the original poorly by cumulation was at most seven to be constant to be constant. The constant to be constant. The constant to be constant to be constant to be constant to be constant. The constant to be constant to be constant to be constant to be constant. The constant to be constant. The constant to be constant to be constant to be constant to be constant. The constant to be constant to be constant to be constant to be constant. The constant to be constant to be constant to be constant to be constant. The constant to be constant to be constant to be constant to be constant. The constant to be constant to be constant to be constant to be constant. The constant to be constant. The consta	conserved size to ensure the second s	targets ince d sites are defaulted contextend script per g onin, actin bi all integral m n related pro terin typosite all integral m n related pro terin typosite sites and sites and site	lude some f not shown. It+ score gene, select nding protein, embrane prote tein 2/3 compi phosphatase-1 tein, alpha 1, 4 tein, alpha 1, 4 <b>r hsa-miR</b> <b>Gene Symb</b> HACD3 SIC44A1 <u>MKD</u> PAX2	[Sories and a second se	ittives. [Re [View tr t table by eight of table	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, bat g 1 g 1 B. DA dehydratase 3 hilly 44 member 1 roophage different	ased on 3P-s Number of 3P-se supporting 1970 601 323 11697 1139 2192 1732	eq tags (or link to sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
3 transcrip base note t ble sorted e table shore rost genes RRO1C E HIM14 E HPC3 E PLAD1 E CON1 E GLN2 E A1 E Freet Target table 1 atable 1 table shore Freet Target table 1 table 1 table shore table shore Freet Target table 1 table 1 table shore Freet Target table 1 table 1 table 1 table shore Freet Target table 1 table 1 ta	sta with constant of the three set of th	served size predicted conserve- to example. served size predicted to example served size size size size size size size size	targets ince d sites are c script per g onin, actin bi all integral m in related pro telein tyrosme siggelin 2 - junction pro siggelin 2 - junction pro	lude some f not shown. It+ score gene, select nding protein, embrane prote tein 2/3 compi phosphatase-1 tein, alpha 1, 4 tein, alpha 1, 4	[Sories of the second s	ittives. [Re [View tr t table by eight of table	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, bat g 1 g 1 B. DA dehydratase 3 A dehydratase 3 Jily 44 member 1	ased on 3P-s Number of 3P-se supporting 1970 601 323 11697 1139 2192 1732	eq tags (or Link to sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
3 transcrip asse note t ble sorted e table shore rrest cene RPC3 E PLAD1 E RC3 E PLAD1 E RC3 E PLAD1 E RC3 E PLAD1 E RC3	ts with con that these is that these is that these is that these is that these is the transition of th	served size predicted conserve- to one trans to one trans to one trans the transt the transt	targets ince d sites are c d sites are c d sites are c d sites are c script per g anin, actin bi anin, actin bi all integral m n related pro tech types anin, actin bi all integral m n related pro tech types and a structure and a s	Iude some f not shown. It+ score gene, select nding protein, embrane prote tein 2/3 compi phosphatase-I tein, alpha 1, 4 tein, alpha 1, 4 tein, alpha 1, 4 HCCD3 H	[Sof or both set of the set of th	in miRD Description in miRD Description in containing in a containing in co	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, bat g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1	An and a second	et tags (or line in UTRS Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
13 transcripe ease note t ones with o bie sorted e table shor urget cenes and table shor protect cenes and table shor protect cenes and table shor table s	ts with con that these is that these is that these is that these is transetic is source is source is transetic is source is transetic is source is source is transetic is source is transetic is source is transetic is source is transetic is source is source is transetic is source is transetic is source is source is source is transetic is source is source is transetic is source is source is transetic is source is source is transetic is source is source is transetic is transetic is source is transetic transetic transetic is transetic transetic transetic transetic is transetic transe	t one trans t one	targets ince d sites are c d sites are c d sites are c d sites are c script per g anin, actin bi all integral m n related pro terin tyrosme an n related pr	Iude some f not shown. It+ score gene, select nding protein, embrane prote tein 2/3 compi phosphatase-1 tein, alpha 1, 4 tein, alpha 1, 4 tein	[Sof or both set of the set of th	in miRD in miRD Description provide a set of the set of	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, bat g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1	Alternative sector of the sect	et tags (or line in UTRS Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
13 transcripe ease note to nees with o bibe sorted e table sho arget gene ported gene ported gene ported gene transformed gene ported gene	ett viht con that these p init poorty by cumulat ows at mos Represent transett instromoze instromoz	licted ta miRM served size of the miRM served size of	targets ind d sites are existent secript per g conin, actin bi all integrat m related prove secrit m related prove m related p	Iude some f not shown. It+ score gene, select inding protein, embrane prote tein 2/3 compl phosphatase-1 tein, alpha 1, 4 tein, alpha 1, 4 tein, alpha 1, 4 <b>r hsa-miR</b> <b>Gene Symb</b> HACD3 SLC4A1 MAD2 PAZ2 CPED1 CPED1	[Sofor be [Sofor be deed for b	in miRD in miRD Description provide a set of the set of	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, bar g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1	Alternative sector of the sect	et tags (or line in UTRS Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
13 transcripe ease note to nees with o bibe sorted e table sho protections oprotections oprotections oprotections oprotections (stable sho protections (stable sho protections) (stable sho protecti	ett viht con that these p init poorty by cumulat ows at mos Represent transet INSTO00022 INSTO00022 INSTO000002 INSTO000022 INSTO000022 INSTO000022 INSTO000022 INSTO000022 INSTO000022 INSTO000022 INSTO000022 INSTO000022 INSTO000022 INSTO00000 INSTO00000 INSTO00000 INSTO00000 INSTO00000 INSTO00000 INSTO00000 INSTO00000 INSTO00000 INSTO00000 INSTO000000 INSTO000000 INSTO000000 INSTO000000 INSTO000000 INSTO0000000 INSTO00000000000 INSTO000000000000000000000000000000000000	licted ta miRM served states for the weight of the weight of the weight of the weight of the served states for the served states sta	targets ino d sites are executed contextured secret per g conin, actin bi bi all integral m m related particular m related particular significant of the secret m related particular significant of the secret m relation of the secret m relation of	lude some f not shown. It+ score gene, select inding protein, embrane prote tein 2/3 compl phosphatase-1 tein, alpha 1, 4 tein, alpha 1, 4 tein, alpha 1, 4 Gene Symb HACD3 SLC4A1 MAD PAX2 GAI SLC4A1 TAGLN2 TINKS2 CPED1 CPED1 CPED1 CPED1 CPED1	[Sofor be [Sofor be Gene na Cene Secon Cene na Cene n	in miRD in miRD becomplete in an ontaining in a containing in containing becomplete correct of a correct frame cycle to frame a containing becomplete correct of a correct frame cycle to frame correct of a correct of a correct of a correct of a correct of a correct of a correct of a correct a correct of a correct of a correct of a correct of a correct of a correct of	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, bar g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1	ased on 3P-so supporting supporting UTR +6 1970 601 233 11697 1139 2192 1732	et tags (or et tags (or sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89
ease note is enswith o bible sorted is ofted is	ett with con that these p init poorty by cumulat ows at mos Represent transet INSTO00022 INSTO0002 INSTO0000 INSTO000 INSTO0000 INSTO000	licted ta miRM served size of the miRM served size of	targets ino d sites are exercised contextured script per g conin, actin bi bi all integral m m related points and the site of	Iude some f not shown. It+ score gene, select Inding protein, embrane prote tein 2/3 compl phosphatase-I tein, alpha 1, 4 Itein, alpha 1,	ISofor book and a second secon	in miRD in miRD Descriptic reserved to make in method to make the method in miRD Descriptic resystemesti	ad more] op predicted targ aggregate P <sub>CT</sub> ] ost prevalent, bar g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1 g 1	A complex subra	et tags (or et tags (or sites in UTF Sites in UTF	the of       total       total    <	2 2 1 1 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 2	ith the rved site 7mer- m8 0 0 0 0 1 0 2	es 7mer- A1 0 0 0 0 0 0 0	Poorty total 8r 0 4 3 4 2 4 1 4 1 4 1 4	er 7me m8 0 1 1 1 1 1 1 1 1 0 0	ed sites       7     7       7     7       1     0       2     0       0     0       0     0       1     1	6 6 6 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Representative miRNA hsa-miR-206 hsa-miR-206 hsa-miR-1-3p hsa-miR-1-3p hsa-miR-1-3p	Cumulativ weighted context++ score -1.08 -1.03 -0.99 -0.97 -0.91 -0.85	-1.09 -1.38 -1.30 -1.11 -0.91 -0.85	Рст 0.96 0.98 < 0.1 0.95 0.95 0.89

Figure 32 screens of each database interrogated for the hsa-miR-133a-3p.

	se							miRl	Base										MANCH
ome Sear	rch Brows	e Help I	Download	Blog Su	bmit hsa	mir-133a-1													
tem-loo	p seque	ence hs	a-mir-1	133a-1															
Acce	ssion MI	0000450 (	<u>change log</u>	3)															
Sy	mbol HG	NC:MIR13	3A1																
Descri	_			a-1 stem-loc	20														
					P														
Gene fa		PF0000029	; <u>mir-155</u>																
	ature earch	inspire 1	<u>384 open</u> (1775 sen	access pape ntences)	ers mention	hsa-mir-13	33a-1												
Stem	-loop	a uuu	g	aa u a	gccuc														
	5'	caaugc        guuacg a uau	cBan ocBar	gu aa gg ac                 ca uu cc ug	caaauc        guuuag guaac	u													
	Ge	a oac	1		Boase														
seque		6052 read	s, <u>543</u> read	ds per millio	n, 143 expe	eriments													
								2											
	nor	wugeuugeuw	GAGCUGGUAAAA	AUGGAACCAAAUCC	CCUCUUCANUGG	NUUGGUCCCCU	CAACCAGCUGUAGCU	NUGCAUUGA											
<b>O</b>	Predictio	on of micro	oRNA targ	gets		Release 7	.1: June 201	7.2 now availa 6 Agarv	val et al., 2	015									
	iR-133a-5p																		
				al of 4083 si e primarily fa		s. IRead m	orel												
	d by cumula				noo pooliti	io. Intonia in	10101												
he table sh	nows at mos	st one tran	script per g	gene, select	ed for bein	g the most	prevalent, bas	sed on 3P-seq t	ags (or the				3' UTI	R, in cas	se of a ti		Download	table]	n
	Bernard							Number o 3P-seq	Link to		Site co	unts	6me	Penre	sentative	Cumulativ weighted	Total	Aggregate	
		entative							Linkto										
Target gene	trans	entative cript			Gene n	ime		tags supporting	sites in UTRs	total 8		ner- 7me n8 At			RNA	context+	score	Рст	
	trans	cript	WNK lysine o	deficient proteir		ime		tags	sites in		smer r	ner- n8 A1 0 4	r- site	s mi		score		Рст N/A	1
/NK2 SRP2	ENST00000	cript 0395475.2 0311083.5		deficient proteir I glycine-rich pr	n kinase 2	ime		tags supporting UTR + 5	sites in UTRs Sites in UTR Sites in UTR	4	o 1	n8 A1 0 4 0 1	5 0	hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p	score -1.06 -1.04	score -1.06 -1.04	N/A N/A	
/NK2 /SRP2 L645730.2	ENST00000 ENST00000 ENST00000	0395475.2 1 0311083.5 0 0448346.1	systeine and	glycine-rich pr	n kinase 2 otein 2			tags supporting UTR + 5 134	Sites in UTRS Sites in UTR Sites in UTR Sites in UTR	4 2 2	0 1 1	n8 A1 0 4	5 0 0	hsa-mif hsa-mif hsa-mif	R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89	-1.06 -1.04 -0.89	N/A N/A N/A	
/NK2 (SRP2 L645730.2 (KAIN3 (ASP3	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000	0395475.2 1 0311083.5 0 0448346.1 0523211.1 1 0393585.2 0	cysteine and Na+/K+ trans caspase 3, a	glycine-rich pr sporting ATPas ipoptosis-relate	n kinase 2 otein 2 e interacting 3 d cysteine pe	1		tags supporting UTR + 5 134 38 5 5 5 43	Sites in UTRS Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	4 2 2 2 2	0 1 1 1 2	m8         A1           0         4           0         1           1         0           0         1           0         0	5 0 0 0 0 0	hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87	-1.06 -1.04 -0.89 -0.88 -0.87	N/A N/A N/A N/A	
VNK2 (SRP2 (L645730.2 (KAIN3 (ASP3) (2orf61	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000	Cript 0395475.2 10 0311083.5 0 0448346.1 0523211.1 1 0393585.2 0 0294947.2 0	vysteine and Na+/K+ trans caspase 3, a chromosome	glycine-rich pr sporting ATPas poptosis-relate 2 open readin	n kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61	1		tags supporting UTR + 5 134 38 5 5 5	Sites in UTRS Sites in UTR Sites in UTR Sites in UTR Sites in UTR	4 2 2 2 2 3	0 1 1 1 2 0	m8         A1           0         4           0         1           1         0           0         1           0         1           0         1           0         1           0         1           1         0	5 0 0 0 0 1	hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87	-1.06 -1.04 -0.89 -0.88	N/A N/A N/A N/A	
VNK2 ISRP2 IL645730.2 IKAIN3 IASP3 I2orf61 I/EZF1 INF562	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000	cript         3395475.2         1           0311083.5         0         311083.5         0           0448346.1         0         0         323211.1         1           0393585.2         0         0         294947.2         0           0584396.1         0         0         3293648.4         2	vysteine and Na+/K+ trans caspase 3, aj chromosome vascular ende zinc finger pro	glycine-rich pr sporting ATPas ipoptosis-relate 2 open readin lothelial zinc fin rotein 562	n kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1	1		tags supporting UTR + 6 134 38 5 5 43 5 209 130	sites in UTRS Sites in UTR Sites in UTR	4 2 2 2 3 3 4	0 1 1 1 2 0 2 1	n8         A1           0         4           0         1           1         0           0         1           0         1           0         0           1         0           0         3	5 0 0 0 0 1 0 7	hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif	R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	-1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79	-1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -1.01 -1.00	N/A N/A N/A N/A N/A N/A N/A	
/NK2 (SRP2) L645730.2 (KAIN3) ASP3 (2orf61) EZF1 NF562 AMD12	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000	cript         3395475.2         1           0311083.5         0         311083.5         0           0448346.1         0         0         393585.2         0           0393585.2         0         0         294947.2         0           0584396.1         0         0         293648.4         2           0393685.2         0         0         0         0         0	vysteine and Na+/K+ trans caspase 3, aj chromosome vascular endi- cinc finger pro- sterile alpha i	glycine-rich pr sporting ATPas poptosis-relate 2 open readin lothelial zinc fin rotein 562 motif domain c	n kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12	1		tags supporting UTR + 5 134 38 5 5 43 5 209	sites in UTRS Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4	0 1 1 2 0 2 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2	5 0 0 0 0 1 0 7 0	hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif hsa-mif	R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.81 -0.79 -0.79	-1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -1.01 -1.00 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A	
VNK2 SRP2 L645730.2 IKAIN3 ASP3 2orf61 EZF1 NF562 AMD12 100A7A	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000	cript         3395475.2         1           0311083.5         0         311083.5         0           0448346.1         0         0         393585.2         0           0393585.2         0         0         294947.2         0           0584396.1         0         0         293648.4         2           0393685.2         0         0         0         0         0	vysteine and Na+/K+ trans caspase 3, aj chromosome vascular ende zinc finger pro stenie alpha i \$100 calcium	glycine-rich pr sporting ATPas ipoptosis-relate 2 open readin lothelial zinc fin rotein 562	n kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12	1		tags supporting UTR + 5 134 38 5 5 43 5 209 130 57 5 5	sites in UTRS Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -1.01 -1.00	N/A N/A N/A N/A N/A N/A N/A	
/NK2 SRP2 L645730.2 KAIN3 ASP3 2orf61 EZF1 NF562 AMD12 100A7A	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000	eript 0395475.2 1 0311083.5 4 0448346 1 0523211 1 1 0393585.2 4 0294947.2 4 0294947.2 4 0294947.2 4 0293648.4 2 0293648.4 2 0409003.4 5 0368729.4 5	vysteine and Na+/K+ trans caspase 3, aj chromosome vascular ende zinc finger pro stenie alpha i \$100 calcium	glycine-rich pr sporting ATPas poptosis-relate 2 open readin lothelial zinc fin rotein 562 motif domain c	n kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12	1		tags supporting UTR + 5 134 38 5 5 43 5 209 130 57 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
VNK2 SRP2 L645730.2 IKAIN3 ASP3 2orf61 EZF1 NF562 AMD12 100A7A	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000	eript 0395475.2 1 0311083.5 4 0448346 1 0523211 1 1 0393585.2 4 0294947.2 4 0294947.2 4 0294947.2 4 0293648.4 2 0293648.4 2 0409003.4 5 0368729.4 5	vysteine and Na+/K+ trans caspase 3, aj chromosome vascular ende zinc finger pro stenie alpha i \$100 calcium	glycine-rich pr sporting ATPas poptosis-relate 2 open readin lothelial zinc fin rotein 562 motif domain c	n kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12	1		tags supporting UTR + 5 134 38 5 5 43 5 209 130 57 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
/NK2 SRP2 L645730.2 KAIN3 ASP3 2orf61 EZF1 NF562 AMD12 100A7A	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000	eript 0395475.2 1 0311083.5 4 0448346 1 0523211 1 1 0393585.2 4 0294947.2 4 0294947.2 4 0294947.2 4 0293648.4 2 0293648.4 2 0409003.4 5 0368729.4 5	vysteine and Na+/K+ trans caspase 3, aj chromosome vascular ende zinc finger pro stenie alpha i \$100 calcium	glycine-rich pr sporting ATPas poptosis-relate 2 open readin lothelial zinc fin rotein 562 motif domain c	n kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12	1		tags supporting UTR + 5 134 38 5 5 43 5 209 130 57 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
/NK2 SRP2 L645730.2 KAIN3 ASP3 2orf61 EZF1 NF562 AMD12 100A7A	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000	eript 0395475.2 1 0311083.5 4 0448346 1 0523211 1 1 0393585.2 4 0294947.2 4 0294947.2 4 0294947.2 4 0293648.4 2 0293648.4 2 0409003.4 5 0368729.4 5	vysteine and Na+/K+ trans caspase 3, aj chromosome vascular ende zinc finger pro stenie alpha i \$100 calcium	glycine-rich pr sporting ATPas poptosis-relate 2 open readin lothelial zinc fin rotein 562 motif domain c	n kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12	1		tags supporting UTR + 5 134 38 5 5 43 5 209 130 57 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
/NK2 SRP2 L645730 2 KÅIN3 2orf61 EZF1 NF562 AMD12 100A7A IM	CONTRACTOR	cript 3395475.2 3311083.5 3311083.5 448346.1 35322111 3393585.2 3294947.2 30584396.1 3 30584396.1 3 3068729.4 3 3068729.4 3 2224237.5 3	systeine and Na+/K+ trans caspase 3, aj chromosome ascular end- cinc finger pr- stenie alpha s100 calcium rimentin	glycine-rich pr sporting ATPas poptosis-relate o 2 open readin otohelial zinc fin rootein 562 motif omain n binding prote	n kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 in A7A	otidase		tags supporting UTR + 5 134 38 5 5 43 5 209 130 57 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
(NK2 SRP2 L6457302 KAIN3 ASP3 20rf61 EZF1 NF562 AMD12 100A7A IM	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000	cript 3395475.2 1 3311083.5 4 34483461 3393585.2 4 32934947 2 4 32936484 2 32936484 2 32936484 2 3398729.4 2 339729.4 2 339	systeine and Na+/K+ trans aspase 3, a chromosome ascular end cinc finger po sterile alpha i 5100 calcium rimentin	glycine-rich pr sporting ATPas poptosis-relate 2 open readin tobeliai zinc fin tobeliai zinc fin motif domain c n binding prote	n kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 n ATA	ptidase p in miRC	рв.	tags supporting UTR + 5 134 38 5 5 43 5 209 130 57 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
INK2 SRP2 E045730 2 KAIN3 ASP3 20rf61 EZF1 EZF1 EZF1 INF562 AMD12 100A7A IM IM	ENST0000C ENST0000C ENST0000C ENST0000C ENST0000C ENST0000C ENST0000C ENST0000C	cript 3395475.2 1 331103.5 d 33448346.1 3393585.2 d 3393585.2 d 3393585.2 d 3393585.2 d 3393585.2 d 3393585.2 d 3393585.2 d 339358361.2 d 339358361.2 d 339358361.2 d 33935835.2 d 33935835.2 d 33935835.2 d 33935835.2 d 3393585.2 d 3395585.2 d 339	systeine and Na+/K+ trans aspase 3, a chromosome rascular end- tinc finger pp sterile alpha i 5100 calcium rimentin	glycine-rich pr sporting ATPas poptosis-relate 2 open readin tothelia zinc fin tothelia zinc fin tothe	h kinase 2 ootein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 in A7A	ptidase p in miRE scription		tags supporting UTR + 5 134 38 5 5 43 5 209 130 57 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
INK2 ISRP2 ISA5730 2 KAIN3 ASP3 20rf61 EZF1 NF562 AMD12 100A7A IM here are arget Tarretail Rate calls 1 Tarretail	e 496 pree e t Score	eript 3395475.2 3311083.5 3311083.5 3448346.1 3393582.2 3294947.2 3393582.2 3294947.2 3394947.2 33968729.4 33988729.4 3388729.4 3388729.4 3388729.4 3388729.4 33888729.4 33888729.4 33888729.4 33888729.4 33888729.4 33888729.4 33888729.4 33888729.4 33888729.4 33888729.4 33888729.4 33888729.4 33888729.4 33888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 3488729.4 34888729.4 34888729.4 34888729.4 34888729.4 34888729.4 3488729.4 3488729.4 3488484848484 3488484844 34884844 34884844 34884844 3488484 34884 34884 34884 34884 34884 34884 34884 34884 34884 34884 34884 34884 34884 34884 34884 34884 3	systeine and Na+/K+ trans caspase 3, aj chromosome vascular end cinc finger po stenie alpha is 5100 calcium imentin	glycine-rich pr sporting ATP as poptosis-relate 2 open readin dothelia zinc. fit dothelia	n kinase 2 otoin 2 e interacting 3 e interacting 3 g frame 61 ger 1 ontaining 12 in A7A	p in miRE scription	zinc finger 1	tags supporting UTR + 5 134 38 5 5 43 5 209 130 57 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
NK2 SRP2 L645730.2 KAIN3 ASP3 20rf61 EZF1 NF562 AMD12 100A7A IM here are arget Tarr letails 1 etails 2 etails 2	trans           ENST0000C           ENST000C           ENST000C           ENST000C           ENST000C           ENST000C           ENST000C           ENST000C           ENST000C </td <td>eript         3395475.2         1           3395475.2         1         3311083.5         1           3313083.5         1         1         1           3323211.1         1         1         1           33352211.1         1         1         1           333582.2         1         1         1           33293487.2         2         1         1           2293648.4         2         1         1           3088729.4         3         1         1           3088729.4         3         1         2           400003.4         2         1         1           3088729.4         3         1         2           3088729.4         3         1         1           13024237.5         1         1         1           13048729.4         3         1         1           13048729.4         3         1         1         1           13048729.4         3         1         1         1           1224237.5         1         1         1         1           13088729.4         1         1         1         1</td> <td>systeine and Na+/K+ trans caspase 3, aj chromosome cascular endition sterile alpha s100 calcium imentin arrgets fo A Name 2-133a-5p 2-133a-5p 2-133a-5p</td> <td>glycine-rich pr sporting ATPas poptosis-relate 2 open readin 2 open readin 2 open readin 2 open readin 2 open readin 2 open readin sports 502 motification protection protection view of the sport protection view of the sport view of the sport view</td> <td>n kinase 2 otoin 2 e interacting 3 e interacting 3 g frame 61 ger 1 ontaining 12 in A7A c-133a-5 ol Gene De Vascular Kruppel I</td> <td>p in miRE scription endothelial 2 ike factor 12 oinositol per</td> <td>zinc finger 1 2 htakisphosphat</td> <td>tega supporting 134 38 5 5 33 5 2000 130 130 57 5 31747</td> <td>Sites in UTR Sites in UTR</td> <td>4 2 2 2 3 3 4 4 3</td> <td>0 1 1 1 2 0 2 1 1 1 1 1</td> <td>n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2</td> <td>5 0 0 0 0 1 0 7 0 0 0</td> <td>b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi</td> <td>RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p</td> <td>score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79</td> <td>-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79</td> <td>N/A N/A N/A N/A N/A N/A N/A N/A N/A</td> <td></td>	eript         3395475.2         1           3395475.2         1         3311083.5         1           3313083.5         1         1         1           3323211.1         1         1         1           33352211.1         1         1         1           333582.2         1         1         1           33293487.2         2         1         1           2293648.4         2         1         1           3088729.4         3         1         1           3088729.4         3         1         2           400003.4         2         1         1           3088729.4         3         1         2           3088729.4         3         1         1           13024237.5         1         1         1           13048729.4         3         1         1           13048729.4         3         1         1         1           13048729.4         3         1         1         1           1224237.5         1         1         1         1           13088729.4         1         1         1         1	systeine and Na+/K+ trans caspase 3, aj chromosome cascular endition sterile alpha s100 calcium imentin arrgets fo A Name 2-133a-5p 2-133a-5p 2-133a-5p	glycine-rich pr sporting ATPas poptosis-relate 2 open readin 2 open readin 2 open readin 2 open readin 2 open readin 2 open readin sports 502 motification protection protection view of the sport protection view of the sport view	n kinase 2 otoin 2 e interacting 3 e interacting 3 g frame 61 ger 1 ontaining 12 in A7A c-133a-5 ol Gene De Vascular Kruppel I	p in miRE scription endothelial 2 ike factor 12 oinositol per	zinc finger 1 2 htakisphosphat	tega supporting 134 38 5 5 33 5 2000 130 130 57 5 31747	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
NK2 SRP2 L645730.2 KAIN3 ASP3 2orf61 EZF1 NF562 AMD12 100A7A IM here are arget Tarr retails 1 ctails 3 ctails 3	ENST0000C ENST0000C ENST0000C ENST0000C ENST0000C ENST0000C ENST0000C ENST0000C ENST0000C	eript 30395475.2 3031083.5 3031083.5 30303685.2 30303685.2 30303685.2 30303685.2 30303685.2 3030368729.4 30308729.4 30308729.4 30308729.4 30308729.4 30308729.4 30308729.4 10308729.4	vysteine and Na+/K+ trans caspase 3, al chromosome rascular endi- teine lapha teine lapha teine lapha steine lapha teine lapha teine lapha stolo calcium imentin argets fo A Name k-133a-5p k-133a-5p k-133a-5p k-133a-5p	glycine-rich pr sporting ATPas poptosis-relate 2 open readin tothelial zinc fin dothelial	t kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 in ATA e e e e e e e e e e e e e e e e e e	p in miRE scription endothelial 2 ike factor 12 oinositol per	zinc finger 1 2 htakisphosphat otein 8 homok	tega supporting 134 38 5 5 33 5 2000 130 130 57 5 31747	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
ANK2 SRP2 L645730 2 KAIN3 ASP3 20rf61 EZF1 NF562 AMD12 100A7A MM M here are arget Tarret etails 1 etails 1 etails 3 etails 3 etails 5 etails 5	tens           ENST0000C           Score           J           90           90           91           98           5           97	cript         33356475.2         1           3331083.5         ci         3331083.5         ci           3332852.2         2         3339852.4         ci           3328471.1         1         3339852.4         ci         ci           32294947.2         339682.9         ci         1         ci         ci           3239643.4         1         2239484.4         ci	systeine and Na+/K+ trans caspase 3, a chromosome cascular endi- tic finger pri- sterile alpha is 5100 calcium imentin imentin argets fo A Name 2-133a-5p 2-133a-5p 2-133a-5p 2-133a-5p	glycine-rich pr sporting ATPas poptosis-relate 2 open reading motif domain c n binding prote pr hsa-miF Gene Symb VE2F1 KLF12 PPIPSK1 ACTR8	t kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 in A7A e-133a-5 e-133a-5 ol Gene De vascular Kruppel Hohosph ARPB act	p in miRC scription endothelial 2 ionositol peri in related pri main contair receptor type	zinc finger 1 2 takisphosphat otein 8 homok ning 5 pe 28	tega supporting 1174 + 6 138 5 5 5 209 130 6 77 5 31747 4 31747 4 4 4 4 4 3 4 3 5 5 4 3 5 5 4 3 5 5 4 3 5 5 4 3 5 5 5 5 5 5 5 5 5 5 5 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
ASP3 SIRP2 L645730 2 KAIN3 ASP3 20161 EZF1 NF562 AMD12 10087A IM M here are arget Tarrest restall Ra statis 3 stealis 4 statis 5 stealis 5 stealis 5 stealis 7 stealis 7	Cans           ENSTD000C           Status           GOT           Status           Status           Status           ENSTD000C	cript         33356475.2         3331083.5         3448346.1           333330585.2         3333685.2         3333685.2         3333685.2         3333685.2         3333685.2         3333685.2         3333685.2         3333687.2         3333687.2         3333687.2         3333687.2         33376.2         33376.2<	vsteine and Na+/K+ trans caspase 3, a chromosome vascular end- clinc finger po- ternle alpha a storile alpha alpha a storile alpha alpha a storile alpha alpha	glycine-rich pr sporting ATPas poptosis-relate 2 open reading motif domain c n binding prote pr hsa-miF Gene Symb VE2F1 KLF12 PPIPSK1 ACTR8 ACTR8 ACTR8	n kinase 2 otini 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 in A7A c-133a-5 ol Gene De Vascular Kruppe1 diphosph ARP8 act FERM doi activin A	pidase p in miRC scription endothelial a ionositol peri in related pri main contair receptor type e RISC catal	zinc finger 1 2 ntakisphosphat otein 8 homok ning 5	tega supporting 1174 + 6 138 5 5 5 209 130 6 77 5 31747 4 31747 4 4 4 4 4 3 4 3 5 5 4 3 5 5 4 3 5 5 4 3 5 5 4 3 5 5 5 5 5 5 5 5 5 5 5 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
INK2 ISRP2 L645730.2 KAIN3 ASP3 20r81 EZF1 NF562 AMD12 100A7A IM M012 100A7A IM M012 100A7A IM M012 100A7A IM Sector I I Sector I Sector I Sector I Sector I Sector I I Sector I I Sector I I Sector I I Sector I I Sector I I I I I I I I I I I I I I I I I I I	Cans           ENSTD000C           Status           GOT           Status           Status           Status           ENSTD000C	cript         3395475 2           331063.55 2         331083.55 2           331083.55 2         331083.52 2           3333585.22 2         3333585 2           3333585.22 3         3333585 2           3339585.24 3         33386729 4           33368729 4         3338729 4           3338729 4         3338729 4           3338729 4         3338729 4           3338729 4         3338729 4           3338729 4         3338729 4           3338729 4         3338729 4           33388729 4         3338729 4           33388729 4         3338729 4           33388729 4         3338729 4           33388729 4         3338729 4           33388729 4         33388729 4           33388729 4         33388729 4           33388729 4         33388729 4           33388729 4         33388729 4           33388729 4         33388729 4           33388729 4         33388729 4           33388729 4         33388729 4           33388729 4         33388729 4           33388729 4         3388729 4           33388729 4         3388729 4           33388729 4         3388729 4           33388729 4 <td>vsteine and Na+/K+ trans caspase 3, al- hromosome vascular end- casc linger po- terite alpha al- storile alpha al- storile alpha al- storile alpha al- storile alpha al- storile alpha al- storile alpha al- terite alpha alpha alpha taggets for A Name Li32a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp</td> <td>glycine-rich pr sporting ATPas poptosis-relate z open residi motif domain c n binding prote pr hsa-miff Gene Symb VEZF1 KLF12 PPIPSK1 ACTR8 ACTR8 ACCR28 AGC4 XIM CASP3 SCRN1</td> <td>n kinase 2 otoin 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 in ATA</td> <td>p in miRE scription endothelial a in related primain contair receptor type e RISC catal 3 1</td> <td>zinc finger 1 2 ttakisphosphat rotein 8 homolo ning 5 be 28 lytic componen</td> <td>tega supporting 1174 + 6 138 5 5 5 209 130 6 77 5 31747 4 31747 4 4 4 4 4 3 4 3 5 5 4 3 5 5 4 3 5 5 4 3 5 5 4 3 5 5 5 5 5 5 5 5 5 5 5 5 5</td> <td>Sites in UTR Sites in UTR</td> <td>4 2 2 2 3 3 4 4 3</td> <td>0 1 1 1 2 0 2 1 1 1 1 1</td> <td>n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2</td> <td>5 0 0 0 0 1 0 7 0 0 0</td> <td>b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi</td> <td>RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p</td> <td>score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79</td> <td>-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79</td> <td>N/A N/A N/A N/A N/A N/A N/A N/A N/A</td> <td></td>	vsteine and Na+/K+ trans caspase 3, al- hromosome vascular end- casc linger po- terite alpha al- storile alpha al- storile alpha al- storile alpha al- storile alpha al- storile alpha al- storile alpha al- terite alpha alpha alpha taggets for A Name Li32a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp Li33a-Sp	glycine-rich pr sporting ATPas poptosis-relate z open residi motif domain c n binding prote pr hsa-miff Gene Symb VEZF1 KLF12 PPIPSK1 ACTR8 ACTR8 ACCR28 AGC4 XIM CASP3 SCRN1	n kinase 2 otoin 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 in ATA	p in miRE scription endothelial a in related primain contair receptor type e RISC catal 3 1	zinc finger 1 2 ttakisphosphat rotein 8 homolo ning 5 be 28 lytic componen	tega supporting 1174 + 6 138 5 5 5 209 130 6 77 5 31747 4 31747 4 4 4 4 4 3 4 3 5 5 4 3 5 5 4 3 5 5 4 3 5 5 4 3 5 5 5 5 5 5 5 5 5 5 5 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
VNIC2 ISRP2 LLG45730 2: IKAIN3 JASP3 J20ff61 TCZF1 INF562 ISP07 INF562 ISP07 INF562 ISP07 INF562 ISP07 INF562 ISP07 INF562 ISP07 INF562 ISP07 IS	Case         Case           ENST0000C         ENST0000C           Source         ENST0000C           Source         ENST0000C           Source         ENST0000C           Source         ENST000C           Source         ENST000C           Source         ENST000C           Source         ENST00C           Source         Source           Source         <	eript 2005475.2 2015475.2 20448346.1 55232111 10330585.2 2024947.2 2024947.2 2024947.2 2024947.2 2024947.2 2024947.2 20249484.4 2024947.2 2024947.2 20249484.4 2024947.2 2024947.5 2	vysteine and           Na+/K+ trans           caspase 3, a           hromosome           inc finger pro-           sterile alpha           stoll calcium           immentin	glycne-rich pr spotting ATPas poptosis-relate poptosis-relate poptosis-relate zo come result motif domain c n binding prote motif domain c n binding prote	n kinase 2 otein 2 e interacting 2 g frame 61 ger 1 ontaining 12 in ATA et 133a-5 Vascular Kruppel 1 diphosph ARP8 act FERM doi activin A argonaut vimentin caspase secernin R81 indu	pidase p in miRC scription endothelial 2 kke factor 12 oinositol per in related pr main contain receptor typ e eRISC catal 3 1 coble colled-	zinc finger 1 2 takisphosphat otein 8 homok ning 5 se 28 lytic componen coll 1	tega supporting 1174 + 6 138 5 5 5 209 130 6 77 5 31747 4 31747 4 4 4 4 4 3 4 3 5 5 4 3 5 5 4 3 5 5 4 3 5 5 4 3 5 5 5 5 5 5 5 5 5 5 5 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
arget Tar Detail Ra Details 1 Details 2 Details 2 Details 3 Details 3 Details 6 Details 6 Details 8 Details 8 Details 1 Details 11 Details 11	Case         Case           ENST0000C         ENST0000C           Score         Score           1         96           2         96           3         95	cript 3036475 2 3036475 2 3036475 2 3036475 2 3036472 4 3030455 2 2024947 2 3030455 2 2024947 2 3030455 2 2024947 2 3030430 1 3030455 2 3040003 4 30308729 4 30204300 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30308729 4 30204400 1 30204400 1 302044000 1 302044000 1 302044000 1 302044000 1 302044000 1 302044000 1 30204000 1 302040000 1 302040000 1 3020400000 1 3020400000 1 3020400000 1 302040000000000000000000000000000000000	vysteine and           Na+/K+ trans           caspase 3, a           horomosome           horomosome           arguets 0, a           inclinear and and           arguets and           stole alpha           S100 calcium           immentin           argets for           A Name           <113a-5p	glycne-rich pr spotting ATPas poptosis-relate poptosis-relate to the second second motif domain c n binding prote motif doma	t kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 in ATA c-133a-5 V d Gene De Vascular Kruppel I diphosph ARP8 act FERM doi activin A argonaut Vimentin caspase secernin R81 indu Kruppel I SIM bHU	ptidase p in miRE scription endothelial 2 kke factor 12 oinositol per ensore the second in related pr main contain receptor typ e RISC catal 3 1 clole colled- kke factor 11 t transcriptik	zinc finger 1 2 tratkisphosphat rotein 8 homolo ning 5 se 28 lytic componen coli 1 l on factor 1	tega supporting UTR + 6 38 5 5 33 5 200 130 57 5 31747	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
VNK2 SSRP2 LLG45730.2 KANN3 C20761 EZ71 INF562 HAMD12 HOM7A HAMD12 HOM7A HAMD12 HOM7A HAMD12 HOM7A HAMD12 HOM7A HAMD12 HOM7A HAMD12 HOM7A HAMD12 HOM7A HAMD12 HOM7A HAMD12 HOM7A HAMD12 HOM7A HAMD12 HOM7A HAMD13 HAMD12 HOM7A HAM12 HOM7A HAM13 HAM12 HOM7A HAM13 HOM7A HAM13 HOM7A HAM13	trans           ENST0000C           Sold	cript 3036475 2 3036475 2 3036475 2 3036475 2 3036472 4 3030455 2 2024947 2 3036452 4 2024947 2 30364396 1 20294947 2 3036479 4 20364396 1 20294947 2 3036479 4 20364396 1 20294947  20364396 1 20294947  20364396 1 20294947  20364396 1 20294947  20364396 1 20294947  20364396 1 20294947  20364396 1 20294947  20364396 1 20294947  20364396 1 2029494 2029494  2029494 2029494 2029494 2029494 2029494 2029494 2029494 2029494 2029494 2029494 2029494 2029494 2029494 2029494 20294 2029494 2029494 2029494 2029494 2029494 202949 20294 2029 2029	variance and variance transmission of variance transmission of variance transmission of variance transmission of variance	glycine-rich pr sporting ATPas poptosis-relate 2 copen reading motif domain c n binding prote motif domain c n binding prote motif domain c n binding prote sport vice sport vice sport vic	n kinase 2 otein 2 e interacting 3 d cysteine pe ger 1 ontaining 12 n ATA containing 12 containing 12 containin containing 12 containing 12 containing 12 cont	p in miRE scription endothelial : factor in the scription endothelial : endothelial :	zinc finger 1 2 ntakisphosphat ing 5 ing 5 be 2B lytic component coll 1 1 on factor 1 nembrane exocu nsmembrane de	tega supporting 1018 + 6 38 5 5 43 39 5 5 31747 5 31747 •••••••••••••••••••••••••••••••••••	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
VNK2 SSRP2 LLG45730.2 KANN3 C20r61 FCZF1 VNF562 S100A7A JMM012 S10A7A JMM012 S10A7A	trans           ENST0000C           Sold	eript 23395475 2 33395475 2 33395452 2 33395452 2 33395452 2 33395452 2 23244947 2 23244947 2 23264396 1 23294494 2 3338729 4 3348729 4	Valence and VariA's transactions of the state of the stat	glycne-rich pr sporting ATPas poptosis-relate 2 open reading motif domain c n binding prote motif domain c n binding prote motif domain c n binding prote motif domain c n binding prote sport vice sport vice sp	t kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 in ATA d ger 1 ontaining 12 in ATA d Gene De vascular Kruppe1 d iphosph ARP8 act Kruppe1 Sim Hull caspase secernin RB1 indu Kruppe1 Sim Hull regulatin Hull	p in miRC scription scription endothelial a in related primain contain receptor type e RISC catal 3 1 1 transcripting g synaptic no i g synapt	zinc finger 1 2 ntakisphosphat ning 5 se 2B lytic componen coil 1 l on factor 1 nembrane exoc nsmembrane 4	tega supporting 1018 + 6 38 5 5 43 39 5 5 31747 5 31747 •••••••••••••••••••••••••••••••••••	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
VNK2 SSRP2 LLG45730.2 KANN3 C20r61 FCZF1 VNF562 SM0012 S100A7A JMM SM012 S100A7A JMM SM012 S100A7A JMM SM012 S100A7A JMM SM012 S100A7A JMM SM012 S10A7A JMM S10A7A JMM SM012 S10	Cans         Cans           ENST0000C         ENST0000C           Status         Status	eript 20395475 2 30395475 2 30395475 2 30395475 2 3039585 2 2024947 2 2024947 2 2024947 2 2024947 2 20236430 1 20236430 1 20236430 1 20236430 1 20236430 1 20236430 1 20236430 1 2024237 5 30	valene and Na-K- trans- acepse 3, it to most memory associate and security and to most the security association security and to memory association to the security association to the security association to the security association to the security associa	glycne-rich pr sporting ATPas poptosis-relate 2 open reading motif domain c n binding prote motif domain c n binding prote motif domain c n binding prote motif domain c n binding prote sport sport domain c n binding prote sport	a kinase 2 otein 2 e interacting 3 d cysteine pe g frame 61 ger 1 ontaining 12 in ATA et 133a-5 ol Gene De vascular Kruppel 1 diphosph ARPB act Kruppel 1 SIM DHLI regulatin RB1 indu Kruppel 1 SIM DHLI regulatin Vissonm DEK proto Clock circ deta like	p in miRE scription scription endothelial a in related price e RISC catal 3 1 1 transcripting g synaptic n l protein tra- o-noncogene adian regula	zinc finger 1 2 ttakisphosphat ting 5 e 2B lytic componen coll 1 lon factor 1 nembrane exoc nsmembrane 4 ator cal Notch ligan	tega supporting 1018 + 6 1018 + 6 10018 + 6 10018 + 6 100	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
VNIC2 SISRP2 LLG457302 JASP3 J200761 /CZF1 INF562 SIMO12 S	Cans           ENST0000C           Score           get           99           4           99           9           9           9	eript 20054175.2 20154175.2 20448346.1 55232111 10330585.2 2024947.2 2024947.2 2024947.2 2024947.2 2024947.2 2024948.4 2024947.2 2024948.4 2024947.2 2024948.4 2024947.2 2024947.5 2	valence and Na-Ke trans Also -Ke trans Also -Ke trans Also - Ke trans	glycne-rich pr spotting ATPas poptosis-relate poptosis-relate into the latic rich for or hsa-miff Gene Symb Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF12 PPIPSA ACO4 Vt271 KLF11X	n kinase 2 otein 2 e interacting 3 d cysteine pe ger 1 ontaining 12 an ATA containing 12 an ATA containing 12 an ATA containing 12 an ATA containing 12 an ATA containing 12 containing	p in miRE scription endothelial : kke factor 12 kke factor 12 in control of the receptor fyr eceptor f	zinc finger 1 2 takisphosphat otein 8 homok ing 5 se 28 se 28 coll 1 i coll 1 i coll 1 coll 1	tega supporting 1018 + 6 1018 + 6 10018 + 6 10018 + 6 100	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
VNIC2 SISRP2 LLG457302 KKAIN3 ASP3 220f61 KKAIN3 ASP3 220f61 KKAIN3 ASP3 220f61 KKAIN3 ASP3 220f61 KKAIN3 SISRP2 CETF1 KKAIN3 CETF1 KKAIN3 CETF1 KKAIN3 CETF1 KKAIN3 CETF1 KKAIN3 CETF1 CETF1 KKAIN3 CETF1 CETF1 KKAIN3 CETF1	Cans           ENST00000           Score           get           1           90           90           90           90           90           90           90           90           90           90           90           90	eript 20054175.2 20154175.2 20448346.1 55232111 10330585.2 2024947.2 2024947.2 2024947.2 2024947.2 2024947.2 2024948.4 2024947.2 2024948.4 2024947.2 2024947.5 2	valence and Na -Ke trans scalars a space 3 and infomosione memory and infomosione memory and infomosione infomosio	glycne-rich pr sporting ATPas poptosis-relate poptosis-relate to the second second motif domain c n binding prote motif doma	n kinase 2 otein 2 e interacting 3 d cysteine pe ger 1 ontaining 12 an ATA containing 12 an ATA containing 12 an ATA containing 12 an ATA containing 12 an ATA containing 12 containing	p in miRE scription endothelial : kke factor 12 in control of the receptor by e RISC catal in control of the e RISC catal in control of the in contro	zinc finger 1 2 takisphosphat takisphosphat takisphosphat takisphosphat per 28 coll 1 be 28 coll 1 coll 1 coll 1 takisphosphat takisphosphat coll 1 takisphosphat takisphosphosphat takisphosphosphosphosphosphosphosphosphospho	tega supporting 134 38 5 5 43 39 5 5 30 5 5 30 5 5 31747 5 5 31747 6 4 3 31747 6 4 3 3 1747 6 4 3 3 1747 6 4 3 3 1747 6 4 3 3 5 5 5 4 3 3 5 5 5 4 3 3 5 5 5 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
NIK2           VINK2           UL045730.2           KAIN3           Zorrifo1           /EZF1	Case         Case           ENST0000C         ENST0000C           Sorra         F           Gamma         Score           Sorra         Score	eript 20054175.2 20154175.2 20448346.1 55232111 10330585.2 2024947.5 2024947.5 202494.5 2024947.5 20	valence and Na -Ke trans acaptes 3, a tribunosome account of the second in the second account of the second account account of the second account of the second account of the second account of the second account account of the second account account account account account account account account account account account account account account account account	glycine-rich pr sporting ATPas poptosis-relate poptosis-relate in the second second motification of the second motification of th	n kinase 2 otein 2 e interacting 3 d cysteine pe ger 1 ontaining 12 an ATA containing 12 an ATA containing 12 an ATA containing 12 an ATA containing 12 an ATA containing 12 containing	p in miRE scription endothelial a in related price in related price e RISC catal a 1 1 transcripti g synaptic a gynaptic a gynaptic in on-canoni his catour a gynaptic in on-canoni his catour and a gynaptic in on-canoni his catour and scriptical a gynaptic scriptical a gynaptic scriptical a gynaptic scriptical a gynaptic in on-canoni his catour and scriptical a gynaptic scriptical a gynaptic scriptic scriptical a gynaptic script	zinc finger 1 2 takisphosphat takisphosphat takisphosphat takisphosphat per 28 coll 1 be 28 coll 1 coll 1 coll 1 takisphosphat takisphosphat coll 1 takisphosphat takisphosphosphat takisphosphosphosphosphosphosphosphosphospho	tega supporting 134 38 5 5 43 39 5 5 30 5 5 30 5 5 31747 5 5 31747 6 4 3 31747 6 4 3 3 1747 6 4 3 3 1747 6 4 3 3 1747 6 4 3 3 5 5 5 4 3 3 5 5 5 4 3 3 5 5 5 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	
VNK2 VNK2 VSRP2 LC45730.2 KANN3 VASP3 220761 TEZF1 VNF562 4M012 100A7A 11M AM012 100A7A 11M AM012 100A7A 11M AM012 100A7A 11M AM012 100A7A 11M AM012 100A7A 11M AM012 100A7A 11M AM012 100A7A 11M 100A7A 11M 100A7A 11M 100A7A 11M 100A7A 11M 100A7A 11M 100A7A 11M 100A7A 11M 100A7A 11M 100A7A 11M 100A7A	Case         Case           ENST0000C         ENST0000C           Sorra         F           Gamma         Score           Sorra         Score	eript 20054175.2 20154175.2 20448346.1 55232111 10330585.2 2024947.5 2024947.5 202494.5 2024947.5 20	valene and Na-K- trans carapas 3, tromosione wascular end sacular	glycne-rich pr sporting ATPas poptosis-relate 2 open reading mott domain c n binding prote mott domain c n binding prote motion so motion so motio	a kinase 2 otein 2 e interacting 3 d cysteine per g frame 61 ger 1 ontaining 12 in ATA	p in miRE scription endothelial a in related price in related price e RISC catal a 1 1 transcripti g synaptic a gynaptic a gynaptic in on-canoni his catour a gynaptic in on-canoni his catour and a gynaptic in on-canoni his catour and scriptical a gynaptic scriptical a gynaptic scriptical a gynaptic scriptical a gynaptic in on-canoni his catour and scriptical a gynaptic scriptical a gynaptic scriptic scriptical a gynaptic script	zinc finger 1 2 takisphosphat takisphosphat takisphosphat takisphosphat per 28 coll 1 be 28 coll 1 coll 1 coll 1 takisphosphat takisphosphat coll 1 takisphosphat takisphosphosphat takisphosphosphosphosphosphosphosphosphospho	tega supporting 134 38 5 5 43 39 5 5 30 5 5 30 5 5 31747 5 5 31747 6 4 3 31747 6 4 3 3 1747 6 4 3 3 1747 6 4 3 3 1747 6 4 3 3 5 5 5 4 3 3 5 5 5 4 3 3 5 5 5 5 5	Sites in UTR Sites in UTR	4 2 2 2 3 3 4 4 3	0 1 1 1 2 0 2 1 1 1 1 1	n8         A1           0         4           0         1           1         0           0         1           0         1           2         1           0         3           1         2           0         3           1         2           0         3           1         2	5 0 0 0 0 1 0 7 0 0 0	b mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	RNA R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p R-133a-5p	score -1.06 -1.04 -0.89 -0.88 -0.87 -0.87 -0.87 -0.81 -0.79 -0.79 -0.79	-1.06 -1.04 -0.89 -0.87 -0.87 -1.01 -1.00 -0.79 -0.79	N/A N/A N/A N/A N/A N/A N/A N/A N/A	

Figure 33 screens of each database interrogated for hsa-miR-208a-3p.

miRBase	<b>-</b>			miRBa	ise								MANC
ne Search	h Browse He	p Download Blog S	Submit hsa-mir-208a										
m-loop	sequence	hsa-mir-208a											
Access		51 <u>(change log)</u>											
Previous													
Syn Descrip		<u>R208A</u> p <u>iens</u> miR-208a stem-loop	n										
Gene far		0178; mir-208	P										
Literat													
	arch	(534 sentences)	pers mention hsa-mir-208a										
Stem-I	u g	g c gg c gcgagcuuuu gc cg uuauac 	c a ug u										
	3' cug u a g	uguucgaaaa cg gc aauaug	lÎg acc cu										
	Get seque	_											
D sequenc		ads, <u>90</u> reads per million,	a, 30 experiments										
				-									
	UGACGGGCG	GCUARUGGCCCGGGUMUNCCUGAUGCU	UCACGUNUAAGACGAGCAAAAAGCUUGUUGGUCA										
	Tarae	etScanHu nicroRNA targets	Uman Rele	ase 7.2 now available	d.								
	Prediction of r	nicroRNA targets	Release 7.1: June	2016 Agarwal	et al., 2015								
					-								
man   miR 74 transcrip		ontaining a total of 6766 s	sites.										
ase note t	hat these predic	ted targets are primarily f	false positives. [Read more]										
		eighted context++ score transcript per gene, selec	cted for being the most prevalen	nt, based on 3P-seq tags	or the one	with the	longes	t 3' UTR	, in cas	e of a tie).	[Dow	nload tabl	le]
	Representat	ive		Number of 3P-seq	f Link to	Site	counts		mer Rea	oresentative	Cumulative	Iotai	Aggregate
larget gene	Representat transcrip	ive .	Gene name	tags supporting	sites in UTRs	total 8me	r 7mer- m8		ites	miRNA	weighted context++ score	context++ score	PCT
GS1		399.4 delta(4)-desaturase, spi	phingolipid 1	UTR + 5 1549		4 3	1	0		miR-208b-5p -		-1.33	N/A
X10 ARD4	ENST00000512		sfer (START) domain containing 4	9 767	Sites in UTR Sites in UTR	5 1	0 4	0	0 hsa-	miR-208b-5p - miR-208b-5p -	0.79	-1.01 -1.28	N/A N/A
X4 orf56		514.2 caudal type homeobox 4 771.1 chromosome 8 open rea		5	Sites in UTR Sites in UTR		0			miR-208b-5p - miR-208b-5p -		-0.75 -0.74	N/A N/A
HRC1 PS28		295.5 collagen triple helix repe 305.1 mitochondrial ribosomal		1504 2728	Sites in UTR Sites in UTR		0			miR-208b-5p - miR-208b-5p -		-0.72 -0.70	N/A N/A
			cleosomal binding domain 3	2124	Sites in UTR Sites in UTR	2 1	0	1	1 hsa-	miR-208b-5p - miR-208b-5p -	0.68	-0.73	N/A N/A
	ENST0000301						0			miR-208b-5p -	0.67	-0.67	N/A
136115.1 099552.4	ENST00000404	869.1 HCG2032337; PRO184 89.1 Uncharacterized protein		5	Sites in UTR							-0.67	N/A
136115.1 099552.4 APL IC2	ENST00000404 ENST00000343 ENST00000374	369.1         HCG2032337; PRO184           289.1         Uncharacterized protein           384.3         NFKB activating protein           793.3         structural maintenance	n-like of chromosomes 2	5 212	Sites in UTR Sites in UTR	2 1 2 1	1 0	0 1	1 hsa- 1 hsa-	miR-208b-5p - miR-208b-5p -	0.65	-0.78	N/A
136115.1 099552.4 APL IC2 IGN2	ENST00000404 ENST00000343 ENST00000374 ENST00000361	869.1         HCG2032337; PRO184           889.1         Uncharacterized protein           884.3         NFKB activating protein	n-like of chromosomes 2	5	Sites in UTR	2 1 2 1 1 1		0 1 0	1 hsa 1 hsa 2 hsa		0.65		
136115.1 099552.4 APL C2 GN2 ST AC9	ENST00000404 ENST00000343 ENST00000374 ENST00000361 ENST00000395 ENST00000372	1         HCG2032337; PRO184           1         Uncharacterized protein           1         Uncharacterized protein           1884.3         NFKB activating protein           193.3         structural maintenance           1827.5         high mobility group nucl           182.2         calpastatin           183.3         placenta-specific 9	n-like of chromosomes 2 cleosomal binding domain 2	5 212 184 4674 7	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
136115.1 099552.4 APL IC2 IGN2 ST AC9	ENST00000404 ENST00000343 ENST00000374 ENST00000361 ENST00000395 ENST00000372	1         HCG2032337; PRO184           1         Uncharacterized protein           188.3         NFKB activating protein           193.3         structural maintenance           127.5         high mobility group nucl           122.2         calpastatin	n-like of chromosomes 2 cleosomal binding domain 2	5 212 184 4674	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67	N/A N/A N/A
136115.1 099552.4 APL IC2 IGN2 ST AC9	ENST00000404 ENST00000343 ENST00000374 ENST00000361 ENST00000395 ENST00000372	1         HCG2032337; PRO184           1         Uncharacterized protein           1         Uncharacterized protein           1884.3         NFKB activating protein           193.3         structural maintenance           1827.5         high mobility group nucl           182.2         calpastatin           183.3         placenta-specific 9	n-like of chromosomes 2 cleosomal binding domain 2	5 212 184 4674 7 165	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
136115.1 099552.4 APL IC2 IGN2 ST AC9	ENST00000404 ENST00000343 ENST00000374 ENST00000361 ENST00000395 ENST00000372	1         HCG2032337; PRO184           1         Uncharacterized protein           1         Uncharacterized protein           1884.3         NFKB activating protein           193.3         structural maintenance           1827.5         high mobility group nucl           182.2         calpastatin           183.3         placenta-specific 9	n-like of chromosomes 2 cleosomal binding domain 2	5 212 184 4674 7	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
136115.1 099552.4 APL IC2 IGN2 ST AC9	ENST00000404 ENST00000343 ENST00000374 ENST00000361 ENST00000395 ENST00000372	1         HCG2032337; PRO184           1         Uncharacterized protein           1         Uncharacterized protein           1884.3         NFKB activating protein           193.3         structural maintenance           1827.5         high mobility group nucl           182.2         calpastatin           183.3         placenta-specific 9	n-like of chromosomes 2 cleosomal binding domain 2	5 212 184 4674 7 165	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
136115.1 099552.4 APL C2 IGN2 ST AC9 5C3A	ENST0000404 ENST0000343 ENST00000349 ENST00000361 ENST00000361 ENST00000372 ENST00000610	609 1 HC20203237, PRO184     809 1 Uncharacterized protein     81981 3 NrKB activating protein     93 3 structural maintenance     72 5 high mobility group nucl     12 capasitalin     33 a placenta-specific 9     40.1 5'-nucleotidase, cytosoli	n-like of chromosomes 2 Geeosomal binding domain 2 Litc IIIA	5 212 184 4674 7 165	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
136115.1 099552.4 APL C2 GN2 ST AC9 5C3A	ENST00000404 ENST00000349 ENST00000374 ENST00000361 ENST00000372 ENST00000610	609 1 HC20203237, PRO184     809 1 Uncharacterized protein     81981 3 NrKB activating protein     93 3 structural maintenance     72 5 high mobility group nucl     12 capasitalin     33 a placenta-specific 9     40.1 5'-nucleotidase, cytosoli	n-like of chromosomes 2 cleosomal binding domain 2	5 212 184 4674 7 165	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
130115.1 099552.4 APL C2 GN2 ST AC9 5C3A ere are S rget Targe	ENST0000404 ENST0000349 ENST0000374 ENST0000361 ENST00000372 ENST00000372 ENST00000610	Biol T HOG203237; PRO148     Biol Tuchardeniced protein     Sinchardeniced protein     Sinchardeniced protein     Sincutral maintenance     Sinchard Structural maintenance     Sinchard Structural     Sinchard Structur	n-like of chromosomes 2 Geeosomal binding domain 2 Litc IIIA	5 212 184 4674 7 165	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
130115.1 099552.4 APL (C2 (C2 GN2 ST AC9 5C3A	ENST0000404 ENST0000349 ENST0000374 ENST0000361 ENST00000361 ENST00000610 ENST00000610 ENST00000610 ENST00000610 ENST00000610 ENST00000610 ENST00000610 ENST00000610 ENST00000610 ENST000000000000000000000000000000000000	deg H (G2Q02337)-PRO148     Uncharacterized protein     Uncharacterized protein     Uncharacterized protein     Visite Status     Visite	nike of chromosomes 2 deosomal binding domain 2 hic: IIIA iR-208a-5p in miRDB. abol Gene Description A sterile alpha motif domain con	5 212 184 4074 7 165	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
130115.1 099552.4 APL C2 GR2 GR2 ST AC9 5C3A	ENST0000444 ENST0000344 ENST0000374 ENST0000372 ENST0000385 ENST00000372 ENST000003610 B13 predicte t Target n k Score n 9 9 hss 9 9 hss	Biol The Coccologity - PRO148     Incharacterized protein     Shark actual maintenance     Josephane Status     Shark actual maintenance     Josephane	nike of chromosomes 2 deosomal binding domain 2 tic: IIIA iR-208a-5p in miRDB. defection and the section of the	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
130115.1 130115.1 1309155.4 APL C2 GN2 ST AC9 SC3A C2 ST AC9 SC3A C2 ST C3 ST ST C3 ST C3 ST C3 ST C3 ST C3 ST ST C3 ST ST ST ST ST ST ST ST ST ST	ENST0000044 ENST0000045 ENST00000345 ENST00000345 ENST00000361 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST0000040 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST0000004 ENST000004 ENST000004 ENST000004 ENST000004 ENST000004 ENST000004 ENST000004 ENST000004 ENST000004 ENST000004 ENST000004 ENST00004 ENST000004 ENST000004 ENST00004 ENST00004 ENST00004 ENST00004 ENST00004 ENST00004 ENST00004 ENST0004 ENST00004 ENST00004 ENST00004 ENST0004 ENST0004 ENST0004 ENST0004 ENST0004 ENST0004 ENST0004 ENST004 ENST0004 ENST004 EN	Biol Teleparation of the second	nike or chromosomes 2 cleosomal binding domain 2 cleosomal binding domain 2 itic IIIA itic IIIA itic -208a-5p in miRDB. tic -208a-5p in m	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
130115.1 099552.4 APL (C2 IGN2 ST AC9 5C3A SC3A SC3A SC3A SC3A SC3A SC3A SC3A S	ENST0000044 ENST0000045 ENST00000345 ENST00000345 ENST00000361 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST0000040 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST000000045 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST0045 ENST00045 ENST	Ben H (C220233), PRO148     Uncharactived protein     Uncharactived protein     Uncharactived protein     Uncharactived protein     Uncharactived protein     Uncharactived protein     Uncharactive     Uncharactiv	nike of chromosomes 2 cleosomal binding domain 2 cleosomal binding domain 2 clic IIIA	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
30115.1 009552.4 APL C2 GN2 ST AC9 SC3A	ENST0000044 ENST0000045 ENST00000345 ENST00000345 ENST00000345 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST0000037 B13 predicte EXT0000037 B13 predicte EXT000037 B13 predicte EXT0000037 B13 predicte EXT0000047 B13 predicte EXT000047 B13 predicte EXT000047 B13 predicte EXT000047 B13 predicte EXT000047 B13 predicte EXT00047 B13 predicte EXT00047 B13 predicte EXT00047 B13 predicte EXT0047 B13 predicte EXT0047	Biol Teleparation of the second	nike of chromosomes 2 cleosomal binding domain 2 cleosomal binding domain 2 iic IIIA iic IIIA iiR-208a-5p in miRDB. their discrete the set of t	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
306115.1           009552.4           APL           C2           GN2           ST           AC09           SCGA             Target tail           Rand           Claits           Calits	ENST0000044 ENST0000045 ENST0000045 ENST0000045 ENST00000045 ENST00000045 ENST0000047 ENST00000472 ENST00000472 ENST00000472 ENST00000472 ENST0000047 ENST0000047 ENST0000047 ENST0000047 ENST0000047 ENST0000044 ENST00000045 ENST00000045 ENST00000045 ENST00000045 ENST0000045 ENST0000045 ENST0000045 ENST00000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST0000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST00045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST000045 ENST0045 ENST00045 ENST00045 ENST004	Bit 1 Co2202337, PRO148     Bit 1 Uncharacterized protein     Sincharacterized protein     Sincharacterized protein     Sincharacterized protein     Sincharacterized protein     Sincharacterized protein     Sincharacterized     Sinchar	nike of chromosomes 2 cleosomal binding domain 2 cleosomal binding domain 2 iic IIIA iic IIIA iiR-208a-5p in miRDB. theil Gene Description 4 sterile alpha motif domain con ubiquitin specific peptidase 42 gamma-animobutyric acid typ defta 4-desaturase, sphingolip cyclin Y like 1 2 zinc finger and BTB domain con ubiquitin sputtific bind animobutyric acid typ defta 4-desaturase, sphingolip cyclin Y like 1 2 zinc finger and BTB domain con integrin subunt beta 8 cyclin J PHD finger protein 20 like 1	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
130115 1 099552 4 APL IC2 IC3 IC3 IC3 IC3 IC3 IC3 IC3 IC3	ENST0000044 ENST0000045 ENST00000345 ENST00000345 ENST00000345 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST0000037 B13 P09 B13 P00000 B13 P00000077 P00000077 P00000077 P00000077 P0000077 P00000077 P00000077 P00000077 P00000077 P0000077 P00000077 P00000077 P00000077 P0000077 P00000077 P00000077 P00000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P0000077 P00000077 P00000000	Bit C2203237, PRO148     Bit Unchardencied protein     Unchardencied protein     Unchardencied protein     Si unclural maintenance     Jos and Status     Si unclural maintenance     Jos and Status	nike of chromosomes 2 cleasomal binding domain 2 cleasomal binding domain 2 clic IIIA iiic IIIA iiic Cooker and the set of the set o	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
130115.1 099552.4 APL C2 C2 GGN2 ST AC0 5C3A	ENST0000044 ENST0000045 ENST00000343 ENST0000034 ENST00000361 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST0000037 B13 P09 B13 P000037 P17 B13 P000000000000000000000000000000000000	Biol C22022337, PRO148     Incharactive protein     Incharactive     Incharact	nike of chromosomes 2 clossomal binding domain 2 clossomal close c	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
130115.1 09952.4 APL C2 C2 G3 ST AC0 5C3A	ENST0000044 ENST0000045 ENST00000343 ENST0000034 ENST0000034 ENST00000342 ENST00000372 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST0000034 ENST00000034 ENST0000042 ENST0000042 ENST0000042 ENST0000042 ENST0000042 ENST0000042 ENST0000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST000042 ENST00044 ENST00044 ENST00044 ENST00044 ENST00044 ENST	Bit         HC2203237, PRO148           Bit         Uncharactivities protein           Bit         Uncharactivities protein           Bit         Uncharactivities protein           Bit         Uncharactivities protein           Bit         Sinducturiti maintenance	nike of chromosomes 2 deosomal binding domain 2 deosomal binding domain 2 dic IIIA iiic IIIA iiic Cooke a state of the second of	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
130115.1 09955.2 AAL AC GO SC3A	ENST0000044 ENST0000045 ENST0000045 ENST00000045 ENST00000045 ENST00000045 ENST00000472 ENST00000472 ENST00000472 ENST00000472 ENST00000472 ENST00000472 ENST0000047 BAS Sector State 90 his 90	Bit         HC2203237, PRO148           Bit         Uncharactivities protein           Bit         Uncharactivities protein           Bit         Uncharactivities protein           Bit         Uncharactivities protein           Bit         Sinducturiti maintenance	nike of chromosomes 2 clossomal binding domain 2 clossomal close c	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
139115.1 099552.4 APL IC2 IC2 IC3 IC3 ST AAC SC3A SC3A SC3A SC3A SC3A SC3A SC3A	ENST0000044 ENST0000045 ENST00000343 ENST0000034 ENST0000034 ENST0000034 ENST00000372 ENST0000372 ENST0000372 ENST0000372 ENST00000372 ENST00000372 ENST0000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST0000000 ENST0000000 ENST0000000 ENST0000000 ENST00000000 ENST00000000 ENST0000000000000 ENST000000000000000000000000000000000000	Bit         HC2203237, PRO148           Bit         Uncharactive de protein           Bit         Uncharactive de protein           Bit         Uncharactive de protein           Bit         Statuctural maintenance           Bit         Sitte           Bit         Sitte <tr< td=""><td>nike of chromosomes 2 cleosomal binding domain 2 cleosomal cleosomal</td><td>5 212 184 4074 7 165</td><td>sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR</td><td>2 1 2 1 1 1 1 1 1 1</td><td>0 0 0</td><td>0 1 0 0</td><td>1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-</td><td>miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -</td><td>0.65 0.63 0.59 0.59</td><td>-0.78 -0.63 -0.67 -0.59</td><td>N/A N/A N/A</td></tr<>	nike of chromosomes 2 cleosomal binding domain 2 cleosomal	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
139115.1 099552.4 APL IC2 IC2 IC3 ST APL IC3 ST AC9 SC3A	ENST0000044 ENST0000045 ENST00000343 ENST0000034 ENST0000034 ENST0000034 ENST00000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST00000372 ENST00000372 ENST00000372 ENST000000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST0000000 ENST0000000 ENST0000000 ENST0000000 ENST00000000 ENST000000000000000000000000000000000000	Bit         HC2203237, PRO148           Bit         Unchardencised protein           Bit         Unchardencised protein           Bit         Unchardencised protein           Bit         Subcurvating protein           Bit         Bit           Bit         Bit           Bit         Bit </td <td>nike of chromosomes 2 cleosomal binding domain 2 cleosomal cleosomal</td> <td>5 212 184 4074 7 165</td> <td>sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR</td> <td>2 1 2 1 1 1 1 1 1 1</td> <td>0 0 0</td> <td>0 1 0 0</td> <td>1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-</td> <td>miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -</td> <td>0.65 0.63 0.59 0.59</td> <td>-0.78 -0.63 -0.67 -0.59</td> <td>N/A N/A N/A</td>	nike of chromosomes 2 cleosomal binding domain 2 cleosomal	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
139115.1 099552.4 APL IC2 IC2 IC3 ST APL IC3 ST AC9 SC3A	ENST0000044 ENST0000045 ENST00000343 ENST00000343 ENST0000034 ENST00000342 ENST00000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST0000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST0000000 ENST0000000 ENST0000000 ENST0000000 ENST00000000 ENST00000000 ENST000000000000000000000000000000000000	Bit         HC2203237, PRO148           Bit         Unchardencised protein           Bit         Unchardencised protein           Bit         Unchardencised protein           Bit         Subcurvating protein           Bit         Sitz           Bit         Sitz           Bit         Sitz           Bit         Sitz           Bitz         Bitz           Bitz         Bitz           Bitz         Bitz           Bitz         Bitz           Bitz         Bitz           Bitz         Bitz	nike of chromosomes 2 cleosomal binding domain 2 cleosomal binding domain 2 cleosomal binding domain 2 clic IIIA clic IIIIA clic IIIA cl	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
139115.1 139115.1 1099552.4 APL IC2 IGN2 ST AAC ST AAC SC3A	ENST0000044 ENST0000045 ENST00000145 ENST00000145 ENST0000016 ENST00000012 ENST00000012 ENST00000012 ENST00000012 ENST0000012 ENST00000012 ENST00000012 ENST00000012 ENST00000012 ENST0000012 ENST0000012 ENST0000012 ENST0000012 ENST0000012 ENST00000012 ENST00000012 ENST00000012 ENST0000012 ENST00000012 ENST00000012 ENST0000012 ENST0000012 ENST00000012 ENST00000012 ENST00000012 ENST0000012 ENST00000012 ENST0000012 ENST00000012 ENST0000012 ENST00000012 ENST00000012 ENST00000012 ENST00000012 ENST0000000 ENST0000000 ENST00000000 ENST00000000 ENST00000000 ENST00000000 ENST000000000000000000000000000000000000	Bit         HC2203237, PRO148           Bit         Unchardencied protein           Bit         Unchardencied protein           Bit         Unchardencied protein           Bit         Statuctural maintenance           Bit         Sinductural maintenance           Bit         Bit         Sinductural maintenance	nike of chromosomes 2 cleosomal binding domain 2 cleosomal	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A
rest         Targettail           traits         1           traits         2           taits         2           taits         2           taits         3           taits         3           taits         3           taits         3           taits         5           taits         7           taits         9           taits         11           taits         12           taits         12           taits         13           taits         14           taits         16           taits         16           taits         12           taits         16           taits         12           taits         12           taits         20           taits         22           taits         22           taits         23           taits         24           taits         25           taits         24	ENST0000044 ENST0000045 ENST00000343 ENST00000343 ENST0000034 ENST00000342 ENST00000372 ENST000000372 ENST000000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST00000372 ENST0000000 ENST0000000 ENST0000000 ENST00000000 ENST00000000 ENST000000000000000000000000000000000000	Bit         HC220323/F PRO184           Bit         Uncharacterized protein           Bit         Statuctural maintenance           Bit<	nike of chromosomes 2 cleosomal binding domain 2 cleosomal	5 212 184 4074 7 165	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	2 1 2 1 1 1 1 1 1 1	0 0 0	0 1 0 0	1 hsa- 1 hsa- 2 hsa- 1 hsa- 0 hsa-	miR-208b-5p - miR-208b-5p - miR-208b-5p - miR-208b-5p -	0.65 0.63 0.59 0.59	-0.78 -0.63 -0.67 -0.59	N/A N/A N/A

Figure 34 screens of each database interrogated for hsa-miR-499a-3p.

miRBase							mik	Base									MANCHEST 1824
ome Searc	h Browse	Help	Download	Blog St	iubmit												
ature se		hsa-i	miR-499	9a-3p													
Acces	nber MIN	1AT0004	772														
		-miR-499															
Previous Stem-I		-miR-499 -mir-499															
Seque			aagucugugcu														
		sequence	-														
C sequen	eep 282	<mark>5</mark> reads,	51 experim	nents													
Predi			: <u>hsa-miR-</u>														
Lar	miR	DB: <u>hsa</u>	-miR-499a-		2												
	mic	orna.org	g: <u>hsa-miR</u>	<u>-499a-3p</u>													
	<b>T</b>		<b>C</b>	-		a la la composición de											
XXX	Predictio		SCC roRNA for		uman	Release 2 elease 7.1: June 2010	7.2 now availe	able! wal et al., 2	2015								
	reaction	- or mic		gen													
uman   mif	R-499a-3p/	499b-3p	,														
874 transcri	pts with sit	es, conta	aining a tota	al of 5133 si e primarily f	sites. false positives.	[Read more]											
ble sorted	by cumulat	tive weig	hted contex	xt++ score		he most prevalent, bas	sed on 3P-sea	tags (or the	one	with t	ne lona	est 3' U	TR, in case of a	tie).	[Downloa	d table]	
	Represe	Sector 1		9000			Number of 3P-seq	Link to			counts	6m	er Representative	Cumula	tive Total	Aggregate	
arget gene	transe	ript			Gene name		tags supporting UTR + 5	utres in UTRs	total	8mer		/mer- sit		contex scor	t++	Рст	
OC8 OX2				nplex compone ne homeobox 2			129 5	Sites in UTR		0	0	0 3			0 -0.73	N/A N/A	
F616	ENST00000	330123.5	zinc finger p	protein 616			45 2215	Sites in UTR	2	2	0	0 0	hsa-miR-499a-3	0-0.72	-0.72	N/A N/A	
RS	ENST00000	392882.2	tryptophanyl	rus NS1A bindi I-tRNA synthet			1916	Sites in UTR	2	1	0	1 1	hsa-miR-499b-3	0-0.62	-0.62	N/A	
PPA-AS1 F7L2			PAPPA antis transcription		2 (T-cell specific, H	IMG-box)	5 650	Sites in UTR Sites in UTR		1	03	0 0 2			-0.61 -0.62	N/A N/A	
APK8 CAF8L1				tivated protein I CUL4 associate	kinase 8 ted factor 8-like 1		227 5	Sites in UTR		2	0	0 1			-0.75	N/A N/A	
MA8	ENST00000	343848.6	proteasome	e (prosome, ma	acropain) subunit,	alpha type, 8	5	Sites in UTR	2	0	2	0 0	hsa-miR-499a-3	-0.59	-0.59	N/A	
P11 P6V1E1			aquaporin 1 ATPase, H+		lysosomal 31kDa,	V1 subunit E1	75 2139	Sites in UTR		1	0		hsa-miR-499a-3 hsa-miR-499a-3		-0.59 -0.58	N/A N/A	
NC1 015987.2	ENST00000 ENST00000		tetratricopep	ptide repeat, ar	inkyrin repeat and	coiled-coil containing 1	618 5	Sites in UTR		2	0		hsa-miR-499b-3 hsa-miR-499a-3		-0.58	N/A N/A	
.C17A6	ENST00000	263160.3				transporter), member 6	5	Sites in UTR	2	2	0	0 0	hsa-miR-499b-3	-0.56	-0.56	N/A	
PRR2G P				e-rich protein 2 intestinal peptic			5	Sites in UTR		1	0	0 0		-0.55	-0.56 -0.55	N/A N/A	
E2E3 VLD				njugating enzy ctate/malate de	yme E2E 3 Jehyrogenase domi	ains	15 39	Sites in UTR		1	1	1 2	hsa-miR-499a-3 hsa-miR-499a-3		-0.63 -0.60	N/A N/A	
			-		- /				_								
							- mil	RDE	3								
ere are	622 pred	licted t	argets fo	or hsa-mií	iR-499a-3p i	in miRDB.											
rget Targ			-	_	nbol Gene Desc												
etail Ran etails 1	k Score 99	miki	IR-499a-3p	TCF7L2		n factor 7 like 2											
etails 2 etails 3	99 99		IR-499a-3p IR-499a-3p	NRIP1 FOXN2	nuclear rece forkhead bo	eptor interacting protein	1										
tails 4 tails 5	98 96	hsa-m	IR-499a-3p IR-499a-3p		Zic family m	e homeobox 2											
tails 6	96	hsa-mi	iR-499a-3p	ADAMTSS		llopeptidase with throm	bospondin type	1 motif 9									
tails 8	96	hsa-mi	IR-499a-3p IR-499a-3p	ZC3H6	zinc finger (	CCCH-type containing 6											
tails 9 tails 10	95	hsa-mi	iR-499a-3p iR-499a-3p	UBE2E3	ubiquitin co	mber of RAS oncogene f njugating enzyme E2 E3	3										
tails 11	95 94	hsa-mi	iR-499a-3p iR-499a-3p	SUCO	SUN domain	cyte myelin glycoproteir n containing ossification											
etails 12	94 94	hsa-m hsa-m	iR-499a-3p iR-499a-3p	SDCBP PLS3	syndecan bi plastin 3	inding protein											
etails 12 etails 13	94 94	hsa-m	IR-499a-3p IR-499a-3p	TAOK3	TAO kinase mitogen-act	3 tivated protein kinase 8	interacting prot	ein 3									
tails         12           tails         13           tails         14           tails         15	94	hsa-m	iR-499a-3p iR-499a-3p	PI15	peptidase in	hibitor 15											
tails         12           tails         13           tails         14           tails         14           tails         15           tails         16           tails         17	94	hsa-m	iR-499a-3p iR-499a-3p	DMXL2 MAP4K3	Dmx like 2 mitogen-act	tivated protein kinase ki	nase kinase kina	ase 3									
tails         12           tails         13           tails         14           tails         14           tails         15           tails         16           tails         17           tails         18           tails         19           tails         20	94	hsa-m	IR-499a-3p IR-499a-3p	KCNE4 IPO8	importin 8	voltage-gated channel su	ubfamily E regul	atory subun	t 4								
etails         12           etails         13           etails         14           etails         14           etails         15           etails         15           etails         17           etails         17           etails         18           getails         18           getails         20           etails         20           etails         21           etails         21	94 94 93 93	hsa-m	псчээц эр.		2 claudin 22	Non antipartica ataba ar	annosidase like	protein 3									
tetails 12 tetails 13 tetails 14 tetails 15 tetails 16 tetails 16 tetails 17 tetails 18 tetails 19 tetails 20 tetails 21 tetails 21 tetails 22 tetails 23 tetails 23	94 94 93 93 93 93 93	hsa-m hsa-m hsa-m	IR-499a-3p IR-499a-3p	EDEM3	ER degradat												
etails 12 etails 13 etails 14 etails 14 etails 15 tetails 16 etails 17 etails 18 tetails 19 etails 20 etails 20 etails 22 etails 23 etails 24 etails 25 etails 26	94 93 93 93 93 93 93 93 93 93	hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	IR-499a-3p IR-499a-3p IR-499a-3p IR-499a-3p	EDEM3 SUGP2 SON	ER degradat SURP and G SON DNA bi	s-patch domain containir inding protein											
tetails 12 tetails 13 tetails 13 tetails 14 tetails 15 tetails 16 tetails 17 tetails 17 tetails 18 tetails 19 tetails 20 tetails 21 tetails 22 tetails 23 tetails 23 tetails 23 tetails 25 tetails 26 tetails 27 tetails 26 tetails 27 tetails 27 tetails 28 tetails 27 tetails 28 tetails 27 tetails 28 tetails 28	94 94 93 93 93 93 93 93 93 93 93	hsa-m hsa-m hsa-m hsa-m hsa-m hsa-m hsa-m	IR-499a-3p IR-499a-3p IR-499a-3p IR-499a-3p IR-499a-3p IR-499a-3p	EDEM3 SUGP2 SON MAN2A1 ANO5	ER degradat SURP and G SON DNA bi mannosidas anoctamin 5	6-patch domain containir inding protein se alpha class 2A membe 5											
etails         12           etails         13           etails         14           etails         15           etails         16           etails         17           etails         18           etails         18           etails         19           etails         20           etails         21           etails         21           etails         22           etails         23           etails         23           etails         24           etails         25           etails         26           etails         25           etails         26           etails         26           etails         26           etails         26           etails         26           etails         27	94 93 93 93 93 93 93 93 93 93 93	hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi hsa-mi	IR-499a-3p IR-499a-3p IR-499a-3p IR-499a-3p IR-499a-3p	EDEM3 SUGP2 SON MAN2A1 ANO5 STIM2 BCLAF1	ER degradat SURP and G SON DNA bi mannosidas anoctamin 5 stromal inte BCL2 associ	ŝ-patch domain containir inding protein se alpha class 2A membe	er 1	coll containt	20.4								

On kidney tissues, the following miRNAs were tested: hsa-miR-21-5p, hsa-miR-205-5p. Figure 35 screens of each database interrogated for hsa-miR-21-5p.

miRBase	÷				ľ	niRBas	ie ie										MANC	
ne Search	Browse	Help Download	Blog Subr	mit hsa-mir-21														
m-loop s	equen	ce hsa-mir-	21															
Accessio	n MI00	00077 <u>(change lo</u> g	g)															
Symbo	ol <u>HGNC</u>	::MIR21																
Descriptio	n <u>Hom</u>	<u>o <i>sapiens</i> miR-21</u> :	stem-loop															
Gene famil	y MIPF	0000060; <u>mir-21</u>																
Literatur searc			en access pape entences)	ers mention hsa-mir-21														
Stem-loo	- u	gu a	a a u uguug cugu	и а g а														
	a .	ucgg agcuvauc gac                         aguc ucggguag cug ug - equence	ac acaac ggua	u c c u														
Dee sequencin	P 3115		<u>a+04</u> reads pe	r million, 159 experiments														
ocquerient		REPORT HAVE OR OTHER		MUSICANCACCAGUCGAUGOGCUGUCUGACA	<ul> <li>reads</li> </ul>													
	0.000																	_
		10																
	arg	of microRNA tar	InHu	man Relea		available!	0.0000											
Pre	ediction	of microRNA tar	gets	Release 7.1: June 2	2016	Agarwal et	al., 2015	5										
_			_			_												
man   miR-2	1-5p/590-	5p																
transcripts v	with conse	erved sites, contai		412 conserved sites and 134	poorly conse	erved sites.												
				se positives. [Read more] [View top predicted t	araote irroe	monthum of cit	0.000000	ration										
		e weighted contex		[Sort table by aggregate P <sub>C</sub>		pective of si	e conser	vation										
table shows	at most o	one transcript per	gene, selected	d for being the most prevalent,	based on 3					-			of a ti	ie). [Dow	vnload tabl	e]	_	
arget Rep	presentativ				Number o 3P-seq	Link to	Conse	rved si	tes	Poorly c	onserve	d sites	6mer	Representative	Cumulative weighted	Total	Aggregat	te
jene i	transcript		Ge	ne name	tags	g UTRs	total 8me	7mer- m8	7mer- A1	to <b>tal</b> 8m	ar 7mer- m8	7mer- A1	sites	miRNA	context++ score	score	Рст	ve
367 ENST	000003752	56.4 zinc finger protei	in 367		UTR + 5 325	Sites in UTR	2 2	0	0	1 0	1	0	0	hsa-miR-21-5p		-0.72	0.71	
					574	Sites in UTR	1 1	0	0	1 1	0	0	1	hsa-miR-21-5p		-0.69	0.74	
	ENST00000394507.1 KRIT1, ankyrin repeat containing ENST00000466512.1 kmlocyte matural killer cell stimulatory factor 1, cytotoxic https://www.cell.cell.cell.cell.cell.cell.cell.c					SHOS IT OTR		0	0							-0.65	0.74	
	000004885	12 1 interleukin 12A (	ENST00000466512 1 Interneukin 12/ (natural killer cell sumulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35) ENST00000340030.3 Fas ligand (TNF superfamily, member 6)														0.14	
A ENST					31	Sites in UTR	1 1	1	0	0 0 0 0	0	0		hsa-miR-21-5p			0.51	
A ENST	000003400 000002746	30.3 Fas ligand (TNF 25.5 fibroblast growth	superfamily, men factor 18		5 5	Sites in UTR Sites in UTR	1 1 2 1 1 1	12	07.0	0 0 0 0	0 0	0	0	hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64	-0.64 -0.64	0.61	
A ENST LG ENST 18 ENST	000003400 000002746	30.3 Fas ligand (TNF	superfamily, men factor 18		5	Sites in UTR		1	0	0 0	0	0	0	hsa-miR-21-5p	-0.64 -0.64	-0.64		
A ENSTI LG ENSTI 18 ENSTI 1 ENSTI 864 ENSTI	000003400 000002746 000002258 000003798	30.3     Fas ligand (TNF       25.5     fibroblast growth       42.3     chemokine (C-C       73.2     G protein-couple	superfamily, men i factor 18 motif) ligand 1 ed receptor 64		5 5 6 175	Sites in UTR Sites in UTR Sites in UTR Sites in UTR		1 0 0	0 0 0 0 0	0 0 0 0 0 0	0 0 0 0	0 0 0	0 0 1	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55	-0.64 -0.64 -0.64 -0.55	0.61 0.74 0.46	
A ENSTI	000003400 000002746 000002258 000003798	30.3 Fas ligand (TNF 25.5 fibroblast growth 42.3 chemokine (C-C 73.2 G protein-couple 15.1 absent in melan	superfamily, men i factor 18 motif) ligand 1 ed receptor 64	nber 6)	5 5 6 175 183	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1	1 0 0 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0	0 0 0 0	0 0 1 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55	-0.64 -0.64 -0.64 -0.55 -0.55	0.61 0.74 0.46 < 0.1	
A ENSTI LG ENSTI 18 ENSTI 64 ENSTI 164 ENSTI 11 ENSTI	000003400 000002746 000002258 000003798 000005278 000005380	30.3     Fas ligand (TNF       25.5     fibroblast growth       42.3     chemokine (C-C       73.2     G protein-couple       15.1     absent in melani       22.1     pleckstrin homol       binding specific)	superfamily, men i factor 18 motif) ligand 1 ed receptor 64 oma 1-like logy domain conta member 1	aining, family A (phosphoinositide	5 5 6 175	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1     1       2     2       1     1       1     1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENST LG ENST 18 ENST 1 ENST 164 ENST 11 ENST 11 ENST	000003400 000002746 000002258 000003798 000005278 000005380	30.3 Fas ligand (TNF 25.5 fibroblast growth 42.3 chemokine (C-C 73.2 G protein-couple 15.1 absent in melani 20.4 pleckstrin homol	superfamily, men i factor 18 motif) ligand 1 ed receptor 64 oma 1-like logy domain conta member 1	aining, family A (phosphoinositide	5 5 6 175 183	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1     1       2     2       1     1       1     1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55	0.61 0.74 0.46 < 0.1	
A ENST LG ENST 18 ENST 1 ENST 864 ENST 1L ENST KHA1 ENST	000003400 000002746 000002258 000003798 000005278 000005380	30.3     Fas ligand (TNF       25.5     fibroblast growth       42.3     chemokine (C-C       73.2     G protein-couple       15.1     absent in melani       22.1     pleckstrin homol       binding specific)	superfamily, men i factor 18 motif) ligand 1 ed receptor 64 oma 1-like logy domain conta member 1	aining, family A (phosphoinositide	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENST LG ENST 18 ENST 1 ENST 864 ENST 1L ENST KHA1 ENST	000003400 000002746 000002258 000003798 000005278 000005380	30.3     Fas ligand (TNF       25.5     fibroblast growth       42.3     chemokine (C-C       73.2     G protein-couple       15.1     absent in melani       22.1     pleckstrin homol       binding specific)	superfamily, men i factor 18 motif) ligand 1 ed receptor 64 oma 1-like logy domain conta member 1	aining, family A (phosphoinositide	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENST LG ENST 18 ENST 1 ENST 864 ENST 1L ENST KHA1 ENST	000003400 000002746 000002258 000003798 000005278 000005380	30.3     Fas ligand (TNF       25.5     fibroblast growth       42.3     chemokine (C-C       73.2     G protein-couple       15.1     absent in melani       22.1     pleckstrin homol       binding specific)	superfamily, men i factor 18 motif) ligand 1 ed receptor 64 oma 1-like logy domain conta member 1	aining, family A (phosphoinositide	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENST LG ENST 18 ENST 1 ENST 864 ENST 1L ENST KHA1 ENST	000003400 000002746 000002258 000003798 000005278 000005380	30.3     Fas ligand (TNF       25.5     fibroblast growth       42.3     chemokine (C-C       73.2     G protein-couple       15.1     absent in melani       22.1     pleckstrin homol       binding specific)	superfamily, men i factor 18 motif) ligand 1 ed receptor 64 oma 1-like logy domain conta member 1	aining, family A (phosphoinositide	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENSTI LG ENSTI 18 ENSTI 11 ENSTI 11 ENSTI 11 ENSTI 11 ENSTI 12 ENSTI	000003400 000002746 000002258 000003798 000005278 000005380 000005380	30.3     Fas ligand (TNF       55     fibroblast growth       42.3     chemokine (C-C       73.2     G protein-couple       15     absent in melan       121     absent in melan       122     protein-couple       13     absent in melan       10     aradical S-adenor	superfamily, men factor 18 motif) ligand 1 ed receptor 64 orma 1-like ogy domain conta member 1 syl methionine dor	aining, family A (phosphoinositide	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENSTI LG ENST 18 ENST 11 ENST 1464 ENST 11 ENST 11 ENST 11 ENST 12 ENST 12 ENST 14 ENST 14 ENST 15 ENST 16 E	000003400 000002746 000002258 000003798 000005278 000005380 000005380 000005380 000003820 9 predic	30.3 Fas ligand (TNF 25.5 fibroblast growth 22.3 chemokine (C- 23.2 G protein-couple 15.1 absent in melan 21.1 plockstrin homol binding specific) 40.3 radical S-adenor	superfamily, men factor 18 moth) ligand 1 id receptor 64 orga 1-like ogy domain conta member 1 syt methionine dor	nber 6) aning, famly A (phosphoinositide main containing 2 21-5p in miRDB.	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENSTI LG ENST 18 ENST 11 ENST 1464 ENST 11 ENST 11 ENST 11 ENST 12 ENST 12 ENST 14 ENST 14 ENST 15 ENST 16 E	000003400 000002746 000002258 0000003798 000005278 000005278 000005380 000003820	30.3 Fas ligand (TNF 25.5 fibroblast growth 22.3 chemokine (C- 23.2 G protein-couple 15.1 absent in melan 21.1 plockstrin homol binding specific) 40.3 radical S-adenor	superfamily, men factor 18 moth) ligand 1 id receptor 64 orga 1-like ogy domain conta member 1 syt methionine dor	nber 6) aining, famly A (phosphoinositide main containing 2	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENSTI LG ENSTI 18 ENSTI 1 ENSTI 14 ENSTI 14 ENSTI 14 ENSTI 15 ENSTI 15 ENSTI 164 ENSTI 164 ENSTI 164 ENSTI 164 ENSTI 165 ENSTI	000003400 000002746 000002258 0000005278 000005278 000005380 000005380 000003820 9 predic Target Score 99 99	30.3 Fas ligand (TNF 25.5 fibroblast growth 22.3 chemokine (C-C 23.2 G protein-couple 25.1 absent melian 21.1 [beckstm homo- binding specific] 20.3 radical S-adenor 21.2 [beckstm homo- binding specific] 21.3 absent melian 22.4 [beckstm homo- binding specific] 23.5 [beckstm homo- binding specific] 24.5 [beckstm homo- binding specific] 25.5 [beckstm homo- 25.5 [be	superfamily, men factor 18 motify ligand 1 dr receptor 64 om 5 Like ogy domain contra member 1 syl methionine doi y methionin	aning, family A (phosphoinositide main containing 2 21-5p in miRDB. Gene Description YOD1 deubiquitinase Fas ligand	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENSTI 10 ENSTI 11 ENSTI 14 ENSTI 154 ENSTI 14 ENSTI 14 ENSTI 154 ENSTI 154 ENSTI 155 ENS	000003400 000002746 000002258 0000005278 000005278 000005380 000005380 000003820 000003820 000003820 000003820 000003820 000003820	30.3 Fas ligand (TNF 25.5 fibroblast growth 22.3 chemokine (C- 23.2 G protein-couple 23.1 absent melian 24.1 pleckstm homo- binding specific) 40.3 radical S-adenor tet d targets for miRNA Name hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	superfamily, men factor 18 motif) ligand 1 dd receptor 64 om 51-like ogy domain content with methor 1 syl methionine dor or hsa-miR- Gene Symbol YODI FASLG PROMILI VCL	aning, famly A (phosphoinosilide main containing 2 21-5p in miRDB. Gene Description YOD1 deubquitinase Fas ligand PR/SET domain 11 Vinculin	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A         ENSTI           LG         ENSTI           10         ENSTI           11         ENSTI           12         ENSTI           14         ENSTI           15         ENSTI           164         ENSTI           11         ENSTI           12         ENSTI           13         ENSTI           14         ENSTI           15         I           16         3           115         5           116         6	000003400 000002746 000002258 0000005380 000005380 000005380 000003820 9 predic Target Score 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	30.3 Fas ligand (TNF 25.5 fibroblast growth 22.3 chemokine (C- 23.2 G protein-couple 21.3 labsent melian 22.1 plockstm homol binding specific) 40.3 radical S-adenor cted targets for miRNA Name hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	superfamily, men factor 18 motif) ligand 1 dd receptor 64 oms 1-like ogy domain content member 1 syl methionine dor y methionine dor Y ODL FASLG PROMILI VCL ZMF362 SKP2	aning, family A (phosphoinositide main containing 2 21-5p in miRDB. Gene Description YOD1 deublquitinase Fas ligand PR/SET domain 11 vinculin zinc finger protein asoCated prot	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A         ENSTI           LG         ENSTI           10         ENSTI           11         ENSTI           12         ENSTI           13         ENSTI           14         ENSTI           15         ENSTI           164         ENSTI           17         ENSTI           18         ENSTI           19         ENSTI           10         ENSTI           11         ENSTI           12         ENSTI           13         ENSTI           14         ENSTI           15         ENSTI           16         ENSTI           17         ENSTI           18         ENSTI           18         ENSTI           18         ENSTI           19         ENSTI	000003400 000002746 000002258 0000005278 000005380 000005380 000003820 9 predic Target Sore 99 99 99 99 99 99 99 99 99 99 99 99 99	203 Fas Igand (TME 255 fibrobiast growth 255 fibrobiast growth 257 grotein-couple 251 absent in melan 252 grotein-couple 251 absent in melan 252 grotein-couple 253 grotein-couple 254 grotein-couple 255 growth 255 growth	superfamily, men factor 18 moth ligand 1 ind receptor 64 oma 1-like ory domain conta momber 1 yt methionine do or hsa-miR- Gene Symbol YODI FASIG PROM11 VCL ZNF3o2 SKP2 GFBL 11.12A	aining, famly A (phosphoinosilide main containing 2 21-5p in miRDB. Gene Description YOD1 deublayUrinase Pas Igand PR/SFT domain 11 Vinculin Zinc finger protein 367 S-phase Kinase associated protect transforming growth factor beta Interfeukin 12A	5 5 6 175 183 1172 5	Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENST LG ENST 18 ENST 10 ENST	000003400 000002746 000002258 000003768 000003820 000003820 000003820 000003820 000003820 000003820 000003820 000003820 000003820	203 Fas Igand (TM 255 fibrobiast growth 255 fibrobiast growth 256 fibrobiast growth 257 grotein-couple 251 absent in malan 252 grotein-couple 251 absent in malan 252 grotein-couple 253 grotein-couple 253 growth 254 growth 255 growt	superfamily, men factor 18 motif) ligand 1 di drecaptor 64 dama 1-lake ogy domain conte member 1 syl methionine do pr hsa-miR- Gene Symbol YOD1 FASLG PROMILI VCL VCL CFRI	anng, famly A (phosphoinosilde main containing 2 21-5p in miRDB. Gene Description YOD1 deublayUrinase Pas Igand PR/SFT domain 11 Vinculin Zinc finger protein 367 S-phase Kinase associated pros- transforming growth factor beta Interfeukin 12A RAB6D, member RAS ancogene adhesion G protein-coupled rea	5 5 6 175 183 1172 5 5	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENST LG ENST 18 ENST 10 E	000003400 000002746 000002258 0000005278 000005278 000005380 000005380 000003820 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	2003 Fas ligand (TNF 255 fibroblas) growth 256 fibroblas growth 257 fibroblas (Sowth 250 fibroblas) growth 251 absent in melan 252 pleckstm homol binding specific) 200 growth absent in melan 252 pleckstm homol binding specific) 200 growth absent in melan 252 pleckstm homol binding specific) 200 growth absent in melan 252 pleckstm homol binding specific) 253 growth absent in melan 254 pleckstm homol binding specific) 254 pleckstm homol binding specific) 254 pleckstm homol binding specific) 255 pleckstm homol binding specific	superfamily, men factor 18 molt Nigand 1 det receptor 64 oran 1-lake org downan content member 1 syl methionine do or hsa-miR- Gene Symbol YOD1 FASLG PROMI1 VCL3 CKF2 GF2 GF2 GF2 GF2 GF2 GF2 GF2 GF2 GF2 G	aning, family A (phosphoinositide main containing 2 21-5p in miRDB. Gene Description YOD1 deubiquitinase Fas ligand PH/SET domain 11 Vinculin Zinc finger protein 3G7 S-phase kinase associated prot transforming growth factor beta Interfeiskin 12A RAB6D, member RAS oncogene adhesion G protein-coupled rece RAB GE With Homain and SH	5 5 6 175 183 1172 5 5	sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1	1 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENST LG ENST 18 ENST 10 E	000003400 000002746 0000002780 000000258 0000005780 0000005780 0000005780 0000005780 0000005780 0000005780 000005780 000005780 000005780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 00000055780 00000055780 00000055780 0000000000	2003 Fas ligand (TNF 2005 fibroblas) growth 2005 fibroblas (growth 2005 fibroblas) growth 2005 fibroblas (growth 2005 fibroblas) 2007 fibroblas 2007 fibrobl	superfamily, men factor 18 molt Nigand 1 det receptor 64 oran 1-lake ory deceptor 64 oran 1-lake orgy domain content member 1 with methionine do or hsa-miR- Gene Symbol YOD1 FASLG PROMI1 VCL3 CKF2 GFR2 GFR2 GFR2 GFR2 GFR2 GFR2 GFR2 GF	aning, family A (phosphoinositide main containing 2 21-5p in miRDB. Cene Description YOD1 deubiquitinase Fas Ilgand PK/SET domain 11 vinculin Zinc finger protein 3G7 S-phase kinase associated prot transforming growth factor beta Interleukin 12A RAB6D, member RAS oncoged athaesin G protein-coupled rece RaB6 GF with domain and SP PLAG1 zinc finger	5 5 6 6 1175 183 1172 5 2 1172 5	sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1		0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENST LG ENST 18 ENST 10 ENST	000003400 0000002746 0000002780 0000002780 0000005780 0000005780 0000005780 0000005780 0000005780 0000005780 000005780 000005780 000005780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 00000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 000055780 000055780 000055780 000055780 000055780 000055780 000055780 000055780 000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 0000055780 00000055780 0000055780 0000055780 00000055780 00000055780 0000000000	2003 Fas ligand (TNF 2005 fibroblas) growth 2007 fibroblas (sowth 2007 fibroblas) for white 2007 fibroblas (sowth 2007 fibroblas) fibroblas 2007 fibroblas 2	superfamily, men factor 18 moth ligand 1 moth ligand 1 motheraptic 44 arma 1-like arma 1-l	aning, family A (phosphoinositide main containing 2 21-5p in miRDB. Cene Description YOD1 deubiquitinase Fas ligand PH/SET domain 11 Vinculin Zinc finger protein 3G7 S-phase kinase associated prot transforming growth factor beat Interfeukin 12A RAB6D, member RAS oncogene adhesion G protein-coupled rece RaB6 GFF with domain and SP I(AG1 zinc finger recombination G arbitiquitin protein ligan CREB3 regulatury factor	5 5 6 6 175 183 1172 5 1172 5 1172 5 1172 103 1172 5 1172 1172 1172 1172 1172 1172 11	sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1		0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A         ENST           LG         ENST           1         ENST           18         ENST           19         ENST           10         ENST           11         ENST           12         ENST           13         ENST           14         ENST           15         ENST           16         ENST           17         ENST           18         ENST           19         ENST           11         ENST           12         ENST           13         ENST           14         ENST           15         ENST           16         ENST           115         ENST           1215         ENST	00003400 0000007258 0000000328 0000000328 00000003280 0000003280 0000003280 0000003820 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	2003 Fas ligand (TNF 2005 fibroblas) growth 2007 fibroblas (Sowth 2007 fibroblas) for the 2007 fibroblas (Sowth 2007 fibroblas) fibroblas 2007 fibroblas 200	superfamily, men factor 18 moth ligand 1 direceptor 64 oma 1-like org / domain conta momber 1 syl methionine do or hsa-miR- Gene Symbol YODI YODI YODI YODI YODI YODI YODI YODI	aning, family A (phosphoinositide main containing 2 21-5p in miRDB. 21-5p in miRDB. Gene Description YOD1 deubiquitinase Fas ligand PH/SET domain 11 Vinculin Zinc finger protein 3G7 S-phase kinase associated prot transforming growth factor beat Interfeukin 12A RAB6D, member RAS oncogene adhesion G protein-coupled rece RaB6GF member RAS oncogene adhesion G protein-coupled rece RaB6GF into finger PLAG1 zinc finger pellino E3 ubiquitin protein ligas CREB3 regulary factor (KRT1, ankyrin repeat containin Sem polycomb group protein ligas	5 5 6 6 1175 183 1172 5 1172 5 1172 5 1172 175 183 1172 5 1172 175 183 1172 5 1175 183 1172 5 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1172 5	Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1		0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A         ENSTI           LG         ENSTI           1	000003400 0000002746 0000002276 00000002278 00000002776 00000002778 00000002778 00000002778 000000002778 000000002778 000000002778 000000002776 00000002776 0000002776 00000002776 00000002776 00000002776 00000002776 00000002776 00000002776 000000002776 00000002776 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 000000002276 00000002276 000000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 00000002276 0000000276 0000000276 0000000276 0000000276 0000000000	20.3 Fas Igand (TWF 25.5 fibrobiast growth 25.5 fibrobiast growth 25.5 fibrobiast growth 25.6 fibrobiast growth 21.6 growth and 22.4 pieckstm homol binding specific) 21.8 growth and 22.4 pieckstm homol 21.4 growth and 21.5 pisar-miR-21.5p 1sar-miR-21.5p 1sar-miR-21.5p 1sar-miR-21.5p 1sar-miR-21.5p 1sar-miR-21.5p 1sar-miR-21.5p 1sar-miR-21.5p 1sar-miR-21.5p 1sar-miR-21.5p 1sar-miR-21.5p	superfamily, men factor 18 moth ligand 1 detreceptor 64 orma 1-like orma 1-lik	anng, famly A (phosphoinosilde main containing 2 21-5p in miRDB. Gene Description YOD1 deublayUrinase Fas Igand PR/SFT domain 11 Vinculin Zinc finger protein 367 S-phase Kinase associated pro- transforming growth factor beta Interleukin 12A RAB6D, member RAS oncogene adhesion & growth factor beta RAB6T, antyring repeat contailutin pro- tein ligator production pro-	5 5 6 6 1175 183 1172 5 1172 5 1172 5 1172 175 183 1172 5 1172 175 183 1172 5 1175 183 1172 5 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1175 183 1172 5	Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1		0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENST LG ENST LG ENST 1 EN	00003406 000002746. 000002258 000000258 000000258 000000258 000000258 000000258 000000258 000000258 000000258 000000258 000000258 000000058 00000000 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	2003 Fas ligand (TWF 2005) Repotent State 25 fibrobias growth 26 chemokine (C-C 21 g protein couple 21 glockstm homol binding specific) 21 absent in melan 22 fibrobias genetic) 20 radical S-adenor 21 glockstm homol binding specific) 20 radical S-adenor 21 glockstm homol 21 glockstm homol 22 fibrobias genetic) 23 radical S-adenor 24 glockstm homol 25 genetics and 25 glock 26 glockstm homol 27 glockstm homol 28 genetics and 21 specific 29 glockstm homol 29 glockstm homol 29 glockstm homol 29 glockstm homol 29 glockstm homol 29 glockstm homol 29 glockstm homol 20 glockstm homol 21 glockstm homol 22 glockstm homol 22 glockstm homol 23 glockstm homol 23 glockstm homol 24 glockstm homol 24 glockstm homol 25 glockstm homol 25 glockstm homol 26 glockstm homol 27 glockstm homol 27 glockstm homol 28 glockstm homol 29 glockstm homol 20 glockstm homol 20 glockstm homol 20 glockstm homol 21 glockstm homol 22 glockstm homol 23 glockstm homol 24 glockstm homol 25 glockstm homol 25 glockstm homol 26 glockstm homol 27 glockstm homol 27 glockstm homol 28 glockstm homol 29 glockstm homol 29 glockstm homol 20 glo	superfamily, men factor 18 moth ligand 1 direceptor (44 oma 1-like org / domain conta momber 1 yr hsa-miR- Gene Symbol YOD1 YOD1 YOD1 YOD1 YOD1 YOD1 YOD1 YOD1	anning, family A (phosphoinosilide main containing 2 21-5p in miRDB. Gene Description VOD1 deubloy/titinase Fas ligand PR/SET domain 11 vincelinger protein 367 PR/SET domain 12 vincelinger protein 367 PR/SET vincelinger domain and SE PR/SET vincelinger brother in SET projection 2000 PR/SET vincelinger domain contain Set polycomb group protein lik radical 3-addressy methioning on polybrono 1 GATA zince finger domain contain	sin 2 binduced family applor G2 is a binding m ober in for immi- is a 1	Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1		0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A ENST LG ENST LG ENST 1 EN	00003406 000002746. 000002258 000000258 000000258 000000258 000000258 000000258 000000258 000000258 000000258 000000258 000000258 0000000578 00000000 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	2003 Fas ligand (TWF 2005) Repotent State 25 fabric State 25 fabric State 21 chemokine (C-C 22 g protein couple 21 absent in melan 22 fabric State 21 absent in melan 23 fabric State 21 absent in 24 absent 24 absent in 24 absent 25 fabric State 26 absent 24 absent 26 absent 24 absent 24 absent 26 absent 24 abse	superfamily, men factor 18 moth ligand 1 direceptor (44 oma 1-like org / domain conta momber 1 yr hear-miRe- face Symbol y Opti Post Post Post Reference Ref	aning, famly A (phosphoinosilde main containing 2 21-5p in miRDB. Gene Description 2014 deubleutinase PR/SET domain 11 encel in the second second second second PR/SET domain 12A RABE0, member RAS encodes and PR/SET domain 12A RABE0, member RAS encodes and PR/SET domain 12A RABE0, member RAS encodes and PR/SET domain 12A RABE0, member RAS encodes and RABE0 provide second second second second recombination signal binding or peline E3 ubiguith protein like CREB aregulatory factor SET and refined second methologies of the polybrom 1 GATA zinc finger domain contain sprouty RTK signaling antagonis pleckstrin homology domain contain	sin 2 induced family pattor G2 is binduced family pattor G2 is binding m otelin for imm is 1 induced family pattor G2 is binding m is 2 is 2 induced family pattor G2 is 2 is 1 is 1 induced family pattor G2 is 2 is 2 is 2 is 2 is 2 is 2 is 2 is	Sites in UTR Sites in UTR	1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1		0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A         ENST           RLG         ENST           RLG         ENST           10         ENST           11         ENST           12         ENST           14         ENST           15         16           16         13           17         13           18         9           19         13           19         15           105         12           18         19           19         15           16         12           16         12           16         12           18         10           19         15           16         12           16         12           16         12           17         13           18         20 <tr< td=""><td>00003406 0000002746. 0000002586 0000002586 0000002580 0000003580 0000003580 0000003580 0000003580 0000003820 000003820 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9</td><td>2003 Fas ligand (TWF 2005) Fas ligand (TWF 2005) Robolast growth 2005) Robolast Growth 2</td><td>superfamily, men factor 18 moth ligand 1 direceptor 64 oran 1-like ory domain conta momber 1 syl methionine do or hsa-miR- Gene Symbol YOD1 YOD1 YOD1 YOD1 YOD1 YOD1 YOD1 YOD1</td><td>anng, famly A (phosphoinosilde main containing 2 21-5p in miRDB. Cene Description VOD1 deubleutinase Fas ligand PR/SET domain 11 vincelinger protein 367 PR/SET domain 12 vincelinger protein 367 PR/SET domain 12 vincelinger 2000 vincelinger 10 vincelinger 10 v</td><td>sin 2 induced family aptor G2 is binduced family aptor G2 is binding m otelin for imm is 1 ing 28 is 1 ttaining A1</td><td>sites in UTR Sites in UTR Sites</td><td>1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1</td><td></td><td>0 0 0 0 0 0</td><td>0 0 0 0 0 0 0 0 0 0 1 0</td><td>0 0 0 0 0 1</td><td>0 0 0 0</td><td>0 0 1 0 0 0</td><td>hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p</td><td>-0.64 -0.64 -0.62 -0.55 -0.55 -0.52</td><td>-0.64 -0.64 -0.64 -0.55 -0.55 -0.55</td><td>0.61 0.74 0.46 &lt; 0.1 0.55</td><td></td></tr<>	00003406 0000002746. 0000002586 0000002586 0000002580 0000003580 0000003580 0000003580 0000003580 0000003820 000003820 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	2003 Fas ligand (TWF 2005) Fas ligand (TWF 2005) Robolast growth 2005) Robolast Growth 2	superfamily, men factor 18 moth ligand 1 direceptor 64 oran 1-like ory domain conta momber 1 syl methionine do or hsa-miR- Gene Symbol YOD1 YOD1 YOD1 YOD1 YOD1 YOD1 YOD1 YOD1	anng, famly A (phosphoinosilde main containing 2 21-5p in miRDB. Cene Description VOD1 deubleutinase Fas ligand PR/SET domain 11 vincelinger protein 367 PR/SET domain 12 vincelinger protein 367 PR/SET domain 12 vincelinger 2000 vincelinger 10 vincelinger 10 v	sin 2 induced family aptor G2 is binduced family aptor G2 is binding m otelin for imm is 1 ing 28 is 1 ttaining A1	sites in UTR Sites	1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1		0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A         ENST           RLG         ENST           RLG         ENST           11         ENST           RLG         ENST           RIG         ENST           RIG         ENST	00003406 0000002746. 0000002258 000000258 000000258 000000258 000000258 0000003820 000003820 000003820 000003820 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	2003 Fas ligand (TWF 2005 Fas ligand (TWF 2005 fast control of the second second 2005 fast control of the second s	superfamily, men factor 18 moth ligand 1 di decaptor 64 orn 1-like ogy domain conte member 1 syl methionine do or hsa-miR- Cene Symbol y YoD1 FASLG PROMI1 VCL SKP2 FASLG PROMI1 VCL SKP2 FASLG PROMI1 VCL SKP2 FASLG PROMI1 VCL SKP2 FASLG PROMI1 VCL SKP2 FASLG PROMI1 VCL SKP2 FASLG PROMI1 VCL SKP2 FASLG PROMI SKR SKR SKR SKR SKR SKR SKR SKR SKR SKR	anna, famly A (phosphoinosilde main containing 2 21-5p in miRDB. Gene Description 221-5p id aubiquitinase Fas ligand 241-5p id aubiquitinase Fas ligand 245-5p in miRDB. Control and the second second 245-5p in miRDB. Control and the second second second second 245-5p in miRDB. Control and second second second second second second second 245-5p in miRDB. Control and second second second second second second second 245-5p in miRDB. Control and second seco	sin 2 binduced family applor 2 common containing an ing 28 is 1 ry subunit 38 re	sites in UTR Sites	1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1		0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A         ENST           LG         ENST           10         ENST           11         ENST           12         ENST           13         ENST           14         ENST           15         ENST           164         ENST           17         ENST           18         ENST           19         ENST           10         ENST           11	00003400 00000007258 9 predia 1 Target Target 99 99 99 99 99 99 99 99 99 9	210 3 Fas legand (TNF 225 finotoblas) growth 236 finotoblas (forwth 237 chemokine (C-C 232 G protein-couple 151 absent in melan 221 pleckstm homol binding specific) 103 ratical S-adenor 103 ratical S-adenor 104 ratical S-adenor 105 ratical	superfamily, men factor 18 moth ligand 1 di decaptor 64 orna 1-like orna 1-lik	aning, family A (phosphoinositide main containing 2 21-5p in miRDB. 21-5p in miRDB. Cene Description YOD1 deubiquitinase Fas ligand PH/SET domain 11 Vinculin Zinc finger protein 3G7 S-phase kinase associated prot transforming growth factor beat Interfeakin 12A RAB6D, member RAS oncogene adhesion G protein-coupled rece RAB6D, Tember RAS oncogene adhesion G protein-coupled rece RAB6F, member RAS oncogene adhesion G protein G protein liga CRAB (are finger domain contain growth RTK signaling antagonic pifekoftain homolyna factor II grotein phosphatase 1 regulator yes associated protein 1	sin 2 induced family pattoria binduced family pattoria binduced family get 2 formain conta mig 2 e 2 formain conta mig 2 e 2 formain conta mig 2 for formain conta mig 2 formain conta mig 2 formain conta mig 2 for formain conta mig 3 for formain c	sites in UTR Sites	1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1		0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	
A         ENST           LG         ENST           10         ENST           11         ENST           12         ENST           13         ENST           14         ENST           15         ENST           164         ENST           17         ENST           18         ENST           19         ENST           10         ENST           11	00003406 0000002746. 0000002258 000000258 000000258 000000258 000000258 0000003820 000003820 000003820 000003820 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	2003 Fas ligand (TWF 2005 Fas ligand (TWF 2005 fast control of the second second 2005 fast control of the second s	superfamily, men factor 18 moth ligand 1 direceptor (44 oma 1-like org / domain conta momber 1 yr hear-miRe- or hear-miRe- gene Symbol y yr methionne do yr hear-miRe- gene Symbol y yr hear mit a Absta PBM11 yr L Step Step Step Step Step Step Step Step	anna, famly A (phosphoinosilde main containing 2 21-5p in miRDB. Gene Description 221-5p id aubiquitinase Fas ligand 241-5p id aubiquitinase Fas ligand 245-5p in miRDB. Control and the second second 245-5p in miRDB. Control and the second second second second 245-5p in miRDB. Control and second second second second second second second 245-5p in miRDB. Control and second second second second second second second 245-5p in miRDB. Control and second seco	5 5 6 6 175 183 1172 5 183 1172 5 175 183 1172 183 1172 177 177 177 177 177 177 177 177 17	sites in UTR Sites	1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1		0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 1 0	0 0 0 0 0 1	0 0 0 0	0 0 1 0 0 0	hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p hsa-miR-21-5p	-0.64 -0.64 -0.62 -0.55 -0.55 -0.52	-0.64 -0.64 -0.64 -0.55 -0.55 -0.55	0.61 0.74 0.46 < 0.1 0.55	

Figure 36 screens of each database interrogated for hsa-miR-205-5p.

Symbol         HGNC:HII           Description         Karzo sar, Gene family         MIPP0000           Literature search         Juissian         Juissian           Stem-loop         Juissian         Juissian           Stem-loop         Juissian         Juissian           Beege         Juissian         Juissian           Beege         Juissian         Juissian           Beege         Secondaria         Juissian           Beege         Regressian         Juissian           Genes with only poorly conserver         Peege         Regressian           Biologones with only poorly conserver         Regressian         Regressian <t< th=""><th>A hear-min Res (change) IR205 IR205 IR206 IR205 IR207 IR20</th><th>2205</th><th>rs mention hsa-mir-205</th><th>e 7.2 now an D16 As oorly conserv ingets, irrespe</th><th>railable! garwal et al., : ed sites. ctive of site cor seq tags (or the</th><th>:015 servati</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></t<>	A hear-min Res (change) IR205 IR205 IR206 IR205 IR207 IR20	2205	rs mention hsa-mir-205	e 7.2 now an D16 As oorly conserv ingets, irrespe	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
Accession         MI000028           Symbol         HGNC:MII           Description         Homo syn HGNC:MII           Description         Homo syn HGNC:MII           Description         Homo syn HGNC:MII           Stem-loop         S           Stem-loop         S           Stem-loop         S           Stem-loop         S           Stem-loop         S           Stem-loop         S           Sequencing         1496079           Oranscripts with conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only convolution on the franceription on the presentative we table shows at most one to transcripts with conserved base note that these prediction of monos with only convolution on the franscription on the presentative we table Size in the presentative we table shows at most one to transcription on the presentative we table shows at most one to transcription on the presentative we table shows at most one to the presentative we the presentative we table shows at most one to transcription on the presentative we table shows at most one to the presentative we the presentative we table shows at most one to the presentative we table the presentative we table the presentative we the prese	IR205 IR205 IR205 IR207 IR205 IR207 IR	taining a total of include some fall ren of shown.	million, 140 experiments According to the second sites and 311 pp (Second sites and sites and 311 pp (Second sites and sites and sites and 311 pp (Second sites and site	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
Accession         MI000028           Symbol         HGNC:MII           Description         Homo syn HGNC:MII           Description         Homo syn HGNC:MII           Description         Homo syn HGNC:MII           Stem-loop         S           Stem-loop         S           Stem-loop         S           Stem-loop         S           Stem-loop         S           Stem-loop         S           Sequencing         1496079           Oranscripts with conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only poorly conserved base note that these prediction of monos with only convolution on the franceription on the presentative we table shows at most one to transcripts with conserved base note that these prediction of monos with only convolution on the franscription on the presentative we table Size in the presentative we table shows at most one to transcription on the presentative we table shows at most one to transcription on the presentative we table shows at most one to the presentative we the presentative we table shows at most one to transcription on the presentative we table shows at most one to the presentative we the presentative we table shows at most one to the presentative we table the presentative we table the presentative we the prese	IR205 IR205 IR205 IR207 IR205 IR207 IR	taining a total of include some fall ren of shown.	million, 140 experiments According to the second sites and 311 pp (Second sites and sites and 311 pp (Second sites and sites and sites and 311 pp (Second sites and site	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
Description         Home same           Gene family         MIPF0000           Literature         Improve same           Stem-loop         1           Sequencing         1           Marcol         1           Peops         1           Sequencing         1           Marcol         1           Seguencing         1           Marcol         Seguencing           Intrascripts         1           Seguencing         <	Access min-24 320 opp (1803 st access of the second access of	25 en access paper sentences) cevery curving gages e+03 reads per e+03 reads per argets	million, 140 experiments According to the second sites and 311 pp (Second sites and sites and 311 pp (Second sites and sites and sites and 311 pp (Second sites and sites and 311 pp (Second sites and sites and 311 pp (Second sites and si	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
Gene family         MIPF0000           Literature search         Juipfold           Stem-loop         Juipfold           Sequencing         Litefold           Sequencing         Litefold           Wana   miR-205-5p         Juipfold           Juipfold         Dranscripts with conserved asse note that these prediction of mi trated and set these prediction of mi reget and set these prediction           Kranz data         Representative tratestration         Representative tratestration           Kranz data         ENST0000037586.3         Hindig           Hondit ENST000000000000000000000000000000000000	acc acaa ucc	25 en access paper sentences) cevery curving gages e+03 reads per e+03 reads per argets	million, 140 experiments According to the second sites and 311 pp (Second sites and sites and 311 pp (Second sites and sites and sites and 311 pp (Second sites and sites and 311 pp (Second sites and sites and 311 pp (Second sites and si	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
Literature search	320 op (1803 st ucc acaa ucc acaa acu c acu	en access paper sentences)	million, 140 experiments According to the second sites and 311 pp (Second sites and sites and 311 pp (Second sites and sites and sites and 311 pp (Second sites and sites and 311 pp (Second sites and sites and 311 pp (Second sites and si	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
Search         Stem-loop           5tem-loop         5,************************************	(1803 : ucag ucag ague agu	eentences)	million, 140 experiments According to the second sites and 311 pp (Second sites and sites and 311 pp (Second sites and sites and sites and 311 pp (Second sites and sites and 311 pp (Second sites and sites and 311 pp (Second sites and si	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
5         ************************************	et sites, con transcript per	taining a total of include some fai are not shown.	And the second s	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
Image: Control of the second	active and an active and active activ	and a total of include some fail are not shown.	And the second s	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
Deep sequencing         1496079           sequencing         1496079           sequencing         sequencing           sequencing         reserved           sequencing         reserved     <	et sites, con microRNA tr ed sites, con cted targets reved sites a veighted con transcript pr	taining a total of include some fal re not shown. text++ score er gene, selected	Arrive State	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
Image: Second	etscomicroRNA to microRNA to ad sites, con cted targets i erved sites a veighted con transcript pr	taining a total of include some fal re not shown. text++ score er gene, selected	Release 7.1: June 20 624 conserved sites and 311 p [Se positives, [Read more] [View top predicted ta [Sort table by aggregate P <sub>CT</sub> d for being the most prevalent, b	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
Control of the second of	etscomicroRNA to microRNA to ad sites, con cted targets i erved sites a veighted con transcript pr	taining a total of include some fal re not shown. text++ score er gene, selected	Release 7.1: June 20 624 conserved sites and 311 p [Se positives, [Read more] [View top predicted ta [Sort table by aggregate P <sub>CT</sub> d for being the most prevalent, b	e 7.2 now an 016 Ag oorly conserv urgets, irrespe ] Dased on 3P-1 Number	railable! garwal et al., : ed sites. ctive of site cor seq tags (or the	:015 servati									
uman   miR-205-5p           30 transcripts with conserved ease note that these predict enes with only pooly conserved bible sorted by cumulative we le table shows at most one to most of a state of the transcript           wreet gene         Representative transcript           Representative wreet gene         Representative transcript           RCC1         ENST0000037980-3 NFAIPB           ENST0000037980-1 SINFAIPB         ENST0000039692-1 ENST0000035980-1 ENST00000035980-1 ENST00000035980-1 MITA           ENST000003578-14 SINTB11         ENST0000035980-1 ENST000002598-20           Intraft         ENST000002598-20           Netraft         ENST000002598-20           Intraft         ENST000002598-20	ed sites, con cted targets i erved sites a reighted con transcript pe	taining a total of nenclude some fal re not shown. text++ score er gene, selected	624 conserved sites and 311 p Ise positives. [Read more] [View top predicted ta [Sort table by aggregate P <sub>CT</sub> d for being the most prevalent, b	016 A oorly conserv irgets, irrespe ) based on 3P-t Number	garwal et al., ; ed sites. ctive of site cor seq tags (or the	servati									
uman   miR-205-5p           30 transcripts with conserved ease note that these predict enes with only pooly conserved bible sorted by cumulative we le table shows at most one to most of a state of the transcript           wreet gene         Representative transcript           Representative wreet gene         Representative transcript           RCC1         ENST0000037980-3 NFAIPB           ENST0000037980-1 SINFAIPB         ENST0000039692-1 ENST0000035980-1 ENST00000035980-1 ENST00000035980-1 MITA           ENST000003578-14 SINTB11         ENST0000035980-1 ENST000002598-20           Intraft         ENST000002598-20           Netraft         ENST000002598-20           Intraft         ENST000002598-20	ed sites, con cted targets i erved sites a reighted con transcript pe	taining a total of nenclude some fal re not shown. text++ score er gene, selected	624 conserved sites and 311 p Ise positives. [Read more] [View top predicted ta [Sort table by aggregate P <sub>CT</sub> d for being the most prevalent, b	016 A oorly conserv irgets, irrespe ) based on 3P-t Number	garwal et al., ; ed sites. ctive of site cor seq tags (or the	servati									
80 transcripts with conserved ease note that these predict enes with only poolly conserved bible sorted by cumulative we te table shows at most one to transcript           wroet gene         Representative transcript           RECT         ENST00000373880.3           NFAIPE         ENST00000373880.4           NFAIPE         ENST00000373880.4           NFAIPE         ENST0000037880.4           NFAIPE         ENST00000357831.4           SD17B11         ENST0000035880.4           DIOT131         ENST0000035820.4           MITA         ENST000002586.5           MEMIA4         ENST000002586.5           MEMIA4         ENST000002586.5           MEMIA4         ENST000002586.5           MEMIA4         ENST000002586.5           MEMIA4         ENST000002585.0	cted targets i erved sites a veighted con transcript pe	include some fal are not shown. text++ score er gene, selected	Ise positives. [Read more] [View top predicted ta [Sort table by aggregate P <sub>CT</sub> d for being the most prevalent, b	irgets, irrespe ] based on 3P-s	ctive of site cor seq tags (or the										
80 transcripts with conserved ease note that these predict enes with only pooly conserved bible sorted by cumulative we te table shows at most one to transcript           wroet gene         Representative transcript           RECT         ENST00000373880.3           NFAIPE         ENST00000373880.4           NFAIPE         ENST00000373880.4           NFAIPE         ENST0000037860.4           UI         ENST0000037860.4           NFAIPE         ENST0000035880.4           SD17BIT         ENST0000035820.4           100rd13         ENST0000035826.5           MEMTA         ENST0000025852.6           MEMTA         ENST0000025852.6           Target         Target           Target         Target<	cted targets i erved sites a veighted con transcript pe	include some fal are not shown. text++ score er gene, selected	Ise positives. [Read more] [View top predicted ta [Sort table by aggregate P <sub>CT</sub> d for being the most prevalent, b	irgets, irrespe ] based on 3P-s	ctive of site cor seq tags (or the										
80 transcripts with conserved lease note that these predict eness with only pooly conserved bable sorted by cumulative we hale sorted by cumulative we reaction of the transcript       arget gene     Representative transcript       Representative transcript     Representative transcript       ICC1     ENST00000379803 3       INFAIRE     ENST00000379804 3       INFAIRE     ENST000003690471 2       HN1     ENST0000036904 4       SD17B11     ENST0000036904 4       IO01131     ENST0000035963 4       SSST1     ENST000002696 5       MEM144     ENST000002696 5       MEM144     ENST000002696 5       MEM144     ENST000002696 5       S12     1     100       heat     Target     Target       Target     Target     Target       Extraction     1     100       heat     Sant     1       Extraction     3     90       heat     5     99       Stalls     5     99       Extails     7     98	cted targets i erved sites a veighted con transcript pe	include some fal are not shown. text++ score er gene, selected	Ise positives. [Read more] [View top predicted ta [Sort table by aggregate P <sub>CT</sub> d for being the most prevalent, b	irgets, irrespe ] based on 3P-s	ctive of site cor seq tags (or the										
lease note that these predict enes with only poorly conservation bele sorted by cumulative we re table shows at most one to transcript           arget gene         Representative transcript           NNI         ENST0000040900.3           EU1         ENST0000039800.3           100r131         ENST0000032802.6           MM17A         ENST0000028652.6           betatat         Ranget         Target           arget         Target         Target           arget         3         9           scalis         1         100           betalis         5         9           scalis         7         9           scalis         7         9	cted targets i erved sites a veighted con transcript pe	include some fal are not shown. text++ score er gene, selected	Ise positives. [Read more] [View top predicted ta [Sort table by aggregate P <sub>CT</sub> d for being the most prevalent, b	irgets, irrespe ] based on 3P-s	ctive of site cor seq tags (or the										
able sorted by cumulative we able sorted by cumulative we ne table shows at most one f           arget gene         Representative transcript           transcript         Representative transcript           transcript         ENST0000037880.3           NFAIPB         ENST000003588.1           NFAIPB         ENST000003588.1           UCC1         ENST000003588.1           UC1         ENST000003588.1           S017B1         ENST000003589.3           S017B1         ENST000003589.0           S017B1         ENST000003587.4           SSST1         ENST000002585.5           MEM144         ENST000002885.2           Here are 737 predicted         arget Target Target Target Core mitstall           stable 1         100         hss           stable 2         9         hss           stable 5         9         hss           stable 5         9         hss           stable 5         9         hss           stable 7         98         hss	veighted con transcript pe	text++ score er gene, selected	[Sort table by aggregate P <sub>CT</sub> d for being the most prevalent, b	based on 3P-	seq tags (or the										
Arget gene         Representative transcript           UCC1         ENST00000373686.3           UFAIP8         ENST00000375087.3           UFAIP8         ENST00000375031.4           US1         ENST00000375031.4           US1         ENST00000375031.4           US1         ENST00000375031.4           US1         ENST00000375031.4           SD17B11         ENST0000032692.6           MM17A         ENST000002596.5           MEM144         ENST0000026962.6           MEM144         ENST0000026962.6           Target         Target           Target <t< th=""><th></th><th></th><th></th><th>Number</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></t<>				Number											
Instruction         Transcript           ICC1         ENST0000037586.3           NFAIP8         ENST0000037586.3           IN1         ENST0000037563.1           Inords         ENST000003693.4           SD17B11         ENST000003863.4           Inords         ENST0000035820.4           MM17A         ENST000003582787.4           SSST1         ENST0000025865.4           MM17A         ENST0000025865.8           MEM144         ENST0000025865.8           Intereare         Target           Target         Target           Stalls         99           Stalls         99           Etalls         7           Etalls         7			Gene name	3P-seg		10 C	100000000000000000000000000000000000000	STREET, STREET				. [Downlo	ad table]	-	
CC1         ENST000037803           CC1         ENST000034703           CC1         ENST00003470344           HN1         ENST00003470344           H0160         ENST0000338203           SU1         ENST0000338203           SU1         ENST0000338203           SU1         ENST0000338203           SU17011         ENST0000338203           SU7011         ENST00000236526           MM17A         ENST00000286526           AEM144         ENST00000286526           AEM144         ENST00000286526           AEM144         ENST00000286526           AEM144         ENST0000286526           AEM144         ENST00000286526           AEM144         ENST0000286526           AEM144         ENST00000286526           AEM145         1           AEM144         ENST00000286526           AEM145         2           AEM146         ENST0000286526           AEM146         ENST0000286526           AEM146         ENST0000286526           AEM146         ENST0000286526           AEM146         9         hss           AEM15         9         hss           AEM15				tags	Link to	Conse	rved site	e Po	orly co	nserved	6m	er Representative	Cumulative weighted context++		Aggregat
IFAIPB         ENST000005047712           IN1         ENST000005047712           IN1         ENST00000350341           UI         ENST00000350341           SD7011         ENST00000350934           SD7011         ENST00000350934           SD7011         ENST00000350934           SD711         ENST00000236424           MM17A         ENST00000236452           AMM17A         ENST000002364526           AEM144         ENST0000025655           AEM144         ENST00000256526           AEM145         Introduction for the state st		homolog 1 /Drosonh		supportin UTR + 5	ng UTRs to	tal 8me	7mer- m8	A1 tot	al 8mer	7mer- m8	7mer-site A1	es miRNA	context++ score	score	Рст
N1         ENST00000406000.3           EU1         ENST00000376931.4           I10r80         ENST0000035802.4           S07781         ENST0000035820.6           100r131         ENST0000032872.6           S3ST1         ENST000002862.6           MM17A         ENST000002865.26           MEM144         ENST000002865.26           Preme         arrget         Target           Rank         ENST000002865.26           Statis         1         100           heat         Arrget         Target           Rank         ENST000002865.26         ENST000002865.26           Statis         1         100           heat         Arrank         ENST000002865.26           Statis         1         100           tatis         1         100           statis         3         99           statis         3         99           statis         5         99         Insa ctalis           zatis         5         99         Insa ctalis         7           zatis         7         98         Insa ctalis         98				165 608	Sites in UTR Sites in UTR		0	0 2			1 1 0 3	hsa-miR-205-5p hsa-miR-205-5p		-0.73	0.61
Hordba         ENST000003680634           SD17B11         ENST000003580634           SD17B11         ENST000003580634           SD17B11         ENST00000358764           S3ST1         ENST00000269654           MM17A         ENST00000269654           MM17A         ENST0000026965           MM144         ENST00000269659           Mem144         ENST00000269529           Intere are 737 predicted           araget         Target           Target         Target           Target         Target           Ramik         Score           Target         Target           Target		and function, supplier into	need protein o	344	Sites in UTR		0	1 0		0		hsa-miR-205-5p		-0.62	0.89
SD17B11         ENST00000358290.4           100r131         ENST00000352344.2           MM17A         ENST00000357287.4           SSS11         ENST00000298528.6           NEM144         ENST00000298528.6           Nemeta         Enst00000298528.6           Statis         1         100           Nemeta         Enst00000298528.6         Nemeta           Etalis         1         100         Inst000000000000000000000000000000000000				6000	Sites in UTR Sites in UTR	1 1 1 1	0	0 0		0		hsa-miR-205-5p		-0.62	0.33
100rf131         ENST00000423344 2           MM17A         ENST0000042787 4           S3ST1         ENST00000028658 6           HEM144         ENST00000028658 6           HEM144         ENST0000028658 6           HEM144         ENST0000028658 6           HEM144         ENST0000028658 6           HEM144         ENST0000028658 6           HEM145         ENST0000028658 6           HEM146         ENST0000028658 6           HEM145         ENST0000028658 6           HEM146         ENST0000028658 6           HEM145         ENST0000028658 6           HEM146         ENST000000000000000000000000000000000000				5 269	Sites in UTR		0	0 1	0	1	0 0			-0.61	0.35
S3STI ENST0000025665 MEM144 ENST00002565266 Argent Arget Target T	2 chromosom	e 10 open reading fr	Irame 131	5	Sites in UTR			0 0		0		hsa-miR-205-5p	-0.55	-0.55	0.72
HEM144 ENST00000284528 6 here are 737 predicted arget Target Target Score mi target 1 100 hss tabls 1 100 hss tabls 3 99 hss tabls 5 99 hss tabls 5 99 hss tabls 7 98 hss tabls 7 98 hss tabls 7 98 hss tabls 7 98 hss tabls 8 98 hss			rial membrane 17 homolog A (yeast)	5594 9	Sites in UTR Sites in UTR			0 1				hsa-miR-205-5p		-0.61	0.51
arget Target Target mit etail Rank Score mi etails 1 100 hsa etails 2 99 hsa etails 3 99 hsa etails 4 99 hsa etails 5 99 hsa etails 6 99 hsa etails 7 98 hsa etails 7 98 hsa			-sunouansierase i	131								hsa-miR-205-5p			< 0.1
reget Target Target mit etail Rank Score mit etails 1 100 hsa etails 2 99 hsa etails 3 99 hsa etails 4 99 hsa etails 5 99 hsa etails 6 99 hsa etails 7 98 hsa etails 7 98 hsa															
arget Target Target mit etail Rank Score mi etails 1 100 hsa etails 2 99 hsa etails 3 99 hsa etails 4 99 hsa etails 5 99 hsa etails 6 99 hsa etails 7 98 hsa etails 7 98 hsa				m	RD	3									
etail         Rank         Score         IIII           etails         1         100         hsa           etails         2         99         hsa           etails         3         99         hsa           etails         3         99         hsa           etails         5         99         hsa           etails         6         99         hsa           etails         7         98         hsa           etails         8         98         hsa	d targets	for hsa-miR-	205-5p in miRDB.												
etails         2         99         hsa           etails         3         99         hsa           etails         4         99         hsa           etails         5         99         hsa           etails         5         99         hsa           etails         6         99         hsa           etails         7         98         hsa           etails         8         98         hsa	niRNA Name	-	Gene Description												
ctails         4         99         hsa           etails         5         99         hsa           etails         5         99         hsa           etails         6         99         hsa           etails         6         99         hsa           etails         7         98         hsa           etails         8         98         hsa	a-miR-205-5 a-miR-205-5 a-miR-205-5	p <u>PPP2R2D</u>	modulator of smoothened protein phosphatase 2 regulatory	y subunit Bdelt	a										
etails         6         99         hsa           etails         7         98         hsa           etails         8         98         hsa	a-miR-205-5	p RAB11FIP1	BicC family RNA binding protein RAB11 family interacting protein	1											
etails 8 98 hsa	a-miR-205-5 a-miR-205-5	p <u>CHN1</u>	cyclin dependent kinase 19 chimerin 1												
	a-miR-205-5 a-miR-205-5	p <u>LPCAT1</u>	RNA binding motif protein 47 lysophosphatidylcholine acyltrans	sferase 1											
	a-miR-205-5 a-miR-205-5		AP2 associated kinase 1 BTB domain containing 3												
etails 11 97 hsa etails 12 97 hsa	sa-miR-205-5 sa-miR-205-5	p <u>NFAT5</u> p <u>TAPT1</u>	nuclear factor of activated T cells transmembrane anterior posterio	or transformati											
etails 13 97 hsa	a-miR-205-5 a-miR-205-5	p <u>MAP3K13</u>	mitogen-activated protein kinase protein tyrosine phosphatase, rec	e kinase kinase				-							
etails 15 97 hsa etails 16 97 hsa	a-miR-205-5 a-miR-205-5	p <u>CCN1</u> p <u>DSC2</u>	cyclin J desmocollin 2												
letails 17 97 hsa	a-miR-205-5 a-miR-205-5	p <u>C9orf153</u>	chromosome 9 open reading fran zinc finger protein 606	ne 153											
etails 19 96 hsa		p PLCB1	phospholipase C beta 1 calcitonin receptor like receptor					-							
etails 21 96 hsa	a-miR-205-5	p <u>CADM1</u>	cell adhesion molecule 1 zinc finger FYVE-type containing	16											
etails 23 96 hsa	sa-miR-205-5 sa-miR-205-5 sa-miR-205-5		cleavage and polyadenylation spe TNF alpha induced protein 8	ecific factor 6											
letails 25 96 hsa	sa-miR-205-5 sa-miR-205-5 sa-miR-205-5 sa-miR-205-5 sa-miR-205-5		cadherin 11 mahogunin ring finger 1					-							
letails 27 96 hsa	a-miR-205-5 a-miR-205-5 a-miR-205-5 a-miR-205-5 a-miR-205-5 a-miR-205-5 a-miR-205-5 a-miR-205-5	p TNFAIP8 p CDH11			AREs 1B			-							
letails 29 95 hsa	sa-miR-205-55 sa-miR-205-55 sa-miR-205-55 sa-miR-205-55 sa-miR-205-55 sa-miR-205-55 sa-miR-205-55 sa-miR-205-55	p         TNFAIP8           p         CDH11           p         MGRN1           p         C11orf86	chromosome 11 open reading fra vesicle transport through interact												
letails 30 95 hsa	sa-miR-205-5 sa-miR-205-5 sa-miR-205-5 sa-miR-205-5 sa-miR-205-5 sa-miR-205-5 sa-miR-205-5 sa-miR-205-5	P         TNFAIP8           p         CDH11           p         MGRN1           p         C11orf86           p         VTI1B           p         LRP6	vesicle transport through interact LDL receptor related protein 6 heparan sulfate-glucosamine 3-si	ulfotrapeforace											

On liver tissue, the following miRNAs were tested: hsa-miR-21-5p, hsa-miR-122-5p, hsa-miR-132-3p, hsa-miR-155-3p. The screens of each database questioned for the hsa-miR-21-5p are reported in figure 35.

Figure 37 screens of each database interrogated for hsa-miR-122-5p.

miRBas	se									m	iRBas	е												MANCH	82 82
ome Sear	rch	Browse	Help Do	wnload	Blog	Sub	mit hsa-r	mir-122																	
em-loo	op s	equen	ce hsa	-mir-	122																				
Acce	ssio	MI000	0442 <u>(ch</u>	ange log	g)																				
Previou	IS ID	s hsa-m	ir-122a																						
Sy	mbo	HGNC	:MIR122																						
Descri	iptio	n <u>Homo</u>	<u>sapiens</u> I	miR-122	stem-	loop																			
Gene f	amil	MIPF0	000095;	<u>mir-122</u>																					
Liter s	atur earc			<mark>62 oper</mark> 3957 sei			s mention	hsa-mir-1	22																
Stem	I-looj Deej	5' cu    3' 88 c Get se	uagcag ag           aucguc uc a quence	gaua uc aa	acacu a	uuaccgca	u c lili li aaac ca a uau a		nte																
seque		9				i.				gawaac															
		ara	ets	6	ınl	Hu	mai	n	Release	7.2 now a	vailable!														
<b>V</b>	Pre	diction of		NA tar	gets		mai	Release 7	Release 7.1: June 201		garwal et d	al., 20	015												
uman   m 20 transcri			rved sites	s, contai	ining a	total of	228 conse	erved sites	s and <b>131</b> po	orly conser	ved sites.														
lease note	that	these pre	dicted ta	rgets ind	clude s	ome fal	se positive	es. [Read	more]					11											
enes with able sorted									predicted targ pregate P <sub>CT</sub> ]	jets, irrespo	ective of site	cons	servat	lion											
ie table sh	nows	at most o	ne transc	ript per	gene,	selected	d for being	g the most	prevalent, ba	sed on 3P-	seq tags (o									a tie)	. [Downle	oad table]			
farget gene	R	epresentat	ive				Gene name			3P-seq tags	Link to		Consei	rved si	L	Poor	rly cor	7mer-	_	6mer	Representative	Cumulative weighted		Aggregat	te
		transcript								supportin	g UTRs	total	8mer	7mer- m8	A1	total	8mer	m8	7mer- A1	sites	miRNA	context++ score	score	Рст	
				_						UTR + 5															
		T00000574								2165	Sites in UTF		1	0	0	1	1	0	0		hsa-miR-122-5p hsa-miR-122-5p		-0.82	< 0.1	
LDOA FXAP	ENS	T00000569	798.1 aldo 476.2 regu	lase A, fru latory fac	uctose-b tor X-as	isphosph sociated	ate protein			2165 21644 682	Sites in UTF Sites in UTF	1 1 1	1	0	0	1 4 1	1 0	1	0 2 0	1 0	hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72	-0.84 -0.72	0.55 < 0.1	
LDOA FXAP LEKHB2	ENS ENS ENS	T00000569	798.1 aldo 476.2 regu 882.2 plec	lase A, fru latory fac kstrin hon	uctose-b tor X-as nology d	isphosph sociated   lomain co	ate protein intaining, fam	nily B (evecti C4/C2 activa	ins) member 2 ting component	2165 21644 682 1358	Sites in UTR Sites in UTR Sites in UTR	1 1 1 1	1	0	0	1 1	1 0 1	1 1 0	0 2 0 0	1 0 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72	-0.84 -0.72 -0.75	0.55 < 0.1 < 0.1	
LDOA FXAP LEKHB2 IASP1	ENS ENS ENS	T00000569 T00000255 T00000438 T00000296	798.1 aldo 476.2 regu 882.2 plec 280.6 man of R	lase A, fru Ilatory fac kstrin hon nan-bindi a-reactive	tor X-as nology d ing lectir factor)	isphosph sociated   lomain co n serine p	ate protein intaining, fam	nily B (evecti C4/C2 activa	ins) member 2 ting component	2165 21644 682	Sites in UTF Sites in UTF	1 1 1 1 2	1 1 1	0	0 0 0	1	1 0	1	0 2 0	1 0 0 3	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70	-0.84 -0.72	0.55 < 0.1	
LDOA FXAP LEKHB2 IASP1 LIC4	ENS ENS ENS ENS	T00000569 T00000255 T00000438 T00000296	798.1 aldo 476.2 regu 882.2 plec 280.6 of R 379.4 chlo	lase A, fru ilatory fac kstrin hon nan-bindi a-reactive ride intrac	uctose-b tor X-as nology d ing lectir factor) cellular c	isphosph sociated ( lomain co n serine p channel 4	ate protein intaining, fam eptidase 1 (C	C4/C2 activa	iting component	2165 21644 682 1358 838 226	Sites in UTF Sites in UTF Sites in UTF Sites in UTF	1 1 1 1 2 2 2	1 1 1	0	0 0 0 0	1 1 0	1 0 1 0	1 1 0 0	0 2 0 0	1 0 0 3	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68	-0.84 -0.72 -0.75 -0.70 -0.68	0.55 < 0.1 < 0.1 0.59 0.36	
LDOA FXAP LEKHB2 ASP1 LIC4 LC52A2	ENS ENS ENS ENS ENS	T00000569 T00000255 T00000438 T00000296 T00000374	798.1 aldo 476.2 regu 882.2 plec 280.6 of R 379.4 chlo 752.1 solu 748.4 prote	lase A, fru ilatory fac kstrin hon nan-bindi a-reactive ride intrac te carrier ein kinase	uctose-b tor X-as nology d ing lectin factor) cellular c family 5.	isphosph sociated p lomain co n serine p channel 4 2 (riboflav	ate protein intaining, fam eptidase 1 (C vin transporte	C4/C2 activa er), member	ting component	2165 21644 682 1358 838 226 483	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 1	1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDOA IFXAP LEKHB2 IASP1 ILIC4 LC52A2	ENS ENS ENS ENS ENS	T00000569 T00000255 T00000438 T00000296 T00000374	798.1 aldo 476.2 regu 882.2 plec 280.6 of R 379.4 chlo 752.1 solu	lase A, fru ilatory fac kstrin hon nan-bindi a-reactive ride intrac te carrier ein kinase	uctose-b tor X-as nology d ing lectin factor) cellular c family 5.	isphosph sociated p lomain co n serine p channel 4 2 (riboflav	ate protein intaining, fam eptidase 1 (C vin transporte	C4/C2 activa er), member	iting component	2165 21644 682 1358 838 226	Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 1	1 1 1 1 1	0 0 1 1	0 0 0 0 0 0	1 1 0	1 0 1 0	1 1 0 0	0 2 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68	0.55 < 0.1 < 0.1 0.59 0.36	
LDOA FXAP EEKHB2 ASP1 LIC4 LC52A2 RKRA	ENS ENS ENS ENS ENS	T00000569 T00000255 T00000438 T00000296 T00000374 T00000526 T00000526	798.1 aldo 4762.2 piec 280.6 man 379.4 chio 752.1 solu 748.4 prot activ	lase A, fru latory fac kstrin hon nan-bindi a-reactive ride intrac te carrier ein kinase ator	tor X-as nology d ng lectire factor) cellular c family 5 e, interfe	isphosphi sociated p tomain con a serine p channel 4 2 (riboflav ron-induc	ate protein Intaining, fam eptidase 1 (C vin transporte ible double s	C4/C2 activa er), member stranded RN	2 A dependent	2165 21644 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
EDOA EXAP EKHB2 ASP1 LIC4 .C52A2 RKRA	ENS ENS ENS ENS ENS ENS ENS	T00000569 T00000255 T00000438 T00000296 T00000374 T00000325	1 aldo 4762 regu 8822 plec 280.6 of man 379.4 chlo 752.1 solu 748.4 prot activ ted targ	lase A, fru latory fac kstrin hon nan-bindi a-reactive ride intrac te carrier ein kinase rator	tor X-as nology d ing lecting factor) cellular c family 5 b, interfe	isphosphi sociated j tomain co h serine p channel 4 2 (riboflav ron-induc	ate protein Intaining, fam eptidase 1 (C vin transporte ible double s	C4/C2 activa er), member stranded RN in miRD	2 A dependent	2165 21644 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDOA FXAP LEKHB2 ASP1 LIC4 LC52A2 RKRA ACC2A2 RKRA ACC2A2 RKRA C2A2 RKRA	ENS ENS ENS ENS ENS ENS ENS ENS ENS	T00000589 T00000255 T00000438 T00000374 T00000526 T00000325 T00000325	1 aldo 1 aldo	lase A, fru latory fac kstrin hon nan-bindi a-reactive ride intrac te carrier ein kinase rator gets fo Name 122-5p	uctose-b tor X-as noglectin e factor) :ellular c family 5 b, interfe br hsa Gene HN Cf	isphosph sociated j tomain co a serine p channel 4 2 (riboflav ron-induc a-miR- Symbol RNPU EB1	ate protein intaining, fam eptidase 1 (C vin transporte ible double s 122-5p i heterogen cytoplasm	c4/C2 activa er), member stranded RN in miRD scription neous nuclei nic polyade	2 A dependent	2165 21644 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDOA FXAP EKHB2 ASP1 LIC4 LC52A2 RKRA RKRA RKRA A RKRA Tetails 2 etails 3 etails 3 etails 3	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	T00000569 T00000255 T00000438 T00000326 T00000374 T00000325 T00000325 T00000325 T00000325 T00000325 T00000325 T00000325 T00000325	798 1 aldo 476 2 regu 882 2 plec 280 6 man of R 379.4 chlo 752 1 solu 752 1 solu 755 1 s	lase A, fr. kstrin hon nan-bindi kiride intrac- te carrier ein kinase ein kinase pets for Name 122-5p 122-5p 122-5p	uctose-b tor X-ass nology d ing lectir factor) ; factor) ; factor ; factor) ; factor ; factor) ; factor ; fact	lisphosph sociated fomain co s serine p s se	ate protein intaining, fam eptidase 1 (C in transporte ible double s 122-5p i Gene Ogen heterogen Cytoplasm CD40 Ilgan Zhirc finger	C4/C2 activa er), member stranded RN in miRD scription neous nucle nol polyade ind r protein 8.	2 A dependent B. ear ribonucleop nylation eleme 27 27	2165 21644 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDOA FXAP EXAP LEKHB2 ASP1 LIC4 LC52A2 RKRA ACCESA2 RKRA ACCESA2 RKRA ACCESA2 EXAP Etails 2 etails 3 etails 3 etails 3 etails 3	ens ens ens ens ens ens ens ens ens ens	T00000569 T00000255 T00000438 T00000296 T00000374 T00000325 T00000325 T00000325 T00000325 T00000325 T00000325 T00000325 T00000325	1 aido 1 aido 1 aido 1 aido 1 co 1 co	lase A, fm latory fac kstm hononan-bind kstm hononan-bind ride intrac- te carrier en kinase ator gets for Name 122-5p 122-5p 122-5p 122-5p 122-5p	uctose-b- tor X-as nology d ing lectir e factor) family 5 b, interfe HN CC CD ZN ANK G	isphosph sociated j tomain co serine p channel 4 2 (riboflav 2 (ri	ate protein intaining, fam eptidase 1 (C in transporte ible double s 122-5p i facenc Des cytoplasm CD40 ligar zinc finger ankyrine rs	c4/c2 activa er), member stranded RN in miRD scription reous nucle in polyade in polyade r protein 8; speat doma synthase 1	2 A dependent B. ear ribonucleop nylation eleme 27 in 13C	2165 21644 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDOA FXAP FXAP LEKHB2 IASP1 LIC4 LC52A2 RKRA LC52A2 RKRA A RRRA A Retails 2 etails 2 etails 2 etails 2 etails 2 etails 2 etails 2 etails 2 etails 2 etails 2 retai 2 retai R R R R R R R R R R R R R R R	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	T00000569 T00000438 T00000438 T00000438 T00000374 T00000376 T00000376 T00000325 T00000325 T00000325 T00000325 T00000325 T00000325 T00000325	1 aidd 476 2 regu 882 2 piec 280 6 of R 379 4 cho of R 379 4 cho of R 1752 1 solu 752 1 solu 752 1 solu 753 4 profession 754 4 profession 755 4 solution 755	lase A, fm liatory fac kstrin hon- indi - hendriv ride intrac- te carrier ein kinase ator	uctose-b- tor X-as nology d ing lectir e factor) sellular c sellular c family 5 b, interfe hing Gene Hing Cf CD Ziny Ank Gane Chan Cf CD Chan Chan Chan Chan Chan Chan Chan Chan	isphosph sociated j tomain co a serine p channel 4 2 (riboflax 2 (riboflax 4 (	ate protein intaining, fam epidase 1 (C in transporte bible double s bible double s <b>122-5p i</b> <b>Gene Des</b> heterogen cytoplasm CD40 ligat zinc finger ankyrin re gNycogen s RAN bindli solute car	C4/C2 activa er), member stranded RN in miRD scription neous nucle inc polyade ind r protein 8: epeat doma synthas 1 ing protein rifer family	2 A dependent B. ear ribonucleop nylation eleme 27 in 13C	2165 21644 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LEGA FXAP LEKABZ LEKABZ LASP1 LIC4 LC52A2 RKRA LC52A2 RKRA Calis 1 ctalis 2 ctalis 3 ctalis 3	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	100000680 100000259 100000438 100000259 100000438 100000274 100000228 100000228 100000228 100000228 100000228 100000228 10000028 10000028 10000028 10000028 100000488 1000000488 1000000488 1000000488 100000488 100000488 100000488 100000488 100000488 100000488 100000488 100000488 100000488 100000028 100000028 100000000 1000000000 100000000 10000000	1981 aidd 4762 regu 882 2 piec 2000 6 man of R 2000 6 man of R	lase A, fm liatory fac skrim hom- inde intrac- te carrier ein kinase altor gets for li22-5p li	uctose-b tor X-as nology d ng lectir sfactor) sellular c family 5 b, interfe Gene HIN CI CD ZN ZN ANK G RAT SLC MI	isphosph sociated   formain co a serine p shannel 4 2 (riboflav ron-induc 2 (riboflav ron-induc 2 (riboflav ron-induc 3 (riboflav 2 (riboflav 5 (riboflav 4 (ribof	ate protein intaining, fam epidase 1 (C in transporte bible double s bible double s <b>1222-5p i</b> <b>Gene Des</b> heterogen Cytoplasm CD40 ligar Zinc finger ankyrin re galycogen s RAN bindit solute carn wyosn IX WD repeat	c4/c2 activa er), member stranded RN in miRD scription heous nuclei nd repeated on succeive ind repeated on succeive ind repeated on succeive synthase 1 ing protein man 4 synthase 1 ing protein man 4 ing protein man 4 ing protein man 4 synthase 1 ing protein man 4 ing protein man 4 synthase 1 ing protein man 4 synthase 1 synthase 1 synth	A dependent     B.     Br     arr ribonucleo     pnylation eleme     27     in 13C     3 like     52 member 2 7 7	2165 21844 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDOA LDOA LDOA FXAP LEKH02 LICK LEKH02 LICK LCS3A2 LICK LCS3A2 LICK A LCS3A2 LICK LCS3A2 L	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	10000059 100000259 100000259 100000259 100000259 100000526 100000526 100000526 100000526 100000526 10000526 10000526 10000526 10000526 100000526 100000526 100000526 100000526 100000526 100000526 100000526 100000526 100000526 100000526 100000526 100000526 100000526 100000526 100000526 100000526 10005526 1000556 1000556	1981 aido 476.2 reguest 882.2 piece market and a second man of R 379.4 chilo and a second rot and rot and rot and rot and rot	lase A, fm liatory fac kstrin hom a-reactive te carrier te carrier	uctose-b tor X-as nology d is factor) :ellular c family 5 b, interfe b, interfe HN CD CD CD CD CD CD CD CD CD CD CD CD CD	kisphosph sociated j formain co a serine p channel 4 2 (riboflax 2	ate protein intraining, fam eptidase 1 (C intransportei ible double s 122-5p i 122-5p i 122-5p i 122-5p i 122-5p i solute car gama-ar TBC1 dom	c4/c2 activa er), member stranded RN scription neous nucle nic polyade nic pol	A dependent     A dependent     B.     Br     ar ribonucleoon     in 13C     3 like     52 member 108     7 c acid type A a     member 108	2165 21844 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDDA LDDA LDDA LDDA LDDA FXAP FXAP FXAP LLCA LLCA LLCA LLCA LLCA LCS2A2 RKRA	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	100000569 100000256 100000268 100000268 100000268 100000268 100000526 10000526 10000526 10000526 10000526 1000055 1000055 1000055 1000055 1000055 1000055 1000055 1000055 1000055 1000055 1000055 1000055 1000055 1000055 1000055 1000055 100005 1000055 1000055 1000055 100000000	1986 1 aido 476 2 rego 882 2 piece 6 mar 280 6 mar 280 6 mar 280 6 mar 280 7 280 7 200 7 2	lase A, fm liatory fac skifin hom a-reactive te carrier te carrier	uctose-b tor X-as nology de family 5 cellular c family 5 c, interfe entropy family 5 c family 5 c f	kisphosph sociated   domain co is serine p channel 4 2 (riboflax ron-Induc 2 (riboflax ron-Induc 2 (riboflax ron-Induc 2 (riboflax 2 (ribo	ate protein infaining, fam epitidase 1 (C infaining, fam epitidase 1 (C infaining, fam epitidase 1 (C infaining, fam epitidase 1 (C infaining) CD40 ligat 20/cogen 2 RAN bindli solute car myosin IX WD repeat gamma-at TBC1 dom SEC22 hot RAB, mem	c4/c2 activa er), member stranded RN scription neous nucle nic polyade nic pol	A dependent     A dependent     A dependent     an a second	2165 21844 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDOA LDOA LDOA LDOA LDOA LLOA LLOA LLOA	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	170000569 1700000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 17000448 1700048 170	1986 1 aido 476 2 regu 882 2 piece 6 mar ado 882 2 piece 6 mar ado 4 mar ado 1974 4 chio 752 1 solution 752 1 solution 753 1 s	lase A, fr. kstin hoa a-bectward a-bectward ride intract te carrier te carrie	uctose-b tor X-as nology d g lectir family 5 family 5 b, interfe d family 5 c family 5 c	isphosph socialed j formain co serine p serine p 2 (riboflav ron-induc 2 (riboflav ron-i	ate protein infaining, fam epitidase 1 (C in transportei ible double s 122-5p i 122-5p i 122-5p i 122-5p i 122-5p i solute car ankyrin re ankyrin re ankyr	c4/c2 activa er), member stranded RN scription neous nucle ind polyade metic polyade metic polyade synthase 1 ring protein 8; epeat dome synthase 1 th domain 4 th domain 4 minobutyri nain family molog C, v mber RAS o ujdraxylase izclicitate sylicitate	A dependent     A dependent     A dependent     an a second	2165 21844 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDOA LDOA LDOA LDOA LDOA LLOA LLOA LLOA	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	170000569 1700000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 170000438 17000448 170004	768 1         aldo           7768 1         aldo           776 2         regular           776 2         776 2           788 2         plec           788 3         plec           787 4         plec           788 4         plec	lase A, fr. later A, fr. kstim hon an-bindi a-teactive tide intrac te carrier in kinase ator 122-5p	uctose-b tor X-as nology d p lactir p factor) cellular c family 5 b, interfe d m c m c m c m c m c m c m c m c m c m	isphosph socialed j formain co serine p serine p 2 (riboflav ron-induc 2 (riboflav ron-i	ate protein intaining, fam epitidase 1 (C in transportei ible double s 122-5p i 122-5p i 122-	er), member er), member erstranded RN erstranded RN erstrander RN erstra	B.  A dependent  A dependent  B.  ar ribonucleop  rylation eleme  rylation eleme  r  r  r  r  r  r  r  r  r  r  r  r  r	2165 21844 682 1358 838 226 483 632	Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF Sites in UTF	2 1 2 1 2 2 2 2 2 2 2 1 2 1	1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDOA LDOA LDOA LDOA LDOA LLOA LLOA LLOA	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	170000569 1700000259 1700000438 1700000438 1700000259 1700000059 1700000529 1700000529 1700000529 1700000529 1700000529 1700000529 170000559 170000559 170000559 170000559 170000559 170000559 170000559 170000559 170000559 170000559 170000559 170000559 170000559 170000559 17005	798 1         aldo           476 2         regular           478 2         regular           482 2         pick           280 6         off R           370 4         chio           371 4         chio           372 4         chio           748 4         polytic           scitu         scitu           144         scitu           145         scitu           146         scitu           146         scitu           146         scitu           147         scitu           148         scitu <tr< td=""><td>lase A, fr. latary fac. skisin hon- nan-bindidiskisin hon- nan-bindidiskisin hon- a - eactive te carrier ein kinase ator laz-Sp</td><td>uctose-b tor X-as nology d participation of the station of the sta</td><td>isphosph sociated j comain coo societa j channel 4 2 (ritoflax 2 (</td><td>ate protein infaining, fam epitidase 1 (C in transportei ible double s 122-5p i 122-5p i 122-</td><td>er), member er), member erstranded RN erstranded RN erstrander RN erstra</td><td>A dependent     A dependent     A dependent     B.     ar ribonucleogn     ar ibonucleogn     in 13C     3 like     52 member 2     7     a cacid typa 10     seicle trafficki     nocogene fami     subunit alphanthase     channe 5     7     c anion transpo</td><td>2165 21844 682 1358 838 226 483 632 The second sec</td><td>Sites in UTF Sites in UTF</td><td></td><td>1 1 1 1 1 1 1</td><td>0 0 0 1 1</td><td>0 0 0 0 0 0 0 0 0</td><td>1 1 0 0</td><td>1 0 1 0 0</td><td>1 1 0 0 0</td><td>0 2 0 0 0 0</td><td>1 0 3 0</td><td>hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p</td><td>-0.79 -0.72 -0.72 -0.70 -0.68 -0.66</td><td>-0.84 -0.72 -0.75 -0.70 -0.68 -0.66</td><td>0.55 &lt; 0.1 &lt; 0.1 0.59 0.36 0.30</td><td></td></tr<>	lase A, fr. latary fac. skisin hon- nan-bindidiskisin hon- nan-bindidiskisin hon- a - eactive te carrier ein kinase ator laz-Sp	uctose-b tor X-as nology d participation of the station of the sta	isphosph sociated j comain coo societa j channel 4 2 (ritoflax 2 (	ate protein infaining, fam epitidase 1 (C in transportei ible double s 122-5p i 122-5p i 122-	er), member er), member erstranded RN erstranded RN erstrander RN erstra	A dependent     A dependent     A dependent     B.     ar ribonucleogn     ar ibonucleogn     in 13C     3 like     52 member 2     7     a cacid typa 10     seicle trafficki     nocogene fami     subunit alphanthase     channe 5     7     c anion transpo	2165 21844 682 1358 838 226 483 632 The second sec	Sites in UTF Sites in UTF		1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDDA LDDA LDDA LDDA LDA LDA LDA LDA LDA	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	170000569 1700000259 1700000438 1700000438 1700000438 1700000258 1700000058 1700000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 170000258 1700000058 170000000 170000000 1700000000 1700000000 1700000000 17000000000 1700000000 1700000000 17000000000 1700000000 17000000000 170000000000	1981 aldo 476 2 regular 476 2 regu	lase A, fr. latary fac. skisin hon- nan-bindi a - eactive skisin hon- nan-bindi a - eactive te carrier air kinase alor laz-Sp	uctose-b- tor X-ass nology d :eliular c family 5 o, interfe d o, interfe d o, interfe d non c no c non c no c non c non c no c n n n n n n n n n n	isphosph sociated j comain coo serine p channel 4 2 (riboflax ron-induc aron-	ate protein intraining, fam epitidase 1 (C in transportei ible double s 122-5p i 122-5p i	er), member er), member erstranded RN erstranded RN erstranded RN erstrander RN erstra	B.     B.     Compared to the second se	2165 21844 682 1358 838 226 483 632 The second sec	Sites in UTF Sites in UTF		1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDDA LDDA LDDA LDDA LDA LDA LDA LDA LDA	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	170000560 170000258 170000258 170000026 170000026 170000026 170000026 170000026 170000025 17000025 17000025 17000025 17000025 17000025 17000025 17000025 17000025 17000025 17000025 17000025 1700005 17000025 1700005	768 1         aldo           476 2         reg           820 6         of R           780 1         aldo           780 4         of R           780 4         chio           780 4         chio           780 4         chio           781 4         prof.           782 4         prof.           783 4         prof.           800 8         miRNA           194 9         miR           194 9         miR <td>lase A, fn lase A, fn nan-bindi e-teacher e-teacher te carrier ini kinasse rater nini kinasse rater nini nini nini nini nini nini nini ni</td> <td>uctose-b tor X-as nology d pipetin factor) family 5 b, interfe entry 5 c, interfe entry 5</td> <td>sociated j sociated j channel 4 2 (riboflav ron-induc 2 (riboflav ron-induc 2 (riboflav ron-induc 2 (riboflav 2 (r</td> <td>ate protein intraining, fam epitidase 1 (C in transportei ible double s 122-5p i Gene Des heterogen cytoplasm CD40 ligat zinc finger ankyrin re ankyrin re</td> <td>and the provided and the provided and</td> <td>2 A dependent 2 B. ear ribonucleop mylation eleme 27 ain 13C 3 like 52 member 108 reside traffakti subunt aphentika chanel 5 7 c acid type A termine traffakti subunt aphentika chanel 5 7 c anion transperfamily memil Te binding 1 est-5-phosphate 1</td> <td>2165 21644 682 1358 838 226 483 632</td> <td>Sites in UTF Sites in UTF sites</td> <td></td> <td>1 1 1 1 1 1 1</td> <td>0 0 0 1 1</td> <td>0 0 0 0 0 0 0 0 0</td> <td>1 1 0 0</td> <td>1 0 1 0 0</td> <td>1 1 0 0 0</td> <td>0 2 0 0 0 0</td> <td>1 0 3 0</td> <td>hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p</td> <td>-0.79 -0.72 -0.72 -0.70 -0.68 -0.66</td> <td>-0.84 -0.72 -0.75 -0.70 -0.68 -0.66</td> <td>0.55 &lt; 0.1 &lt; 0.1 0.59 0.36 0.30</td> <td></td>	lase A, fn lase A, fn nan-bindi e-teacher e-teacher te carrier ini kinasse rater nini kinasse rater nini nini nini nini nini nini nini ni	uctose-b tor X-as nology d pipetin factor) family 5 b, interfe entry 5 c, interfe entry 5	sociated j sociated j channel 4 2 (riboflav ron-induc 2 (riboflav ron-induc 2 (riboflav ron-induc 2 (riboflav 2 (r	ate protein intraining, fam epitidase 1 (C in transportei ible double s 122-5p i Gene Des heterogen cytoplasm CD40 ligat zinc finger ankyrin re ankyrin re	and the provided and	2 A dependent 2 B. ear ribonucleop mylation eleme 27 ain 13C 3 like 52 member 108 reside traffakti subunt aphentika chanel 5 7 c acid type A termine traffakti subunt aphentika chanel 5 7 c anion transperfamily memil Te binding 1 est-5-phosphate 1	2165 21644 682 1358 838 226 483 632	Sites in UTF Sites		1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
2etails         3           4etails         4           4etails         4           4etails         4           4etails         5           4etails         6           4etails         6           4etails         6           4etails         6           4etails         6           4etails         1           4etails         1           1         1           4etails         1           4etails         1           1         1           4etails         1           4etails         1           4etails         1           4etails         2           4etails         2           4etails         2           4etails         2           4etails         2           4etails         2	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	170000569 1700000259 1700000438 1700000438 170000029 17000029 170000029 17000000 17000000 17000000 170000000 170000000 170000000 170000000 170000000 170000000 170000000 170000000 1700000000 1700000000 17000000000 170000000000	1984 addo 4776 2 regular 4786 2 regular 2806 6 wR 3704 4 chio 9752 1 solut 7484 9 profession 7484 9 profesion 7484 9 pro	lase A, fn lase A, fn nan-bindi kstrin hon nan-bindi te carrier ini kinass nator nan-bindi te carrier ini kinas nator nan-bindi te carrier ini ini kinas nator nan-bindi te carrier ini kinas nator nan-bindi te carrier ini kinas nator nan-bindi te carrier ini kinas nator nan-bindi te carrier ini kinas nator nan-bindi te carrier ini kinas nator nan-bindi te carrier ini kinas nan-bindi te carrier ini kinas nator nan-bindi te carrier	uctose-b tor X-as nology d pr hsa or hsa centre interference interference contr	sociated j sociated j onain colomain co	ate protein intraining, fam epitidase 1 (C in transportei ible double s 122-5p i 122-5p i	er), member er), member stranded RN er), member stranded RN er), member er, m	2 A dependent 2 B. ear ribonucleop mylation eleme 27 ain 13C 3 like 52 member 108 reside traffakti subunt aphentika chanel 5 7 c acid type A termine traffakti subunt aphentika chanel 5 7 c anion transperfamily memil Te binding 1 est-5-phosphate 1	2165 21644 682 1358 838 226 483 632	Sites in UTF Sites		1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	
LDOA LDOA LDOA LLOA LLOA LLOA LLOA LLOA	ENS ENS ENS ENS ENS ENS ENS ENS ENS ENS	170000560 1700000256 17000000556 1700000256 1700000256 1700000256 1700000256 1700000256 1700000256 1700000556 1700000556 1700000556 1700000556 1700000556 1700000556 1700000556 1700000556 1700000556 1700000556 170000056 170000056 170000056 170000056 170000556 170000556 170000556 170000556 170000556 170000556 170000556 1700056	1996 1 aldo 476 2 regu 278 2 piece 280 6 mol 379 4 chio 752 1 solution 754 4 proto- 754 4 proto- 754 4 proto- 754 4 proto- 755 1 solution 755 4 solution 755	lase A, from latery factors and the latery factors for an an-bind and an analysis for how the latery factors and the latery factors and the latery factors for an analysis for an	uctose-b tor X-as nology d ng lectir factor) of the second of the second of the second of the second of the second	sociated in comain colomain co	ate protein intraining, fam epitidase 1 (C in transporte ibble double s ibble dou	in miRD scription scription scription mice polyade and scription and scr	Adependent     A	2165 21644 682 1358 838 226 483 632	Sites in UTF Sites		1 1 1 1 1 1 1	0 0 0 1 1	0 0 0 0 0 0 0 0 0	1 1 0 0	1 0 1 0 0	1 1 0 0 0	0 2 0 0 0 0	1 0 3 0	hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p hsa-miR-122-5p	-0.79 -0.72 -0.72 -0.70 -0.68 -0.66	-0.84 -0.72 -0.75 -0.70 -0.68 -0.66	0.55 < 0.1 < 0.1 0.59 0.36 0.30	

Figure 38 screens of each database interrogated for hsa-miR-132-3p.

miRBas							miF	Rase									MANCHE
me Sear	rch Br	owse Help	Download	l Blog St	ubmit hsa-mir-132												
		<u> </u>	hsa-mir-														
	ssion		19 <u>(change lo</u>	29)													
Sy Descri	mbol	HGNC:MI	<u>R132</u> p <i>iens</i> miR-13	2 stam-loop													
Gene f			065; mir-13														
Liter					oers mention hsa-m	ir-132											
	curcii	2127		sentences)													
Stem	-loop	c ccc			uucgu (												
		5' cgc     3' gcg c cac	cgca ga g c	cccg ugguaccga	u gauuguuacu g                   a cugacaaugg c cau aggu a												
		Get sequen	_	c	cau aggu a	1											
	Deep	<u>82337</u> rea	ads, <u>752</u> rea	ds per million	n, 157 experiments												
seque	ncing							reads									
		CCGCCCCCGC	SUCUCCAGGGGAAC	CGUGGCUUUCGAUU	GUUNCUGUGGGANCUGGAGGUN	ACAGUEUNCAGECAUGGUEGE	CCGCAGCACGO	CONCECCEC									
	T.		+5.04	an Li	man	Balages 7.2		lablet									
<b>V</b>	Pred	iction of m	icroRNA ta	annu argets	man Releas	Release 7.2 e 7.1: June 2016		rwal et al., :	2015								
	Tree	choir or m	ICIORNA IG	igeis	Refeas	e 7.1. Solle 2016	Ago	iwai er al.,	2013								
uman   mi																	
				otal of 1396 si nclude false p	ites. positives. [Read mor	e]											
able sortec	d by cu	mulative we	eighted conte	ext++ score	ted for being the mo		on 3P-se	a tags (or the	one w	ith the lo	ngest '	3' 1 17	R in case of	a tie)	[Downlo	ad table]	
le table si			lanschpt pei	r gene, seleci	ted for being the fric	ist prevalent, basec	Number o 3P-seg	Link to		ite counts				Cumulative			
arget gene	Rep	resentative anscript			Gene name		tags	sites in	total 8m	ner 7mer-	7mer-	6mer sites	Representative miRNA	weighted context++	context++	Aggregate PCT	
FAB	ENSTO	000537858.1	TRAF-intera	acting protein wit	h forkhead-associated d	omain, family member E	UTR+5	Sites in UTR	3 2	2 1	0	1	hsa-miR-132-5p	score -1.41	-1.41	N/A	
WA1	ENSTO	0000338660 5	von Willebra	and factor A dom njugating enzym	ain containing 1		145 4657	Sites in UTR Sites in UTR	4 3	3 1 1 0	0		hsa-miR-132-5p hsa-miR-132-5p		-2.12	N/A N/A	
591479.1	ENSTO	0000594172.1	Uncharacter	rized protein			5	Sites in UTR	3 1	1 1	1	0	hsa-miR-132-5p	-0.96	-0.96	N/A	
				mber RAS oncog e 3 (secreted gly			799 207	Sites in UTR Sites in UTR	100		0		hsa-miR-132-5p hsa-miR-132-5p		-0.94	N/A N/A	
				sferase 8-like (G e activating prote	GCN5-related, putative)		220	Sites in UTR Sites in UTR		1 3 1 1			hsa-miR-132-5p hsa-miR-132-5p		-0.92 -0.88	N/A N/A	
17orf72	ENSTO	0000412177.1	chromosome	e 17 open readin	ng frame 72		5	Sites in UTR	2 1	1 0	1	2	hsa-miR-132-5p	-0.88	-0.88	N/A	
				spaced zinc finge n binding glutami	er motifs ic acid-rich protein like 2		1321 32	Sites in UTR Sites in UTR					hsa-miR-132-5p hsa-miR-132-5p		-0.85	N/A N/A	
PP1R3G	ENST0	0000405617.2	protein phos	sphatase 1, regu	latory subunit 3G		29				0	0	hsa-miR-132-5p	-0.83	-0.83	N/A	
				arbon receptor in hosphate isomer	teracting protein-like 1 rase		5 8230	Sites in UTR Sites in UTR					hsa-miR-132-5p hsa-miR-132-5p		-0.82	N/A N/A	
					SDR family) member 3		19						hsa-miR-132-5p		-0.79	N/A	
							mi	זחכ	2								
	61 p	redicted f	targets fo	r hsa-miR-	-132-5p in miRI	DB.											
ere are		anget	-	-	-												
		core	iRNA Name I-miR-132-5p		WIZ zinc finger	n					_						
etail Ra			-miR-132-5p	IRX2	WIZ zinc finger iroquois homeobo												
etails 1 etails 2	nk S L 2		-miR-132-5p -miR-132-5p	FSTL3	follistatin like 3	mily 3 member A2											
etails Target Rai etails 11 etails 2 etails 3 etails 4	nk 5 1 2 3 4	91 hsa 90 hsa		PCDH9	protocadherin 9 SUMO specific pe	otidase 3											
etails 1 etails 2 etails 3 etails 4 etails 5	nk 5 1 2 3 4 5	91 hsa 90 hsa 89 hsa	-miR-132-5p	SENP3													
etails 1 etails 1 etails 2 etails 3 etails 4 etails 5 etails 6 etails 7	nk         S           1         2           2         3           3         4           5         5           5         7	91 hsa 90 hsa 89 hsa 89 hsa 83 hsa	-miR-132-5p -miR-132-5p -miR-132-5p	DYNC1LI2	dynein cytoplasm	ic 1 light intermediat											
etails 1 etails 2 etails 3 etails 3 etails 4 etails 5 etails 5 etails 6 etails 7 etails 8 etails 9	nk         S           1         2           3         4           5         5           7         3           3         9	91         hsa           90         hsa           89         hsa           89         hsa           83         hsa           81         hsa           79         hsa	I-miR-132-5p I-miR-132-5p I-miR-132-5p I-miR-132-5p I-miR-132-5p	SENP3           DYNC1LI2           CRTC1           PGBD5	dynein cytoplasm CREB regulated tr piggyBac transpo	ic 1 light intermediat anscription coactivat sable element derived	15										
etails 1 etails 1 etails 3 etails 3 etails 3 etails 4 etails 5 etails 6 etails 6 etails 7 etails 8 etails 9 etails 10 etails 10	nk         5           2         3           3         4           5         5           7         3           9         0           1         1	91         hsa           90         hsa           89         hsa           89         hsa           83         hsa           81         hsa           79         hsa           79         hsa           79         hsa           79         hsa           79         hsa	miR-132-5p miR-132-5p miR-132-5p miR-132-5p miR-132-5p miR-132-5p miR-132-5p	SENP3           DYNC1L12           CRTC1           PGBD5           TRPS1           TDRD10	dynein cytoplasm CREB regulated tr piggyBac transpose transcriptional rep tudor domain con	ic 1 light intermediat anscription coactivat sable element derived pressor GATA binding taining 10	15										
etails 7 etails 1 etails 1 etails 3 etails 3 etails 4 etails 5 etails 6 etails 6 etails 8 etails 8 etails 9 etails 10 etails 11 etails 11 etails 11	nk         5           1         22           23         4           55         5           7         3           90         0           1         2           3         3	91         hsa           90         hsa           89         hsa           89         hsa           83         hsa           81         hsa           79         hsa           79         hsa           79         hsa           78         hsa	a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p	SENP3           DYNC1LI2           CRIC1           PGBD5           TRPS1           TDRD10           TCTEX1D1           SLC9A2	dynein cytoplasm CREB regulated tr piggyBac transpor transcriptional reg tudor domain con Tctex1 domain co solute carrier fam	ic 1 light intermediat anscription coactivat sable element derive pressor GATA binding taining 10 ntaining 1 ily 9 member A2	15										
arget Tarretail etails 1 etails 2 etails 3 etails 4 etails 6 etails 6 etails 6 etails 7 etails 8 etails 1 etails 1 etails 1 etails 1 etails 1 etails 1 etails 1 etails 1	nk         5           2         3           3         4           5         5           6         7           7         3           9         0           1         2           3         4           4         4	91         hsa           90         hsa           89         hsa           89         hsa           81         hsa           79         hsa           78         hsa           78         hsa           76         hsa	a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p	SENP3           DYNC1L12           CRTC1           PGBD5           TRPS1           TDRD10           TCTEX1D1           SLC9A2           TP53INP1	<ul> <li>dynein cytoplasm</li> <li>CREB regulated tr</li> <li>piggyBac transport</li> <li>transcriptional reg</li> <li>tudor domain con</li> <li>Tctex1 domain co</li> <li>solute carrier fam</li> <li>tumor protein p5:</li> <li>von Willebrand fa</li> </ul>	ic 1 light intermediat anscription coactivat sable element deriveo pressor GATA binding taining 10 ntaining 1 lily 9 member A2 8 inductble nuclear pr ctor A domain contai	1 5 1 otein 1										
arget Tarretail Ran etails 1 etails 2 etails 3 etails 3 etails 6 etails 6 etails 7 etails 6 etails 9 etails 10 etails 11 etails 11 etails 12 etails 12 etail	nk         5           1         -           2         -           3         -           5         -           5         -           7         -           8         -           9         -           0         -           1         -           2         -           3         -           4         -           5         -           6         -	91         hsa           90         hsa           89         hsa           89         hsa           81         hsa           79         hsa           79         hsa           78         hsa           76         hsa           76         hsa           75         hsa	a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p	SENP3           DYNC1L12           CRIC1           PGBD5           TDRD10           TCTEXID1           SLC9A2           TP53INP1           YWA1           SCD	2 dynein cytoplasm CREB regulated tr piggy8ac transport transcriptional reg tudor domain con 1 Tctex1 domain con solute carrier fam tumor protein p5: von Willebrand fa stearoyl-CoA des	ic 1 light intermediat anscription coactivat iable element derivee ressor GATA binding taining 10 ntaining 1 ily 9 member A2 i inducible nuclear pr ctor A domain contain turase	1 5 1 otein 1										
arget Target etails 1 etails 1 etails 2 etails 3 etails 4 etails 5 etails 5 etails 6 etails 7 etails 8 etails 10 etails 11 etails 11 etails 11 etails 11 etails 11 etails 11 etails 11 etails 11 etails 11	nk         5           1         -           2         -           3         -           4         -           5         -           6         -           7         -           8         -	91         hsa           90         hsa           89         hsa           89         hsa           81         hsa           79         hsa           79         hsa           78         hsa           76         hsa           75         hsa           75         hsa	a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p a-miR-132-5p	SENP3           PYNC1L12           CRTC1           PGBD5           TRPS1           TORD10           TCEX103           SLC9A2           TP53INP1           VWA1           SCD           RAB36           SPEG	dynein cytoplasm CREB regulated tr plgyyBac transpos transcriptional reg tudor domain con Tctex1 domain con solute carrier fam tumor protein p53 von Willebrand Fa stearoyl-CoA dess RAB36, member I striated muscle ei	ic 1 light intermediat anscription coactivat sable element deriveo pressor GATA binding taining 10 ntaining 1 lily 9 member A2 8 inductble nuclear pr ctor A domain contai	d 5 1 otein 1 ning 1										
arget Target etails 1 etails 2 etails 2 etails 3 etails 4 etails 5 etails 4 etails 5 etails 6 etails 7 etails 10 etails 11 etails 11 eta	mk         5           1         -           2         -           3         -           5         -           7         -           8         -           6         -           7         -           88         -           9         -           00         -	91         hsa           90         hsa           89         hsa           89         hsa           83         hsa           83         hsa           83         hsa           841         hsa           79         hsa           79         hsa           79         hsa           78         hsa           76         hsa           76         hsa           75         hsa	1-miR-132-5p -miR-132-5p 1-miR-132-5p	•         SENP3           •         DYNC1L12           •         DYNC112           •         PGBD5           •         TRP51           •         TORD10           •         SC0           •         SPEG           •         CRAT	dynein cytoplasm CREB regulated tr plggyBac transportranscriptional rep tudor domain con tudor domain con clute carrier fam tumor protein p53 von Willebrand fa stearoyi-CoA dess RAB36, member I striated muscle e proline rich 29 carnitine O-acetyl	ic 1 light intermediat anscription coactivat atable element deriver pressor GATA binding taining 10 IN 9 member A2 i inducible nuclear pr ttor A domain contail turase AS oncogene family priched protein kinase transferase	d 5 1 ootein 1 ning 1 e	ng G5									
etails 1 etails 2 etails 2 etails 3 etails 3 etails 4 etails 4 etails 4 etails 6 etails 6 etails 6 etails 1 etails 2 etails 3 etails 3 eta	mk         5           1         -           2         -           3         -           4         -           5         -           6         -           7         -           8         -           9         -           0         -           1         -           2         -	91         hsa           90         hsa           89         hsa           89         hsa           81         hsa           83         hsa           79         hsa           79         hsa           78         hsa           76         hsa           76         hsa           75         hsa           75         hsa           75         hsa           75         hsa           72         hsa           75         hsa           75         hsa           76         hsa           75         hsa           75         hsa           76         hsa           75         hsa           75         hsa           72         hsa           73         hsa           74         hsa           75         hsa           76         hsa           75         hsa           75         hsa           76         hsa           75         hsa           76         hsa	a-miR-132-5p a-miR-132-5p	>         SENP3           >         DYNC1L12           >         DYNC112           >         PGBD5           >         TRP51           >         TRP51           >         TCEX10           >         SLC9A2           >         SLC9A2           >         SCD           >         SCD           >         RAB36           >         SPEG           >         CRAT           >         PLEKHG5           >         PLEKHG5	dynein cytoplasm CREB regulated tr piggyBac transpop transcriptional reg tudor domain con solute carrier fam tumor protein p52 von Willebrand fa stearoyl-CoA dess RAB33, member striated muscle proline rich 29 carnitine O-acetyl pleckstrin homolo cytochrome P450	ic 1 light intermediat anscription coactivat able element derivee ressor GATA binding talning 10 inducible nuclear pr i inducible nuclear pr i inducible nuclear pr tor A domain contai turase tAS oncogene family ariched protein kinasi transferase gy and RhoGEF domi	d 5 1 otein 1 ning 1 e ain containi										
erget Tarreteil Ram etails 1 etails 2 etails 3 etails 4 etails 3 etails 4 etails 5 etails 6 etails 6 etails 1 etails 2 etails 2 e	mk         S           1         -           2         -           33         -           55         -           56         -           57         -           60         -           7         -           66         -           7         -           99         -           11         -           22         -           33         -           44         -           99         -           11         -           23         -           33         -           4         -	91         hsa           90         hsa           91         hsa           89         hsa           83         hsa           83         hsa           83         hsa           83         hsa           83         hsa           79         hsa           79         hsa           78         hsa           76         hsa           75         hsa           75         hsa           75         hsa           75         hsa           70         hsa           69         hsa           67         hsa           67         hsa           667         hsa	n mR-132-5p nmR-1	>         SENP3           >         DYNC1L12           >         DYNC1L2           >         CRTC1           >         PGB05           >         TRP51           >         TDRD10           ICTEX10         SLC9A2           >         TP53INP1           >         WA1           >         SC0           >         RAB36           >         SPEG           PLEKHG5         PLKHG5           >         DHX8           PRKA82A         PRKA82A	dynein cytoplaam CREB regulated it pigytka: transcop transcriptional reg tudor domain con Tetext domain co Solute carrier fam tumor protein p52 von Wilebrand fa stearoyi-CoA des RAB30, member striated muscle en proliner ich 20 carritine O-acetyi pleckstrin hornolo DEAH-box helicas protein kinase CA	ic 1 light intermediate anscription coactivate anscription coactivate able element derives ressor GATA binding taining 10 taining 11 y 9 member A2 inductible nuclear pri inductible nuclear pri inductible nuclear pri tor A domain contait turase tAS oncogene family triched protein kinase transferase gy and RhoGEF domit and y aufamily 2 e 8 M-dependent type I family 26 aufamily 26 aufami	d 5 1 otein 1 ning 1 e ain containi B member	1	1								
erget Tan etails 1 etails 2 etails 2 etails 3 etails 4 etails 5 etails 6 etails 6 etails 6 etails 1 etails 2 etails 2 et	ink         5           1         3           3         5           5         5           5         7           3         3           3         3           3         3           3         3           5         5           6         7           7         8           9         0           1         1           2         2           3         4           5         5           5         5           5         5           6         6           5         5           5         5           5         5           5         5	91         hsa           89         hsa           89         hsa           89         hsa           89         hsa           81         hsa           82         hsa           83         hsa           81         hsa           79         hsa           79         hsa           79         hsa           78         hsa           76         hsa           75         hsa           75         hsa           75         hsa           67         hsa           67         hsa           67         hsa           67         hsa           66         hsa	n mR-132-5p imR-1	b         SENP3           b         DYNCILI2           c         CRIC1           pgBD5         TRPS1           t         TRS1NP1           t         TRS3NP1           v         WA1           s         SCD           RAB36         SPEG           t         PRR29           c         CRA1           t         PLEKHG5           t         PKA82A           PRKA82A         PRKA82A           PCMT2         AIPL1	dynein cytoplaam CKEB regulated th piggyBac transcop transcriptional reg tudor domain con solute carrier fam tumor protein p5: von Wilebrand fa stearoyf-coA des: RAB30, member t striated muscle ep poline rich 29 Extrint domain co solute o-saetyl pleckstrin homolo cytochrome P450 DEAH-box helicas protein kinase CA protein O-mannoa aryl hydrocarbon	c 1 light intermediat ansarchiton coactivat able element derives mascription coactivat able element derives ressor GATA binding taining 10 training 11 linducible nuclear pri Inducible nuclear pri Abo Sen	d 5 1 otein 1 ning 1 e aln containi B member I regulatory protein like	1 subunit alph	3								
rectail Ran etails 1 etails 2 etails 3 etails 4 etails 5 etails 4 etails 5 etails 6 etails 6 etails 7 etails 8 etails 1 etails 2 etails 2	ink         5           2         2           3         4           5         5           7         2           90         1           1         2           33         4           5         5           6         7           7         8           9         0           11         2           23         3           4         4           5         6           12         3           33         3           4         5           6         6           7         7	91         hsa           90         hsa           89         hsa           89         hsa           89         hsa           81         hsa           82         hsa           83         hsa           81         hsa           79         hsa           79         hsa           78         hsa           76         hsa           75         hsa           75         hsa           70         hsa           75         hsa           75         hsa           67         hsa           66         hsa           66         hsa           65         hsa	n mR-132-5p imR-1	>         SERP3           >         CRTC1           >         OWNCILLS           >         ORDER           >         TRPS1           >         TRPS1           >         TCTEXID           >         TCTEXID           >         TCTEXID           >         SCD           >         PR829           >         CRAT           >         PPR829           >         CRAT           >         PPKRAZA           >         PPKRAZA           >         PPKAZA           >         POMT2           >         STAUL	dynein cytoplaam CKEB regulated th piggyBac transcop transcriptional reg tudor domain con solute carrier fam tumor protein p5: von Wilebrand fa stearoyf-coA des: RAB30, member t striated muscle ep poline rich 29 Extrint domain co solute o-saetyl pleckstrin homolo cytochrome P450 DEAH-box helicas protein kinase CA protein O-mannoa aryl hydrocarbon	Li Light intermediat asscription coactivat able element derives ressors GATA binding taining 10 taining 10 tidy of member A2 tor A domain contait turasie MS oncogene family and RhoGEF domain transferase y and RhoGEF domain family 26 subfamily e 8 4P-dependent type 1 4P-dependent typ	d 5 1 otein 1 ning 1 e aln containi B member I regulatory protein like	1 subunit alph	1								

Figure 39 screens of each database interrogated for hsa-miR-155-3p.

miRBas	se	mi	RBase												MANCHE
ne Searc	rch Browse Help Download Blog Submit hsa-mir-155														
em-loo	p sequence hsa-mir-155														
Acces	MI0000681 ( <u>change log</u> )														
Sy	mbol HGNC:MIR155														
Descri															
Gene fa															
Litera	earch 1009 open access papers mention hsa-mir-155														
	(8229 sentences)														
Stem	-loop														
	5' cuguuaaugcuaau gug uagggguu uug c														
	3' gacaauuacgauua uac auccucag aac u uc c														
	Get sequence														
sequer	Deep 177884 reads, 356 reads per million, 149 experiments														
	CUCUMMUSCUMMUSCUCAMUSCSCUCCAMUSACAUMAAAAAAA														
<b>S</b>	TargetScanHuman         Release           Prediction of microRNA targets         Release 7.1: June	ase 7.2 now ave	ailable!												
	Prediction of microRNA targets Release 7.1: June	2016 Ag	arwal et al.	, 201	5										
uman   mi	iR-155-5p														
	ipts with conserved sites, containing a total of 592 conserved sites and 239	poorly conserve	d sites.												
	that these predicted targets include some false positives. [Read more] only poorly conserved sites are not shown. [View top predicted	targata irraanaa	tive of site o	00000	nuntion	-1									
	d by cumulative weighted context++ score [Sort table by aggregate P		tive of site c	onser	vauo	U.									
e table sh	nows at most one transcript per gene, selected for being the most prevalent	, based on 3P-se	eq tags (or ti									[Downloa	ad table]		
Torret cono	Representative Gene name	Number of 3P-seq	Link to	C	onserv	red sites	Poo	orty co	nserve	d sites	6mer	Representative	Cumulative weighted	lotal	Aggrega
Target gene	transcript	tags supporting UTR + 5	sites in UTRs	total	8mer	mer-7n m8	tota	I 8me	r 7mer m8	7mer A1	sites	miRNA	context++ score	context+ score	Рст
NF385D	ENST00000281523.2 zinc finger protein 385D	5	Sites in UTR		0		1 4	1	1	2	1	hsa-miR-155-5p		-0.80	0.64
MPRSS11BN AV3	NL ENST00000432593.3 TMPRSS11B N-terminal like ENST00000370056.4 vav 3 guanine nucleotide exchange factor	5 1128	Sites in UTR Sites in UTR		1		0 2 0 1		1	0	0	hsa-miR-155-5p hsa-miR-155-5p		-0.68 -0.64	0.24 < 0.1
CTA1	ENST00000366684.3 actin, alpha 1, skeletal muscle	14	Sites in UTR	1	1	0	0 0	0	0	0	0	hsa-miR-155-5p	-0.59	-0.59	0.42
RID2	ENST00000457135.1 AT rich interactive domain 2 (ARID, RFX-like)	891	Sites in UTR	2	1	1	0 0	0	0	0	1	hsa-miR-155-5p	-0.58	-0.58	0.71
3F3A	ENST00000366813.1 H3 histone, family 3A	15	Sites in UTR	1	1	0	0 0	0	0	0	0	hsa-miR-155-5p	-0.58	-0.58	0.34
TS1	ENST00000345075.4 v-ets avian erythroblastosis virus E26 oncogene homolog 1	1423	Sites in UTR	2	2	0	0 0	0	0	0	1	hsa-miR-155-5p	-0.57	-0.60	0.52
NF652	ENST00000362063.2 zinc finger protein 652	33		2	1	1	0 2	0	1	1	3	hsa-miR-155-5p	-0.57	-0.70	0.93
	EN3100000302003.2 Zinc higer protein 032		Sites in UTR	_			0 0	0	0	0		hsa-miR-155-5p		-0.54	< 0.1
MA21	ENST00000330374.6 VMA21 vacuolar H+-ATPase homolog (S. cerevisiae)	2162	Sites in UTR	1	1							hsa-miR-155-5p		-0.53 -0.53	< 0.1 ORF
MA21 CTL7A				1	1 1 1	0	0 0 0 0	0	0	0	0	hsa-miR-155-5p	-0.00		0.77
MA21 CTL7A M6SF1	ENST00000330374.6 VMA21 vacuolar H+-ATPase homolog (S. cerevisiae) ENST00000333999.3 actin-like 7A	2162 5	Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0				hsa-miR-155-5p hsa-miR-155-5p		-0.56	
MA21 CTL7A M6SF1	ENST00000330374 6 VMA21 vacualar H+-ATPase homolog (S. cerevisiae) ENST0000033999-3 actin-like 7A ENST00000376390-6 transmembrane 6 superfamily member 1	2162 5 211	Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1	ENST00000330374 6 VMA21 vacualar H+-ATPase homolog (S. cerevisiae) ENST0000033999-3 actin-like 7A ENST00000376390-6 transmembrane 6 superfamily member 1	2162 5 211	Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1	ENST00000330374 6 VMA21 vacualar H+-ATPase homolog (S. cerevisiae) ENST0000033999-3 actin-like 7A ENST00000376390-6 transmembrane 6 superfamily member 1	2162 5 211	Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1	ENST00000330374 6 VMA21 vacualar H+-ATPase homolog (S. cerevisiae) ENST0000033999-3 actin-like 7A ENST00000376390-6 transmembrane 6 superfamily member 1	2162 5 211	Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1 EBPB	ENST00000330374 0 VMA21 vacuolar HATPase homolog (S. cerevisiae) ENST00000339993 a data-mike 7A ENST0000030300 0 transmerizate Superfamily member 1 ENST0000303004 3 CCAAT/enhancer binding protein (C/EBP), beta	2162 5 211	Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1 EBPB	ENST00000330374 0 VMA21 vacualar HATPase homolog (S. cerevisiae) ENST0000330969 3 actim-like 7A ENST000003000 0 transmerizen 6 superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (C/EBP), beta	2162 5 211	Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A MOSF1 EBPB nere are orget Targ Rar	ENST00000330374 0 VMA21 vacualar HATPase homolog (S. cerevisiae) ENST00000330969 3 actim-like 7A ENST000003000 0 transmerization de superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (C/EBP), beta	2162 5 211 3178	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1 EBPB EBPB arget Tarç etail Rar etails 1	ENST00000330374 VMA21 vacualar HATPase homolog (S. cerevisiae) ENST00000330969 à actim-like 7A ENST000003000 d transmerizane 6 superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (CEBP), beta enter the superfamily for the superfamily for the superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (CEBP), beta enter the superfamily for the superfamily member 1 ENST000030004 3 CCAAT/enhancer binding protein (CEBP), beta enter the superfamily for the superfamily member 1 ENST000030004 3 CCAAT/enhancer binding protein (CEBP), beta enter the superfamily for the superfamily for the superfamily member 1 ENST000030004 3 CCAAT/enhancer binding protein (CEBP), beta enter the superfamily for the superfam	2162 5 211 3178	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1 EBP8 here are arget Targ etail Rar etails 1 etails 2 etails 2	ENST00000330374 0 VMA21 vacualar HATPase homolog (S. cerevisiae) ENST00000330969 3 actin-like 7A ENST000003000 6 transmerizane 6 superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (CEBP), beta end to be the superfamily of the superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (CEBP), beta end to be the superfamily of the superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (CEBP), beta end to be the superfamily of the superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (CEBP), beta end to be the superfamily of the s	2162 5 211 3178	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1 EBP8 rectail etails 1 etails 1 etails 3 etails 3 etails 4 etails 4	ENST000003303740 VMA21 vacualar HATPase homolog (S. cerevisiae) ENST00000330969 a dtm.smernare 6 superfamily member 1 ENST000003000 dtm.smernare 6 superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (C/EBP), beta	2162 5 211 3178	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A MOSF1 EBPB Terre are retails 1 tetails 1 tetails 3 tetails 3 tetails 5 tetails 6 tetails 6	ENST000003303740 VMA21 vacualar HATPase homolog (S. cerevisiae) ENST00000330993 actin-like 7A ENST000003000 & transmerize 6 superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (C/EBP), beta 701 predicted targets for hsa-miR-155-5p in miRDB. get Target miRNA Name Gene Symbol Gene Description 1 99 hsa-miR-155-5p ZNF62 zinc finger protein 652 2 99 hsa-miR-155-5p ZNF62 zinc finger protein 652 3 99 hsa-miR-155-5p ZNF62 zinc finger protein 53 5 97 hsa-miR-155-5p IRE2022 zinc finger protein 53 5 97 hsa-miR-155-5p IRE2022 zinc finger protein 98	2162 5 211 3178	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A MOSF1 EBPB etals etals etals etals etals etals etals fatals etals fa	ENST000003303740 VMA21 vacualar HATPase homolog (S. cerevisiae) ENST00000330993 actin-like 7A ENST0000033090 b transmerize 6 superfamily member 1 ENST0000030004 3 CCAAT/enhancer binding protein (C/EBP), beta <b>5 701 predicted targets for hsa-miR-155-5p in miRDB.</b> <b>9 701 screet</b> <b>1 99</b> hsa-miR-155-5p 2MF82 zinc finger protein 652 <b>1 99</b> hsa-miR-155-5p 2MF82 zinc finger protein 98 <b>1 99</b> hsa-miR-155-5p 2MF82 zinc finger protein 98 <b>1 99</b> hsa-miR-155-5p 2MF82 zinc finger protein 98 <b>1 97</b> hsa-miR-155-5p 2MF82 zinc finger protein 98 <b>3 97</b> hsa-miR-155-5p 2MF82 zinc finger	2162 5 211 3178	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1 EBP8 EBP8 EBP8 ECTAIL ECTAI	ENST000003303740 VMA21 vacualar HATPase homolog (S. cerevisiae) ENST00000330949 a star-like 7A ENST0000033094 a star-like 7A ENST000003000 & transmerize 6 superfamily member 1 ENST0000030004 a CCAAT/enhancer binding protein (C/EBP), beta <b>5 701 predicted targets for hsa-miR-155-5p in miRDB.</b> <b>9 701 screet</b> <b>1 8 10 10 10 10 10 10 10 10 10 10 10 10 10 </b>	2162 5 211 3178 a domain containin 1 inding protein 2	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1 EBP8 EBP8 EBP8 EBP8 EBP8 EBP8 EBP8 EBP8	ENST000003303740 VMA21 vacualar HATPase homolog (S. cerevisiae) ENST00000330949 atch-sike 7A ENST00000330949 atch-sike 7A ENST0000030004 as CCAAT/enhancer binding protein (C/EBP), beta P 701 predicted targets for hsa-miR-155-5p in miRDB. get Target miRNA Name Gene Symbol Gene Description Store hsa-miR-155-5p JARID2 [Jumon]1 and AT-rich Interaction 2 99 hsa-miR-155-5p JARID2 [Jumon]1 and AT-rich Interaction 2 99 hsa-miR-155-5p JARID2 [Jumon]1 and AT-rich Interaction 2 99 hsa-miR-155-5p JARID2 [Jumon]1 and AT-rich Interaction 3 99 hsa-miR-155-5p JARID2 [Jumon]1 and AT-rich Interaction 3 99 hsa-miR-155-5p JARID2 [Jumon]1 and AT-rich Interaction 3 99 hsa-miR-155-5p JR12B/J2 [Jumon]1 and AT-rich Interaction 3 97 hsa-miR-155-5p JR12B/J2 [Jumon]1 and AT-rich Interaction 3 96 hsa-miR-155-5p JR18B/J2 [Jumon]1 and AT-rich Interaction 1 [Jumon]1 and AT-rich	2162 5 211 3178 a domain containin 1 oinding protein 2 ubunit A	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A MOSF1 EBP8 EEP8 etail etails etai	ENST000003303740         VMA21 vacualar H+-ATPase homolog (S. cerevisiae)           ENST00000330903         atcm-like 7A           ENST00000330903         atcm-like 7A           ENST0000033000         transmitzer A           ENST000003000013         CCAAT/enhancer binding protein (C/EBP), beta           P 701 predicted targets for hsa-miR-155-5p in miRDB.           get         Target Score           miRNA Name Score         Gene Symbol           get         Target Name           get         Target Name           get         Target Score           get         Target Name           get         Target Name           get         Target Score           get         Target Name           get         Name           get         Target Name           get         Name           get         Name           get         Name           get         Name           get         Nam	2162 5 211 3178 domain containin 1 oinding protein 2 ubunit A scription factor su	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A M6SF1 EBP8 EBP8 EBP8 EBP8 EBP8 EBP8 EBP8 EBP8	ENST000003303740         VMA21 vacualar Hr-ATPase homolog (S. cerevisiae)           ENST00000330960         Brannentrane 6 superfamily member 1           ENST000003000         Brannentrane 6 superfamily member 1           ENST0000030000         Brannentrane 6 superfamily member 1           ENST000003000013         CCAAT/enhancer binding protein (CEBP), beta           PO1 predicted targets for hsa-miR-155-5p in miRDB.           get         Target Score           Name         Gene Symbol           9         hsa-miR-155-5p	2162 5 211 3178 domain containin 1 oinding protein 2 ubunit A scription factor su	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A MGSF1 EDPB Tere are arget Target etails 1 statis 2 statis 2 statis 3 statis 4 statis 4 statis 4 statis 4 statis 4 statis 1 statis 1 stat	ENST000003303740         VMA21 vacualar Hr-ATPase homolog (S. cerevisiae)           ENST00000330960         Brasmantrane 6 superfamily member 1           ENST0000033000         Brasmantrane 6 superfamily member 1           ENST000003000013         CCAAT/enhancer binding protein (CEBP), beta           POID predicted targets for hsa-miR-155-5p in miRDB.           get         Target Score           Nammer Score         miRNA Name           Gene Symbol         Gene Symbol           9         hsa-miR-155-5p           9	2162 5 211 3178 domain containin 1 oinding protein 2 ubunit A scription factor su	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A MGSF1 EDPB Tere are arget Target etails 1 statis 2 statis 2 statis 2 statis 2 statis 2 statis 2 statis 2 statis 2 statis 1 statis 2 statis 2 statis 1 statis 1 stat	ENST000003303740         VMA21 vacualar Hr-ATPase homolog (S. cerevisiae)           ENST00000330960         Brasmerizare A           ENST00000330960         Brasmerizare A           ENST0000030000         Brasmerizare A           ENST000003000013         CCAAT/enhancer binding protein (CEBP), beta           POID predicted targets for hsa-miR-155-5p in miRDB.           Image: Socie         miRNA Name           Socie         Been Symbol           9         hsa-miR-155-5p	2162 5 211 3178 domain containin 1 inding protein 2 scription factor su -type finger 1 uclear protein 1 ed protein like 1	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				-0.56	
MA21 CTL7A MGSF1 EDPB CTCTAA MGSF1 EDPB CTCTAA EDPB CTCTAA EDPB CTCTAA EDPB CTCTAA EDPB CTCTAA EDBBC CTCTAA EDBBCCTAA EDBBCCTAA	ENST000003303740         VMA21 vacualar Hr-ATPase homolog (S. cerevisiae)           ENST00000330960         Brammerizare A           ENST00000330960         Brammerizare A           ENST000003000         Brammerizare A           ENST0000030000         Brammerizare A           ENST000003000013         CCAAT/enhancer binding protein (CEBP), beta           POID predicted targets for hsa-miR-155-5p in miRDB.           get         Target Score           Nammerizare         Gene Symbol           9         hsa-miR-155-5p           9         hsa-miR-155-5p           9         hsa-miR-155-5p           29         hsa-miR-155-5p           9         hsa-miR-155-5p           29         hsa-miR-155-5p           30 <td< td=""><td>2162 5 211 3178 domain containin 1 oinding protein 2 oinding protein 2 oinding protein 2 oinding protein 2 oinding protein 1 scription factor su -type finger 1 uclear protein 1 ed protein 1 3</td><td>Sites in UTR Sites in UTR Sites in UTR Sites in UTR</td><td>1 1 1</td><td>1</td><td>0</td><td>0 0</td><td>0</td><td>0</td><td>0</td><td></td><td></td><td></td><td>0.56</td><td></td></td<>	2162 5 211 3178 domain containin 1 oinding protein 2 oinding protein 2 oinding protein 2 oinding protein 2 oinding protein 1 scription factor su -type finger 1 uclear protein 1 ed protein 1 3	Sites in UTR Sites in UTR Sites in UTR Sites in UTR	1 1 1	1	0	0 0	0	0	0				0.56	
MA21 CTL7A MGSF1 EDPB CTCTCA EDPB CTCTCA EDPB CTCTCA EDPB CTCTCA EDPB CTCTCA EDPB CTCTCA EDPB CTCTCA EDBS CTCTCTCA EDBS CTCTCA	ENST000003303740         VMA21 vacualar HATPase homolog (S. cerevisiae)           ENST00000330960         Brasmerizare A           ENST00000330960         Brasmerizare A           ENST0000030000         Brasmerizare A           ENST00000300000         Brasmerizare A           ENST000003000013         CCAAT/enhancer binding protein (CEBP), beta           PO1 predicted targets for hsa-miR-155-5p in miRDB.           get         Target Score           Nammerizare A         Gene Symbol           90         hsa-miR-155-5p           90         hsa-miR-155-5p           90         hsa-miR-155-5p           90         hsa-miR-155-5p           91         hsa-miR-155-5p           92         hsa-miR-155-5p           93         hsa-miR-155-5p           94         hsa-miR-155-5p           97         hsa-miR-155-5p           97         hsa-miR-155-5p           98         hsa-miR-155-5p           99         hsa-miR-155-5p           99         hsa-miR-155-5p           99         hsa-miR-155-5p           99         hsa-miR-155-5p           99         hsa-miR-155-5p           90         hsa-miR-155-5p           91	2162 5 211 3178 domain containin 1 9inding protein 2 9inding protein 2 9inding protein 2 9inding protein 2 9inding protein 1 9inding prote	stes in UTR Stes in UTR Stes in UTR Stes in UTR Stes in UTR	1 1 1	1	0	0 0	0	0	0				0.56	
MA21 CTL7A MGSF1 EDPB Professional EDPB Professional EDPB Professional EDPB Professional EDPB Professional EdDB EdDB EdDB EdDB EdDB EdDB EdDB EdDB	ENST000003303740         VMA21 vacualar HATPase homolog (S. cerevisiae)           ENST00000330960         Brasmerizare A           ENST00000330960         Brasmerizare A           ENST0000030000         Brasmerizare A           ENST000003000013         CCAAT/enhancer binding protein (CEBP), beta           PO11 predicted targets for hsa-miR-155-5p in miRDB.           get         Target Score           Name         Gene Symbol           9         hsa-miR-155-5p	2102 5 211 3178 domain containin 1 9inding protein 2 9inding protein 2 9inding protein 2 9inding protein 2 9inding protein 2 9inding protein 1 9inding prote	stes in UTR Stes in UTR Stes in UTR Stes in UTR Stes in UTR	1 1 1	1	0	0 0	0	0	0				0.56	
MA21 CTL7A MOSF1 EBPB And CTL7A MOSF1 EBPB And CTL7A C	ENST000003303740         VMA21 vacualar H+-ATPase homolog (S. cerevisiae)           ENST00000330903         atcm-like 7A           ENST00000330903         tatcm-like 7A           ENST0000033004         atcm-like 7A           ENST0000033004         atcm-like 7A           ENST0000030004         atcAliner framework and the second attraction of the second attraction	2162 5 211 3178 a domain containir 1 oinding protein 2 ubunit A scription factor su -type finger 1 uclear protein 1 different 1 subunit 1 3 geg factor 3 mplex partner 1 por corepressor II	stes in UTR Stes in UTR Stes in UTR Stes in UTR Stes in UTR	1 1 1	1	0	0 0	0	0	0				0.56	

On brain tissue, the following miRNAs were tested: hsa-miR-21-5p, hsa-miR-132-3p, hsa-miR-200b-3p, hsa-miR-34a-5p, hsa-miR-124-5p. The screens of each database questioned

for hsa-miR-21-5p are reported in figure 35. The screens of each database questioned for hsa-miR-132-3p are reported in figure 38.

Figure 40 screens of each database interrogated for hsa-miR-200b-3p.




Figure 41 screens of each database interrogated for hsa-miR-34a-5p.




Figure 42 screens of each database interrogated for hsa-miR-124-5p.

						miR	Base										MANCH
ne Seard	h Browse	Help I	Download	Blog Sul	bmit hsa-mir-124-1												
m-loop	o seque	nce hs	a-mir-1	124-1													
Acces	sion MIO	000443 ((	<u>:hange log</u>	)													
Previous		-mir-124a															
		IC:MIR12															
Descrip				-1 stem-loop													
Gene fa Litera		F0000021	; <u>mir-124</u>														
	arch		<u>429 open</u> (3733 sen		rs mention hsa-mir-124-1												
Stem-		ggccuc uc	cc cu guguuci	ac gog couu	uaaau gauu g      u												
	3' 8	ucgggg ag	a cguaag ac	ug cgc ggaai g ac	uaa c cauac												
	Get	sequence															
C sequen		553 reads	s, <u>255</u> read	ds per millior	n, 106 experiments												
acquei	cing					reads											
	AGG		SUGUUCACAGO	GGACCUUGAUUUAA	NGUCOMINCANUUNAGCOCGCGGUGANUGCCANGANUGGG	ecue -											
	T		<b>C</b>														
<b>V</b>	lar	ger	sca	INHU	Release 7.1: June 2016												
	Prediction	of micro	oRNA targ	gets	Release 7.1: June 2016	Agai	wal et al.,	2015									
man   miF	R-124-5p																
2 transcri	pts with site			al of 4336 site													
	that these p				lse positives. [Read more]												
					ed for being the most prevalent, base			e one	with t	he lor	ngest	3' UT	R, in case of a	a tie).	[Downloa	ad table]	
	Represe	ntative				Number of 3P-seq	Link to	L	Site o	ounts		6mer	Representative	Cumulative weighted	Total	Aggregate	
rget gene	transc	ript			Gene name	tags supporting UTR + 5	sites in UTRs	total	8mer	7mer- m8	7mer- A1	sites	miRNA	context++ score	context++ score	Рст	
					, subfamily C, member 2	5	Sites in UTF	1	1	0	0		hsa-miR-124-5p		-1.03	N/A	
				al ribosomal pro ane protein 257		267 5	Sites in UTF Sites in UTF			0	1		hsa-miR-124-5p hsa-miR-124-5p		-0.89 -0.89	N/A N/A	
11-58C22.1 X19	ENST00000				nbly homolog 19 (S. cerevisiae)	5 734	Sites in UTF		1	0	0		hsa-miR-124-5p hsa-miR-124-5p		-0.85 -0.95	N/A N/A	
320OS	ENST00000	379848.2	SPG20 oppo	osite strand		5	Sites in UTF	1	1	0	0	0	hsa-miR-124-5p	-0.80	-0.80	N/A	
DC2	ENST00000			eaminase, tRN/ containing 2	4-specific 2	1973	Sites in UTF	2	1	1	0		hsa-miR-124-5p hsa-miR-124-5p	-0.76	-0.91 -0.76	N/A N/A	
					te-rich protein 1 te-rich protein 1	2452 2452	Sites in UTF Sites in UTF		0	3 3	1		hsa-miR-124-5p hsa-miR-124-5p		-0.87 -0.87	N/A N/A	
P15		320330.0		ns 15 kDa seler	noprotein (SEP15), transcript variant 2, mRNA	2047	Sites in UTF		1	0	1		hsa-miR-124-5p hsa-miR-124-5p		-0.78 -0.71	N/A N/A	
		401030.3		e kinase													
KK PCB	ENST00000	401030.3 408962.2 249269.4	hydroxylysin peptidase (m	nitochondrial pro	ocessing) beta	653	Sites in UTF	2					hsa-miR-124-5p	-0.71	-0.79	N/A	
KK PCB 11-345J4.3 11-	ENST00000 ENST00000	401030.3 408962.2 249269.4 549950.1	hydroxylysin peptidase (m Uncharacteri	nitochondrial pro ized protein	ocessing) beta	653 5	Sites in UTF Sites in UTF	2 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.79 -0.68 -0.68	N/A	
KK PCB	ENST00000	401030.3 408962.2 249269.4 549950.1	hydroxylysin peptidase (m Uncharacteri	nitochondrial pro ized protein	ocessing) beta	5	Sites in UTF	2 1	1	0	0	0	hsa-miR-124-5p	-0.71 -0.68	-0.68		
KK PCB 11-345J4.3 11-	ENST00000 ENST00000	401030.3 408962.2 249269.4 549950.1	hydroxylysin peptidase (m Uncharacteri	nitochondrial pro ized protein	ocessing) beta	5	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK PCB 11-345J4.3 11-	ENST00000 ENST00000	401030.3 408962.2 249269.4 549950.1	hydroxylysin peptidase (m Uncharacteri	nitochondrial pro ized protein	scessing) bela	5	Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK PCB 11-345J4.3 11-	ENST00000 ENST00000	401030.3 408962.2 249269.4 549950.1	hydroxylysin peptidase (m Uncharacteri	nitochondrial pro ized protein	ccessing) bela	5	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK PCB 11-345J4.3 11-	ENST00000 ENST00000	401030.3 408962.2 249269.4 549950.1	hydroxylysin peptidase (m Uncharacteri	nitochondrial pro ized protein	ccessing) bela	5	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK PCB 11-345J4.3 11- C12.3	ENST00000 ENST000002 ENST000003 ENST000003	401030 3 408962 2 49269 4 549950 1 550538 1 4	hydroxylysin peptidase (m Uncharacteri Uncharacteri	nitochondrial protein	-124-5p in miRDB.	5	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK PCB 11-345J4.3 11- C12.3 ere are s get Targ	ENST00000 ENST00000 ENST00000 ENST00000 515 pred et Target	401030.3 1 408962.2 2 249269.4 2 559950.1 1 550538.1 1	hydroxylysin peptidase (m Uncharacteri Uncharacteri	nitochondrial protein ized protein ized protein		5	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK PCB 11-345J4 3 11- C12 3 ere are 1 get Targ tail Ran alls 1	ENST00000 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST0000002 ENST0000002 ENST0000002 ENST0000002 ENST0000002 ENST0000002 ENST0000002 ENST00002 ENST000002 ENST000000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST0000000 ENST0000000 ENST00000000 ENST00000000 ENST000000000000000000000000000000000000	401030.3 4 408962.2 4 249269.4 5 549950.1 5 550538.1 1 icted ta miRN/ hsa-mil	hydroxylysin peptidase (m Uncharacteri Uncharacteri Uncharacteri Rest fo A Name R-124-5p	nitochondrial pro ized protein ized protein or hsa-miR Gene Symbo MEF2A	-124-5p in miRDB.	5	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK PCB 11-345J4.3 11- C12.3 ere are s rget Targ tail Ran alls 1 :ails 2 alls 3	ENST00000 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000000 ENST000000 ENST000000 ENST000000 ENST0000002 ENST0000002 ENST0000002 ENST0000002 ENST00002 ENST000002 ENST00002 ENST00002 ENST000000 ENST00000 ENST0000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST00000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST0000000 ENST0000000 ENST000000000000000000000000000000000000	401030.3 1 408802 2 249209 4 549950 1 550538.1 1 550538.1 1 hsa-mil hsa-mil hsa-mil	rgets fo A Name R-124-5p R-124-5p R-124-5p	or hsa-miR Gene Symbo AZI2	-124-5p in miRDB. Gene Description mycyte enhancer factor 2A dipeptidyl peptidase like 10 5-szazytidue induced 2	5	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK PCB 11-345J4 3 11- C12 3 Pere are 9 get Targ tail Ran alls 1 alls 1 alls 2 alls 3 alls 4 alls 4	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST000 ENST0000 ENST000 ENST000 ENST000 ENST000 ENST000 ENST000 ENST000 ENST000 ENST000 ENST00 ENST000 ENST00	401030.3 1 408962 2 49269.4 g 49969.1 1 550538.1 1 550538.1 1 550538.1 1 hsa-mil hsa-mil hsa-mil hsa-mil hsa-mil	hydroxylysin peptdase (m Uncharacteri Uncharacteri Uncharacteri R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p	nitochondrial protein ized protein er hsa-miR Gene Symbo MEF2A DPP10 AZ12 ILGST RFV3L	-124-5p in miRDB. Gene Description myocyte enhancer factor 2A dipeptidyi peptidase like 10 5-szacytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase 2	5 5	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK PCB 11-345J4.3 11- C12 3 get Targ tail Ran alls 1 alls 2 alls 3 alls 3 alls 4 alls 5 alls 6 alls 6 alls 6	ENST00000 ENST00000 ENST00000 ENST00000 515 pred et Target 8 98 98 98 98 98 98 98 98 98 98 98 98 98	401030.3 1 408962 2 549259.4 5 549550.1 1 550538.1 1 550555555555555555555555555555555555	hydroxylysin pepidase (m Uncharacteri Uncharacteri R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p	nitochondrial pro ized protein ized protein or hsa-miR Gene Symbo MEF2A DPP10 A 212 IL6ST REV3L PRGR1 SECo2	-124-5p in miRDB. Gene Description myocyte enhancer factor 2A digeptidyl paptidase like 10 5-azacytidine induced 2 interleukin 6 signal transducer ReV3 like, DNA directed polymerase z PAXIPJ associated glutamate rich pro SEC62 homolog, preprotein transloca	5 5 reta catalytic tein 1	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
CK PCB PCB I1-345J4 3 I1- C12 3 PCE PCE PCB I1- C12 3 PCE PCB I1- C12 3 PCE PCB I1- C12 3 PCE PCB I1- C12 3 PCE PCB PCB I1- C12 3 PCE PCB PCB I1- C12 3 PCE PCB PCB I1- C12 3 PCE PCB PCB I1- C12 3 PCE PCB PCB PCB PCB PCB I1- C12 3 PCE PCB PCB PCB PCB PCB PCB PCB PCB	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST0000 ENST00000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST000 ENST000 ENST000 ENST000 ENST000 ENST000 ENST00 ENST00 ENST000 ENST00 E	401030.3 1 408962 2 549269.4 1 550538.1 1 550555555555555555555555555555555555	hydroxylysin pepidase (m Uncharacteri Uncharacteri R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p	nitochondrial pro ized protein ized protein or hsa-miR MEF2A DPP10 AZ12 IL65T REV3L PAGRI SEC02 CSTF2 RBM11	-124-5p in miRDB. Gene Description mycoyte enhancer factor 2A dipeptidyi paptidase like 10 5-azacytidan induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase z PAXIP1 associated glutamate rich pro SEC62 homolog, preprotein translocal cleavage stimulation factor subunt 2 RNA binding motif protein 11	5 5 reta catalytic tein 1	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
ckk PCB III-345J4 3 III-345J4 3 III-C12 3 Ere are 3 get Targ tail Ran alls 1 alls 2 alls 3 alls 4 alls 5 alls 5 alls 5 alls 6 alls 7 alls 9 alls 10 alls 10 al	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 98 98 98 98 98 98 98 98 98 98 98 98 98	401030.3 408662.2 549269.4 549269.4 550538.1 5505555555555555555555555555555555555	hydroxylysin pepidase (m Uncharacteri Uncharacteri Uncharacteri R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p	itizchondrial przyca ized protein izzed protein or hsa-miR Gene Symbo MEF2A DPP10 A212 IL65T REV31 PAGR4 SEC62 CSTF2 RBM11 TSPAN8 ERCC612	-124-5p in miRDB. Gene Description myocyte enhancer factor 2A digeptidyl peptidase like 10 5-azacytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase z PAXIPI associated glutamate rich pro SEC02 homolog, preprotein translocal cleavage stimulation factor subunit 2 RNA binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2	5 5	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
CK PCB PCB II-345J4 3 II- C12 3 Ere are 1 get Targ tail Ran alls A alls 4 alls 5 alls 4 alls 5 alls 4 alls 7 alls 4 alls 5 alls 6 alls 7 alls 11 alls 12 alls 12 alls 12 alls 11 alls 12 alls 12 alls 13 alls 12 alls 13 alls 12 alls 11 alls 12 alls 13 alls 12 alls 11 alls 12 alls 13 alls 12 alls 11 alls 12 alls 11 alls 12 alls 1	ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 et Target k Score 98 98 98 98 98 97 95 95 95 95 95 94 94 94 94	401030.3 408662.2 549269.4 549269.4 549269.4 550538.1 5505555555555555555555555555555555555	hydroxylysin peptidase (m Uncharacteri Uncharacteri Karacteri R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p R-124-5p	Intochondrial program ized protein ized protein ized protein or hsa-miR Gene Symbo MEF2A DPD10 A212 IL65T REV31 PAGR4 SEC62 CSTF2 RBM11 SEC62 CSTF2 RBM11 SEC62 CAD10 SPP13	-124-5p in miRDB. Gene Description mycoyte enhancer factor 2A digeptidyl peptidase like 10 5-aracytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase z PAXIPI associated glutamate rich pro SEC02 homolog, preprotein translocal cleavage stimulation factor subuit 2 CRAb binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2 acyl-CoA dehydrogenase family memi signal peptide peptidase like 3	5 5	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
CK PCB CB C12 3 C12 3 C1	ENST00000- ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 ENST000002 State Stat	401030 3 408062 2 249209 4 549950 1 550538 1 5505538 1 5505555 5505555 5505555 55055555555 550555555	hydroxylysin peptidase (m Uncharacteri Uncharacteri Karting R 124-5p R 124-	itzed protein zzed protein zzed protein zzed protein dr. hsa-miR Gene Symbo MEF2A DPD10 A212 ILGST REV31 PAGR1 SEC02 CSTF2 REM11 ISPANE ERCCA12 ACAD10 SPP13 SELENOE DPH6	-124-5p in miRDB. Gene Description mycoyte enhancer factor 2A digeptidyi peptidase like 10 5-azaytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase z PAXIPI associated glutamate rich pro SEC02 homolog, preprotein translocat cleavage stimulation factor subunt 2 RNA binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2 acyl-CoA dehydrogenase family mem signal peptide peptidase like 3 selenoprotein F dighthamine biosynthesis 6	5 5 reta catalytic tein 1 tion factor	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
Green         Target           PCB         11-           C12 3         31-           Breen         are           Seren         are           Seren<	ENST00000- ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 Start 98 98 98 98 98 98 98 98 97 95 94 94 94 94 94 94 93 93 93	401003 31 400962 21 400962 14 400962 14 40095 11 550538 1 1 550538 1 1 1 550538 1 1 1 550538 1 1 1 550538 1 1 1 550538 1 1 1 550538 1 1 1 550538 1 1 1 550538 1 1 550538 1 1 550538 1 1 550538 1 1 550538 1 1 550538 1 550538 1 55055558 1 550558 1 5505558 1 5	nydroxylysino peptidase (m Uncharacteri Uncharacteri Uncharacteri R 124-5p R 124-5p	ized protein ized protein ized protein or hsa-miR Gene Symb- MEF2A DEP10 AZ12 IL65T REV3L PAG81 SEC02 CSTF2 RBM11 SEC02 CSTF2 RBM11 SEC04 CSTF2 RBM11 SEC04 CSTF2 RBM11 SELENOE	-124-5p in miRDB. and Gene Description myocyte enhancer factor 2A digeptidy petidase like 10 5-azacytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase 2 RAVIPI associated glutamater ich pro SEC62 homolog, preprotein translocat cleavage stimulation factor subunit 2 RNA binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2 acyl-CoA dehydrogenase family memi signal peptide peptidase like 3 selenoprotein F dighthamine biosynthesis 6 metabolism of cobalamin associated f	5 5 reta catalytic tein 1 tion factor	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
Gradiest	ENST00000- ENST00000- ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 B S S S S S S S S S S S S S S S S	101003.01 100962.21 100962	nydroxylysin peptidase (m Uncharacteri Uncharacteri Karateri Karateri R-124-5p	ized protein ized protein ized protein or hsa-miR Gene Symb- MEF2A DEP10 AZ12 IL65T REV3L PAG81 SEC02 CSTF2 RBM11 SEC02 CSTF2 RBM11 SEC04 CSTF2 RBM11 SEC04 CSTF2 RBM11 SELENOE	-124-5p in miRDB. and Gene Description myocyte enhancer factor 2A digeptidy petidase like 10 5-azacytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase 2 RAVIPI associated glutamater ich pro SEC62 homolog, preprotein translocat cleavage stimulation factor subunit 2 RNA binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2 acyl-CoA dehydrogenase family memi signal peptide peptidase like 3 selenoprotein F dighthamine biosynthesis 6 metabolism of cobalamin associated f	5 5 reta catalytic tein 1 tion factor	Sites in UTF Sites in UTF Sites in UTF	2 1 1	1	0	0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK         KK           1134543         3           1134543         3           1134543         3           1134543         3           11345         3           11345         3           1135         3           114         1           115         3           115         3           116         3           118         3           118         4           118         6           118         10           118         11           118         11           118         12           118         12           118         14           118         12           118         14           118         14           118         14           118         14           118         16           118         18           118         18           118         18           118         18           118         18           118         18           118         18 <td>ENST00000- ENST00000- ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 98 98 98 98 98 98 98 97 95 98 98 98 98 97 95 94 94 94 94 94 94 93 93 93 93 93 93</td> <td>40100.3 40100.2 2402204 2402204 14095011 1 1 1 1 1 1 1 1 1 1 1 1</td> <td>Nydroxylysino poptidase (m Uncharacteri Uncharacteri Uncharacteri R 124-5p R-124-5p</td> <td>Intechendrial program ized protein ized protein ized protein dr hsa-miR Gene Symbo AEF2A DPD10 AZ12 NGF2A DPD10 AZ12 NGF2A DPD10 AZ12 NGF2A DPD10 AZ12 NGF2A DPD10 AZ12 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62</td> <td>-124-5p in miRDB. of Gene Description myocyte enhancer factor 2A digeptidy petidase like 10 5-zazcytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase 2 RNA binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2 RNA binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2 acyl-CoA dehydrogenase family memi signal peptide peptidase like 3 asteinoprotein F dighthamine biosynthesis 6 metabolism of cobalamin associated 1 transmembrane protein 170B anakyrin 3 chloride voltage-gated channel 4 muciele acid binding protein 1</td> <td>5 5 reta catalytic tein 1 tion factor ber 10</td> <td>Sites in UTF Sites in UTF RDI</td> <td>2 1 1</td> <td>1</td> <td></td> <td>0</td> <td>0</td> <td>hsa-miR-124-5p hsa-miR-124-5p</td> <td>-0.71 -0.68</td> <td>-0.68</td> <td>N/A</td> <td></td>	ENST00000- ENST00000- ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 98 98 98 98 98 98 98 97 95 98 98 98 98 97 95 94 94 94 94 94 94 93 93 93 93 93 93	40100.3 40100.2 2402204 2402204 14095011 1 1 1 1 1 1 1 1 1 1 1 1	Nydroxylysino poptidase (m Uncharacteri Uncharacteri Uncharacteri R 124-5p R-124-5p	Intechendrial program ized protein ized protein ized protein dr hsa-miR Gene Symbo AEF2A DPD10 AZ12 NGF2A DPD10 AZ12 NGF2A DPD10 AZ12 NGF2A DPD10 AZ12 NGF2A DPD10 AZ12 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62 CSTF2 REM11 SEC62	-124-5p in miRDB. of Gene Description myocyte enhancer factor 2A digeptidy petidase like 10 5-zazcytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase 2 RNA binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2 RNA binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2 acyl-CoA dehydrogenase family memi signal peptide peptidase like 3 asteinoprotein F dighthamine biosynthesis 6 metabolism of cobalamin associated 1 transmembrane protein 170B anakyrin 3 chloride voltage-gated channel 4 muciele acid binding protein 1	5 5 reta catalytic tein 1 tion factor ber 10	Sites in UTF Sites in UTF RDI	2 1 1	1		0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK         KK           11.3454 3         3           11.3454 3         1           11.1         1           11.1         1           11.1         1           11.1         1           11.1         1           11.1         1           11.1         1           11.1         1           12.1         1           13.1         1           14.1         1           15.2         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1           14.1         1     <	ENST00000- ENST00000- ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 S15 98 98 98 98 98 98 98 98 98 98 98 98 98	40100.5 40100.5 240229.4 140950.1 140950.1 1 1 1 1 1 1 1 1 1 1 1 1 1	vydovytvau Juncharacter Uncharacter Inchar	czed protein zced protein zced protein zced protein or hsa-miR Gene Symb- MEF2A DEP10 AZ12 IL6ST REV3L PAGRI SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 CSTF2 REV3L SEC02 SEC0	-124-5p in miRDB. Gene Description mycoyte enhancer factor 2A digeptidyi peptidase like 10 5-azaytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase 2 PAXIPI associated glutamate rich pro SEC02 homolog, preprotein translocat cleavage stimulation factor subunt 2 RNA binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2 acyl-CoA dehydrogenase family mem signal peptide peptidase like 3 selenoprotein F dighthamine biosynthesis 6 metabolism of cobalamin associated 1 transmembrane protein 170B ankyrin 3 chloride voltage-gated channel 4	5 5 s reta catalytic tein 1 tion factor ber 10 o	Sites in UTF Sites in UTF RDI	2 1 1	1		0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
OK         OK           11.3454 3         3           11.3454 3         1           11.1         -           12.3454 3         3           11.3454 3         3           11.3454 3         3           11.3454 3         3           11.345         3           12.34         3           13.4         1           13.4         3           13.4         3           14.3         6           13.4         14           14.5         16           13.4         14           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16           14.5         16	ENST00000- ENST00000- ENST00000 ENST0000 ENST0000 ENST00000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST0000 ENST000 ENST000 ENST0000 ENST0000 ENST000 ENST0000 ENST000 ENST0000 ENST000 ENST0000 ENST00000 ENST0000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST0000000 ENST0000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST0000000 ENST0000000000 ENST000000000000000000000000000000000000	40100.5 40100.5 240229.4 240229.4 140950.1 1 1 1 1 1 1 1 1 1 1 1 1 1	vydovybau Juncharacter Uncharacter Inchara	czed protein zced protein zced protein zced protein w hsa-miR Gene Symb- MEF2A DPP10 AZ12 IL65T REV3L PAGR1 SEC02 CSTF2 REM11 SEC02 CSTF2 REM11 SEC02 CSTF2 REM11 SELENOE DP16 MMADHC TSPAR SELENOE DP16 MMADHC TSPAR SELENOE DP16 MMADHC ACA31A ABP13	-124-5p in miRDB. of Gene Description myocyte enhancer factor 2A digeptidy petidase like 10 5-azacytidine induced 2 interleukin 5 signal transducer REV3 like, DNA directed polymerse z PAXIPI associated glutamater ich pro SEC62 homolog, preprotein translocac cleavage stimulation factor subunit 2 RRA binding motif protein 11 tetraspania Petide peptidase like 3 selenoprotein F dighthamine biosynthesis 6 metabolism of cobalamin associated 11 transmembrane protein 120B anakyrin 3 chloride voltage-gated channel 4 nucleic acid binding protein 1 alpha-1,3-mannosyl-glycoprotein 1 4-binding motosis regulator and mRNA stability cell cycle associated protein 1	5 5 s reta catalytic tein 1 tion factor ber 10 o	Sites in UTF Sites in UTF RDI	2 1 1	1		0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
OK         OK           11.3454 3         3           11.1	ENST00000- ENST00000- ENST00000 ENST0000 ENST00000 ENST00000 ENST00000 ENST00000 ENST0000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST0000000 ENST0000000 ENST0000000 ENST0000000 ENST0000000 ENST0000000 ENST00000000 ENST00000000 ENST000000000000000000000000000000000000	40100.5 40100.5 401052 1 401050 1 1 401050 1 401050 1 1 401050 1 401050 1 40100 1 4000 1 4	vydovybau Juncharacter Uncharacter Inchara	czed protein zced protein zced protein zced protein w hsa-miR Gene Symb- MEF2A DP910 AZ12 IL65T REV3L PAG81 SEC02 CSTF2 RBM11 SEC02 CSTF2 RBM11 SEC02 CSTF2 RBM11 SELENOE DP910 SPP13 SELENOE DP916 MMADHC TMENZOB SELENOE DP916 MMADHC ACA310 SELENOE DP916 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 SELENOE DP16 SELENOE DP16 SELENOE SELENOE SELENOE DP16 SELENOE SELENOE DP16 SELENOE SELEN	-124-5p in miRDB. and Gene Description myocyte enhancer factor 2A digeptidy petidase like 10 5-azacytidine induced 2 interleukin 5 signal transducer REV3 like, DNA directed polymerse z PAXIPI associated glutamater ich pro SEC62 homolog, preprotein translocac cleavage stimulation factor subunit 2 RRA binding motif protein 11 tetraspanis 8 ERCC excision repair 6 like 2 acyl-CoA dehydrogenase family memi signal peptide peptidase like 3 selenoprotein F diphthamine biosynthesis 6 metabolism of cobalamin associated II transmembrane protein 1208 anakyrin 3 chloride voltage-gated channel 4 muceicia cald binding protein 1 alpha-1,3-mannosyl-glycoprotein 4-binding molosis regulator and mRNA stability cell cycle associated protein 1 Ras suppressor protein 1 Ras suppressor protein 1 Ras suppressor protein 1	5 5 s reta catalytic tein 1 tion factor ber 10 o	Sites in UTF Sites in UTF RDI	2 1 1	1		0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
or 	ENST00000- ENST00000- ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ST ST ST ST ST ST ST ST ST ST ST ST ST	10100.5 101002.7 240229.4 1240250.1 140550.1 140550.1 1 1 1 1 1 1 1 1 1 1 1 1 1	vydovybau Juncharacter Uncharacter Inchara	czed protein zced protein zced protein zced protein w hsa-miR Gene Symb- MEF2A DP910 AZ12 IL65T REV3L PAGB1 SEC02 CSTP2 RBM11 SEC02 CSTP2 RBM11 SELENOE DP910 SELENOE DP913 SELENOE DP913 SELENOE DP914 SELENOE DP914 SELENOE DP914 SELENOE DP915 SELENOE	-124-5p in miRDB. myocyte enhancer factor 2A digeptidy petidase like 10 5-azacytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase 2 RAVIPI associated glutamater ich pro SEC62 homolog, preprotein translocat cleavage stimulation factor subunit 2 RNA binding motif protein 11 tetraspanin 8 ERCC excision repair 6 like 2 acvi-CoA dehydrogenase family memi signal peptide peptidase like 3 selenoprotein F diphthamine biosynthesis 6 metabolism of cobalamin associated 1 transmembrane protein 1708 ankyrin 3 chloride voltage-gated channel 4 moteis regulator and mRNA stability cell cycle associated protein 1 Ras suppressor protein 1 Ras suppres	5 5 s reta catalytic tein 1 tion factor ber 10 o	Sites in UTF Sites in UTF RDI	2 1 1	1		0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
KK         KK           11.3454 3         3           11.3454 3         3           11.3454 3         3           11.3454 3         3           11.3454 3         3           11.3454 3         3           11.3454 3         3           11.345 3         3	ENST00000- ENST00000- ENST00000 ENST0000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST0000 ENST0000 ENST0000 ENST0000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST000000 ENST0000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST000000 ENST000000 ENST000000 ENST0000000 ENST0000000 ENST000000 ENST000000 ENST0000000 ENST0000000 ENST000000000000 ENST000000000000000000000000000000000000	40100.3 40100.3 401002 1 401050 1 4000 1 40	vydovybau Juncharacter Uncharacter Inchara	cr hsa-miR zed protein zed protein zed protein wir hsa-miR Gene Symb- MEF2A DPP10 AZ12 IL65T REV3L PAGR1 SEC02 CSTF2 REM11 SEC02 CSTF2 REM11 SELENOE DP16 MMADHC TSPAN SELENOE DP16 MMADHC TSPAN SELENOE DP16 MMADHC TSPAN SELENOE DP16 MMADHC TSPAN SELENOE DP16 MMADHC TSPAN SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 MMADHC SELENOE DP16 SELENOE DP17 SELENOE SELENOE DP17 SELENOE SELENOE DP17 SELENOE	-124-5p in miRDB. -124-5p in miRDB. myocyte enhancer factor 2A digeptidy petidase like 10 5-azacytidine induced 2 interleukin 6 signal transducer REV3 like, DNA directed polymerase 2 RRA binding motif protein 11 tetraspania 8 cleavage stimulation factor subunit 2 RRA binding motif protein 11 tetraspania 6 cleavage stimulation factor subunit 2 RRA binding motif protein 11 tetraspania 6 cleavage stimulation factor subunit 2 RRA binding motif protein 11 tetraspania 6 cleavage stimulation factor subunit 2 ransmembrane protein 120B anakyrin 3 chloride voltage-gated channel 4 mucelic acid binding protein 1 alpha-1,3-mannosyl-glycoprotein 1 Abit of the subunit binding protein 1 alpha-1,3-mannosyl-glycoprotein 1 RRA suppressor protein 1 Ras suppressor protein 11 Ras suppressor Ras and RAS stability RAS and RAS and RAS and RAS stability RAS and RAS an	5 5 5 reta catalytic tein 1 tion factor ber 10 0 factor 1 0) member B	Sites in UTF Sites in UTF R D I subunit	2 1 1	1		0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	
GC         GC           1134543         3           1134543         3           1134543         3           1134543         3           1134543         3           1134543         3           1134543         3           11345         3           11345         3           11345         3           11345         3           11345         13 <td>ENST00000- ENST00000- ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 90 90 90 90 90 90 90 90 90 90 90 9</td> <td>10100.3 1 100992 2) 100992 2) 10092 2) 10002 2002 2) 10002 20000 20000 200000000000</td> <td>rgets fo Uncharacter Uncharacter Uncharacter Uncharacter National States</td> <td>Creation of the second second</td> <td>-124-5p in miRDB. Gene Description mycyte enhancer factor 2A dipeptidyi peptidase like 10 5-aracytidine Induced 2 interfeakin 6 signal transducer REV3 like, DNA directed polymerase z PAXIPI associated guitamate rich pro SEC02 honolog, preprotein translocat cleavage stimulation factor subunt 2 SEC02 honolog, preprotein translocat cleavage stimulation factor subunt 2 RAN binding motif protein 11 tetraspanin 8 Secoce stranspanin 8 Secoce cleavage stimulation factor subunt 2 acyl-CoA dehydrogenase family mem signal peptide peptidase like 3 selenoprotein F diphthamine biosynthesis 6 metabolism of cobalamin associated 1 transmembrane protein 170B ankyrin 3 choride voltage-gated channel 4 nucclic acid binding protein 1 alpha -1,3-amnosyl-glycoprotein 4-b projvl 4-hydroxylase subunt beta metosis regulator and mRNA stability cell cycle associated protein 1 acidic residue methyltransferase 1 sorting nexin 2 cyclicin 2 zinc finger protein 117</td> <td>5 5 5 reta catalytic tein 1 tion factor ber 10 0 factor 1 0) member B</td> <td>Sites in UTF Sites in UTF R D I subunit</td> <td>2 1 1</td> <td>1</td> <td></td> <td>0</td> <td>0</td> <td>hsa-miR-124-5p hsa-miR-124-5p</td> <td>-0.71 -0.68</td> <td>-0.68</td> <td>N/A</td> <td></td>	ENST00000- ENST00000- ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 ENST00000 90 90 90 90 90 90 90 90 90 90 90 9	10100.3 1 100992 2) 100992 2) 10092 2) 10002 2002 2) 10002 20000 20000 200000000000	rgets fo Uncharacter Uncharacter Uncharacter Uncharacter National States	Creation of the second	-124-5p in miRDB. Gene Description mycyte enhancer factor 2A dipeptidyi peptidase like 10 5-aracytidine Induced 2 interfeakin 6 signal transducer REV3 like, DNA directed polymerase z PAXIPI associated guitamate rich pro SEC02 honolog, preprotein translocat cleavage stimulation factor subunt 2 SEC02 honolog, preprotein translocat cleavage stimulation factor subunt 2 RAN binding motif protein 11 tetraspanin 8 Secoce stranspanin 8 Secoce cleavage stimulation factor subunt 2 acyl-CoA dehydrogenase family mem signal peptide peptidase like 3 selenoprotein F diphthamine biosynthesis 6 metabolism of cobalamin associated 1 transmembrane protein 170B ankyrin 3 choride voltage-gated channel 4 nucclic acid binding protein 1 alpha -1,3-amnosyl-glycoprotein 4-b projvl 4-hydroxylase subunt beta metosis regulator and mRNA stability cell cycle associated protein 1 acidic residue methyltransferase 1 sorting nexin 2 cyclicin 2 zinc finger protein 117	5 5 5 reta catalytic tein 1 tion factor ber 10 0 factor 1 0) member B	Sites in UTF Sites in UTF R D I subunit	2 1 1	1		0	0	hsa-miR-124-5p hsa-miR-124-5p	-0.71 -0.68	-0.68	N/A	

# 4.5 Questionnaire results

Two hundred forty-seven subjects correctly filled in the questionnaire (mean age 29.58  $\pm$  9.72 years). 47.35 % were male (mean age 29.74  $\pm$  10.07 years), while 52.6% were female (mean age 29.44  $\pm$  9.43 years). All subjects enrolled were Italian and resident in the South of Italy. The main characteristics are summarized in table 16:

		GEN	ERAL DA	ГА	
	SUBJECTS	AGE (MEAN)	WEIGHT (MEAN - Kg)	HEIGHT (MEAN - m)	BMI (MEAN)
MALE	117	29,74±10,07	77,75±11,19	1,78±0,06	24,38±2,92
FEMALE	130	29,44±9,43	59,64±10,76	1,64±0,06	21,91±3,57
ТОТ	247	29,58±9,72	68,22±14,20	1,71±0,09	23,08±3,5

**Table 16.** Summary of the main data of the interviewed people.

The questionnaire results demonstrated that 8 subjects (6 females and 2 males) admitted using AASs (about 3.23%). The main characteristics of the AAS users/abusers are summarized in table 17.

		ABUS			
	SUBJECTS	AGE (MEAN)	WEIGHT (MEAN - Kg)	HEIGHT (MEAN - m)	BMI (MEAN)
MALE	2	33,5±7,77	83±18,38	1,85±0,14	24,04±1,68
FEMALE	6	30,16±9,19	56,16±4,70	1,62±0,05	21,26±1,4
ТОТ	8	31±8,45	62,87±14,77	1,68±0,12	21,95±1,86

Figure 43 summarizes the data under the sex criteria, subdividing users from non-users.




Figure 43. Percentages of males and females of the interviewed people, highlighting the differences between users/abusers under sex evaluation.

The data of the MBSR questionnaire were used to obtain the score related to "appearance evaluation" and "appearance orientation" in the AAS users vs non-users. Through the box plot analysis, the results demonstrated that the values of both items evaluated were higher in the AAS users than non-users (figure 44).




Figure 44. Box plot analysis showing that the score values of the two items analyzed ("appearance evaluation" and "appearance orientation") were higher in AAS users.

These differences were statistically significant for both analyzed items (p<0.05). Moreover, analyzing the kind of self-administrated AASs during use/abuse, in 7 out of 8 cases, the subjects injected the anabolic agents. Only one subject used AASs in pill form (figure 45).




Figure 45. Type of the anabolic agents used by the users/abusers interviewed.

Moreover, energy drink use was evaluated in the interviewed people. The results are

summarized in figure 46. The most used energy drink was the coffee, followed by classic Coca Cola, Pepsi, Red Bull, tea and Monster drink.






Figure 46. Type of energy drinks used by the interviewed people.

Comparing the data through box plot analysis, the score values related to energy drink use is higher in the AAS users compared to other people, even if it was no significant, p=0.09 (figure 47).





Finally, the use of supplements was evaluated in the interviewed people. The results are summarized in figure 48. The most used was Vitamin C, followed by B Complex, Organic and liquid magnesium, creatin monohydrate and soy protein.




Figure 48. Type of the supplements used by the interviewed people.

Comparing the data through box plot analysis, the score values related to supplement use is significantly higher in the AAS users compared to other people, p<0.05 (figure 49).




Figure 49. The box plot summarizes the data about the use of supplements in AAS users vs other interviewed people.

# **Chapter 5. DISCUSSION AND CONCLUSIONS**

# 5.1. AASs adverse effects and miRNAs applications: a literature review

It may be expected that the use of AASs through self-administration combined with physiological production, both by men and women, yields circulating androgen levels that are orders of magnitude higher than normal physiological levels. AAS effects are strictly linked to the age of the abuser. Several studies in humans suggest that adolescents may be more sensitive than adults (O'Connor et al., 2004) and females may be more sensitive than males (Franke and Berendonk, 1997).

The main adverse effect described in AAS users is a significant and often permanent change in sexual behavior and their reproductive system (Frati et al., 2014). The adverse effects of AAS use/abuse on the reproductive system are suppression of gonadal steroidogenesis, amenorrhoea, clitoral hypertrophy, testicular atrophy, disproportionate growth of the inner prostate, and masculinization of female fetuses (Barone et al., 2017; Pomara et al., 2016). Other organs that are involved in the adverse effects after AAS assumption are the liver and cardiovascular systems. Several studies have described liver tissue damage, such as impaired function, hepatic cholestasis (bile canal obstruction) causing jaundice, peliosis hepatitis (blood-filled sacs in the liver), and liver tumors (increased risk) (Pope et al., 2014b, 2014a).

Moreover, the cardiovascular system can be considered as one of the most critical systems involved in the evaluation of AAS abuse damage. Indeed, several diseases were previously described in AAS users: increased risk of thrombotic events such as myocardial infarction or stroke (raised LDL, lowered HDL and apolipoprotein-1, raised hematocrit (due to polycythemia), and lowered plasma fibrinogen, cardiac damage (left ventricular hypertrophy, fibrosis, and heart failure), and sudden cardiac death (Frati et al., 2015; Kanayama et al., 2008b; Pope et al., 2014b, 2014a).

In this PhD project, 5 cases of subjects who had died after AAS use/abuse were selected. Based on the autoptic evidence, in 4 cases the subject had died of heart failure after steroid assumption. It is very interesting to note that in the last selected case, the cause of death was related to immunodeficiency. Particularly, the subject died of septic shock subsequent to necrotizing myofasciitis. This pathological condition may develop in the site of any injury, such as surgical incision, skin biopsy, lacerations, abrasions, cuts, insect bites, surgical wounds, skin abscesses, ulcers, burns, blunt trauma, and injection site, as in the analyzed case (Puvanendran et al., 2009; Wong et al., 2003). Over the past few years, there have only been reported a few cases of athletes who have developed necrotizing fasciitis or pyomyositis or any other soft tissue infection, often in association with AAS use, by intramuscular injection (Grant et al., 2010; Hughes and Ahmed, 2011; Souza et al., 2011). Both testosterone and AAS adversely influence immune response, affecting leucocyte growth or activity, antibody and cytokine production, above all at supraphysiological doses mimicking a condition of secondary immunodeficiency (Choi and Lee, 2015; Hughes et al., 1995; W. Brenu et al., 2011). Secondary immunodeficiency, much more common than primary immunodeficiency (that is to say those caused by genetic defects affecting the cells of the immune system), includes various causes that affect a normal immune system, including infectious, iatrogenic, metabolic and environmental causes (Chinen and Shearer, 2010). These immune deficiencies are manifested clinically with an increased frequency or unusual complications of common infections and occasionally with the onset of opportunistic pathogen infections. Depending on the etiopathogenesis, secondary immunodeficiency will manifest with different clinical conditions, on which act, moreover, the magnitude of the triggering cause and the susceptibility of the host. For example, immunodeficiency induced by the use of corticosteroids depends on the dose used (Tan et al., 2006).

Considering the adverse effects caused by AAS use/abuse, the identification of new tools for AAS use/abuse represents an important challenge for the scientific community. In the last few years, several studies have highlighted the role of miRNAs as a highly accurate diagnostic tool. To date, the limits of traditional techniques for the diagnosis of numerous diseases (such as cardiac imaging) are costs and not being quantitative. The detection of circulating miRNAs could go beyond these limitations as diagnostic or prognostic tools of several diseases, both because miRNAs are very sensitive, and their detection requires minimal peripheral blood. Several advantages are linked to the use of circulating miRNAs as anti-doping methods: high stability during transport and storage, the long period for detection, no sensitivity to unregulated room-temperature storage, and the stability in plasma subjected to multiple freeze-thaw cycles (Leuenberger et al., 2013a).

At the light of this PhD work, a pivotal role could be played by miRNAs that seem dysregulated in cardiovascular or liver diseases, considering that these organs are involved in adverse effects caused by AAS use.

Knowledge regarding miRNAs in human diseases related to AAS use/abuse may eventually lead to identify serum or tissue biomarkers with anti-doping potential. In this regard, the

need for careful validation of diagnostic miRNA candidates in well-annotated toxicological studies is mandatory. The rapid progress in anti-doping technologies using miRNA based strategies for the discovery of drug-abuse, such as AAS use/abuse, could optimize new approaches based on existing and emerging knowledge.

#### 5.2. Abuser characteristics

In all selected cases, the AAS users were males with a BMI > 25. For all cases, at the external examination, it was not possible to clarify the exact cause of death. After autopsy, combining all findings (histological and toxicological examination), the cause of death was clarified: it was always strictly related to the adverse effects of AAS use, both direct and indirect ways. In the reported cases, the blood and/or urine and/or hair analysis revealed the presence of AASs and their principal metabolite (19-norandrosterone). In all cases, the high testosterone/epitestosterone ratio (1:6) suggested the use of androgens, such as dihydrotestosterone (DHT) and dehydroepiandrosterone (DHEA) or, more likely, testosterone. Inhibition of natural androgens occurs secondary to inappropriate and prolonged use of anabolic hormones. Chronic AAS abuse results in different patterns of pathologic alterations that depend on the dose, frequency, and mode of use: for example, in case 5, death was caused by infective risk post AAS assumption. This event is uncommon in AAS users as discussed in the previous paragraph.

Contrariwise, as well described in the literature, the cardiovascular adverse effects generated by AAS use/abuse could be considered very important in the determination of the cause of death. In 4 out of the 5 tested cases, the use of AAS damaged the cardiovascular system, probably through the alteration of the lipoprotein metabolism that may be strictly linked to myocardial infarction and/or other adverse effects.

Cardiovascular effects of AASs are frequently reported in published case reports: indeed, acute myocardial infarction can be linked to premature atherosclerosis. Acute non-fatal myocardial infarction was first reported in 1988 (Büttner and Thieme, 2010) and fatal myocardial infarction in 1990 (D'Andrea et al., 2007). Myocardial infarction without significant coronary atherosclerotic disease has also been reported (Ferenchick and Adelman, 1992; Hoffman et al., 2009; McNutt et al., 1988; Montisci et al., 2012). Other adverse cardiovascular effects such as left ventricular hypertrophy, impaired left ventricular function, arterial thrombosis, and pulmonary embolism have been described (Büttner and Thieme, 2010; D'Andrea et al., 2007; Fineschi et al., 2001, 2007; Montisci et al., 2012; Parkinson and Evans, 2006; Payne et al., 2004; Thiblin et al., 2009). The most typical myocardial abnormality in AAS abusers is left ventricular hypertrophy, associated with fibrosis and myocytolysis (Frati et al., 2014; Montisci et al., 2012).

Until today, 19 fatal cases (89.5% males), age range 18–37 years, have been reported in medical literature (Di Paolo et al., 2007; Dickerman et al., 1995; Ferenchick, 1991; Fineschi

et al., 2001, 2007; Hausmann et al., 1998; Kennedy and Lawrence, 1993; Luke et al., 1990; Montisci et al., 2012; Payne et al., 2004; Thiblin et al., 2009), but with only one case of occlusive thrombus in the left coronary artery (Ferenchick, 1991).

Melchert and Welder (Melchert and Welder, 1995) suggested that there are at least four hypothetical models of ASS-induced adverse cardiovascular effects: atherogenic, thrombosis, vasospasm, and direct myocardial injury.

Cardiovascular responses to AASs are due to specific myocardial receptors, which have transcriptional regulatory functions. The cardiac hypertrophy induced by AASs appears to be generated by a direct action on cardiac androgen receptors, whose effects are directly proportional to the dose, time and duration of drug administration (Ferrera et al., 1997; Marsh et al., 1998; Montisci et al., 2012; Wu and Von Eckardstein, 2003).

The sympathetic nervous system involved in the neurological control of the cardiovascular system may be influenced by AASs when combined with exercise and confer an increased risk of life-threatening arrhythmias (Thiblin and Petersson, 2005; van Amsterdam et al., 2010).

According to Achar et al. (Achar et al., 2010), AASs are often consumed concomitantly with GH, erythropoietin, and other agents. This is important because GH may lead to cardiomyopathy, abnormal lipoprotein profiles (Saugy et al., 2006; Thomas et al., 2013), and left ventricular hypertrophy (Karila et al., 2003). Erythropoietin abuse is linked to hypertension and increased risk of thromboembolic events (Baron et al., 2013). These effects may be difficult to separate from the results of AAS abuse alone and motivate the need for more rigorous clinical and forensic screening.

#### 5.3 miRNA quantification

miRNAs have been considered to play a pivotal role in precision medicine. Apparently, this depends not only on differences at the interindividual level but also at the intercellular level (Collins and Varmus, 2015).

Indeed, miRNAs are exquisite regulators of gene expression that inhibit translation and/or promote mRNA degradation by base pairing to precise complementary sequences within the 3'-untranslated region.

miRNAs are expressed in a cell-specific manner and, for these reasons, they are used as selective treatments, targeting bad cells and preserving good cells. The major applications studied by the scientific community concern the fight against cancer, even if scientific efforts are also applied to several other disorders (Edwards et al., 2010; Santulli, 2015).

Moreover, in the near future, clinicians will have to deal with miRNAs, not just as diagnostic biomarkers but also as potential tools to design selective treatments, alongside their emerging important role in prognostic signatures and prediction models (Santulli, 2015).

In this scenario, one of the significant challenges in the anti-doping field is the identification of specific and sensitive non-invasive biomarkers that can be routinely measured in easily accessible samples.

In the same way that specific biomarkers are used to detect the biological fingerprint of disease, other biomarkers can be used to identify the biological fingerprint of doping.

The potential use of circulating miRNAs as specific biomarkers in the antidoping field has been demonstrated by several groups (Gasparello et al., 2019; Gunnarsdottir et al., 2019; Leuenberger et al., 2013a).

Based on this evidence, the research hypothesis of this project was the detection of the misexpression of several miRNAs at the different organs that were identified as target organs linked to AAS use. In the light of the results of the first year of this project, different miRNAs were tested on the following tissues: heart, kidney, liver, and brain.

# 5.3.1 Heart and musculoskeletal systems

Four miRNAs (miR-133a-3p, miR-208a-3p, miR-499a-3p, and miR-1-3p) were tested in the two groups: HF group and AAS group.

Cardiovascular disease is the leading cause of morbidity and mortality in developed countries. Cardiovascular remodeling represents an important aspect of disease progression in heart failure (HF), regardless of cause. It manifests clinically by changes in cardiac size,

shape, and function in response to aging, cardiac injury, or increased load. The importance of remodeling as a pathogenic mechanism is not completely understood because the factors leading to remodeling have not been fully investigated. Generally, pathological processes of the heart are associated with an altered expression profile of genes that are important for cardiac function (Kumarswamy and Thum, 2013; Williams et al., 2009; Zampetaki et al., 2013).

The cardiac genes involved in the remodeling are very numerous, and each gene is individually controlled by multiple transcription factors. Moreover, epigenetic and post-transcriptional regulations can be very important in gene expression. Cardiovascular remodeling involves many pathologies including myocardial ischemia/myocardial infarction (MI), cardiac hypertrophy, cardiac fibrosis, arrhythmia, and vascular diseases (Olson, 2006; Williams and Carroll, 2009).

Tissue-specific expression of miRNAs was first reported in 2002 (Lagos-Quintana et al., 2002). It is known that there is a family of so-called myomiRs that are encoded within the introns of the separate myosin heavy chain genes. miR-208a, miR-208b, and miR-499 are located within the Myh6, Myh7, and Myh7b genes, respectively. It was reported that miR-208 -/- mice show reduced cardiac hypertrophy in response to pressure overload (Van Rooij et al., 2007). Targets of miR-208a include thyroid hormone receptor-associated protein 1 (Callis et al., 2009; Van Rooij et al., 2007), suggesting that miR-208a initiates cardiomyocyte hypertrophy by regulating triiodothyronine-dependent repression of β-MHC expression. Overexpression of miR-208a was sufficient to upregulate Myh7 and to elicit cardiac hypertrophy, resulting in systolic dysfunction (Callis et al., 2009). Although miR-208a is required for cardiac hypertrophy, the role of miR-208b in these pathologic conditions remains to be elucidated. The therapeutic inhibition of miR-208a using the antimiR-208a during hypertension-induced heart failure in animal model improving cardiac function, overall health, and survival (Montgomery et al., 2011). Moreover, it was described that miR-208a is sufficient to induce arrhythmias, cardiac remodeling, and to regulate the expression of hypertrophy pathway components and the cardiac conduction system. The emerging role of miR-208a in the heart suggested that it is involved in the regulation of the myosin heavy chain isoform switch during development and in pathophysiological conditions (Oliveira-Carvalho et al., 2013). The results of this research project confirmed a pivotal role for the miR-208 considering that it has been detected overexpressed both in HF group and in AASs group. Indeed, these results suggest that the expression levels of this miRNA could be related to heart tissue damage in a direct way: when more remodeling on

the heart tissue was detected, the miRNA level was higher. No modification on the expression levels of this miRNA on the musculoskeletal tissue was reported.

In a recent study a pivotal role for the miR-1 and miR-499 in discriminating sudden cardiac death (SCD) from acute myocardial infarction (AMI) was reported (Pinchi et al., 2019): both miRNAs were overexpressed compared to the control group for SCD and AMI even if significant differences were described among them.

miR-1 is also a cardiac and skeletal muscle-specific miRNA, and it is probably one of the most abundant miRNAs in the heart. It was reported to target a cytoskeletal regulatory protein, Twinfilin-1 (Twf1), which binds to actin monomers and prevents their assembly into filaments (Li et al., 2010b). The role of this miRNA was investigated in heart diseases. Tang et al. reported a pro-apoptotic effect on cardiomyocytes by targeting Bcl-2 when this miRNA was overexpressed. They reported that Bcl-2 was silenced by miR-1 at the protein and mRNA levels (Tang et al., 2009). The mechanisms of apoptosis in ischemic heart disease (IHD) and dilated cardiomyopathy (DCM) have yet to be clearly elucidated. Apoptosis and necrosis in heart failure may be induced by the same agents, with the type of cell death being dependent on the severity of the insult. Post-transcriptional repression of Bcl-2 by miR-1 is probably one of the mechanisms underlying their regulation of apoptosis versus survival (Latif et al., 2000). In agreement with a previous study (Pinchi et al., 2019), the results of the present study suggest that this miRNA is overexpressed compared to controls in both the AAS and HF groups, although no significant differences were reported among groups. Contrariwise, this miRNA has been detected significantly higher in the AAS group in the musculoskeletal tissue compared to the other groups. miR-1 and miR-133 are specifically expressed in adult cardiac and skeletal muscle tissues, but not in other tissues tested (Sempere et al., 2004). miR-1 and miR-133 modulate muscle proliferation and differentiation, in part, by targeting HDAC4 and Serum Response Factor (SRF), respectively. Particularly, overexpression of miR-1 led to the downregulation of endogenous HDAC4 protein, while overexpression of miR-133 repressed the expression of endogenous SRF proteins (Chen et al., 2006). Moreover, both miR-1 and miR-133 are involved in cardiac repolarization acting on cardiac ion channel genes such as GJA1/Cx43/IJ (Yang et al., 2007), KCNJ2/Kir2.1/IK1 (Yang et al., 2007), potassium voltage-gated channel, subfamily H (eag-related) member 2 (KCNH2)/human ether-à-go-go-related gene (HERG)/IKr (Xiao et al., 2007), potassium voltagegated channel, KQT-like subfamily, member 1 (KCNQ1)/KvLQT1/IKs, and potassium voltage-gated channel, Isk-related family, member 1 (KCNE1)/mink/IKs (Luo et al., 2007). The aberrant expression of miR-

133 was usually accompanied with cardiac hypertrophy, arrhythmogenesis and heart failure (Lau et al., 2001). Although miR-133 has been demonstrated to be involved in pathogenesis and progression of heart failure (HF), its effect remains controversial (Liu et al., 2017). Nevertheless, miR-133 has been described as one of the most promising biomarkers for understanding the biological response to physical activity and for the potential use for diagnosing muscle injury as well as in anti-doping testing (Danese et al., 2017). In the present study, the expression levels of this miRNA were higher in all tested groups compared to controls, suggesting that anabolic agent use is related to higher expression levels, similarly to those of the HF group.

miR-499 is encoded in an intron of the myh7 gene and is considered likely to play a role in myosin gene regulation (Bell et al., 2010; van Rooij et al., 2009). Similarly, miR-499 and miR-30 family members diminished apoptosis in injured hearts by attenuating activation of dynamin-related protein-1 and thus inhibiting mitochondrial fission (Li et al., 2010a; Wang et al., 2011). In the present PhD study, miR-499 resulted overexpressed in the HF group, while, in the AAS group, it had about the same expression values as the control. Even if this miRNA was expressed similarly to the control in the AAS group, the results related to the HF group suggested that miR-499 could be used as a prognostic marker for clinicians and pathologists for heart diseases, even if further studies are needed.

The results of the present study highlight a pivot role in the cardiovascular remodeling both for miR-499 and miR-208. The data obtained concerning the expression levels of miR-1 and miR-133 suggest that their role remains not completely known: the scientific community should consider to improve their effort in this field of research in order to better clarify all aspects.

#### 5.3.2 Kidney tissue

Analyzing the results about the kidney tissue, the two tested miRNAs (mir-21 and miR-205) were improved in both tested groups (AASs vs CKD), even if significant differences were described only for miR-21. This miRNA is widely expressed in all tissues and is expressed quite highly in the normal kidney, heart, spleen, liver, and lung as well. Indeed, the expression levels were higher in the CKD groups compared to AAS group.

As previously described, miR-21 was upregulated in injury with fibrosis both in mouse and human models (Chau et al., 2012). In addition to its involvement in kidney fibrosis (Zarjou et al., 2011; Zhong et al., 2011), several studies indicated that miR-21 may play an important role in stimulating fibrosis in other tissues after injury, such as cardiac and pulmonary tissues

(Liu et al., 2010; Thum et al., 2008). Moreover, it has been described that high levels of this miRNA promote kidney injury and fibrosis, while the inhibition of miR-21 in animal models ameliorates the effects (Chau et al., 2012).

The way to regulate these mechanisms has been investigated in heart tissue: miR-21 regulates the ERK–MAP kinase signaling pathway in cardiac fibroblasts, impacting global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK–MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy (Thum et al., 2008). It is commonly thought that the same pathway was followed for kidney tissue. Moreover, the action of this miRNA is exerted on PPAR $\alpha$  as a major upstream regulator of lipid metabolism. The major miR-21 targets in the kidney are epithelial metabolic pathways, particularly the PPAR $\alpha$ -regulated lipid metabolic signaling pathway (Lefebvre et al., 2006). For these reasons, miR-21 represents a post-transcriptional regulator in kidney tissue that amplifies injury responses, resulting in increased fibrosis.

In the present study, the levels of miR-205 were overexpressed in both groups compared to controls. Even if the expression values were higher in the CKD groups compared to the AAS group, no significant differences were reported. These data were in agreement with previous studies. Wang et al. reported that the level of intra-renal of miR-205, similarly to other miRNA investigated, resulted significantly higher in patients with hypertensive nephrosclerosis than controls (Wang et al., 2010b). Moreover, high intra-renal expression of miR-205 was also found in renal biopsies of patients with hypertensive glomerulosclerosis: these expression values were correlated with disease severity (Schena et al., 2014). It is very important to note that the overexpression of this miRNA is related to no cancer diseases: indeed, miR-205 was markedly upregulated in non-tumor tissues (Ying et al., 2018).

Finally, the results of the present study suggest that kidney damage in AAS abusers is similar to subjects suffering from chronic kidney disease, remarking that these miRNAs could be considered candidate markers for the identification of AAS abusers.

# 5.3.3 Liver tissue

As previously described, miR-21 is expressed in liver tissue similarly to other tissues. Its role has been largely discussed by the scientific community, resulting in controversy. Using an animal model, a recent study reported that MiR-21 expression was increased in the liver

of mice fed a high-fat diet (HFD) compared with controls (Loyer et al., 2016). This study demonstrated that miR-21 inhibition or suppression decreased liver injury, inflammation and fibrosis, in different murine models of non-alcoholic steatohepatitis (NASH), by restoring PPAR $\alpha$  expression. MiR-21 has been reported to be upregulated in many inflamed states: this feature might explain the upregulation of miR-21 in NASH since plasma lipopolysaccharide levels are higher in patients and mice with NAFLD than controls (Mouzaki et al., 2013; Thuy et al., 2008). Analyzing the expression data from the liver tissue in the two tested groups (AASs and NAFLD), a pivotal role for miR-21 in fibrosis in liver tissue clearly appears. Particularly, the expression values of this miRNA are significantly higher in the AAS group, suggesting its possible use as a molecular biomarker both in anti-doping and in diagnostic usage.

MicroRNA-122 (miR-122) is involved in various physiological processes in hepatic function as well as in liver pathology; moreover, it is the most abundant liver-specific microRNA (Hu et al., 2012). The molecular mechanisms underlying regulation of lipid homeostasis by miR-122 are still unclear, both AMP-activated protein kinase (APK) and circadian metabolic regulators of the peroxisome proliferator-activated receptor (PPAR) family have been suggested to be putative effectors of miR-122-mediated metabolic controls (Bandiera et al., 2015). The results of the present study show that the expression levels of miR-122 were significant higher in the NAFLD group compared to the AAS group. Moreover, this miRNA was overexpressed in both groups, compared to controls. Recent studies were performed on miRNAs involved in the control of lipid metabolism (such as MiR-122, MiR-16, miR-33, miR-34, miR-103, miR-104, and miR-370), with the aim of identifying new tools for modern anti-doping. For example, Salamin et al. (2016) identified three potential candidate miRNAs for testosterone use, even if one of these showed a response related to dose-effect: in fact, levels of miR-122 increased 3.5-fold after 1 day of drug intake. These results suggest that miR-122 could be used as a reliable fingerprint of testosterone misuse (Salamin et al., 2016).

miR-132 was investigated because it plays an important role in liver tissue: it targets mRNAs that regulate key biological processes including metabolism (Purushotham et al., 2009; Stiles et al., 2004), cell proliferation (Anand et al., 2010), epigenetic regulation (Lagos et al., 2010) and inflammation (via suppression of acetylcholinesterase) (Shaked et al., 2009), as well as nervous system-related cholinergic functions (Hanin et al., 2018). miR-132 targets such as Pten and Sirt1, associated with hepatic steatosis, hyperlipidaemia and glucose regulation; moreover, it was elevated in a mouse model of alcoholic liver disease

(Hanin et al., 2018). The results of the present study show that the expression levels of miR-132 were overexpressed in both groups compared to controls, resulting higher in the AAS group even if no significant differences were reported. These findings could be considered very important because the adverse effects generated by AAS assumption may cause the same organ damage as NAFLD.

Finally, miR-155 was tested on selected samples. In recent years, the role of miR-155 in several cellular processes such as fatty acid metabolism and fibrogenic events has also been investigated (Bala et al., 2016). miR-155 targets genes involved in lipid metabolism (Fab4, Cpt1a) and early fibrosis (C/EBP $\beta$ , Smad3) (Csak et al., 2015). A recent study conducted on animal models reported that alcohol-induced liver injury, steatosis and inflammation were significantly reduced in miR-155 knockout (KO) mice compared to controls. The same study demonstrated that the inhibition of miR-155 using a specific miR-155 inhibitor resulted in an increase in PPAR $\gamma$  gene expression, with a subsequent benefit in treatment. Moreover, considering that alcohol use/abuse reduces PPAR $\alpha$  (Kersten et al., 2010), steatogenic, inflammatory and fibrogenic changes observed in miR-155 KO mice after ethanol diet are likely due to the effect of miR-155 on PPAR signaling. (Bala et al., 2016). The results of the present study show that the expression levels of miR-155 were overexpressed in both groups compared to controls, resulting higher in the AAS group even if no significant differences were reported. These findings could be linked to the organ damage generated by AAS use/abuse.

## 5.3.4 Brain tissue

The data obtained from brain tissue in the tested group are very interesting. Brain damage is a complex dysfunction that involves a variety of conditions whose pathogenesis includes a number of mediators that lead to clinical sequelae. For this reason, the identification of specific circulating and/or tissue biomarkers that could indicate brain injury is challenging (Zaninotto et al., 2016). Moreover, this is true whether diagnosing early in order to benefit patients by starting appropriate treatment early or whether investigating the cause of death, except for cases in which the circumstances of the event are strongly evocative.

In this context, miRNAs can play an important role in modulating a variety of brain conditions and can serve as new biomarkers. The miRNAs selected in this study (miR-21, miR-34, miR-124, miR-132, and miR-200b), have been predicted to control important target genes involved in neuronal apoptosis and neuronal stress-induced adaptation.

In detail, as well as being a strong indicator of widespread axonal damage (Pinchi et al.,

2018), miR-21 could be a diagnostic biomarker of cerebral ischemia (Liu et al., 2016). The miR-21 pathway of expression seems to be related to the activity of Akt signaling by suppression of phosphatase and tensin homolog (PTEN)-gene expression, resulting in further suppression of caspase-3 expression (Han et al., 2014). This cascade prevents apoptosis of cortical neurons. In addition, patients with stroke and atherosclerosis show significantly higher plasmatic levels of miR-21, which has been interpreted as a strong anti-apoptotic prevention measure (Tsai et al., 2013). Furthermore, the study conducted by Buller et al., employing in situ hybridization, demonstrated that miR-21 expression was upregulated in neurons in the area adjacent to the ischemic area as an expression of protection from ischemic neuronal death (Buller et al., 2010). Finally, miR-21 acts as an anti-inflammatory marker during ischemic stroke (Gaudet et al., 2018). This evidence is in line with our results with miR-21 expression levels being significantly higher in the AAS, SG and AG groups compared to the control trauma group and the DG group.

Analyzing the data about miR-34, it was found to be overexpressed in the AAS and DG groups. The overexpression of miR-34 was related to an increased rate of apoptosis associated with a decrease in Bcl-2 expression in mouse models and in human cell lines (Khanna et al., 2011). In contrast, an induced down-regulation of miR-34 blocked the inhibition of the expression of the target gene, Bcl-2. In addition, the high levels of the post-transcriptional protein that were induced, were accompanied by concomitant low levels of Bax expression and low cleavage by caspases. This mechanism was also observed in the brains of mice on a low-calorie diet. Furthermore, in an experimental study on the hippocampus of rats, in order to evaluate the evolution of neurodegenerative diseases, such as Alzheimer's disease, miR-34 levels were found to be elevated (Zovoilis et al., 2011). Therefore, in our analysis, the expression values of miR-34 were higher in all four groups compared to the control group, probably interpretable as an important index of neurodegeneration being statistically significant in the DG and AAS groups.

This trend is confirmed analyzing the data about the expression values of miR-124. Concerning the literature, similar considerations have been made about miR-124. In fact, Jeyaseelan et al. demonstrated that miR-124 was increased in a murine model following cerebral artery occlusion and 24 h reperfusion (Jeyaseelan et al., 2008). Moreover, miR-124 is significantly increased, as well as miR-21, in the area surrounding an ischemic zone. In the same animal model, the nervous overexpression of miR-124 correlated with a decreased infarct size (Sun et al., 2013). The probable explanation would result in the anti-apoptotic genes targeted by miR-124 being Bcl-2 and Bcl-xL (Graham et al., 2000). According to this

data, miR-124 expression showed significant differences, resulting in a higher expression in the SG and AAS groups with respect to the other two groups. A further target of miR-124 is the REST (RE1 Silencing Transcription Factor) gene that determines a reduction of the expression of neuronal plasticity genes (synaptophysin, BDNF, and Brain Derived Neurotrophic Factor). Cocaine induces REST and suppresses miR-124, influencing tolerance, sensitization, and addiction (Chandrasekar and Dreyer, 2009). In our experimental setting, the expression values of this miRNA were significantly higher in the DG group with respect to the AG group. Moreover, this neuroprotective function of miR-124 could also be extended to other neurodegenerative diseases. In fact, the miR-124 level in the brain of patients with Alzheimer's disease is down-regulated, in parallel to the increase in expression of beta-site expression APP-cleaving enzyme 1 (BACE1) (Sun et al., 2015). In addition to this mechanism of neurodegeneration, miR-124 is involved in longterm plasticity affecting the transcription factor CREB (cAMP response element-binding protein) (Rajasethupathy et al., 2009). The experimental findings of this PhD project showed that miR-124 expression in the AG group was similar to that in the control group, showing the lowest statistical significance in inter-group variation. The expression was statistically higher in the SG and in AAS groups, leading us to hypothesize its role as a diagnostic tool in the diagnosis of ischemic stroke, or for brain damages linked to AASs use/abuse. However, cognitive decline can be attributed to complex interactions involving cellular dysfunction, cumulative over time, and life habits that cause the reduction of plasticity in the elderly.

Moreover, for miR-132 the expression values in the AAS group were about the same of the DG group. In the SG group, which had expression values about the same as the controls, an important role was played by miR-132, whose function is to regulate the glutamate receptor expression level as well as post-stroke excitotoxicity (Karr et al., 2009). In fact, some recent studies have shown that the use of miR-132 antagomir during cerebral ischemic attacks may have neuroprotective effects through the suppression of glutamate receptor expression, acting on CREB as stated for miR-124 (Luikart et al., 2011; Nudelman et al., 2010). Moreover, higher serum miR-132 levels were recently suggested as biomarkers for mild cognitive impairment, a stage often preceding Alzheimer's disease (Hadar et al., 2018). Considering this effect on memorization processes, recent studies have proved that miR-132 is induced in culture by neurotrophins and neuronal activity and is able to modulate dendritic morphology via the suppression of p250 GTPase-activating protein (p250GAP) (Vo et al., 2005; Wayman et al., 2008). Acting between the neural and immune system, miR-132 has

recently been discovered to reduce brain inflammation and to increase the level of acetylcholine (O'Neill, 2009; Shaked et al., 2009; Wanet et al., 2012). In our experimental setting, the expression levels of miR-132 were higher in all four groups. Therefore, the DG and AAS groups presented significantly higher levels than the SG and AG groups.

The reason for this could be found in some studies demonstrating the upregulation of mature miR-132 expression in rats following cocaine self-administration (SA). Furthermore, recent observations from Hollander et al. confirmed that 6 h (but not 1 h) access to cocaine SA for 7 days increased miR-132 expression in the rat striatum (Hollander et al., 2010). The significant increase in miR-132 levels was long-lasting and remained high in rats that had been withdrawn from cocaine SA. Changes in dopamine and glutamate neurotransmission, alterations in specific signaling pathways, and/or epigenetic regulation have been advocated as a possible explanation. As chronic cocaine exposure alters dopamine and glutamate signaling by stimulating the dopamine D1 and glutamate NMDA receptors, these targets trigger the activation of the corresponding downstream signaling pathways and lead to CREB-dependent gene expression (Sadakierska-Chudy et al., 2017).

Finally, the data about mir-200b showed higher values in the AAS group: this result suggests a positive response in order to reduce brain damage in a subject who used AASs. miR-200b is expressed in brain tissue, particularly in microglia, and involved in inflammatory response. Oligodendrocytes (OL) are myelin-forming cells of the CNS that are vulnerable to cerebral ischemia. The loss of OL and myelin impairs axonal function and is detrimental to functional recovery. Another study by Buller et al. proved that ischemic stroke causes an up-regulation of Serum response factor (SRF) and a down-regulation of miR-200b in OL white matter (Buller et al., 2012), indicating that miR-200b plays an important role in strokeinduced SRF up-regulation, which ultimately affects OL progenitor cell differentiation. Analogously, microglia treated with miR-200b-inhibitor cause neuronal apoptosis in cell culture that is due to an excessive release of inflammatory cytokines and NO in the conditioned medium via increased c-Jun activity (Jadhav et al., 2014). In addition, impaired microglial migration has been shown to contribute to the pathogenesis of several brain diseases such as Prion disease (Ciesielski-Treska et al., 2004), Parkinson's disease (Park et al., 2008), and Alzheimer's disease (Mizuno, 2012), and it inhibits axonal regeneration during acute CNS injury (Vargas and Barres, 2007). However, further experiments are required to ascertain the possible neuroprotective role of microglial miR-200b. These literature data are in line with the statistical results of our experimental setting: the expression levels of miRNA-21 and miRNA-200b were higher in the AAS, SG and AG

groups compared to the control group, while in the DG group, the expression was similar to that in the control group.

The main limitation of this step is related to the characteristics of the enrolled subjects in the AAS group. Indeed, even if the androgen use was ascertained through the toxicological examination, the data about the utilization time is unknown. For this reason, it is impossible to establish if the adverse effects can be considered as a consequence of chronic or short term use.

Moreover, to achieve the goal of identification of new molecular biomarkers, the levels of the tested miRNAs should be evaluated in the blood, as for miR-122 by Salamin et al. (Salamin et al., 2016). However, in this PhD project, several difficulties were encountered in enrolling AAS users, making impossible the *"in vivo"* studies. Indeed, the Italian regulation in this field discourages the people from declaring the use of androgens, even only for research purposes. Contrariwise, as reported in the next paragraph, the use was declared anonymously. To solve this critical problem, in the upcoming future, collaborations with universities of other countries should be activated.

## **5.4 Questionnaire results**

Anabolic-androgenic steroid(s) (AAS) refer to testosterone and its synthetic derivatives mainly used non-medically for enhancing muscle growth and strength, boosting physical activity or sports performance, and for aesthetic purposes as well as for enhancing psychological well-being (Sagoe et al., 2014a). During assumption, users sometimes combine different injectable and oral AASs. This phenomenon is referred to as 'steroid stacking' or simply 'stacking' (McVeigh et al., 2012). Moreover, many users complement AAS use or stacking with the use of other substances. In this respect, AAS use has been found to be associated with the use of both licit and illicit substances in systematic reviews of predominantly quantitative literature (Sagoe et al., 2014b, 2015).

It has been noted that one of the major drawbacks to successful AAS interventions is public health officials' failure to recognize AAS users' extensive pharmacological regimen (Sagoe et al., 2015). A synthesis of the qualitative or descriptive literature on polypharmacy by AAS users is, both from a clinical and research perspective, important in order to increase the understanding of the polypharmacy often associated with AAS use.

The analysis of the questionnaire data demonstrated that the use of AASs in a young Italian population is 3.23 %. Analyzing the data obtained through the questionnaires in the USA reported in a recent study, the percentage of users among the interviewed people was between 1-2% (Pope et al., 2014a). The AAS users reported a significantly higher appearance evaluation and orientation compared to no-users.

It is singular to note that the kind of the anabolic agents used has been self-administrated through injection in 87.5% of cases. Considering the sex differentiation in AAS users, in a study performed in the USA, it has been reported that the rarity of female AAS use and dependence is hardly surprising (McCabe et al., 2007), in this report the prevalence of users was female (6 on 8).

Energy drinks are non-alcoholic beverages that typically contain high levels of caffeine (>150 mg/L) and sugar in combination with other ingredients known to have stimulant properties. They are marketed explicitly as a way to relieve fatigue and improve mental alertness, in contrast with sports or isotonic drinks which are intended to help athletes rehydrate after exercise (Ballard et al., 2010). In a recent report about the consumption data for energy drinks in 16 European countries it was reported that young people aged 10–18 years old had the highest reported consumption prevalence (68%), compared with adults over 18 years old (30%) and children under 10 years old (18%) (Zucconi et al., 2017). In the report, 105 subjects (42.5%) declared that they used Energy drinks. In agreement with

the scientific literature, the users declared that the consumption was related to the effects of the energy drink, increasing cognitive performance, enhanced mood, more physical energy and promotion of wakefulness (Ganio et al., 2009; Goldstein et al., 2010; Spriet, 2014). However, evidence is emerging on the harmful physiological and psychological effects of these drinks, and it is possible that prolonged use may affect physical and mental well-being (Ishak et al., 2012). In the present study, about 42% declare coffee assumption, and 10.5% of the interviewed people declared consuming more than 3 coffees/day, while 36% declared that they used Red Bull and 17% used Monster. Based on the known effects of caffeine, consumption of energy drinks may lead to the following: caffeine intoxication and withdrawal; sleep disruption and insomnia; and disruptive, hyper-active and risky behavior (Mahoney et al., 2019; Terry-McElrath et al., 2014). Furthermore, these drinks are also likely to be negative in terms of health implications associated with excessive sugar intake, such as dental erosion, obesity and type 2 diabetes (Greenwood et al., 2014; Nissinen et al., 2009). Moreover, new developments in marketing are also aimed at increasing the perceived health safety of energy drinks in order to gain acceptance in an increasingly health-driven society. As energy drink sales are rarely regulated by age, like alcohol and tobacco, and there is a proven negative effect of caffeine on children, there is the potential for a significant public health problem in the future. To date, policy development has been limited. Where policies exist, they are yet to be systematically evaluated in terms of their impact on heavy energy drink consumption, particularly among children and young adults. From a cautionary viewpoint, further research and policy action is necessary to minimize the risk of harm from heavy and long-term energy drink consumption. Moreover, it is very important to note that energy drink consumption is frequently combined with supplements. Previous independent reviews on energy drinks highlighted a number of implications for users' health and wellbeing (Ali et al., 2015; Alsunni, 2015). Finally, based on the result of the present study, energy drink use is higher in subjects who reported AAS consumption: this event could be considered in the evaluation of the adverse effects linked to the use of these kinds of substances.

Another important aspect analyzed through the questionnaire is related to supplement use. What it is known is that the majority of these products can be bought from internet web sites anonymously, with the risk of buying something different, counterfeit or completely fake (Pacifici et al., 2016); caffeinated energy drinks are often mixed with alcoholic beverages with an increased risk of binge drinking, impaired driving, risky sexual behavior, and decreased perceived intoxication (Marczinski and Fillmore, 2014); and male sexual

enhancement products (e.g. sildenafil) have been used concomitantly with cocaine with severe cardiovascular effects (Famularo et al., 2001; Megalla et al., 2011).

Another sizable emerging consumption is that of physical performance enhancers, which is recognized as unsafe by half of the responders and are consumed to replace "perceived" nutritional deficiency and to improve performance (Fernandez and Hosey, 2009; Yager and O'Dea, 2014).

The reason of performance increase is shared with AASs, taken by a minority of responders and with drugs for sexual enhancement, used exclusively by males with a prevalence of older males (Kanayama et al., 2009; Pantalone et al., 2008). Surprisingly, physical performance enhancers that are dietary supplements and both steroids and drugs for sexual enhancement, are medicinal and similarly perceived as harmful to health. In addition, steroid consumers are more likely to also use alcohol, smart-drugs and energy drinks. Whereas recreational substances such as energy drinks and smart-drugs were mainly consumed for fun, related to nightlife and associated to influence by peers and internet use, compounds enhancing physical performance were associated with training (Breda et al., 2014; Polak et al., 2016).

In the present study, the combined use of AASs with supplements is significantly higher compared to non-users, demonstrating the idea of polypharmacy for AAS users.

Although the present study has an important limitation of participants who cannot be perfectly representative of the Italian population, the sample size and its diffusion throughout the national territory support the validity of the study. In addition, it has to be remembered that results are based on self-reported answers to the questionnaire with no objective assessment (i.e. consumption biomarkers in biological fluids) of personal statements.

There was a significant association (p < 0.05) between the intake of anabolic steroids and consumption of other substances, such as energy drinks and smart-drugs.

A typical trend of the 21st century is that these substances can be anonymously supplied through the internet, where they are sold with alleged effects on mental, physical and sexual performance without any real evidence-based research. Moreover, considering that in Italy the sale of the AASs is not allowed, it could be related to the online/black market. This is true for energy drinks, smart-drugs and physical performance enhancers whose advantage/disadvantage ratio is not systematically established and for androgenic anabolic steroids and drugs for sexual enhancement administered without any real hormonal or sexual dysfunction (Yager and O'Dea, 2014).

The potential health risks related to heavy consumption of these products have largely gone unaddressed. For these reasons, the efforts of the scientific community, both to better understand and to better communicate the risks linked to the use of these substances, should be improved.

#### Significance and impact of PhD research

In the light of the results discussed in this project, it would appear that concerns in the scientific community and among the public regarding the potential adverse health effects of the increased consumption of energy drinks, supplements and AASs are broadly valid. As extensively discussed, AAS use is not limited to athletes, but concerns young people who use these kinds of substances for esthetical purposes. For these reasons, this field of ongoing research is very challenging for the scientific community, in particular for the forensic field, involving a large number of people. Although AAS use is strictly linked to the adverse effects on several organs, the use of these substances is constantly increasing. As demonstrated in this research project, the main organ involved is the heart; in several cases, the pathologies could be fatal for the abusers as described in the selected cases. Moreover, other organs are damaged during AAS use/abuse, such as reproductive systems, liver, kidney and brain. The identification of new molecular biomarkers can be considered of interest for the scientific community, not only for anti-doping purposes but for public health too.

In this project, the evaluation of several miRNAs was performed in different selected tissues (heart, liver, kidney, brain). At the end of this project, several miRNAs were identified as candidate miRNAs that could be used for anti-doping. Moreover, the identification of new molecular biomarkers for different pathologies could be very useful in clinical practice to quickly orient diagnosis and determine the most suitable treatment in the shortest time. For these reasons the results obtained with this study are very promising to encompass both new anti-doping methods and new biomarkers linked to organ damage.

Finally, evaluating all the data of the performed questionnaire, a complete scenario could be obtained on the voluptuary practices linked to AAS or smart drug use. Considering the results obtained through the questionnaires, the previous suggestions of associations between AAS use and the use of a wide range of other licit and illicit substances have been corroborated. AAS-related polypharmacy has potential serious harmful effects for people who engage in such behavior, which should be of serious public health concern. Clinicians, policymakers, researchers, and public health workers dealing with AAS users must be made aware of these issues. Importantly, efforts must be intensified to fight the debilitating effects of AAS concomitant polypharmacy. Furthermore, there needs to be ongoing research to investigate trends in AAS use and polypharmacy.

# REFERENCES

- Achar, S., Rostamian, A., and Narayan, S. M. (2010). Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. *Am. J. Cardiol.* doi:10.1016/j.amjcard.2010.05.013.
- Afshar, A. S., Xu, J., and Goutsias, J. (2014). Integrative identification of deregulated MiRNA/TF-mediated gene regulatory loops and networks in prostate cancer. *PLoS One* 9. doi:10.1371/journal.pone.0100806.
- Ai, J., Zhang, R., Li, Y., Pu, J., Lu, Y., Jiao, J., et al. (2010). Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. *Biochem. Biophys. Res. Commun.* 391, 73–77. doi:10.1016/j.bbrc.2009.11.005.
- Ali, F., Rehman, H., Babayan, Z., Stapleton, D., and Joshi, D. D. (2015). Energy drinks and their adverse health effects: A systematic review of the current evidence. *Postgrad. Med.* doi:10.1080/00325481.2015.1001712.
- Alsunni, A. A. (2015). Energy drink consumption: Beneficial and adverse health effects. *Int. J. Heal. Sci.* doi:10.12816/0031237.
- Anand, S., Majeti, B. K., Acevedo, L. M., Murphy, E. A., Mukthavaram, R., Scheppke, L., et al. (2010). MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. *Nat. Med.* doi:10.1038/nm.2186.
- Badal, S. S., and Danesh, F. R. (2015). MicroRNAs and their applications in kidney diseases. *Pediatr. Nephrol.* 30, 727–740. doi:10.1007/s00467-014-2867-7.
- Bailey, R. L., Gahche, J. J., Miller, P. E., Thomas, P. R., and Dwyer, J. T. (2013). Why US adults use dietary supplements. *JAMA Intern. Med.* 173, 355–361. doi:10.1001/jamainternmed.2013.2299.
- Bala, S., Csak, T., Saha, B., Zatsiorsky, J., Kodys, K., Catalano, D., et al. (2016). The proinflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J. Hepatol. doi:10.1016/j.jhep.2016.01.035.
- Ballard, S. L., Wellborn-Kim, J. J., and Clauson, K. A. (2010). Effects of commercial energy drink consumption on athletic performance and body composition. *Phys. Sportsmed.* doi:10.3810/psm.2010.04.1768.
- Bandiera, S., Pfeffer, S., Baumert, T. F., and Zeisel, M. B. (2015). MiR-122 A key factor and therapeutic target in liver disease. *J. Hepatol.* doi:10.1016/j.jhep.2014.10.004.
- Baron, D. A., Reardon, C. L., and Baron, S. H. (2013). "Doping in Sport," in *Clinical Sports Psychiatry: An International Perspective* doi:10.1002/9781118404904.ch3.
- Barone, R., Pitruzzella, A., Marino Gammazza, A., Rappa, F., Salerno, M., Barone, F., et al. (2017). Nandrolone decanoate interferes with testosterone biosynthesis altering blood-testis barrier components. J. Cell. Mol. Med. doi:10.1111/jcmm.13092.
- Bartel, D. P. (2004). MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. *Cell* 116, 281–297. doi:10.1016/S0092-8674(04)00045-5.
- Bell, M. L., Buvoli, M., and Leinwand, L. A. (2010). Uncoupling of Expression of an Intronic MicroRNA and Its Myosin Host Gene by Exon Skipping. *Mol. Cell. Biol.* doi:10.1128/mcb.01370-09.
- Bertozzi, G., Salerno, M., Pomara, C., and Sessa, F. (2019a). Neuropsychiatric and Behavioral Involvement in AAS Abusers. A Literature Review. *Medicina (B. Aires)*. doi:10.3390/medicina55070396.
- Bertozzi, G., Sessa, F., Albano, G. D., Sani, G., Maglietta, F., Roshan, M. H. K., et al. (2017). The Role of Anabolic Androgenic Steroids in Disruption of the Physiological Function in Discrete Areas of the Central Nervous System. *Mol. Neurobiol.*, 1–9.

doi:10.1007/s12035-017-0774-1.

- Bertozzi, G., Sessa, F., Maglietta, F., Cipolloni, L., Salerno, M., Fiore, C., et al. (2019b). Immunodeficiency as a side effect of anabolic androgenic steroid abuse: a case of necrotizing myofasciitis. *Forensic Sci. Med. Pathol.* doi:10.1007/s12024-019-00144z.
- Bond, P., Llewellyn, W., and Van Mol, P. (2016). Anabolic androgenic steroid-induced hepatotoxicity. *Med. Hypotheses*. doi:10.1016/j.mehy.2016.06.004.
- Breda, J. J., Whiting, S. H., Encarnação, R., Norberg, S., Jones, R., Reinap, M., et al. (2014). Energy drink consumption in Europe: A review of the risks, adverse health effects, and policy options to respond. *Front. Public Heal.* doi:10.3389/fpubh.2014.00134.
- Bremner, W. J., Vitiello, M. V., and Prinz, P. N. (1983). Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. *J. Clin. Endocrinol. Metab.* doi:10.1210/jcem-56-6-1278.
- Brown, T. A., Cash, T. F., and Mikulka, P. J. (1990). Attitudinal Body-Image Assessment: Factor Analysis of the Body-Self Relations Questionnaire. J. Pers. Assess. doi:10.1080/00223891.1990.9674053.
- Bucknall, V., Rehman, H., Bassindale, T., and Clement, R. G. (2014). The athlete biological passport: Ticket to a fair commonwealth games. *Scott. Med. J.* 59, 143–148. doi:10.1177/0036933014542062.
- Buller, B., Chopp, M., Ueno, Y., Zhang, L., Zhang, R. L., Morris, D., et al. (2012). Regulation of serum response factor by miRNA-200 and miRNA-9 modulates oligodendrocyte progenitor cell differentiation. *Glia*. doi:10.1002/glia.22406.
- Buller, B., Liu, X., Wang, X., Zhang, R. L., Zhang, L., Hozeska-Solgot, A., et al. (2010). MicroRNA-21 protects neurons from ischemic death. *FEBS J.* doi:10.1111/j.1742-4658.2010.07818.x.
- Büttner, A., and Thieme, D. (2010). Side effects of anabolic androgenic steroids: Pathological findings and structure-activity relationships. *Handb. Exp. Pharmacol.* doi:10.1007/978-3-540-79088-4\_19.
- Cadwallader, A. B., De La Torre, X., Tieri, A., and Botrè, F. (2010). The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: Pharmacology, toxicology and analysis. *Br. J. Pharmacol.* 161, 1–16. doi:10.1111/j.1476-5381.2010.00789.x.
- Callis, T. E., Pandya, K., Hee, Y. S., Tang, R. H., Tatsuguchi, M., Huang, Z. P., et al. (2009). MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. doi:10.1172/JCI36154.
- Cash, T. F. (2000a). MBSRQ Users Manual. Unpubl. Test Man.
- Cash, T. F. (2000b). The multidimensional body-self relations questionnaire. *Unpubl. Test Man.*
- Cash, T. F. (2017). "Multidimensional Body–Self Relations Questionnaire (MBSRQ)," in *Encyclopedia of Feeding and Eating Disorders* doi:10.1007/978-981-287-104-6\_3.
- Catalanotto, C., Cogoni, C., and Zardo, G. (2016). MicroRNA in control of gene expression: An overview of nuclear functions. *Int. J. Mol. Sci.* 17. doi:10.3390/ijms17101712.
- Chana, G., Bousman, C. A., Money, T. T., Gibbons, A., Gillett, P., Dean, B., et al. (2013). Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. *Front. Cell. Neurosci.* doi:10.3389/fncel.2013.00095.
- Chandrasekar, V., and Dreyer, J. L. (2009). microRNAs miR-124, let-7d and miR-181a regulate Cocaine-induced Plasticity. *Mol. Cell. Neurosci.* doi:10.1016/j.mcn.2009.08.009.

- Chau, B. N., Xin, C., Hartner, J., Ren, S., Castano, A. P., Linn, G., et al. (2012). MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. *Sci. Transl. Med.* doi:10.1126/scitranslmed.3003205.
- Chen, C., Ridzon, D. A., Broomer, A. J., Zhou, Z., Lee, D. H., Nguyen, J. T., et al. (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic Acids Res.* doi:10.1093/nar/gni178.
- Chen, J. F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. M., et al. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. *Nat. Genet.* doi:10.1038/ng1725.
- Chinen, J., and Shearer, W. T. (2010). Secondary immunodeficiencies, including HIV infection. J. Allergy Clin. Immunol. doi:10.1016/j.jaci.2009.08.040.
- Choi, S. M., and Lee, B.-M. (2015). Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids. *Expert Opin. Drug Saf.* doi:10.1517/14740338.2015.1094052.
- Christou, M. A., Christou, P. A., Markozannes, G., Tsatsoulis, A., Mastorakos, G., and Tigas, S. (2017). Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis. *Sport. Med.* doi:10.1007/s40279-017-0709-z.
- Christou, M. A., and Tigas, S. (2018). Recovery from reproductive impact of androgen abuse. *Curr. Opin. Endocrinol. Diabetes Obes.* doi:10.1097/MED.00000000000406.
- Ciesielski-Treska, J., Grant, N. J., Ulrich, G., Corrotte, M., Bailly, Y., Haeberle, A. M., et al. (2004). Fibrillar Prion Peptide (106-126) and Scrapie Prion Protein Hamper Phagocytosis in Microglia. *Glia*. doi:10.1002/glia.10363.
- Cole, M., Hopker, J. G., Wiles, J. D., and Coleman, D. A. (2018). The effects of acute carbohydrate and caffeine feeding strategies on cycling efficiency. *J. Sports Sci.* doi:10.1080/02640414.2017.1343956.
- Collins, F. S., and Varmus, H. (2015). A new initiative on precision medicine. *N. Engl. J. Med.* doi:10.1056/NEJMp1500523.
- Csak, T., Bala, S., Lippai, D., Kodys, K., Catalano, D., Iracheta-Vellve, A., et al. (2015). MicroRNA-155 deficiency attenuates liver steatosis and fibrosis without reducing inflammation in a mouse model of steatohepatitis. *PLoS One.* doi:10.1371/journal.pone.0129251.
- D'Andrea, A., Caso, P., Salerno, G., Scarafile, R., De Corato, G., Mita, C., et al. (2007). Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: A Doppler myocardial and strain imaging analysis. *Br. J. Sports Med.* doi:10.1136/bjsm.2006.030171.
- Damrose, E. J. (2009). Quantifying the impact of androgen therapy on the female larynx. *Auris Nasus Larynx*. doi:10.1016/j.anl.2008.03.002.
- Danese, E., Benati, M., Sanchis-Gomar, F., Tarperi, C., Salvagno, G. L., Paviati, E., et al. (2017). Physiological determinants of urine and plasma myomiRNAs in recreational, middle-age athletes. J. Lab. Precis. Med. May 2017. Available at: http://jlpm.amegroups.com/article/view/3637.
- de la Torre, B., Sjöberg, B., Hedman, M., Bártfai, G., and Diczfalusy, E. (1981). A study of the short-time variation and interrelationship of plasma hormone levels reflecting pituitary, adrenocortical and testicular function in fertile men. *Int. J. Androl.* doi:10.1111/j.1365-2605.1981.tb00736.x.
- Demers, L. M., Leizman, D. J., and Liggett, M. (1991). Endocrine effects in female weight lifters who self-administer testosterone and anabolic steroids. *Am. J. Obstet. Gynecol.* doi:10.1016/S0002-9378(12)90768-1.

- Demling, R. H., and DeSanti, L. (2003). Effect of the anabolic steroid oxandrolone on the rate of catabolism in acute necrotizing fasciitis. *Wounds*.
- Desvignes, T., Batzel, P., Berezikov, E., Eilbeck, K., Eppig, J. T., McAndrews, M. S., et al. (2015). MiRNA Nomenclature: A View Incorporating Genetic Origins, Biosynthetic Pathways, and Sequence Variants. *Trends Genet.* 31, 613–626. doi:10.1016/j.tig.2015.09.002.
- Di Paolo, M., Agozzino, M., Toni, C., Luciani, A. B., Molendini, L., Scaglione, M., et al. (2007). Sudden anabolic steroid abuse-related death in athletes. *Int. J. Cardiol.* doi:10.1016/j.ijcard.2005.11.033.
- Dickerman, R. D., Schaller, F., Prather, I., and McConathy, W. J. (1995). Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. *Cardiology*. doi:10.1159/000176867.
- Dickinson, A., Blatman, J., El-Dash, N., and Franco, J. C. (2014). Consumer Usage and Reasons for Using Dietary Supplements: Report of a Series of Surveys. J. Am. Coll. Nutr. 33, 176–182. doi:10.1080/07315724.2013.875423.
- Donadeu, F. X., Mohammed, B. T., and Ioannidis, J. (2017). A miRNA target network putatively involved in follicular atresia. *Domest. Anim. Endocrinol.* 58, 76–83. doi:10.1016/j.domaniend.2016.08.002.
- Drug abuse handbook (1998). Choice Rev. Online. doi:10.5860/choice.35-5686.
- Dwivedi, Y. (2014). Emerging role of microRNAs in major depressive disorder: Diagnosis and therapeutic implications. *Dialogues Clin. Neurosci.* 16, 43–61.
- Edwards, J. K., Pasqualini, R., Arap, W., and Calin, G. A. (2010). MicroRNAs and ultraconserved genes as diagnostic markers and therapeutic targets in cancer and cardiovascular diseases. *J. Cardiovasc. Transl. Res.* doi:10.1007/s12265-010-9179-5.
- Eisenberg, I., Eran, A., Nishino, I., Moggio, M., Lamperti, C., Amato, A. A., et al. (2007). Distinctive patterns of microRNA expression in primary muscular disorders. *Proc. Natl. Acad. Sci. U. S. A.* 104, 17016–17021. doi:10.1073/pnas.0708115104.
- El Osta, R., Almont, T., Diligent, C., Hubert, N., Eschwège, P., and Hubert, J. (2016). Anabolic steroids abuse and male infertility. *Basic Clin. Androl.* 26. doi:10.1186/s12610-016-0029-4.
- Elsharkawy, A. M., McPherson, S., Masson, S., Burt, A. D., Dawson, R. T., and Hudson, M. (2012). Cholestasis secondary to anabolic steroid use in young men. *BMJ*. doi:10.1136/bmj.e468.
- Enriquez, A., and Frankel, D. S. (2017). Arrhythmogenic effects of energy drinks. J. Cardiovasc. Electrophysiol. doi:10.1111/jce.13210.
- Famularo, G., Polchi, S., Di Bona, G., and Manzara, C. (2001). Acute aortic dissection after cocaine and sildenafil abuse [3]. *J. Emerg. Med.* doi:10.1016/S0736-4679(01)00345-6.
- Ferenchick, G. S. (1991). Anabolic/androgenic steroid abuse and thrombosis: Is there a connection? *Med. Hypotheses*. doi:10.1016/0306-9877(91)90079-E.
- Ferenchick, G. S., and Adelman, S. (1992). Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter. *Am. Heart J.* doi:10.1016/0002-8703(92)90620-B.
- Fernandez, M. M. F., and Hosey, R. G. (2009). Performance-enhancing drugs snare nonathletes, too. *J. Fam. Pract.*
- Ferrera, P. C., Putnam, D. L., and Verdile, V. P. (1997). Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. *Cardiol.* doi:10.1159/000177333.
- Fineschi, V., Baroldi, G., Monciotti, F., Reattelli, L. P., and Turillazzi, E. (2001). Anabolic steroid abuse and cardiac sudden death: A pathologic study. *Arch. Pathol. Lab. Med.* doi:10.1043/0003-9985(2001)125<0253:ASAACS>2.0.CO;2.

- Fineschi, V., Riezzo, I., Centini, F., Silingardi, E., Licata, M., Beduschi, G., et al. (2007). Sudden cardiac death during anabolic steroid abuse: Morphologic and toxicologic findings in two fatal cases of bodybuilders. *Int. J. Legal Med.* doi:10.1007/s00414-005-0055-9.
- Franke, W. W., and Berendonk, B. (1997). Hormonal doping and androgenization of athletes: A secret program of the German Democratic Republic government. in *Clinical Chemistry*.
- Frati, P., Busardo, F., Cipolloni, L., Dominicis, E., and Fineschi, V. (2014). Anabolic Androgenic Steroid (AAS) Related Deaths: Autoptic, Histopathological and Toxicological Findings. *Curr. Neuropharmacol.* doi:10.2174/1570159x13666141210225414.
- Frati, P., Kyriakou, C., Del Rio, A., Marinelli, E., Vergallo, G. M., Zaami, S., et al. (2015). Smart drugs and synthetic androgens for cognitive and physical enhancement: Revolving doors of cosmetic neurology. *Curr. Neuropharmacol.* 13, 5–11. doi:10.2174/1570159X13666141210221750.
- Ganio, M. S., Klau, J. F., Casa, D. J., Armstrong, L. E., and Maresh, C. M. (2009). Effect of caffeine on sport-specific endurance performance: A systematic review. *J. Strength Cond. Res.* doi:10.1519/JSC.0b013e31818b979a.
- Gasparello, J., Lamberti, N., Papi, C., Lampronti, I., Cosenza, L. C., Fabbri, E., et al. (2019). Altered erythroid-related miRNA levels as a possible novel biomarker for detection of autologous blood transfusion misuse in sport. *Transfusion*. doi:10.1111/trf.15383.
- Gaudet, A. D., Fonken, L. K., Watkins, L. R., Nelson, R. J., and Popovich, P. G. (2018). MicroRNAs: Roles in Regulating Neuroinflammation. *Neuroscientist*. doi:10.1177/1073858417721150.
- Gilad, S., Meiri, E., Yogev, Y., Benjamin, S., Lebanony, D., Yerushalmi, N., et al. (2008). Serum microRNAs are promising novel biomarkers. *PLoS One* 3. doi:10.1371/journal.pone.0003148.
- Glaser, R., and Dimitrakakis, C. (2013). Testosterone therapy in women: Myths and misconceptions. *Maturitas*. doi:10.1016/j.maturitas.2013.01.003.
- Goldman, A., and Basaria, S. (2018). Adverse health effects of androgen use. *Mol. Cell. Endocrinol.* doi:10.1016/j.mce.2017.06.009.
- Goldstein, E. R., Ziegenfuss, T., Kalman, D., Kreider, R., Campbell, B., Wilborn, C., et al. (2010). International society of sports nutrition position stand: Caffeine and performance. J. Int. Soc. Sports Nutr. doi:10.1186/1550-2783-7-5.
- Graham, S. H., Chen, J., and Clark, R. S. B. (2000). Bcl-2 family gene products in cerebral ischemia and traumatic brain injury. *J. Neurotrauma*. doi:10.1089/neu.2000.17.831.
- Grant, S., Dearing, J., Ghosh, S., Collier, A., and Bal, A. M. (2010). Necrotizing myositis of the deltoid following intramuscular injection of anabolic steroid. *Int. J. Infect. Dis.* doi:10.1016/j.ijid.2010.05.012.
- Grasser, E. K., Yepuri, G., Dulloo, A. G., and Montani, J. P. (2014). Cardio- and cerebrovascular responses to the energy drink Red Bull in young adults: a randomized cross-over study. *Eur. J. Nutr.* doi:10.1007/s00394-014-0661-8.
- Greenwood, D. C., Threapleton, D. E., Evans, C. E. L., Cleghorn, C. L., Nykjaer, C., Woodhead, C., et al. (2014). Association between sugar-sweetened and artificially sweetened soft drinks and type 2 diabetes: Systematic review and dose-response meta-analysis of prospective studies. *Br. J. Nutr.* doi:10.1017/S0007114514001329.
- Grgic, J., and Mikulic, P. (2017). Caffeine ingestion acutely enhances muscular strength and power but not muscular endurance in resistance-trained men. *Eur. J. Sport Sci.* doi:10.1080/17461391.2017.1330362.

- Gunnarsdottir, M. G., Jonsson, T., and Halldorsdottir, A. M. (2019). Circulating plasma microRNAs as biomarkers for iron status in blood donors. *Transfus. Med.* doi:10.1111/tme.12554.
- Hadar, A., Milanesi, E., Walczak, M., Puzianowska-Kuźnicka, M., Kuźnicki, J., Squassina, A., et al. (2018). SIRT1, miR-132 and miR-212 link human longevity to Alzheimer's Disease. *Sci. Rep.* doi:10.1038/s41598-018-26547-6.
- Hajsadeghi, S., Mohammadpour, F., Manteghi, M. J., Kordshakeri, K., Tokazebani, M., Rahmani, E., et al. (2016). Effects of energy drinks on blood pressure, heart rate, and electrocardiographic parameters: An experimental study on healthy young adults. *Anatol. J. Cardiol.* doi:10.5152/akd.2015.5930.
- Hampl, R., Kubátová, J., and Stárka, L. (2016). Steroids and endocrine disruptors -History, recent state of art and open questions. J. Steroid Biochem. Mol. Biol. doi:10.1016/j.jsbmb.2014.04.013.
- Han, Z., Chen, F., Ge, X., Tan, J., Lei, P., and Zhang, J. (2014). MiR-21 alleviated apoptosis of cortical neurons through promoting PTEN-Akt signaling pathway in vitro after experimental traumatic brain injury. *Brain Res.* doi:10.1016/j.brainres.2014.07.045.
- Handelsman, D. J., Sikaris, K., and Ly, L. P. (2015). Estimating age-specific trends in circulating testosterone and sex hormone-binding globulin in males and females across the lifespan. *Ann. Clin. Biochem.* 53, 377–384. doi:10.1177/0004563215610589.
- Hanin, G., Yayon, N., Tzur, Y., Haviv, R., Bennett, E. R., Udi, S., et al. (2018). miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. *Gut.* doi:10.1136/gutjnl-2016-312869.
- Harmer, P. A. (2010). Anabolic-androgenic steroid use among young male and female athletes: Is the game to blame? *Br. J. Sports Med.* doi:10.1136/bjsm.2009.068924.
- Hata, A. (2013). *Functions of microRNAs in cardiovascular biology and disease*. doi:10.1146/annurev-physiol-030212-183737.
- Hausmann, R., Hammer, S., and Betz, P. (1998). Performance enhancing drugs (doping agents) and sudden death A case report and review of the literature. *Int. J. Legal Med.* doi:10.1007/s004140050165.
- Hoffman, J. R., Kraemer, W. J., Bhasin, S., Storer, T., Ratamess, N. A., Haff, G. G., et al. (2009). Position stand on androgen and human growth hormone use. J. strength Cond. Res. / Natl. Strength & Cond. Assoc. 23.
- Hoffman, J. R., and Ratamess, N. A. (2006). Medical issues associated with anabolic steroid use: are they exaggerated? *J. Sports Sci. Med.*
- Hollander, J. A., Im, H. I., Amelio, A. L., Kocerha, J., Bali, P., Lu, Q., et al. (2010). Striatal microRNA controls cocaine intake through CREB signalling. *Nature*. doi:10.1038/nature09202.
- Hu, J., Xu, Y., Hao, J., Wang, S., Li, C., and Meng, S. (2012). MiR-122 in hepatic function and liver diseases. *Protein Cell*. doi:10.1007/s13238-012-2036-3.
- Hughes, M., and Ahmed, S. (2011). Anabolic androgenic steroid induced necrotising myopathy. *Rheumatol. Int.* 31, 915–917. doi:10.1007/s00296-009-1235-6.
- Hughes, T. K., Fulep, E., Juelich, T., Smith, E. M., and Stanton, G. J. (1995). Modulation of immune responses by anabolic androgenic steroids. *Int. J. Immunopharmacol.* doi:10.1016/0192-0561(95)00078-X.
- Ibrahim, W., Choura, M., Bshesh, F., Paul, T., and Elzouki, A.-N. (2018). Severe cholestasis with marked weight loss mimicking malignancy: An overlooked etiology. *Libyan J. Med. Sci.* doi:10.4103/ljms.ljms\_10\_18.
- Ishak, W. W., Ugochukwu, C., Bagot, K., Khalili, D., and Zaky, C. (2012). Energy drinks:

Psychological effects and impact on well-being and quality of life-A literature review. *Innov. Clin. Neurosci.* 

- Jadhav, S. P., Kamath, S. P., Choolani, M., Lu, J., and Dheen, S. T. (2014). MicroRNA-200b modulates microglia-mediated neuroinflammation via the cJun/MAPK pathway. *J. Neurochem.* doi:10.1111/jnc.12731.
- Jeyaseelan, K., Lim, K. Y., and Armugam, A. (2008). Neuroprotectants in stroke therapy. *Expert Opin. Pharmacother.* doi:10.1517/14656566.9.6.887.
- Joladarashi, D., Thandavarayan, R. A., Babu, S. S., and Krishnamurthy, P. (2014). Small engine, big power: MicrorNAS as regulators of cardiac diseases and regeneration. *Int. J. Mol. Sci.* 15, 15891–15911. doi:10.3390/ijms150915891.
- Junior, J. F. C. R., Silva, A. S., Cardoso, G. A., Silvino, V. O., Martins, M. C. C., and Santos, M. A. P. (2018). Androgenic-anabolic steroids inhibited post-exercise hypotension: a case control study. *Brazilian J. Phys. Ther.* 22, 77–81. doi:10.1016/j.bjpt.2017.07.001.
- Kanayama, G., Hudson, J. I., and Pope, H. G. (2008a). Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: A looming public health concern? *Drug Alcohol Depend*. 98, 1–12. doi:10.1016/j.drugalcdep.2008.05.004.
- Kanayama, G., Hudson, J. I., and Pope, H. G. (2008b). Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: A looming public health concern? *Drug Alcohol Depend*. doi:10.1016/j.drugalcdep.2008.05.004.
- Kanayama, G., Hudson, J. I., and Pope, H. G. (2009). Features of men with anabolicandrogenic steroid dependence: A comparison with nondependent AAS users and with AAS nonusers. *Drug Alcohol Depend*. doi:10.1016/j.drugalcdep.2009.02.008.
- Kanayama, G., Hudson, J. I., and Pope, H. G. (2010). Illicit anabolic-androgenic steroid use. *Horm. Behav.* doi:10.1016/j.yhbeh.2009.09.006.
- Karila, T. A. M., Karjalainen, J. E., Mäntysaari, M. J., Viitasalo, M. T., and Seppälä, T. A. (2003). Anabolic androgenic steroids produce dose-dependent increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. *Int. J. Sports Med.* doi:10.1055/s-2003-40702.
- Karr, J., Vagin, V., Chen, K., Ganesan, S., Olenkina, O., Gvozdev, V., et al. (2009). Regulation of glutamate receptor subunit availability by microRNAs. J. Cell Biol. doi:10.1083/jcb.200902062.
- Keane, J., Tajouri, L., and Gray, B. (2015). The effect of growth hormone administration on the regulation of mitochondrial apoptosis in-vivo. *Int. J. Mol. Sci.* 16, 12753– 12772. doi:10.3390/ijms160612753.
- Kennedy, M. C., and Lawrence, C. (1993). Anabolic steroid abuse and cardiac death. *Med. J. Aust.* doi:10.5694/j.1326-5377.1993.tb121797.x.
- Kersten, S., Rakhshandehroo, M., Knoch, B., and Müller, M. (2010). Peroxisome proliferator-activated receptor alpha target genes. *PPAR Res.* doi:10.1155/2010/612089.
- Khanna, A., Muthusamy, S., Liang, R., Sarojini, H., and Wang, E. (2011). Gain of survival signaling by down-regulation of three key miRNAs in brain of calorie-restricted mice. *Aging (Albany. NY)*. doi:10.18632/aging.100276.
- Kicman, A. T. (2008). Pharmacology of anabolic steroids. *Br. J. Pharmacol.* doi:10.1038/bjp.2008.165.
- Kierzkowska, B., Stańczyk, J., and Kasprzak, J. D. (2005). Myocardial infarction in a 17year-old body builder using clenbuterol. *Circ. J.* doi:10.1253/circj.69.1144.
- Kirby, T. J., Chaillou, T., and McCarthy, J. J. (2015). The role of microRNAs in skeletal muscle health and disease. *Front. Biosci. Landmark* 20, 37–77. doi:10.2741/4298.
- Kristensen, H., Thomsen, A. R., Haldrup, C., Dyrskjøt, L., Høyer, S., Borre, M., et al.

(2016). Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling. *Oncotarget* 7, 30760–30771. doi:10.18632/oncotarget.8953.

- Kroh, E. M., Parkin, R. K., Mitchell, P. S., and Tewari, M. (2010). Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). *Methods*. doi:10.1016/j.ymeth.2010.01.032.
- Kumarswamy, R., and Thum, T. (2013). Non-coding RNAs in cardiac remodeling and heart failure. *Circ. Res.* doi:10.1161/CIRCRESAHA.113.300226.
- Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., and Tuschl, T. (2002). Identification of tissue-specific MicroRNAs from mouse. *Curr. Biol.* doi:10.1016/S0960-9822(02)00809-6.
- Lagos, D., Pollara, G., Henderson, S., Gratrix, F., Fabani, M., Milne, R. S. B., et al. (2010). MiR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. *Nat. Cell Biol.* doi:10.1038/ncb2054.
- Latif, N., Khan, M. A., Birks, E., O'Farrell, A., Westbrook, J., Dunn, M. J., et al. (2000). Upregulation of the Bcl-2 family of proteins in end stage heart failure. J. Am. Coll. Cardiol. doi:10.1016/S0735-1097(00)00647-1.
- Lau, N. C., Lim, L. P., Weinstein, E. G., and Bartel, D. P. (2001). An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. *Science (80-. )*. doi:10.1126/science.1065062.
- Lecellier, C.-H., Dunoyer, P., Arar, K., Lehmann-Che, J., Eyquem, S., Himber, C., et al. (2005). A cellular microRNA mediates antiviral defense in human cells. *Science (80-.)*. 308, 557–560. doi:10.1126/science.1108784.
- Lefebvre, P., Chinetti, G., Fruchart, J. C., and Staels, B. (2006). Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. *J. Clin. Invest.* doi:10.1172/JCI27989.
- Leuenberger, N., Robinson, N., and Saugy, M. (2013a). Circulating miRNAs: A new generation of anti-doping biomarkers Anti-doping Analysis. *Anal. Bioanal. Chem.* 405, 9617–9623. doi:10.1007/s00216-013-7340-0.
- Leuenberger, N., and Saugy, M. (2015). "Circulating microRNAs: The future of biomarkers in anti-doping field," in *Advances in Experimental Medicine and Biology* doi:10.1007/978-3-319-22671-2\_20.
- Leuenberger, N., Schumacher, Y. O., Pradervand, S., Sander, T., Saugy, M., and Pottgiesser, T. (2013b). Circulating microRNAs as Biomarkers for Detection of Autologous Blood Transfusion. *PLoS One* 8. doi:10.1371/journal.pone.0066309.
- Li, J., Donath, S., Li, Y., Qin, D., Prabhakar, B. S., and Li, P. (2010a). miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. *PLoS Genet*. doi:10.1371/journal.pgen.1000795.
- Li, Q., Song, X. W., Zou, J., Wang, G. K., Kremneva, E., Li, X. Q., et al. (2010b). Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. *J. Cell Sci.* doi:10.1242/jcs.067165.
- Li, Y., Fang, Y., Liu, Y., and Yang, X. (2015). MicroRNAs in ovarian function and disorders. *J. Ovarian Res.* 8. doi:10.1186/s13048-015-0162-2.
- Lippi, G., and Plebani, M. (2011). Athlete's biological passport: To test or not to test? *Clin. Chem. Lab. Med.* 49, 1393–1395. doi:10.1515/CCLM.2011.658.
- Liu, G., Friggeri, A., Yang, Y., Milosevic, J., Ding, Q., Thannickal, V. J., et al. (2010). miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. doi:10.1084/jem.20100035.
- Liu, W., Chen, X., and Zhang, Y. (2016). Effects of microRNA-21 and microRNA-24 inhibitors on neuronal apoptosis in ischemic stroke. *Am. J. Transl. Res.*

- Liu, Y., Liang, Y., Zhang, J. fang, and Fu, W. ming (2017). MicroRNA-133 mediates cardiac diseases: Mechanisms and clinical implications. *Exp. Cell Res.* doi:10.1016/j.yexcr.2017.03.037.
- Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the  $2-\Delta\Delta CT$  method. *Methods*. doi:10.1006/meth.2001.1262.
- Loyer, X., Paradis, V., Hénique, C., Vion, A. C., Colnot, N., Guerin, C. L., et al. (2016). Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. *Gut.* doi:10.1136/gutjnl-2014-308883.
- Luikart, B. W., Bensen, A. S. L., Washburn, E. K., Perederiy, J. V., Su, K. G., Li, Y., et al. (2011). MiR-132 mediates the integration of newborn neurons into the adult dentate gyrus. *PLoS One*. doi:10.1371/journal.pone.0019077.
- Luke, J. L., Farb, A., Virmani, R., and Sample, R. H. B. (1990). Sudden Cardiac Death During Exercise in a Weight Lifter Using Anabolic Androgenic Steroids: Pathological and Toxicological Findings. *J. Forensic Sci.* doi:10.1520/jfs12981j.
- Luo, X., Xiao, J., Lin, H., Li, B., Lu, Y., Yang, B., et al. (2007). Transcriptional activation by stimulating protein 1 and post-transcriptional repression by muscle-specific microRNAs of I Ks-encoding genes and potential implications in regional heterogeneity of their expressions. J. Cell. Physiol. doi:10.1002/jcp.21030.
- Luo, Y.-B., and Mastaglia, F. L. (2015). Dermatomyositis, polymyositis and immunemediated necrotising myopathies. *Biochim. Biophys. Acta - Mol. Basis Dis.* 1852, 622–632. doi:10.1016/j.bbadis.2014.05.034.
- MacFarlane, L.-A., and Murphy, P. R. (2010). MicroRNA: Biogenesis, function and role in cancer. *Curr. Genomics* 11, 537–561. doi:10.2174/138920210793175895.
- Mahoney, C. R., Giles, G. E., Marriott, B. P., Judelson, D. A., Glickman, E. L., Geiselman, P. J., et al. (2019). Intake of caffeine from all sources and reasons for use by college students. *Clin. Nutr.* doi:10.1016/j.clnu.2018.04.004.
- Marczinski, C. A., and Fillmore, M. T. (2014). Energy drinks mixed with alcohol: What are the risks? *Nutr. Rev.* doi:10.1111/nure.12127.
- Marsh, J. D., Lehmann, M. H., Ritchie, R. H., Gwathmey, J. K., Green, G. E., and Schiebinger, R. J. (1998). Androgen receptors mediate hypertrophy in cardiac myocytes. *Circulation*. doi:10.1161/01.CIR.98.3.256.
- Marshall-Gradisnik, S., Green, R., Brenu, E. W., and Weatherby, R. P. (2009). Anabolic androgenic steroids effects on the immune system: A review. *Cent. Eur. J. Biol.* doi:10.2478/s11535-008-0058-x.
- McCabe, S. E., Brower, K. J., West, B. T., Nelson, T. F., and Wechsler, H. (2007). Trends in non-medical use of anabolic steroids by U.S. college students: Results from four national surveys. *Drug Alcohol Depend*. doi:10.1016/j.drugalcdep.2007.04.004.
- McGinnis, L. K., Luense, L. J., and Christenson, L. K. (2015). MicroRNA in ovarian biology and disease. *Cold Spring Harb. Perspect. Med.* 5. doi:10.1101/cshperspect.a022962.
- McNutt, R. A., Ferenchick, G. S., Kirlin, P. C., and Hamlin, N. J. (1988). Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. *Am. J. Cardiol.* doi:10.1016/0002-9149(88)91390-2.
- McVeigh, J., Evans-Brown, M., and Bellis, M. A. (2012). Human enhancement drugs and the pursuit of perfection. *Adicciones*. doi:10.20882/adicciones.88.
- Megalla, S., Shaqra, H., and Bhalodkar, N. C. (2011). Non-ST-segment elevation myocardial infarction in the setting of sexual intercourse following the use of cocaine and sildenafil. *Rev. Cardiovasc. Med.* doi:10.3909/ricm0560.

- Mehler, M. F., and Mattick, J. S. (2007). Noncoding RNAs and RNA editing in brain development, functional diversification, and neurological disease. *Physiol. Rev.* 87, 799–823. doi:10.1152/physrev.00036.2006.
- Melchert, R. B., and Welder, A. A. (1995). Cardiovascular effects of anclrogenic-anabolic steroids. *Med. Sci. Sports Exerc.* doi:10.1249/00005768-199509000-00004.
- Mewis, C., Spyridopoulos, I., Kühlkamp, V., and Seipel, L. (1996). Manifestation of severe coronary heart disease after anabolic drug abuse. *Clin. Cardiol.* 19, 153–155. doi:10.1002/clc.4960190216.
- Mizuno, T. (2012). The biphasic role of microglia in Alzheimer's disease. *Int. J. Alzheimers. Dis.* doi:10.1155/2012/737846.
- Montanini, V., Simoni, M., Chiossi, G., Baraghini, G. F., Velardo, A., Baraldi, E., et al. (1988). Age-related changes in plasma dehydroepiandrosterone sulphate, cortisol, testosterone and free testosterone circadian rhythms in adult men. *Horm. Res. Paediatr.* doi:10.1159/000180956.
- Montgomery, R. L., Hullinger, T. G., Semus, H. M., Dickinson, B. A., Seto, A. G., Lynch, J. M., et al. (2011). Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. *Circulation*. doi:10.1161/CIRCULATIONAHA.111.030932.
- Montisci, M., El Mazloum, R., Cecchetto, G., Terranova, C., Ferrara, S. D., Thiene, G., et al. (2012). Anabolic androgenic steroids abuse and cardiac death in athletes: Morphological and toxicological findings in four fatal cases. *Forensic Sci. Int.* doi:10.1016/j.forsciint.2011.10.032.
- Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., et al. (2013). Intestinal microbiota in patients with nonalcoholic fatty liver disease. *Hepatology*. doi:10.1002/hep.26319.
- Niedfeldt, M. W. (2018). Anabolic Steroid Effect on the Liver. *Curr. Sports Med. Rep.* doi:10.1249/JSR.00000000000467.
- Nielsen, L. B., Wang, C., Sørensen, K., Bang-Berthelsen, C. H., Hansen, L., Andersen, M.-L. M., et al. (2012). Circulating levels of MicroRNA from children with newly diagnosed type 1 diabetes and healthy controls: Evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. *Exp. Diabetes Res.* 2012. doi:10.1155/2012/896362.
- Nieschlag, E., and Vorona, E. (2015). MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. *Eur. J. Endocrinol.* doi:10.1530/eje-15-0080.
- Nissinen, K., Mikkilä, V., Männistö, S., Lahti-Koski, M., Räsänen, L., Viikari, J., et al. (2009). Sweets and sugar-sweetened soft drink intake in childhood in relation to adult BMI and overweight. the Cardiovascular Risk in Young Finns Study. *Public Health Nutr.* doi:10.1017/S1368980009005849.
- Nudelman, A. S., Dirocco, D. P., Lambert, T. J., Garelick, M. G., Le, J., Nathanson, N. M., et al. (2010). Neuronal activity rapidly induces transcription of the CREBregulated microRNA-132, in vivo. *Hippocampus*. doi:10.1002/hipo.20646.
- O'Connor, D. B., Archer, J., and Wu, F. C. W. (2004). Effects of testosterone on mood, aggression, and sexual behavior in young men: A double-blind, placebo-controlled, cross-over study. in *Journal of Clinical Endocrinology and Metabolism* doi:10.1210/jc.2003-031354.
- O'Neill, L. A. J. (2009). Boosting the Brain's Ability to Block Inflammation via MicroRNA-132. *Immunity*. doi:10.1016/j.immuni.2009.11.004.
- Oberlander, J. G., Porter, D. M., Penatti, C. A. A., and Henderson, L. P. (2012). Anabolic androgenic steroid abuse: Multiple mechanisms of regulation of GABAergic

synapses in neuroendocrine control regions of the rodent forebrain. J. Neuroendocrinol. doi:10.1111/j.1365-2826.2011.02151.x.

- Oliveira-Carvalho, V., Carvalho, V. O., and Bocchi, E. A. (2013). The emerging role of miR-208a in the heart. *DNA Cell Biol.* doi:10.1089/dna.2012.1787.
- Olson, E. N. (2006). Gene regulatory networks in the evolution and development of the heart. *Science (80-. ).* doi:10.1126/science.1132292.
- Pacifici, R., Palmi, I., Vian, P., Andreotti, A., Mortali, C., Berretta, P., et al. (2016). Emerging trends in consuming behaviours for non-controlled substances by Italian urban youth: a cross sectional study. *Ann. Ist. Super. Sanita*. doi:10.4415/ANN 16 01 17.
- Pan, M. M., and Kovac, J. R. (2016). Beyond testosterone cypionate: Evidence behind the use of nandrolone in male health and wellness. *Transl. Androl. Urol.* doi:10.21037/tau.2016.03.03.
- Pantalone, D. W., Bimbi, D. S., and Parsons, J. T. (2008). Motivations for the recreational use of erectile enhancing medications in urban gay and bisexual men. *Sex. Transm. Infect.* doi:10.1136/sti.2008.031476.
- Park, J. Y., Paik, S. R., Jou, I., and Park, S. M. (2008). Microglial phagocytosis is enhanced by monomeric α-synuclein, not aggregated α-synuclein: Implications for Parkinson's disease. *Glia*. doi:10.1002/glia.20691.
- Parkinson, A. B., and Evans, N. A. (2006). Anabolic androgenic steroids: A survey of 500 users. *Med. Sci. Sports Exerc.* 38, 644–651. doi:10.1249/01.mss.0000210194.56834.5d.
- Payne, J. R., Kotwinski, P. J., and Montgomery, H. E. (2004). Cardiac effects of anabolic steroids. *Heart*. doi:10.1097/00000542-199004000-00039.
- Piacentino, D., Kotzalidis, G. D., del Casale, A., Aromatario, M. R., Pomara, C., Girardi, P., et al. (2015). Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. *Curr. Neuropharmacol.* 13, 101–121. doi:10.2174/1570159X13666141210222725.
- Pinchi, E., Frati, A., Cipolloni, L., Aromatario, M., Gatto, V., La Russa, R., et al. (2018). Clinical-pathological study on β-APP, IL-1β, GFAP, NFL, Spectrin II, 80HdG, TUNEL, MIR-21, MIR-16, MIR-92 expressions to verify DAI-diagnosis, grade and prognosis. *Sci. Rep.* doi:10.1038/s41598-018-20699-1.
- Pinchi, E., Frati, P., Aromatario, M., Cipolloni, L., Fabbri, M., La Russa, R., et al. (2019). miR-1, miR-499 and miR-208 are sensitive markers to diagnose sudden death due to early acute myocardial infarction. J. Cell. Mol. Med. doi:10.1111/jcmm.14463.
- Polak, K., Dillon, P., Koch, J. R., Miller, W. G., Thacker, L., and Svikis, D. (2016). Energy drink use is associated with alcohol and substance use in eighth, tenth, and twelfth graders. *Prev. Med. Reports*. doi:10.1016/j.pmedr.2016.06.019.
- Pomara, C., Barone, R., Marino Gammazza, A., Sangiorgi, C., Barone, F., Pitruzzella, A., et al. (2016). Effects of Nandrolone Stimulation on Testosterone Biosynthesis in Leydig Cells. J. Cell. Physiol. 231, 1385–1391. doi:10.1002/jcp.25272.
- Pomportes, L., Brisswalter, J., Casini, L., Hays, A., and Davranche, K. (2017). Cognitive performance enhancement induced by caffeine, carbohydrate and guarana mouth rinsing during submaximal exercise. *Nutrients*. doi:10.3390/nu9060589.
- Ponzetto, F., Giraud, S., Leuenberger, N., Boccard, J., Nicoli, R., Baume, N., et al. (2016). *Methods for Doping Detection*. doi:10.1159/000445177.
- Pope, H. G., Kanayama, G., Athey, A., Ryan, E., Hudson, J. I., and Baggish, A. (2014a). The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: Current best estimates. *Am. J. Addict.* doi:10.1111/j.1521-0391.2013.12118.x.

- Pope, H. G., and Katz, D. L. (1994). Psychiatric and Medical Effects of Anabolic-Androgenic Steroid Use: A Controlled Study of 160 Athletes. Arch. Gen. Psychiatry 51, 375–382. doi:10.1001/archpsyc.1994.03950050035004.
- Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., and Bhasin, S. (2014b). Adverse health consequences of performance-enhancing drugs: An endocrine society scientific statement. *Endocr. Rev.* doi:10.1210/er.2013-1058.
- Porkka, K. P., Pfeiffer, M. J., Waltering, K. K., Vessella, R. L., Tammela, T. L. J., and Visakorpi, T. (2007). MicroRNA expression profiling in prostate cancer. *Cancer Res.* 67, 6130–6135. doi:10.1158/0008-5472.CAN-07-0533.
- Purushotham, A., Schug, T. T., Xu, Q., Surapureddi, S., Guo, X., and Li, X. (2009). Hepatocyte-Specific Deletion of SIRT1 Alters Fatty Acid Metabolism and Results in Hepatic Steatosis and Inflammation. *Cell Metab.* doi:10.1016/j.cmet.2009.02.006.
- Puvanendran, R., Huey, J. C. M., and Pasupathy, S. (2009). Necrotizing fasciitis. *Can. Fam. Physician*.
- Rahnema, C. D., Lipshultz, L. I., Crosnoe, L. E., Kovac, J. R., and Kim, E. D. (2014). Anabolic steroid-induced hypogonadism: Diagnosis and treatment. *Fertil. Steril.* 101, 1271–1279. doi:10.1016/j.fertnstert.2014.02.002.
- Rajasethupathy, P., Fiumara, F., Sheridan, R., Betel, D., Puthanveettil, S. V., Russo, J. J., et al. (2009). Characterization of Small RNAs in Aplysia Reveals a Role for miR-124 in Constraining Synaptic Plasticity through CREB. *Neuron*. doi:10.1016/j.neuron.2009.05.029.
- Reardon, C., and Creado, S. (2014). Drug abuse in athletes. *Subst. Abuse Rehabil.* doi:10.2147/sar.s53784.
- Rottlaender, D., Motloch, L. J., Reda, S., Larbig, R., and Hoppe, U. C. (2012). Cardiac arrest due to long QT syndrome associated with excessive consumption of energy drinks. *Int. J. Cardiol.* doi:10.1016/j.ijcard.2011.10.017.
- Saad, F., Doros, G., Haider, A., and Traish, A. (2013). Obese hypogonadal men benefit from long-term testosterone treatment with testosterone undecanoate injections in multiple ways. *J. Sex. Med.*
- Sadakierska-Chudy, A., Frankowska, M., Miszkiel, J., Wydra, K., Jastrzębska, J., and Filip, M. (2017). Prolonged Induction of miR-212/132 and REST Expression in Rat Striatum Following Cocaine Self-Administration. *Mol. Neurobiol.* doi:10.1007/s12035-016-9817-2.
- Sader, M. A., Griffiths, K. A., McCredie, R. J., Handelsman, D. J., and Celermajer, D. S. (2001). Androgenic anabolic steroids and arterial structure and function in male bodybuilders. *J. Am. Coll. Cardiol.* doi:10.1016/S0735-1097(00)01083-4.
- Sagoe, D., Andreassen, C. S., and Pallesen, S. (2014a). The aetiology and trajectory of anabolic-androgenic steroid use initiation: A systematic review and synthesis of qualitative research. *Subst. Abus. Treat. Prev. Policy.* doi:10.1186/1747-597X-9-27.
- Sagoe, D., McVeigh, J., Bjørnebekk, A., Essilfie, M. S., Andreassen, C. S., and Pallesen, S. (2015). Polypharmacy among anabolic-androgenic steroid users: A descriptive metasynthesis. *Subst. Abus. Treat. Prev. Policy*. doi:10.1186/s13011-015-0006-5.
- Sagoe, D., Molde, H., Andreassen, C. S., Torsheim, T., and Pallesen, S. (2014b). The global epidemiology of anabolic-androgenic steroid use: A meta-analysis and meta-regression analysis. *Ann. Epidemiol.* doi:10.1016/j.annepidem.2014.01.009.
- Salamin, O., Jaggi, L., Baume, N., Robinson, N., Saugy, M., and Leuenberger, N. (2016). Circulating microRNA-122 as potential biomarker for detection of testosterone abuse. *PLoS One* 11. doi:10.1371/journal.pone.0155248.
- Salerno, M., Cascio, O., Bertozzi, G., Sessa, F., Messina, A., Monda, V., et al. (2018). Anabolic androgenic steroids and carcinogenicity focusing on Leydig cell: A

literature review. Oncotarget 9. doi:10.18632/oncotarget.24767.

- Sanchez, A. M., Flamini, M. I., Polak, K., Palla, G., Spina, S., Mannella, P., et al. (2012). Actin cytoskeleton remodelling by sex steroids in neurones. *J. Neuroendocrinol.* doi:10.1111/j.1365-2826.2011.02258.x.
- Sansone, A., Romanelli, F., Sansone, M., Lenzi, A., and Di Luigi, L. (2017). Gynecomastia and hormones. *Endocrine*. doi:10.1007/s12020-016-0975-9.
- Santulli, G. (2015). "Exploiting microrna specifi city and selectivity: Paving a sustainable path towards precision medicine," in *Advances in Experimental Medicine and Biology* doi:10.1007/978-3-319-22671-2\_1.
- Saugy, M., Robinson, N., Saudan, C., Baume, N., Avois, L., and Mangin, P. (2006). Human growth hormone doping in sport. *Br. J. Sports Med.* doi:10.1136/bjsm.2006.027573.
- Schena, F. P., Serino, G., and Sallustio, F. (2014). MicroRNAs in kidney diseases: New promising biomarkers for diagnosis and monitoring. *Nephrol. Dial. Transplant.* doi:10.1093/ndt/gft223.
- Segura, M. F., Belitskaya-Lévy, I., Rose, A. E., Zakrzewski, J., Gaziel, A., Hanniford, D., et al. (2010). Melanoma microRNA signature predicts post-recurrence survival. *Clin. Cancer Res.* 16, 1577–1586. doi:10.1158/1078-0432.CCR-09-2721.
- Sempere, L. F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., and Ambros, V. (2004). Expression profiling of mammalian microRNAs uncovers a subset of brainexpressed microRNAs with possible roles in murine and human neuronal differentiation. *Genome Biol.* 5.
- Sessa, F., Salerno, M., Di Mizio, G., Bertozzi, G., Messina, G., Tomaiuolo, B., et al. (2018). Anabolic androgenic steroids: Searching new molecular biomarkers. *Front. Pharmacol.* 9. doi:10.3389/fphar.2018.01321.
- Shaked, I., Meerson, A., Wolf, Y., Avni, R., Greenberg, D., Gilboa-Geffen, A., et al. (2009). MicroRNA-132 Potentiates Cholinergic Anti-Inflammatory Signaling by Targeting Acetylcholinesterase. *Immunity*. doi:10.1016/j.immuni.2009.09.019.
- Sinha-Hikim, I., Taylor, W. E., Gonzalez-Cadavid, N. F., Zheng, W., and Bhasin, S. (2004). Androgen receptor in human skeletal muscle and cultured muscle satellite cells: Up-regulation by androgen treatment. *J. Clin. Endocrinol. Metab.* 89, 5245– 5255. doi:10.1210/jc.2004-0084.
- Slezak-Prochazka, I., Selvi, D., Kroesen, B.-J., and Van Den Berg, A. (2010). MicroRNAs, macrocontrol: Regulation of miRNA processing. *RNA* 16, 1087–1095. doi:10.1261/rna.1804410.
- Solimini, R., Rotolo, M. C., Mastrobattista, L., Mortali, C., Minutillo, A., Pichini, S., et al. (2017). Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping. *Eur. Rev. Med. Pharmacol. Sci.*
- Song, M. A., Paradis, A. N., Gay, M. S., Shin, J., and Zhang, L. (2015). Differential expression of microRNAs in ischemic heart disease. *Drug Discov. Today* 20, 223– 235. doi:10.1016/j.drudis.2014.10.004.
- Souza, N., Filho, C., Figueirido Gaspar, E., Siqueira, K. L., Monteiro, G. C., Andreoli, C. V., et al. (2011). Pyomyositis in athletes after use of anabolic steroids Case reports. Soc. Bras. Ortop. e Traumatol. doi:10.1016/S2255-4971(15)30185-3.
- Spriet, L. L. (2014). Exercise and Sport Performance with Low Doses of Caffeine. *Sport. Med.* doi:10.1007/s40279-014-0257-8.
- Stannard, J. P., and Bucknell, A. L. (1993). Rupture of the triceps tendon associated with steroid injections. *Am. J. Sports Med.* 21, 482–485. doi:10.1177/036354659302100327.
- Stiles, B., Wang, Y., Stahl, A., Bassilian, S., Lee, W. P., Kim, Y. J., et al. (2004). Live-

specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. *Proc. Natl. Acad. Sci. U. S. A.* doi:10.1073/pnas.0308617100.

- Sun, Y., Gui, H., Li, Q., Luo, Z. M., Zheng, M. J., Duan, J. L., et al. (2013). MicroRNA-124 protects neurons against apoptosis in cerebral ischemic stroke. *CNS Neurosci. Ther.* doi:10.1111/cns.12142.
- Sun, Y., Luo, Z. M., Guo, X. M., Su, D. F., and Liu, X. (2015). An updated role of microRNA-124 in central nervous system disorders: A review. *Front. Cell. Neurosci.* doi:10.3389/fncel.2015.00193.
- Szabo, G., and Bala, S. (2013). MicroRNAs in liver disease. *Nat. Rev. Gastroenterol. Hepatol.* 10, 542–552. doi:10.1038/nrgastro.2013.87.
- Tan, H. P., Smaldone, M. C., and Shapiro, R. (2006). Immunosuppressive preconditioning or induction regimens: Evidence to date. *Drugs*. doi:10.2165/00003495-200666120-00001.
- Tang, Y., Zheng, J., Sun, Y., Wu, Z., Liu, Z., and Huang, G. (2009). MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. *Int. Heart J.* doi:10.1536/ihj.50.377.
- Terry-McElrath, Y. M., O'Malley, P. M., and Johnston, L. D. (2014). Energy drinks, soft drinks, and substance use among united states secondary school students. J. Addict. Med. doi:10.1097/01.ADM.0000435322.07020.53.
- Thiblin, I., Mobini-Far, H., and Frisk, M. (2009). Sudden unexpected death in a female fitness athlete, with a possible connection to the use of anabolic androgenic steroids (AAS) and ephedrine. *Forensic Sci. Int.* doi:10.1016/j.forsciint.2008.11.004.
- Thiblin, I., and Petersson, A. (2005). Pharmacoepidemiology of anabolic androgenic steroids: A review. *Fundam. Clin. Pharmacol.* doi:10.1111/j.1472-8206.2004.00298.x.
- Thomas, G. A., Kraemer, W. J., Comstock, B. A., Dunn-Lewis, C., Maresh, C. M., and Volek, J. S. (2013). Obesity, growth hormone and exercise. *Sport. Med.* doi:10.1007/s40279-013-0064-7.
- Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., et al. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature*. doi:10.1038/nature07511.
- Thuy, S., Ladurner, R., Volynets, V., Wagner, S., Strahl, S., Königsrainer, A., et al. (2008). Nonalcoholic Fatty Liver Disease in Humans Is Associated with Increased Plasma Endotoxin and Plasminogen Activator Inhibitor 1 Concentrations and with Fructose Intake. J. Nutr. doi:10.1093/jn/138.8.1452.
- Tsai, P. C., Liao, Y. C., Wang, Y. S., Lin, H. F., Lin, R. T., and Juo, S. H. H. (2013). Serum microrna-21 and microrna-221 as potential biomarkers for cerebrovascular disease. J. Vasc. Res. doi:10.1159/000351767.
- Unger, C. A. (2014). Gynecologic care for transgender youth. *Curr. Opin. Obstet. Gynecol.* doi:10.1097/GCO.00000000000103.
- van Amsterdam, J., Opperhuizen, A., and Hartgens, F. (2010). Adverse health effects of anabolic-androgenic steroids. *Regul. Toxicol. Pharmacol.* doi:10.1016/j.yrtph.2010.02.001.
- van Rooij, E., Quiat, D., Johnson, B. A., Sutherland, L. B., Qi, X., Richardson, J. A., et al. (2009). A Family of microRNAs Encoded by Myosin Genes Governs Myosin Expression and Muscle Performance. *Dev. Cell* 17, 662–673. doi:10.1016/j.devcel.2009.10.013.
- Van Rooij, E., Sutherland, L. B., Liu, N., Williams, A. H., McAnally, J., Gerard, R. D., et al. (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. *Proc. Natl. Acad. Sci. U. S. A.* 103, 18255–

18260. doi:10.1073/pnas.0608791103.

- Van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., and Olson, E. N. (2007). Control of stress-dependent cardiac growth and gene expression by a microRNA. *Science (80-. ).* doi:10.1126/science.1139089.
- Vargas, M. E., and Barres, B. A. (2007). Why Is Wallerian Degeneration in the CNS So Slow? *Annu. Rev. Neurosci.* doi:10.1146/annurev.neuro.30.051606.094354.
- Vo, N., Klein, M. E., Varlamova, O., Keller, D. M., Yamamoto, T., Goodman, R. H., et al. (2005). A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. *Proc. Natl. Acad. Sci. U. S. A.* doi:10.1073/pnas.0508448102.
- Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc. Natl. Acad. Sci. U. S. A.* 103, 2257–2261. doi:10.1073/pnas.0510565103.
- W. Brenu, E., McNaughton, L., and M. Marshall-Gradisnik, S. (2011). Is there a Potential Immune Dysfunction with Anabolic Androgenic Steroid Use?: A Review. *Mini-Reviews Med. Chem.* doi:10.2174/138955711795445907.
- Walia, R., Bhansali, A., Dutta, P., Khandelwal, N., Sialy, R., and Bhadada, S. (2011). Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline. *Indian J. Med. Res.*
- Walker, W. H. (2009). Molecular mechanisms of testosterone action in spermatogenesis. *Steroids*. doi:10.1016/j.steroids.2008.11.017.
- Wanet, A., Tacheny, A., Arnould, T., and Renard, P. (2012). MiR-212/132 expression and functions: Within and beyond the neuronal compartment. *Nucleic Acids Res.* doi:10.1093/nar/gks151.
- Wang, G.-K., Zhu, J.-Q., Zhang, J.-T., Li, Q., Li, Y., He, J., et al. (2010a). Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. *Eur. Heart J.* 31, 659–666. doi:10.1093/eurheartj/ehq013.
- Wang, G., Kwan, B. C. H., Lai, F. M. M., Choi, P. C. L., Chow, K. M., Li, P. K. T., et al. (2010b). Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. *Am. J. Hypertens.* doi:10.1038/ajh.2009.208.
- Wang, J. X., Jiao, J. Q., Li, Q., Long, B., Wang, K., Liu, J. P., et al. (2011). MiR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. *Nat. Med.* doi:10.1038/nm.2282.
- Wayman, G. A., Davare, M., Ando, H., Fortin, D., Varlamova, O., Cheng, H. Y. M., et al. (2008). An activity-regulated microRNA controls dendritic plasticity by downregulating p250GAP. *Proc. Natl. Acad. Sci. U. S. A.* doi:10.1073/pnas.0803072105.
- Wei, Q., Mi, Q.-S., and Dong, Z. (2013). The regulation and function of micrornas in kidney diseases. *IUBMB Life* 65, 602–615. doi:10.1002/iub.1174.
- White, N. D., and Noeun, J. (2017). Performance-enhancing drug use in adolescence. *Am. J. Lifestyle Med.* 11, 122–124. doi:10.1177/1559827616680593.
- Williams, A. H., Liu, N., van Rooij, E., and Olson, E. N. (2009). MicroRNA control of muscle development and disease. *Curr. Opin. Cell Biol.* doi:10.1016/j.ceb.2009.01.029.
- Williams, T. M., and Carroll, S. B. (2009). Genetic and molecular insights into the development and evolution of sexual dimorphism. *Nat. Rev. Genet.* doi:10.1038/nrg2687.
- Wittert, G. (2014). The relationship between sleep disorders and testosterone. *Curr. Opin. Endocrinol. Diabetes Obes.* doi:10.1097/MED.00000000000069.
- Wong, C. H., Chang, H. C., Pasupathy, S., Khin, L. W., Tan, J. L., and Low, C. O. (2003). Necrotizing fasciitis: Clinical presentation, microbiology, and determinants of

mortality. J. Bone Jt. Surg. - Ser. A. doi:10.2106/00004623-200308000-00005.

- Wong, L. L., Wang, J., Liew, O. W., Richards, A. M., and Chen, Y.-T. (2016). MicroRNA and heart failure. *Int. J. Mol. Sci.* 17. doi:10.3390/ijms17040502.
- Wu, F. C. W., and Von Eckardstein, A. (2003). Androgens and coronary artery disease. Endocr. Rev. doi:10.1210/er.2001-0025.
- Xiao, J., Luo, X., Lin, H., Zhang, Y., Lu, Y., Wang, N., et al. (2007). MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. *J. Biol. Chem.* doi:10.1074/jbc.C700015200.
- Yager, Z., and O'Dea, J. A. (2014). Relationships between body image, nutritional supplement use, and attitudes towards doping in sport among adolescent boys: Implications for prevention programs. J. Int. Soc. Sports Nutr. doi:10.1186/1550-2783-11-13.
- Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., et al. (2007). The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. *Nat. Med.* 13, 486–491. doi:10.1038/nm1569.
- Yesalis, C. E., and Bahrke, M. S. (1995). Anabolic-Androgenic Steroids: Current Issues. Sport. Med. 19, 326–340. doi:10.2165/00007256-199519050-00003.
- Ying, G., Wu, R., Xia, M., Fei, X., He, Q. E., Zha, C., et al. (2018). Identification of eight key miRNAs associated with renal cell carcinoma: A meta-analysis. *Oncol. Lett.* doi:10.3892/ol.2018.9384.
- Yu, S.-L., Chen, H.-Y., Chang, G.-C., Chen, C.-Y., Chen, H.-W., Singh, S., et al. (2008). MicroRNA Signature Predicts Survival and Relapse in Lung Cancer. *Cancer Cell* 13, 48–57. doi:10.1016/j.ccr.2007.12.008.
- Zampetaki, A., Dudek, K., and Mayr, M. (2013). Oxidative stress in atherosclerosis: The role of microRNAs in arterial remodeling. *Free Radic. Biol. Med.* doi:10.1016/j.freeradbiomed.2013.06.025.
- Zaninotto, A. L., Vicentini, J. E., Fregni, F., Rodrigues, P. A., Botelho, C., de Lucia, M. C. S., et al. (2016). Updates and current perspectives of psychiatric assessments after traumatic brain injury: A systematic review. *Front. Psychiatry*. doi:10.3389/fpsyt.2016.00095.
- Zarjou, A., Yang, S., Abraham, E., Agarwal, A., and Liu, G. (2011). Identification of a microRNA signature in renal fibrosis: Role of miR-21. Am. J. Physiol. - Ren. Physiol. doi:10.1152/ajprenal.00273.2011.
- Zhong, X., Chung, A. C. K., Chen, H. Y., Meng, X. M., and Lan, H. Y. (2011). Smad3mediated upregulation of miR-21 promotes renal fibrosis. J. Am. Soc. Nephrol. doi:10.1681/ASN.2010111168.
- Zhou, Y., Fang, L., Yu, Y., Niu, J., Jiang, L., Cao, H., et al. (2015). Erythropoietin protects the tubular basement membrane by promoting the bone marrow to release extracellular vesicles containing tPA-targeting miR-144. Am. J. Physiol. - Ren. Physiol. 310, F27–F40. doi:10.1152/ajprenal.00303.2015.
- Zovoilis, A., Agbemenyah, H. Y., Agis-Balboa, R. C., Stilling, R. M., Edbauer, D., Rao, P., et al. (2011). MicroRNA-34c is a novel target to treat dementias. *EMBO J.* doi:10.1038/emboj.2011.327.
- Zucconi, S., Volpato, C., Adinolfi, F., Gandini, E., Gentile, E., Loi, A., et al. (2017). Gathering consumption data on specific consumer groups of energy drinks. *EFSA Support. Publ.* doi:10.2903/sp.efsa.2013.en-394.